> top > docs > PMC:7228307 > spans > 2471-62115 > annotations

PMC:7228307 / 2471-62115 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 32717-32723 https://glytoucan.org/Structures/Glycans/G82576YO denotes fucose
T2 43666-43672 https://glytoucan.org/Structures/Glycans/G82576YO denotes fucose
T3 43702-43708 https://glytoucan.org/Structures/Glycans/G82576YO denotes fucose
T4 44825-44831 https://glytoucan.org/Structures/Glycans/G82576YO denotes fucose

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id tao:has_standard_notation
35 325-346 Disease denotes inflammatory diseases MESH:D007249
36 359-366 Disease denotes cancers MESH:D009369
37 397-409 Disease denotes malignancies MESH:D009369
42 1463-1467 Gene denotes FcγR Gene:2213
43 831-849 Disease denotes autoimmune disease MESH:D001327
44 892-901 Disease denotes infection MESH:D007239
45 929-936 Disease denotes allergy MESH:D004342
48 2000-2004 Gene denotes FcγR Gene:2213
49 1788-1792 Gene denotes FcγR Gene:2213
58 2503-2510 Gene denotes FcγRIIb Gene:2213
59 3016-3023 Gene denotes FcγRIIb Gene:2213
60 2672-2676 Gene denotes FcγR Gene:2213
61 2215-2219 Gene denotes FcγR Gene:2213
62 2073-2077 Gene denotes FcγR Gene:2213
63 3050-3062 Species denotes participants Tax:9606
64 2571-2579 Chemical denotes tyrosine MESH:D014443
65 2322-2334 Disease denotes cytotoxicity MESH:D064420
84 3417-3425 Gene denotes FcγRIIIa Gene:2214
85 3580-3588 Gene denotes FcγRIIIa Gene:2214
86 3808-3815 Gene denotes FcγRIIb Gene:2213
87 4109-4116 Gene denotes FcγRIIb Gene:2213
88 4550-4557 Gene denotes FcγRIIb Gene:2213
89 3940-3944 Gene denotes FcγR Gene:2213
90 3567-3571 Gene denotes FcγR Gene:2213
91 3318-3322 Gene denotes FcγR Gene:2213
92 4663-4667 Gene denotes FcγR Gene:2213
93 4155-4162 Gene denotes FcγRIIb Gene:2213
94 4980-4983 Gene denotes BCR Gene:613
95 3593-3600 Gene denotes FcγRIIa Gene:2212
96 3836-3844 Chemical denotes tyrosine MESH:D014443
97 4178-4186 Chemical denotes tyrosine MESH:D014443
98 4278-4282 Chemical denotes ITAM
99 3400-3412 Disease denotes cytotoxicity MESH:D064420
100 4439-4442 Disease denotes APC MESH:D011125
101 4953-4965 Disease denotes cytotoxicity MESH:D064420
119 5291-5299 Gene denotes FcγRIIIa Gene:2214
120 5392-5400 Gene denotes FcγRIIIa Gene:2214
121 5402-5409 Gene denotes FcγRIIa Gene:2212
122 5411-5416 Gene denotes FcγRI Gene:2214
123 5488-5493 Gene denotes FcγRI Gene:2214
124 5495-5503 Gene denotes FcγRIIIa Gene:2214
125 5634-5637 Gene denotes BCR Gene:613
126 5703-5710 Gene denotes FcγRIIb Gene:2213
127 5771-5778 Gene denotes FcγRIIb Gene:2213
128 6016-6023 Gene denotes FcγRIIb Gene:2213
129 6030-6037 Gene denotes FcγRIIa Gene:2212
130 6039-6044 Gene denotes FcγRI Gene:2214
131 5990-5994 Gene denotes FcγR Gene:2213
132 5668-5672 Gene denotes FcγR Gene:2213
133 5120-5124 Gene denotes FcγR Gene:2213
134 5479-5486 Gene denotes FcγRIIa Gene:2212
135 5246-5258 Disease denotes cytotoxicity MESH:D064420
137 5051-5055 Gene denotes FcγR Gene:2213
140 6046-6049 Gene denotes BCR Gene:613
141 6089-6097 Chemical denotes tyrosine MESH:D014443
143 6130-6134 Gene denotes FcγR Gene:2213
145 6285-6293 Disease denotes COVID-19 MESH:C000657245
150 6843-6847 Gene denotes FcRn Gene:2217
151 6972-6988 Gene denotes Fc receptor‐like Gene:84824
152 6642-6646 Gene denotes FcγR Gene:2213
153 6626-6631 Species denotes human Tax:9606
156 7006-7010 Gene denotes FcγR Gene:2213
157 7000-7005 Species denotes Human Tax:9606
170 7145-7150 Gene denotes FcγRI Gene:2214
171 7161-7168 Gene denotes FcγRIIc Gene:9103
172 7170-7178 Gene denotes FcγRIIIa Gene:2214
173 7223-7228 Gene denotes CD32a Gene:2212
174 7230-7235 Gene denotes CD32c Gene:9103
175 7237-7242 Gene denotes CD16a Gene:2214
176 7247-7252 Gene denotes CD16b Gene:2215
177 7322-7329 Gene denotes FcγRIIb Gene:2213
178 7342-7347 Gene denotes CD32b Gene:2213
179 7152-7159 Gene denotes FcγRIIa Gene:2212
180 7034-7039 Species denotes human Tax:9606
181 7183-7191 Gene denotes FcγRIIIb Gene:2215
189 8213-8217 Gene denotes FcγR Gene:2213
190 8697-8701 Gene denotes FcγR Gene:2213
191 8475-8479 Gene denotes FcγR Gene:2213
192 8317-8321 Gene denotes FcγR Gene:2213
193 7984-7988 Gene denotes FcγR Gene:2213
194 8197-8202 Species denotes human Tax:9606
195 8469-8474 Species denotes human Tax:9606
213 8847-8852 Gene denotes FcγRI Gene:2214
214 8866-8870 Gene denotes IgG3 Gene:3502
215 8889-8901 Gene denotes interferon‐γ Gene:3458
216 9004-9008 Gene denotes IgG3 Gene:3502
217 9153-9157 Gene denotes IgG3 Gene:3502
218 9174-9182 Gene denotes FcγRIIIa Gene:2214
219 9195-9199 Gene denotes IgG3 Gene:3502
220 9389-9393 Gene denotes IgG3 Gene:3502
221 9407-9414 Gene denotes FcγRIIb Gene:2213
222 9427-9431 Gene denotes IgG3 Gene:3502
223 9591-9599 Gene denotes FcγRIIIb Gene:2215
224 9066-9072 Species denotes people Tax:9606
225 9368-9376 Gene denotes FcγRIIIb Gene:2215
226 8984-8991 Gene denotes FcγRIIa Gene:2212
227 9348-9351 Chemical denotes Phe MESH:D010649
228 9265-9282 Disease denotes myeloid dendritic MESH:D007635
229 9532-9549 Disease denotes myeloid dendritic MESH:D007635
231 8786-8790 Gene denotes FcγR Gene:2213
233 9764-9770 Species denotes people Tax:9606
235 9877-9885 Disease denotes COVID-19 MESH:C000657245
246 10746-10751 Gene denotes FcγRI Gene:2214
247 10753-10760 Gene denotes FcγRIIb Gene:2213
248 10771-10774 Gene denotes CH1 Gene:51430
249 10410-10413 Gene denotes CH1 Gene:51430
250 10269-10273 Gene denotes FcγR Gene:2213
251 10172-10176 Gene denotes FcγR Gene:2213
252 10762-10769 Gene denotes FcγRIIc Gene:9103
253 10394-10401 Gene denotes FcγRIIa Gene:2212
254 10489-10498 Chemical denotes disulfide MESH:D004220
255 10728-10738 Chemical denotes disulfides MESH:D004220
257 11027-11035 Disease denotes COVID-19 MESH:C000657245
259 11254-11258 Gene denotes FcγR Gene:2213
262 11338-11342 Gene denotes FcγR Gene:2213
263 11322-11327 Species denotes human Tax:9606
275 11974-11979 Gene denotes FcγRI Gene:2214
276 11984-11991 Gene denotes FcγRIIb Gene:2213
277 12099-12104 Gene denotes FcγRI Gene:2214
278 12106-12113 Gene denotes FcγRIIa Gene:2212
279 12118-12126 Gene denotes FcγRIIIa Gene:2214
280 12134-12141 Gene denotes FcγRIIb Gene:2213
281 12057-12064 Gene denotes FcγRIIa Gene:2212
282 11940-11944 Gene denotes FcγR Gene:2213
283 11686-11690 Gene denotes FcγR Gene:2213
284 11556-11560 Gene denotes FcγR Gene:2213
285 11632-11637 Species denotes human Tax:9606
287 12188-12192 Gene denotes FcγR Gene:2213
293 12231-12236 Gene denotes FcγRI Gene:2214
294 12297-12309 Gene denotes interferon‐γ Gene:3458
295 12432-12437 Gene denotes FcγRI Gene:14129
296 12441-12453 Gene denotes interferon‐γ Gene:15978
297 12538-12543 Species denotes mouse Tax:10090
305 12699-12706 Gene denotes FcγRIIa Gene:2212
306 13016-13021 Species denotes human Tax:9606
307 13204-13209 Species denotes human Tax:9606
308 13035-13040 Species denotes human Tax:9606
309 12949-12966 Disease denotes thrombocytopenias MESH:D013921
310 13285-13313 Disease denotes systemic lupus erythematosus MESH:D008180
311 13367-13383 Disease denotes hyper‐responsive MESH:D012130
318 13793-13800 Gene denotes FcγRIIb Gene:2213
319 13914-13921 Gene denotes FcγRIIc Gene:9103
320 13494-13498 Gene denotes FcγR Gene:2213
321 13469-13476 Gene denotes FcγRIIc Gene:9103
322 13608-13614 Species denotes humans Tax:9606
323 13900-13907 Gene denotes FcγRIIa Gene:2212
335 14161-14168 Gene denotes FcγRIII Gene:2214
336 14213-14221 Gene denotes FcγRIIIa Gene:2214
337 14226-14234 Gene denotes FcγRIIIb Gene:2215
338 14240-14248 Gene denotes FcγRIIIa Gene:2214
339 14363-14371 Gene denotes FcγRIIIa Gene:2214
340 14811-14818 Gene denotes FcγRIIa Gene:2212
341 14483-14489 Species denotes humans Tax:9606
342 14627-14632 Species denotes human Tax:9606
343 14731-14739 Gene denotes FcγRIIIb Gene:2215
344 14461-14469 Gene denotes FcγRIIIb Gene:2215
345 14710-14717 Gene denotes FcγRIIa Gene:2212
354 15213-15220 Gene denotes FcγRIIb Gene:2213
355 15273-15281 Gene denotes FcγRIIb1 Gene:1555
356 15427-15450 Gene denotes B‐cell antigen receptor Gene:613
357 15452-15455 Gene denotes BCR Gene:613
358 15678-15686 Gene denotes FcγRIIb1 Gene:1555
359 15148-15152 Gene denotes FcγR Gene:2213
360 14866-14870 Gene denotes FcγR Gene:2213
361 15836-15841 Species denotes human Tax:9606
369 16085-16093 Gene denotes FcγRIIIa Gene:2214
370 16128-16135 Gene denotes FcγRIIa Gene:2212
371 16137-16144 Gene denotes FcγRIIb Gene:2213
372 16148-16156 Gene denotes FcγRIIIa Gene:2214
373 15905-15909 Gene denotes FcγR Gene:2213
374 16055-16059 Gene denotes FcγR Gene:2213
375 16098-16102 Disease denotes αβ T MESH:D001260
382 16492-16496 Gene denotes FcγR Gene:2213
383 16696-16703 Gene denotes FcγRIIb Gene:2213
384 16917-16924 Gene denotes FcγRIIb Gene:2213
385 16954-16961 Gene denotes FcγRIIb Gene:2213
386 17366-17373 Gene denotes FcγRIIb Gene:2213
387 16330-16334 Gene denotes FcγR Gene:2213
389 17527-17531 Gene denotes FcγR Gene:2213
395 18043-18046 Gene denotes BCR Gene:613
396 17738-17741 Gene denotes BCR Gene:613
397 17984-17988 Gene denotes FcγR Gene:2213
398 17629-17633 Gene denotes FcγR Gene:2213
399 18106-18114 Chemical denotes tyrosine MESH:D014443
402 18236-18244 Gene denotes FcγRIIb1 Gene:1555
403 18339-18342 Gene denotes BCR Gene:613
405 19006-19010 Gene denotes FcγR Gene:2213
410 19348-19352 Gene denotes FcγR Gene:2213
411 20037-20041 Gene denotes FcγR Gene:2213
412 19604-19608 Gene denotes FcγR Gene:2213
413 19474-19478 Gene denotes FcγR Gene:2213
418 20937-20942 Disease denotes flush MESH:D005483
419 21177-21189 Disease denotes cytotoxicity MESH:D064420
420 21240-21252 Disease denotes cytotoxicity MESH:D064420
421 21359-21364 Disease denotes flush MESH:D005483
426 21855-21859 Gene denotes FcγR Gene:2213
427 21746-21750 Gene denotes FcγR Gene:2213
428 21696-21700 Chemical denotes ADCP
429 21679-21691 Disease denotes cytotoxicity MESH:D064420
432 22009-22013 Gene denotes FcγR Gene:2213
433 22257-22263 Chemical denotes glycan MESH:D011134
443 22657-22665 Gene denotes FcγRIIIa Gene:2214
444 22918-22925 Gene denotes FcγRIIa Gene:2212
445 22930-22935 Gene denotes FcγRI Gene:2214
446 23136-23143 Gene denotes FcγRIII Gene:2214
447 23166-23173 Gene denotes FcγRIIa Gene:2212
448 23178-23183 Gene denotes FcγRI Gene:2214
449 22561-22565 Gene denotes FcγR Gene:2213
450 23034-23042 Species denotes patients Tax:9606
451 22865-22871 Disease denotes cancer MESH:D009369
463 23369-23376 Gene denotes FcγRIIb Gene:2213
464 23536-23543 Gene denotes FcγRIIb Gene:2213
465 23676-23679 Gene denotes BCR Gene:613
466 23757-23765 Gene denotes FcγRIIb1 Gene:1555
467 23836-23841 Gene denotes FcγRI Gene:2214
468 23843-23850 Gene denotes FcγRIIa Gene:2212
469 23861-23868 Gene denotes FcγRIII Gene:2214
470 24190-24193 Gene denotes BCR Gene:613
471 24322-24325 Gene denotes BCR Gene:613
472 24385-24393 Gene denotes FcγRIIB1 Gene:1555
473 23852-23859 Gene denotes FcγRIIc Gene:9103
481 24754-24761 Gene denotes FcγRIIb Gene:14130
482 24994-25001 Gene denotes FcγRIIb Gene:14130
483 24719-24723 Gene denotes FcγR Gene:2213
484 24581-24585 Gene denotes FcγR Gene:2213
485 24494-24500 Species denotes humans Tax:9606
486 25029-25033 Species denotes mice Tax:10090
487 25038-25044 Species denotes humans Tax:9606
493 25654-25658 Gene denotes FcγR Gene:2213
494 25534-25538 Species denotes mice Tax:10090
495 25612-25620 Species denotes patients Tax:9606
496 25570-25583 Disease denotes recall memory MESH:D008569
497 25712-25717 Disease denotes tumor MESH:D009369
504 26124-26129 Gene denotes FcγRI Gene:2214
505 25889-25893 Gene denotes FcγR Gene:2213
506 25798-25802 Gene denotes FcγR Gene:2213
507 26118-26123 Species denotes human Tax:9606
508 26173-26177 Species denotes mice Tax:10090
509 26133-26138 Species denotes human Tax:9606
511 26551-26558 Gene denotes FcγRIIb Gene:2213
513 26777-26784 Gene denotes FcγRIIb Gene:2213
515 27004-27008 Gene denotes FcγR Gene:2213
524 28100-28105 Gene denotes CD357 Gene:8784
525 27937-27941 Gene denotes FcγR Gene:2213
526 27899-27903 Gene denotes FcγR Gene:2213
527 27760-27764 Gene denotes FcγR Gene:2213
528 27389-27393 Gene denotes FcγR Gene:2213
529 27121-27125 Gene denotes FcγR Gene:2213
530 27016-27020 Gene denotes FcγR Gene:2213
531 27068-27080 Species denotes participants Tax:9606
535 28151-28155 Gene denotes FcγR Gene:2213
536 28378-28389 Chemical denotes daratumumab MESH:C556306
537 28319-28324 Disease denotes death MESH:D003643
544 29305-29310 Gene denotes FcγRI Gene:2214
545 29570-29575 Gene denotes FcγRI Gene:2214
546 29641-29653 Gene denotes interferon‐γ Gene:3458
547 29008-29012 Gene denotes FcγR Gene:2213
548 28868-28872 Gene denotes FcγR Gene:2213
549 29710-29722 Disease denotes inflammation MESH:D007249
554 29915-29919 Gene denotes IgG3 Gene:3502
555 30170-30177 Gene denotes FcγRIIb Gene:2213
556 30219-30226 Gene denotes FcγRIII Gene:2214
557 29737-29742 Species denotes human Tax:9606
562 30429-30437 Gene denotes FcγRIIIa Gene:2214
563 30358-30362 Gene denotes FcγR Gene:2213
564 30533-30546 Chemical denotes phenylalanine MESH:D010649
565 30547-30553 Chemical denotes valine MESH:D014633
572 30792-30799 Gene denotes FcγRIIb Gene:2213
573 30840-30845 Gene denotes FcγRI Gene:2214
574 30977-30984 Gene denotes FcγRIIa Gene:2212
575 30712-30716 Gene denotes FcγR Gene:2213
576 31063-31072 Chemical denotes histidine MESH:D006639
577 31293-31301 Chemical denotes arginine MESH:D001120
579 31399-31403 Gene denotes FcγR Gene:2213
583 31551-31556 Gene denotes FcγRI Gene:2214
584 31499-31503 Gene denotes FcγR Gene:2213
585 31450-31454 Gene denotes FcγR Gene:2213
588 31679-31683 Gene denotes FcγR Gene:2213
589 31720-31725 Species denotes human Tax:9606
602 31985-31990 Gene denotes FcγRI Gene:2214
603 32002-32009 Gene denotes FcγRIII Gene:2214
604 32657-32665 Gene denotes FcγRIIIa Gene:2214
605 31992-31998 Gene denotes FcγRII Gene:2214
606 32533-32537 Gene denotes FcγR Gene:2213
607 32129-32133 Gene denotes FcγR Gene:2213
608 31956-31961 Species denotes human Tax:9606
609 32327-32342 Chemical denotes N‐linked glycan
610 32346-32356 Chemical denotes asparagine MESH:D001216
611 32362-32366 Chemical denotes N297
612 32717-32723 Chemical denotes fucose MESH:D005643
613 32741-32756 Chemical denotes oligosaccharide MESH:D009844
617 32835-32839 Gene denotes FcγR Gene:2213
618 33006-33010 Gene denotes FcγR Gene:2213
619 32883-32887 Gene denotes FcγR Gene:2213
621 33184-33193 Chemical denotes disulfide MESH:D004220
624 33801-33810 Chemical denotes disulfide MESH:D004220
625 34199-34208 Chemical denotes disulfide MESH:D004220
630 34459-34462 Gene denotes CH1 Gene:51430
631 34601-34604 Gene denotes CH1 Gene:51430
632 34913-34917 Gene denotes FcγR Gene:2213
633 34324-34333 Chemical denotes disulfide MESH:D004220
635 35000-35004 Gene denotes IgG3 Gene:3502
639 35412-35416 Gene denotes FcγR Gene:2213
640 35781-35785 Gene denotes FcγR Gene:2213
641 35611-35615 Gene denotes FcγR Gene:2213
645 36638-36645 Gene denotes FcγRIIb Gene:2213
646 36568-36572 Gene denotes FcγR Gene:2213
647 36263-36268 Species denotes human Tax:9606
652 36797-36801 Gene denotes FcγR Gene:2213
653 37371-37375 Gene denotes FcγR Gene:2213
654 37319-37323 Gene denotes FcγR Gene:2213
655 37028-37036 Species denotes patients Tax:9606
680 38043-38047 Gene denotes HER2 Gene:2064
681 38054-38058 Gene denotes EGFR Gene:1956
682 38216-38220 Gene denotes HER2 Gene:2064
683 38242-38246 Gene denotes EGFR Gene:1956
684 38526-38534 Gene denotes FcγRIIIa Gene:2214
685 38555-38562 Gene denotes FcγRIIb Gene:2213
686 38615-38622 Gene denotes FcγRIIb Gene:2213
687 38637-38642 Gene denotes FcγRI Gene:2214
688 38644-38651 Gene denotes FcγRIIa Gene:2212
689 38808-38815 Gene denotes FcγRIIb Gene:2213
690 39092-39096 Gene denotes FcγR Gene:2213
691 38858-38862 Gene denotes FcγR Gene:2213
692 38515-38519 Gene denotes FcγR Gene:2213
693 38320-38324 Gene denotes FcγR Gene:2213
694 38083-38087 Gene denotes FcγR Gene:2213
695 38268-38273 Species denotes human Tax:9606
696 38175-38184 Chemical denotes rituximab MESH:D000069283
697 38198-38209 Chemical denotes trastuzumab MESH:D000068878
698 38226-38235 Chemical denotes cetuximab MESH:D000068818
699 37811-37831 Disease denotes Cytotoxic mAb cancer MESH:D064420
700 37958-37977 Disease denotes death of the cancer MESH:D009369
701 38130-38135 Disease denotes tumor MESH:D009369
702 38683-38688 Disease denotes tumor MESH:D009369
703 38740-38746 Disease denotes cancer MESH:D009369
714 39693-39701 Gene denotes FcγRIIIa Gene:2214
715 39831-39838 Gene denotes FcγRIIb Gene:2213
716 40002-40009 Gene denotes FcγRIII Gene:2214
717 40045-40053 Gene denotes FcγRIIIa Gene:2214
718 39873-39877 Gene denotes FcγR Gene:2213
719 39674-39678 Gene denotes FcγR Gene:2213
720 39523-39527 Gene denotes FcγR Gene:2213
721 40113-40120 Species denotes patient Tax:9606
722 39760-39765 Disease denotes tumor MESH:D009369
723 40178-40184 Disease denotes cancer MESH:D009369
725 40329-40344 Chemical denotes N‐linked glycan
793 40637-40663 Gene denotes Matrix Metalloproteinase 9 Gene:4318
794 40665-40669 Gene denotes MMP9 Gene:4318
795 41047-41054 Gene denotes FcγRIII Gene:2214
796 41472-41479 Gene denotes FcγRIII Gene:2214
797 41676-41680 Gene denotes HER2 Gene:2064
798 41743-41750 Gene denotes FcγRIII Gene:2214
799 41799-41828 Gene denotes C–C chemokine receptor type 4 Gene:1233
800 41830-41834 Gene denotes CCR4 Gene:1233
801 41877-41884 Gene denotes FcγRIII Gene:2214
802 42019-42026 Gene denotes FcγRIII Gene:2214
803 42071-42075 Gene denotes PD‐1 Gene:5133
804 42211-42218 Gene denotes FcγRIII Gene:2214
805 42323-42330 Gene denotes FcγRIII Gene:2214
806 42379-42383 Gene denotes PD‐1 Gene:5133
807 42511-42518 Gene denotes FcγRIII Gene:2214
808 43131-43138 Gene denotes FcγRIII Gene:2214
809 42928-42932 Gene denotes FcγR Gene:2213
810 42903-42907 Gene denotes FcγR Gene:2213
811 42724-42728 Gene denotes FcγR Gene:2213
812 42626-42630 Gene denotes FcγR Gene:2213
813 41269-41273 Gene denotes FcγR Gene:2213
814 40945-40949 Gene denotes FcγR Gene:2213
815 40852-40856 Gene denotes FcγR Gene:2213
816 43011-43015 Gene denotes PD‐1 Gene:5133
817 42782-42786 Gene denotes PD‐1 Gene:5133
818 41184-41189 Gene denotes PD‐L1 Gene:29126
819 40902-40907 Gene denotes PD‐L1 Gene:29126
820 41093-41118 Disease denotes ear nose throat disorders MESH:D004427
821 41381-41400 Disease denotes Metabolic disorders MESH:D008659
822 41626-41651 Disease denotes musculoskeletal disorders MESH:D009140
823 42112-42130 Disease denotes Infectious disease MESH:D003141
824 42420-42429 Disease denotes Infection MESH:D007239
825 42532-42555 Disease denotes Hematological disorders MESH:D006402
826 42738-42757 Disease denotes Metabolic disorders MESH:D008659
827 43023-43028 Mutation denotes S228P rs1469294455
828 41197-41202 Mutation denotes L234F p.L234F
829 41204-41209 Mutation denotes L235E p.L235E
830 41211-41216 Mutation denotes P331S p.P331S
831 40930-40935 Mutation denotes N297A p.N297A
832 40780-40785 Mutation denotes L234F p.L234F
833 40787-40792 Mutation denotes L235E p.L235E
834 40794-40799 Mutation denotes P331S p.P331S
835 42794-42799 Mutation denotes S228P rs1469294455
836 42391-42396 Mutation denotes S228P rs1469294455
837 41688-41693 Mutation denotes F243L p.F243L
838 41695-41700 Mutation denotes L235V p.L235V
839 41702-41707 Mutation denotes R292P p.R292P
840 41709-41714 Mutation denotes Y300L p.Y300L
841 41716-41721 Mutation denotes P396L p.P396L
842 41985-41990 Mutation denotes S239D p.S239D
843 41992-41997 Mutation denotes I332E p.I332E
844 42083-42088 Mutation denotes S228P rs1469294455
845 42289-42294 Mutation denotes P247I p.P247I
846 42296-42301 Mutation denotes A339Q p.A339Q
847 41572-41577 Mutation denotes S228P rs1469294455
848 42703-42708 Mutation denotes L234A p.L234A
849 42815-42820 Mutation denotes L235A p.L235A
850 42605-42610 Mutation denotes L234A p.L234A
851 42710-42715 Mutation denotes L235A p.L235A
852 41352-41357 Mutation denotes S228P rs1469294455
853 42801-42806 Mutation denotes E233P p.E233P
854 42808-42813 Mutation denotes F234V rs755807976
855 42612-42617 Mutation denotes L235A p.L235A
856 42822-42827 Mutation denotes D265A p.D265A
857 42829-42834 Mutation denotes L309V p.L309V
858 42836-42841 Mutation denotes R409K p.R409K
859 40678-40683 Mutation denotes S228P rs1469294455
861 43321-43329 Disease denotes COVID-19 MESH:C000657245
863 43571-43577 Chemical denotes glycan MESH:D011134
879 43756-43764 Gene denotes FcγRIIIa Gene:2214
880 43769-43777 Gene denotes FcγRIIIb Gene:2215
881 43850-43857 Gene denotes FcγRIIb Gene:2213
882 43955-43963 Gene denotes FcγRIIIa Gene:2214
883 44060-44064 Gene denotes HER2 Gene:2064
884 44071-44075 Gene denotes EGFR Gene:1956
885 44217-44224 Gene denotes FcγRIII Gene:2214
886 44328-44335 Gene denotes FcγRIII Gene:2214
887 44472-44480 Gene denotes FcγRIIIa Gene:2214
888 44526-44533 Gene denotes FcγRIIa Gene:2212
889 44456-44464 Gene denotes FcγRIIIb Gene:2215
890 43598-43613 Chemical denotes N‐linked glycan
891 43666-43672 Chemical denotes fucose MESH:D005643
892 43702-43708 Chemical denotes fucose MESH:D005643
893 44026-44031 Disease denotes tumor MESH:D009369
900 44795-44803 Species denotes patients Tax:9606
901 44676-44688 Chemical denotes obinutuzumab MESH:C543332
902 44825-44831 Chemical denotes fucose MESH:D005643
903 44843-44852 Chemical denotes rituximab MESH:D000069283
904 44926-44932 Chemical denotes glycan MESH:D011134
905 44766-44794 Disease denotes chronic lymphocytic leukemia MESH:D015451
914 45376-45384 Gene denotes FcγRIIIa Gene:2214
915 45420-45428 Gene denotes FcγRIIIa Gene:2214
916 45466-45473 Gene denotes FcγRIII Gene:14131
917 45546-45551 Species denotes mouse Tax:10090
918 45257-45285 Disease denotes chronic lymphocytic leukemia MESH:D015451
919 45519-45542 Disease denotes reduced lymphoma growth MESH:D006130
920 45331-45336 Mutation denotes S329D p.S329D
921 45341-45346 Mutation denotes I332E p.I332E
941 45641-45645 Gene denotes HER2 Gene:2064
942 45679-45683 Gene denotes HER2 Gene:2064
943 45800-45808 Gene denotes FcγRIIIa Gene:2214
944 45886-45893 Gene denotes FcγRIIb Gene:2213
945 46047-46051 Gene denotes HER2 Gene:13866
946 46118-46122 Gene denotes HER2 Gene:13866
947 45928-45932 Gene denotes FcγR Gene:2213
948 46149-46153 Species denotes mice Tax:10090
949 45560-45572 Chemical denotes Margetuximab MESH:C000617981
950 45650-45661 Chemical denotes trastuzumab MESH:D000068878
951 45988-45999 Chemical denotes trastuzumab MESH:D000068878
952 46005-46017 Chemical denotes margetuximab MESH:C000617981
953 45695-45702 Disease denotes cancers MESH:D009369
954 46134-46139 Disease denotes tumor MESH:D009369
955 45742-45747 Mutation denotes L235V p.L235V
956 45749-45754 Mutation denotes F243L p.F243L
957 45756-45761 Mutation denotes R292P p.R292P
958 45763-45768 Mutation denotes Y300L p.Y300L
959 45773-45778 Mutation denotes P396L p.P396L
967 46462-46470 Gene denotes FcγRIIIa Gene:2214
968 46169-46181 Chemical denotes ocaratuzumab MESH:C550337
969 46273-46280 Disease denotes cancers MESH:D009369
970 46292-46312 Disease denotes non‐Hodgkin lymphoma MESH:D008228
971 46317-46345 Disease denotes chronic lymphocytic leukemia MESH:D015451
972 46367-46372 Mutation denotes P247I p.P247I
973 46377-46382 Mutation denotes A339Q p.A339Q
976 46589-46597 Gene denotes FcγRIIIa Gene:2214
977 46569-46575 Chemical denotes glycan MESH:D011134
979 46715-46719 Gene denotes FcγR Gene:2213
984 47418-47422 Gene denotes FcγR Gene:2213
985 47104-47108 Gene denotes FcγR Gene:2213
986 46960-46964 Gene denotes FcγR Gene:2213
987 46786-46790 Gene denotes FcγR Gene:2213
1003 47951-47957 Gene denotes CTLA‐4 Gene:1493
1004 47965-47970 Gene denotes PD‐L1 Gene:29126
1005 47971-47975 Gene denotes PD‐1 Gene:5133
1006 48185-48189 Gene denotes PD‐1 Gene:5133
1007 48417-48423 Gene denotes CTLA‐4 Gene:1493
1008 47751-47755 Gene denotes FcγR Gene:2213
1009 47614-47618 Gene denotes FcγR Gene:2213
1010 47505-47509 Gene denotes FcγR Gene:2213
1011 48132-48145 Chemical denotes Pembrolizumab MESH:C582435
1012 48147-48156 Chemical denotes nivolumab MESH:D000077594
1013 48161-48171 Chemical denotes cemiplimab MESH:C000627974
1014 48393-48405 Chemical denotes tremelimumab MESH:C520704
1015 48073-48078 Disease denotes tumor MESH:D009369
1016 48220-48226 Disease denotes cancer MESH:D009369
1017 48319-48324 Mutation denotes S228P rs1469294455
1022 48641-48646 Gene denotes FcγRI Gene:2214
1023 48850-48855 Gene denotes FcγRI Gene:2214
1024 48933-48940 Gene denotes FcγRIIb Gene:2213
1025 48827-48831 Gene denotes PD‐1 Gene:5133
1031 49486-49491 Gene denotes PD‐L1 Gene:29126
1032 49556-49560 Gene denotes FcγR Gene:2213
1033 49384-49388 Gene denotes FcγR Gene:2213
1034 49340-49355 Chemical denotes N‐linked glycan
1035 49459-49471 Chemical denotes Atezolizumab MESH:C000594389
1044 49937-49941 Gene denotes FcγR Gene:2213
1045 49693-49697 Gene denotes FcγR Gene:2213
1046 49645-49649 Gene denotes FcγR Gene:2213
1047 49765-49772 Chemical denotes leucine MESH:D007930
1048 49840-49847 Chemical denotes alanine MESH:D000409
1049 49995-50005 Chemical denotes teplizumab MESH:C502540
1050 50010-50020 Chemical denotes spesolimab
1051 49849-49860 Mutation denotes L234A L235A p.L234,235A,A
1063 50299-50304 Gene denotes PD‐L1 Gene:29126
1064 50616-50619 Gene denotes C1q Gene:712
1065 50563-50567 Gene denotes FcγR Gene:2213
1066 50167-50171 Gene denotes FcγR Gene:2213
1067 50526-50530 Gene denotes FcγR Gene:2213
1068 50106-50110 Gene denotes FcγR Gene:2213
1069 50282-50292 Chemical denotes durvalumab MESH:C000613593
1070 50310-50321 Chemical denotes anifrolumab MESH:C582345
1071 50408-50413 Mutation denotes L234F p.L234F
1072 50447-50452 Mutation denotes L235E p.L235E
1073 50476-50481 Mutation denotes P331S p.P331S
1088 50711-50716 Gene denotes FcγRI Gene:2214
1089 50721-50728 Gene denotes FcγRIIb Gene:2213
1090 50984-50988 Gene denotes FcγR Gene:2213
1091 50783-50787 Gene denotes FcγR Gene:2213
1092 51286-51290 Gene denotes FcγR Gene:2213
1093 51108-51118 Chemical denotes disulfides MESH:D004220
1094 50744-50770 Disease denotes PD‐1 antibody tislelizumab MESH:D010300
1095 50899-50904 Mutation denotes E233P p.E233P
1096 50906-50911 Mutation denotes F234V rs755807976
1097 50913-50918 Mutation denotes L235A p.L235A
1098 50946-50951 Mutation denotes D265A p.D265A
1099 51049-51054 Mutation denotes S228P rs1469294455
1100 51067-51072 Mutation denotes L309V p.L309V
1101 51077-51082 Mutation denotes R409K p.R409K
1104 51510-51514 Gene denotes FcγR Gene:2213
1105 51379-51383 Gene denotes FcγR Gene:2213
1107 51602-51609 Gene denotes FcγRIIb Gene:2213
1110 51665-51672 Gene denotes FcγRIIb Gene:2213
1111 51693-51697 Gene denotes FcγR Gene:2213
1113 51841-51849 Chemical denotes tyrosine MESH:D014443
1122 51949-51956 Gene denotes FcγRIIb Gene:2213
1123 52151-52154 Gene denotes BCR Gene:613
1124 52540-52547 Gene denotes FcγRIIb Gene:2213
1125 52641-52648 Gene denotes FcγRIIb Gene:2213
1126 52304-52308 Gene denotes FcγR Gene:2213
1127 52656-52658 Chemical denotes Fc
1128 52193-52221 Disease denotes systemic lupus erythematosus MESH:D008180
1129 52271-52280 Disease denotes allergies MESH:D004342
1136 52911-52914 Gene denotes BCR Gene:613
1137 53037-53044 Gene denotes FcγRIIb Gene:2213
1138 53121-53124 Gene denotes BCR Gene:613
1139 52851-52869 Disease denotes autoimmune disease MESH:D001327
1140 52960-52965 Mutation denotes S267E p.S267E
1141 52970-52975 Mutation denotes L328F p.L328F
1147 53791-53798 Gene denotes FcγRIIb Gene:2213
1148 53743-53746 Gene denotes BCR Gene:613
1149 53188-53206 Disease denotes IgE mAb omalizumab MESH:D007589
1150 53252-53270 Disease denotes allergic disorders MESH:D004342
1151 54013-54020 Disease denotes allergy MESH:D004342
1162 54223-54230 Gene denotes FcγRIIb Gene:2213
1163 54766-54773 Gene denotes FcγRIIb Gene:2213
1164 54503-54510 Gene denotes FcγRIIa Gene:2212
1165 54538-54546 Species denotes patients Tax:9606
1166 54176-54184 Chemical denotes arginine MESH:D001120
1167 54702-54707 Mutation denotes P238D p.P238D
1168 54709-54714 Mutation denotes E233D p.E233D
1169 54716-54721 Mutation denotes G237D p.G237D
1170 54730-54735 Mutation denotes P271G p.P271G
1171 54740-54745 Mutation denotes A330R p.A330R
1176 54898-54905 Gene denotes FcγRIIb Gene:2213
1177 55039-55046 Gene denotes FcγRIIb Gene:2213
1178 55497-55504 Gene denotes FcγRIIb Gene:2213
1179 55438-55446 Species denotes patients Tax:9606
1181 55586-55590 Gene denotes FcγR Gene:2213
1188 55853-55857 Gene denotes OX40 Gene:7293
1189 55930-55933 Gene denotes DR4 Gene:3126
1190 55935-55938 Gene denotes DR5 Gene:8795
1191 55846-55851 Gene denotes 4‐1BB Gene:3604
1192 55892-55897 Disease denotes death MESH:D003643
1193 55911-55917 Disease denotes cancer MESH:D009369
1197 56042-56049 Gene denotes FcγRIIb Gene:2213
1198 56174-56181 Gene denotes FcγRIIb Gene:2213
1199 55961-55965 Gene denotes FcγR Gene:2213
1206 56534-56541 Gene denotes FcγRIIb Gene:2213
1207 56674-56677 Gene denotes DR5 Gene:8795
1208 56873-56880 Gene denotes FcγRIIb Gene:2213
1209 56938-56942 Gene denotes OX40 Gene:7293
1210 56725-56730 Disease denotes death MESH:D003643
1211 56735-56757 Disease denotes decreased tumor growth MESH:D006130
1215 57028-57035 Gene denotes FcγRIIb Gene:2213
1216 57112-57117 Gene denotes CD137 Gene:3604
1217 57139-57143 Gene denotes OX40 Gene:7293
1220 57471-57475 Gene denotes FcγR Gene:2213
1221 57599-57605 Chemical denotes glycan MESH:D011134
1233 58401-58405 Gene denotes FcγR Gene:2213
1234 59126-59130 Gene denotes Her2 Gene:2064
1235 58660-58707 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
1236 58709-58719 Species denotes SARS‐CoV‐2 Tax:2697049
1237 59090-59100 Chemical denotes pertuzumab MESH:C485206
1238 59105-59116 Chemical denotes trastuzumab MESH:D000068878
1239 58507-58525 Disease denotes infectious disease MESH:D003141
1240 58633-58651 Disease denotes infectious disease MESH:D003141
1241 58721-58730 Disease denotes infection MESH:D007239
1242 58986-59004 Disease denotes infectious disease MESH:D003141
1243 59038-59052 Disease denotes adenocarcinoma MESH:D000230
1246 59299-59303 Gene denotes FcγR Gene:2213
1247 59483-59487 Gene denotes FcγR Gene:2213

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T14 818-827 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T15 905-919 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T16 920-925 Body_part denotes (Ig)E http://purl.org/sig/ont/fma/fma62875
T17 921-923 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T18 967-971 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T19 1130-1133 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T20 1241-1247 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T21 1432-1444 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T22 1432-1436 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T23 1556-1559 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T24 2281-2285 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T25 2289-2297 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T26 2308-2312 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T27 2356-2364 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T28 2375-2379 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T29 2571-2579 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T30 2772-2780 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T31 2865-2870 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T32 2880-2904 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T33 2899-2904 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T34 3270-3274 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T35 3347-3366 Body_part denotes Natural killer cell http://purl.org/sig/ont/fma/fma63147
T36 3362-3366 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T37 3367-3375 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T38 3386-3390 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T39 3431-3439 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T40 3450-3454 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T41 3738-3762 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T42 3757-3762 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T43 3789-3793 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T44 3836-3844 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T45 3893-3897 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T46 3970-3975 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T47 3984-3995 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T48 4000-4009 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T49 4026-4029 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T50 4178-4186 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T51 4332-4336 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T52 4598-4602 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T53 4647-4655 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T54 4675-4679 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T55 4724-4728 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T56 4806-4811 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T57 4838-4847 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T58 4898-4906 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T59 4920-4928 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T60 4939-4943 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T61 4967-4969 Body_part denotes Ag http://purl.org/sig/ont/fma/fma61898
T62 4987-4991 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T63 5002-5004 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T64 5006-5020 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T65 5213-5221 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T66 5232-5236 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T67 5285-5289 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T68 5300-5308 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T69 5319-5323 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T70 5386-5390 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T71 5525-5529 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T72 5554-5558 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T73 5573-5581 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T74 5612-5616 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T75 5950-5954 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T76 6010-6014 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T77 6053-6057 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T78 6089-6097 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T79 6538-6542 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T80 6603-6606 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T81 6632-6641 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T82 6719-6722 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T83 6763-6773 Body_part denotes antibody’s http://purl.org/sig/ont/fma/fma62871
T84 6797-6802 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T85 7040-7049 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T86 7490-7494 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T87 7851-7855 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T88 7895-7899 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T89 8203-8212 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T90 8812-8815 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T91 8829-8833 Body_part denotes Cell http://purl.org/sig/ont/fma/fma68646
T92 8905-8914 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T93 8916-8927 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T94 8929-8940 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T95 8942-8956 Body_part denotes dendritic cell http://purl.org/sig/ont/fma/fma273565
T96 8952-8956 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T97 8973-8983 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T98 8978-8983 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T99 9079-9089 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T100 9094-9103 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T101 9117-9130 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T102 9165-9173 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T103 9168-9173 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T104 9202-9210 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T105 9205-9210 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T106 9212-9223 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T107 9254-9263 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T108 9273-9288 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T109 9283-9288 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T110 9290-9301 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T111 9395-9406 Body_part denotes Neutrophils http://purl.org/sig/ont/fma/fma62860
T112 9439-9452 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T113 9459-9468 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T114 9491-9500 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T115 9502-9513 Body_part denotes eosinophils http://purl.org/sig/ont/fma/fma62861
T116 9540-9555 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T117 9550-9555 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T118 9557-9565 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T119 9560-9565 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T120 9600-9604 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T121 9641-9647 Body_part denotes muscle http://purl.org/sig/ont/fma/fma32558
T122 9655-9663 Body_part denotes placenta http://purl.org/sig/ont/fma/fma63934
T123 9665-9690 Body_part denotes follicular dendritic cell http://purl.org/sig/ont/fma/fma83037
T124 9686-9690 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T125 9691-9693 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T126 9695-9709 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T127 9711-9718 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T128 9714-9718 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T129 9720-9739 Body_part denotes natural killer cell http://purl.org/sig/ont/fma/fma63147
T130 9735-9739 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T131 10131-10134 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T132 10158-10161 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T133 10880-10883 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T134 10902-10904 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T135 10906-10920 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T136 11273-11290 Body_part denotes hemopoietic cells http://purl.org/sig/ont/fma/fma83598
T137 11285-11290 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T138 11295-11301 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T139 11328-11337 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T140 11596-11600 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T141 11638-11648 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T142 11654-11663 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T143 11868-11873 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T144 11903-11911 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T145 12016-12024 Body_part denotes monocyte http://purl.org/sig/ont/fma/fma62864
T146 12079-12090 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T147 12178-12187 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T148 12279-12288 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T149 12313-12322 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T150 12324-12335 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T151 12337-12348 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T152 12350-12366 Body_part denotes microglial cells http://purl.org/sig/ont/fma/fma54539
T153 12361-12366 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T154 12374-12379 Body_part denotes brain http://purl.org/sig/ont/fma/fma50801
T155 12381-12396 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T156 12391-12396 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T157 12401-12411 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T158 12406-12411 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T159 12813-12823 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T160 12847-12856 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T161 13125-13136 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T162 13210-13220 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T163 13410-13420 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T164 13443-13445 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T165 13536-13546 Body_part denotes nucleotide http://purl.org/sig/ont/fma/fma82740
T166 13684-13689 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T167 13710-13714 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T168 13848-13859 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T169 14198-14202 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T170 14265-14273 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T171 14268-14273 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T172 14316-14327 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T173 14388-14399 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T174 14531-14544 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T175 14531-14535 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T176 14633-14644 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T177 14751-14762 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T178 14895-14899 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T179 15077-15081 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T180 15172-15177 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T181 15245-15251 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T182 15310-15323 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T183 15338-15348 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T184 15349-15360 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T185 15429-15433 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T186 15515-15524 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T187 15529-15540 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T188 15574-15584 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T189 15579-15584 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T190 15586-15601 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T191 15596-15601 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T192 15611-15620 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T193 15621-15632 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T194 15653-15664 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T195 15844-15849 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T196 15877-15883 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T197 15926-15931 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T198 16022-16034 Body_part denotes T‐lymphocyte http://purl.org/sig/ont/fma/fma62870
T199 16071-16076 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T200 16103-16108 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T201 16224-16232 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T202 16303-16308 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T203 16398-16416 Body_part denotes hematopoietic cell http://purl.org/sig/ont/fma/fma83598
T204 16412-16416 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T205 16526-16531 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T206 16726-16751 Body_part denotes follicular dendritic cell http://purl.org/sig/ont/fma/fma83037
T207 16747-16751 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T208 16767-16773 Body_part denotes muscle http://purl.org/sig/ont/fma/fma32558
T209 16778-16783 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T210 16784-16795 Body_part denotes endothelium http://purl.org/sig/ont/fma/fma63916
T211 16824-16829 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T212 16830-16840 Body_part denotes sinusoidal http://purl.org/sig/ont/fma/fma63131
T213 16841-16858 Body_part denotes endothelial cells http://purl.org/sig/ont/fma/fma66772
T214 16853-16858 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T215 17047-17052 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T216 17145-17151 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T217 17748-17752 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T218 17776-17779 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T219 17799-17802 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T220 18072-18085 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T221 18072-18076 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T222 18106-18114 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T223 18279-18283 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T224 18439-18447 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T225 18474-18485 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T226 18570-18578 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T227 18663-18671 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T228 18689-18697 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T229 18747-18752 Body_part denotes lipid http://purl.org/sig/ont/fma/fma67264
T230 18756-18763 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T231 18764-18772 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T232 18826-18830 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T233 19202-19205 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T234 19260-19265 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T235 19430-19433 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T236 20113-20118 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T237 20147-20165 Body_part denotes actin cytoskeleton http://purl.org/sig/ont/fma/fma84684
T238 20188-20205 Body_part denotes glycosaminoglycan http://purl.org/sig/ont/fma/fma63011
T239 20206-20216 Body_part denotes glycocalyx http://purl.org/sig/ont/fma/fma66838
T240 20261-20274 Body_part denotes glycoproteins http://purl.org/sig/ont/fma/fma62925
T241 20447-20451 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T242 20700-20704 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T243 21088-21096 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T244 21223-21231 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T245 21380-21393 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T246 21380-21384 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T247 21752-21757 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T248 22034-22047 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T249 22034-22038 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T250 22669-22677 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T251 22672-22677 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T252 22714-22725 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T253 22766-22773 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T254 22769-22773 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T255 23217-23221 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T256 23342-23346 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T257 23601-23605 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T258 23778-23782 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T259 23794-23804 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T260 23892-23895 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T261 23921-23924 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T262 24092-24096 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T263 24135-24140 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T264 24221-24225 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T265 24406-24410 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T266 24929-24935 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T267 25175-25178 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T268 25280-25289 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T269 25293-25296 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T270 25323-25331 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T271 25385-25393 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T272 26257-26265 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T273 26360-26384 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T274 26379-26384 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T275 26417-26432 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T276 26427-26432 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T277 26446-26459 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T278 26486-26518 Body_part denotes major histocompatibility complex http://purl.org/sig/ont/fma/fma84079
T279 26566-26572 Body_part denotes stroma http://purl.org/sig/ont/fma/fma81494
T280 26581-26607 Body_part denotes follicular dendritic cells http://purl.org/sig/ont/fma/fma83037
T281 26602-26607 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T282 26619-26627 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T283 26658-26666 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T284 26684-26696 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T285 26684-26688 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T286 26737-26742 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T287 26873-26884 Body_part denotes lymphocytes http://purl.org/sig/ont/fma/fma62863
T288 26985-26989 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T289 27010-27015 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T290 27032-27037 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T291 27139-27142 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T292 27181-27193 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T293 27181-27185 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T294 27206-27210 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T295 27325-27329 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T296 27432-27436 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T297 27538-27542 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T298 27600-27604 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T299 27725-27729 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T300 27777-27782 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T301 27800-27809 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T302 27827-27831 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T303 27846-27854 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T304 27915-27920 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T305 28220-28224 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T306 28337-28341 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T307 28453-28458 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T308 28498-28501 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T309 28643-28646 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T310 28679-28682 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T311 28829-28841 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T312 28829-28833 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T313 29140-29143 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T314 29253-29256 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T315 29383-29386 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T316 29484-29487 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T317 29498-29501 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T318 29624-29629 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T319 29743-29746 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T320 29812-29822 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T321 30533-30546 Body_part denotes phenylalanine http://purl.org/sig/ont/fma/fma82754
T322 30547-30553 Body_part denotes valine http://purl.org/sig/ont/fma/fma82766
T323 30587-30590 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T324 31063-31072 Body_part denotes histidine http://purl.org/sig/ont/fma/fma82755
T325 31096-31099 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T326 31293-31301 Body_part denotes arginine http://purl.org/sig/ont/fma/fma82763
T327 31326-31329 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T328 31391-31394 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T329 31613-31616 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T330 31656-31659 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T331 31867-31870 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T332 32436-32439 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T333 32636-32639 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T334 32717-32723 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T335 32741-32756 Body_part denotes oligosaccharide http://purl.org/sig/ont/fma/fma82742
T336 33856-33867 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T337 33916-33924 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T338 33930-33933 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T339 35274-35281 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T340 35350-35358 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T341 35603-35606 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T342 35659-35664 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T343 36105-36108 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T344 36269-36272 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T345 36331-36334 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T346 36746-36754 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T347 36968-36976 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T348 37397-37400 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T349 37431-37434 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T350 37953-37957 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T351 37978-37982 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T352 38279-38287 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T353 38594-38599 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T354 38702-38712 Body_part denotes macrophage http://purl.org/sig/ont/fma/fma63261
T355 38747-38751 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T356 38929-38933 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T357 38965-38969 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T358 39128-39132 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T359 39766-39771 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T360 40352-40362 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T361 40530-40533 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T362 40534-40542 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T363 40992-41005 Body_part denotes Interleukin 5 http://purl.org/sig/ont/fma/fma264830
T364 40992-41003 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578
T365 41093-41096 Body_part denotes ear http://purl.org/sig/ont/fma/fma52780
T366 41097-41101 Body_part denotes nose http://purl.org/sig/ont/fma/fma46472
T367 41102-41108 Body_part denotes throat http://purl.org/sig/ont/fma/fma228738
T368 41335-41342 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T369 41493-41515 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T370 41549-41560 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578
T371 41803-41812 Body_part denotes chemokine http://purl.org/sig/ont/fma/fma241981
T372 41898-41920 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T373 43152-43174 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T374 43196-43198 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T375 43200-43214 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T376 43666-43672 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T377 43676-43686 Body_part denotes Antibodies http://purl.org/sig/ont/fma/fma62871
T378 43702-43708 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T379 44380-44387 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T380 44383-44387 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T381 44415-44425 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T382 44501-44511 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T383 44774-44785 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T384 44825-44831 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T385 45036-45047 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T386 45066-45077 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T387 45110-45113 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T388 45175-45183 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T389 45265-45276 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T390 45729-45740 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T391 46053-46058 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T392 46325-46336 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T393 46741-46744 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T394 46865-46868 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T395 47241-47244 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T396 47543-47552 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T397 47699-47702 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T398 47841-47850 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T399 48122-48130 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T400 48424-48432 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T401 48454-48462 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T402 48505-48510 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T403 48712-48722 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T404 49618-49628 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T405 49765-49772 Body_part denotes leucine http://purl.org/sig/ont/fma/fma82757
T406 49840-49847 Body_part denotes alanine http://purl.org/sig/ont/fma/fma82749
T407 50077-50087 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T408 50253-50264 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T409 50749-50757 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T410 51179-51181 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T411 51458-51467 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T412 51841-51849 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T413 52080-52088 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T414 52168-52173 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T415 52236-52245 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T416 52250-52259 Body_part denotes mast cell http://purl.org/sig/ont/fma/fma66784
T417 52255-52259 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T418 52332-52342 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T419 52346-52354 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T420 52364-52370 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T421 52507-52519 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T422 52507-52511 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T423 53170-53175 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T424 53188-53191 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T425 53475-53478 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T426 53527-53535 Body_part denotes basophil http://purl.org/sig/ont/fma/fma62862
T427 53540-53549 Body_part denotes mast cell http://purl.org/sig/ont/fma/fma66784
T428 53545-53549 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T429 53664-53667 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T430 53689-53693 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T431 53694-53697 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T432 53739-53742 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T433 53756-53768 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T434 53756-53760 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T435 53880-53883 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T436 53898-53901 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T437 53905-53910 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T438 53952-53955 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T439 54043-54046 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T440 54176-54184 Body_part denotes arginine http://purl.org/sig/ont/fma/fma82763
T441 54203-54206 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T442 55074-55084 Body_part denotes Antibodies http://purl.org/sig/ont/fma/fma62871
T443 55098-55106 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T444 55177-55180 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T445 55184-55193 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T446 55410-55413 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T447 55469-55472 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T448 55645-55650 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T449 55798-55822 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T450 55817-55822 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T451 55828-55833 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T452 55918-55923 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T453 57118-57126 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T454 57444-57452 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T455 57584-57587 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T456 57939-57947 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T457 58223-58231 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T458 59398-59411 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T459 59497-59505 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T2 6797-6802 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T3 9655-9663 Body_part denotes placenta http://purl.obolibrary.org/obo/UBERON_0001987
T4 11295-11301 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T5 12374-12379 Body_part denotes brain http://purl.obolibrary.org/obo/UBERON_0000955
T6 13137-13141 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T7 13860-13864 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T8 15245-15251 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T9 15877-15883 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T10 16778-16783 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T11 16784-16795 Body_part denotes endothelium http://purl.obolibrary.org/obo/UBERON_0001986
T12 16824-16829 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T13 17145-17151 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T14 18486-18490 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T15 21075-21079 Body_part denotes pore http://purl.obolibrary.org/obo/UBERON_0008915
T16 21210-21214 Body_part denotes pore http://purl.obolibrary.org/obo/UBERON_0008915
T17 24929-24935 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T18 26566-26572 Body_part denotes stroma http://purl.obolibrary.org/obo/UBERON_0003891
T19 33930-33933 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T20 35239-35244 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T21 35659-35664 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T22 41093-41096 Body_part denotes ear http://purl.obolibrary.org/obo/UBERON_0001690
T23 41097-41101 Body_part denotes nose http://purl.obolibrary.org/obo/UBERON_0000004
T24 41102-41108 Body_part denotes throat http://purl.obolibrary.org/obo/UBERON_0000341
T25 41493-41515 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T26 41501-41515 Body_part denotes nervous system http://purl.obolibrary.org/obo/UBERON_0001016
T27 41898-41920 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T28 41906-41920 Body_part denotes nervous system http://purl.obolibrary.org/obo/UBERON_0001016
T29 43152-43174 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T30 43160-43174 Body_part denotes nervous system http://purl.obolibrary.org/obo/UBERON_0001016
T31 52364-52370 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T32 59398-59411 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T8 325-346 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166
T9 831-849 Disease denotes autoimmune disease http://purl.obolibrary.org/obo/MONDO_0007179
T10 883-901 Disease denotes virus in infection http://purl.obolibrary.org/obo/MONDO_0005108
T11 892-901 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T12 929-936 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T13 1811-1817 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T14 2138-2141 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T15 2240-2243 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T16 2336-2340 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T17 2419-2423 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T18 3070-3073 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T19 4914-4918 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T20 6285-6293 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T21 7932-7935 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T22 9877-9885 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T23 11027-11035 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T24 12644-12647 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T25 12942-12966 Disease denotes immune thrombocytopenias http://purl.obolibrary.org/obo/MONDO_0002048|http://purl.obolibrary.org/obo/MONDO_0008558
T27 13285-13313 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T28 13294-13313 Disease denotes lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0004670
T29 13428-13439 Disease denotes anaphylaxis http://purl.obolibrary.org/obo/MONDO_0100053
T30 16608-16611 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T31 19943-19947 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T32 20857-20861 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T33 20866-20870 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T34 20874-20878 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T35 21135-21139 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T36 21300-21304 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T37 21415-21419 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T38 21564-21568 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T39 21573-21577 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T40 21696-21700 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T41 21884-21887 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T42 22493-22497 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T43 22515-22519 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T44 22524-22528 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T45 22774-22778 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T46 22823-22826 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T47 22865-22871 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T48 22894-22898 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T49 23027-23030 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T50 24050-24053 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T51 25198-25201 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T52 25712-25717 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T53 27088-27091 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T54 28371-28374 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T55 29710-29722 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T56 35931-35934 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T57 36312-36315 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T58 36731-36735 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T59 36737-36741 Disease denotes ADCP http://purl.obolibrary.org/obo/MONDO_0022697
T60 37102-37105 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T61 37754-37758 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T62 37825-37831 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T63 37971-37977 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T64 38118-38122 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T65 38130-38135 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T66 38683-38688 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T67 38740-38746 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T68 39735-39739 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T69 39760-39765 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T70 40178-40184 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T71 41093-41118 Disease denotes ear nose throat disorders http://purl.obolibrary.org/obo/MONDO_0024623
T72 41381-41400 Disease denotes Metabolic disorders http://purl.obolibrary.org/obo/MONDO_0005066
T73 41626-41651 Disease denotes musculoskeletal disorders http://purl.obolibrary.org/obo/MONDO_0002081
T74 42112-42130 Disease denotes Infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T75 42420-42429 Disease denotes Infection http://purl.obolibrary.org/obo/MONDO_0005550
T76 42532-42555 Disease denotes Hematological disorders http://purl.obolibrary.org/obo/MONDO_0005570
T77 42738-42757 Disease denotes Metabolic disorders http://purl.obolibrary.org/obo/MONDO_0005066
T78 43321-43329 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T79 44026-44031 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T80 44397-44401 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T81 44766-44794 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T82 44774-44794 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T83 44786-44794 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059
T84 45257-45285 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T85 45265-45285 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T86 45277-45285 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059
T87 45483-45487 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T88 45527-45535 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T89 45579-45583 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T90 46034-46038 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T91 46134-46139 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T92 46292-46312 Disease denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0011508|http://purl.obolibrary.org/obo/MONDO_0018908
T94 46296-46312 Disease denotes Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0004952
T95 46304-46312 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T96 46317-46345 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T97 46325-46345 Disease denotes lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0005402
T98 46337-46345 Disease denotes leukemia http://purl.obolibrary.org/obo/MONDO_0005059
T99 46500-46504 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T100 46828-46831 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T101 48073-48078 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T102 48220-48226 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T103 48482-48486 Disease denotes ADCC http://purl.obolibrary.org/obo/MONDO_0008734
T104 52193-52221 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T105 52202-52221 Disease denotes lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0004670
T106 52711-52714 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T107 52851-52869 Disease denotes autoimmune disease http://purl.obolibrary.org/obo/MONDO_0007179
T108 53252-53260 Disease denotes allergic http://purl.obolibrary.org/obo/MONDO_0004980
T109 54013-54020 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T110 55122-55125 Disease denotes MOA http://purl.obolibrary.org/obo/MONDO_0016702
T111 55911-55917 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T112 56745-56750 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T113 58507-58525 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T114 58633-58651 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T115 58660-58707 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T116 58660-58693 Disease denotes severe acute respiratory syndrome http://purl.obolibrary.org/obo/MONDO_0005091
T117 58709-58713 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T118 58721-58730 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T119 58986-59004 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T120 59038-59052 Disease denotes adenocarcinoma http://purl.obolibrary.org/obo/MONDO_0004970

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T31 246-247 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T32 536-539 http://purl.obolibrary.org/obo/CLO_0050884 denotes ten
T33 883-888 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T34 967-971 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T35 972-982 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T36 1241-1247 http://purl.obolibrary.org/obo/UBERON_0001969 denotes plasma
T37 1271-1281 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T38 1407-1409 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T39 1432-1436 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T40 1463-1465 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T41 1538-1539 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T42 1575-1585 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T43 1627-1637 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T44 1643-1645 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T45 1646-1648 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T46 1788-1790 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T47 1888-1898 http://purl.obolibrary.org/obo/CLO_0001658 denotes activities
T48 1997-1999 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T49 2000-2002 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T50 2073-2075 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T51 2215-2217 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T52 2272-2273 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T53 2281-2285 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T54 2308-2312 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T55 2375-2379 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T56 2503-2505 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T57 2580-2590 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T58 2623-2632 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T59 2672-2674 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T60 2686-2687 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T61 2784-2789 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T62 2865-2870 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T63 2899-2904 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T64 2996-2998 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T65 2999-3001 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T66 3016-3018 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T67 3142-3143 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T68 3211-3212 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T69 3247-3248 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T70 3249-3255 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T71 3270-3274 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T72 3318-3320 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T73 3344-3345 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T74 3347-3366 http://purl.obolibrary.org/obo/CL_0000623 denotes Natural killer cell
T75 3386-3390 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T76 3417-3419 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T77 3428-3429 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T78 3450-3454 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T79 3541-3551 http://purl.obolibrary.org/obo/CL_0000234 denotes phagocytes
T80 3556-3566 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T81 3567-3569 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T82 3580-3582 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T83 3593-3595 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T84 3757-3762 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T85 3789-3793 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T86 3794-3804 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T87 3808-3810 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T88 3845-3855 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T89 3878-3887 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T90 3891-3897 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T91 3929-3939 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T92 3940-3942 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T93 3970-3975 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T94 4030-4032 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T95 4068-4078 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T96 4109-4111 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T97 4155-4157 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T98 4290-4299 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T99 4332-4336 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T100 4503-4505 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T101 4506-4508 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T102 4514-4515 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T103 4550-4552 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T104 4562-4568 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T105 4598-4602 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T106 4663-4665 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T107 4675-4679 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T108 4690-4691 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T109 4692-4698 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T110 4724-4728 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T111 4769-4779 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T112 4806-4811 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T113 4852-4859 http://www.ebi.ac.uk/efo/EFO_0000876 denotes extreme
T114 4939-4943 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T115 4985-4991 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T116 5051-5053 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T117 5120-5122 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T118 5201-5211 http://purl.obolibrary.org/obo/CLO_0001658 denotes Activation
T119 5232-5236 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T120 5285-5289 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T121 5291-5293 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T122 5319-5323 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T123 5386-5390 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T124 5392-5394 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T125 5402-5404 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T126 5411-5413 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T127 5479-5481 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T128 5488-5490 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T129 5495-5497 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T130 5523-5529 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T131 5554-5558 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T132 5559-5569 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T133 5612-5616 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T134 5617-5627 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T135 5642-5652 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T136 5668-5670 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T137 5674-5676 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T138 5681-5683 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T139 5703-5705 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T140 5749-5759 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T141 5771-5773 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T142 5841-5843 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T143 5849-5850 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T144 5950-5954 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T145 5990-5992 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T146 6010-6014 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T147 6016-6018 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T148 6030-6032 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T149 6039-6041 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T150 6051-6057 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T151 6098-6108 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T152 6116-6117 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T153 6119-6129 http://purl.obolibrary.org/obo/CLO_0001658 denotes Activating
T154 6130-6132 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T155 6523-6542 http://purl.obolibrary.org/obo/CLO_0009985 denotes focuses on the cell
T156 6626-6631 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T157 6642-6644 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T158 6723-6725 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T159 6856-6866 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T160 6972-6974 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T161 7000-7005 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes Human
T162 7006-7008 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T163 7034-7039 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T164 7118-7128 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T165 7145-7147 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T166 7152-7154 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T167 7161-7163 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T168 7170-7172 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T169 7183-7185 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T170 7322-7324 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T171 7404-7406 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T172 7407-7409 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T173 7490-7494 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T174 7596-7598 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T175 7599-7601 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T176 7613-7614 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T177 7827-7829 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T178 7830-7832 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T179 7851-7861 http://purl.obolibrary.org/obo/CL_0000000 denotes cell types
T180 7895-7899 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T181 7984-7986 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T182 8197-8202 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T183 8213-8215 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T184 8262-8263 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T185 8317-8319 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T186 8382-8384 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T187 8469-8474 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T188 8475-8477 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T189 8507-8515 http://purl.obolibrary.org/obo/NCBITaxon_9443 denotes primates
T190 8517-8523 http://purl.obolibrary.org/obo/NCBITaxon_33208 denotes animal
T191 8687-8696 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humanized
T192 8697-8699 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T193 8786-8788 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T194 8829-8833 http://purl.obolibrary.org/obo/GO_0005623 denotes Cell
T195 8847-8849 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T196 8905-8914 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T197 8942-8956 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cell
T198 8978-8983 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T199 8984-8986 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T200 9042-9044 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T201 9117-9118 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T202 9131-9133 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T203 9139-9140 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T204 9165-9173 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T205 9174-9176 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T206 9202-9210 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T207 9254-9263 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T208 9265-9288 http://purl.obolibrary.org/obo/CL_0000782 denotes myeloid dendritic cells
T209 9368-9370 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T210 9407-9409 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T211 9439-9440 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T212 9459-9468 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T213 9532-9555 http://purl.obolibrary.org/obo/CL_0000782 denotes myeloid dendritic cells
T214 9557-9565 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T215 9591-9593 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T216 9600-9604 http://purl.obolibrary.org/obo/OGG_0000000002 denotes gene
T217 9627-9633 http://purl.obolibrary.org/obo/UBERON_0001005 denotes Airway
T218 9641-9647 http://purl.obolibrary.org/obo/UBERON_0001630 denotes muscle
T219 9641-9647 http://purl.obolibrary.org/obo/UBERON_0005090 denotes muscle
T220 9641-9647 http://www.ebi.ac.uk/efo/EFO_0000801 denotes muscle
T221 9641-9647 http://www.ebi.ac.uk/efo/EFO_0001949 denotes muscle
T222 9655-9663 http://purl.obolibrary.org/obo/UBERON_0001987 denotes placenta
T223 9655-9663 http://www.ebi.ac.uk/efo/EFO_0001407 denotes placenta
T224 9676-9690 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cell
T225 9711-9718 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cell
T226 9720-9739 http://purl.obolibrary.org/obo/CL_0000623 denotes natural killer cell
T227 9741-9742 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T228 10144-10146 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T229 10172-10174 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T230 10237-10239 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T231 10269-10271 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T232 10320-10322 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T233 10394-10396 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T234 10410-10413 http://purl.obolibrary.org/obo/CLO_0002408 denotes CH1
T235 10688-10689 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T236 10746-10748 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T237 10753-10755 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T238 10762-10764 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T239 10771-10774 http://purl.obolibrary.org/obo/CLO_0002408 denotes CH1
T240 11254-11256 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T241 11285-11290 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T242 11322-11327 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T243 11338-11340 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T244 11404-11406 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T245 11556-11558 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T246 11596-11600 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T247 11632-11637 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T248 11686-11688 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T249 11844-11854 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T250 11868-11873 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T251 11940-11942 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T252 11974-11976 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T253 11984-11986 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T254 11992-11994 http://purl.obolibrary.org/obo/CLO_0050510 denotes 18
T255 12016-12024 http://purl.obolibrary.org/obo/CL_0000576 denotes monocyte
T256 12057-12059 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T257 12069-12078 http://purl.obolibrary.org/obo/CLO_0001658 denotes activated
T258 12099-12101 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T259 12106-12108 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T260 12118-12120 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T261 12134-12136 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T262 12188-12190 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T263 12231-12233 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T264 12313-12322 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T265 12350-12366 http://purl.obolibrary.org/obo/CL_0000129 denotes microglial cells
T266 12374-12379 http://purl.obolibrary.org/obo/UBERON_0000955 denotes brain
T267 12374-12379 http://www.ebi.ac.uk/efo/EFO_0000302 denotes brain
T268 12381-12396 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cells
T269 12406-12411 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T270 12432-12434 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T271 12480-12488 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T272 12515-12525 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T273 12538-12543 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T274 12575-12578 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T275 12579-12580 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T276 12699-12701 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T277 12728-12736 http://purl.obolibrary.org/obo/NCBITaxon_9443 denotes primates
T278 12778-12780 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T279 12781-12783 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T280 12968-12969 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T281 13016-13021 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T282 13035-13040 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T283 13137-13141 http://purl.obolibrary.org/obo/UBERON_0002415 denotes tail
T284 13169-13171 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T285 13183-13184 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T286 13204-13209 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T287 13346-13355 http://purl.obolibrary.org/obo/OBI_0100026 denotes organisms
T288 13346-13355 http://purl.obolibrary.org/obo/UBERON_0000468 denotes organisms
T289 13356-13358 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T290 13359-13360 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T291 13392-13393 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T292 13466-13468 http://purl.obolibrary.org/obo/CLO_0050507 denotes 22
T293 13469-13471 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T294 13483-13493 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T295 13494-13496 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T296 13608-13614 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T297 13682-13689 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T298 13690-13692 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T299 13696-13699 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T300 13710-13714 http://purl.obolibrary.org/obo/OGG_0000000002 denotes gene
T301 13793-13795 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T302 13860-13864 http://purl.obolibrary.org/obo/UBERON_0002415 denotes tail
T303 13880-13890 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T304 13900-13902 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T305 13914-13916 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T306 13944-13954 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T307 13984-13985 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T308 14103-14110 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T309 14161-14163 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T310 14198-14202 http://purl.obolibrary.org/obo/OGG_0000000002 denotes gene
T311 14213-14215 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T312 14226-14228 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T313 14240-14242 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T314 14265-14273 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T315 14291-14301 http://purl.obolibrary.org/obo/CL_0000234 denotes phagocytes
T316 14363-14365 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T317 14433-14434 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T318 14461-14463 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T319 14483-14489 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T320 14507-14509 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T321 14510-14512 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T322 14531-14535 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T323 14536-14544 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T324 14549-14550 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T325 14627-14632 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T326 14710-14712 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T327 14731-14733 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T328 14811-14813 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T329 14833-14835 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T330 14866-14868 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T331 14886-14887 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T332 14895-14899 http://purl.obolibrary.org/obo/OGG_0000000002 denotes gene
T333 14937-14946 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T334 15075-15081 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T335 15082-15092 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T336 15132-15142 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T337 15148-15150 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T338 15172-15177 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T339 15213-15215 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T340 15273-15275 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T341 15310-15311 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T342 15333-15337 http://purl.obolibrary.org/obo/CLO_0001564 denotes a 20
T343 15333-15337 http://purl.obolibrary.org/obo/CLO_0050194 denotes a 20
T344 15385-15393 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T345 15427-15433 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T346 15458-15460 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T347 15579-15584 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T348 15586-15601 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cells
T349 15611-15620 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T350 15634-15636 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T351 15678-15680 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T352 15747-15757 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T353 15792-15794 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T354 15836-15841 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T355 15842-15849 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T356 15905-15907 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T357 15924-15931 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T358 15932-15935 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T359 16055-16057 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T360 16069-16076 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T361 16085-16087 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T362 16101-16108 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T363 16128-16130 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T364 16137-16139 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T365 16148-16150 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T366 16266-16268 http://purl.obolibrary.org/obo/CLO_0050509 denotes 27
T367 16303-16308 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T368 16330-16332 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T369 16398-16416 http://purl.obolibrary.org/obo/CL_0000988 denotes hematopoietic cell
T370 16492-16494 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T371 16526-16531 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T372 16696-16698 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T373 16737-16751 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cell
T374 16753-16759 http://purl.obolibrary.org/obo/UBERON_0001005 denotes airway
T375 16767-16773 http://purl.obolibrary.org/obo/UBERON_0001630 denotes muscle
T376 16767-16773 http://purl.obolibrary.org/obo/UBERON_0005090 denotes muscle
T377 16767-16773 http://www.ebi.ac.uk/efo/EFO_0000801 denotes muscle
T378 16767-16773 http://www.ebi.ac.uk/efo/EFO_0001949 denotes muscle
T379 16778-16783 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T380 16778-16783 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T381 16784-16795 http://purl.obolibrary.org/obo/UBERON_0001986 denotes endothelium
T382 16824-16829 http://purl.obolibrary.org/obo/UBERON_0002107 denotes liver
T383 16824-16829 http://www.ebi.ac.uk/efo/EFO_0000887 denotes liver
T384 16841-16858 http://purl.obolibrary.org/obo/CL_0000115 denotes endothelial cells
T385 16917-16919 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T386 16954-16956 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T387 16994-17003 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T388 17047-17052 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T389 17250-17251 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T390 17315-17320 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T391 17366-17368 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T392 17527-17529 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T393 17532-17542 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T394 17557-17566 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T395 17613-17623 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T396 17629-17631 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T397 17643-17652 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T398 17746-17752 http://purl.obolibrary.org/obo/CL_0000084 denotes T‐cell
T399 17789-17791 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T400 17812-17814 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T401 17880-17882 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T402 17927-17937 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T403 17938-17944 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T404 17973-17983 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T405 17984-17986 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T406 18072-18076 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T407 18077-18085 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T408 18146-18149 http://purl.obolibrary.org/obo/CLO_0009132 denotes Src
T409 18179-18189 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T410 18206-18208 http://purl.obolibrary.org/obo/CLO_0001302 denotes 34
T411 18229-18231 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T412 18232-18234 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T413 18236-18238 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T414 18249-18251 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T415 18279-18283 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T416 18322-18331 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T417 18350-18360 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T418 18366-18368 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T419 18369-18371 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T420 18386-18388 http://purl.obolibrary.org/obo/CLO_0053733 denotes 11
T421 18486-18490 http://purl.obolibrary.org/obo/UBERON_0002415 denotes tail
T422 18535-18537 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T423 18599-18608 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T424 18609-18625 http://purl.obolibrary.org/obo/GO_0043235 denotes receptor complex
T425 18826-18830 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T426 18831-18841 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T427 18844-18846 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T428 18944-18946 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T429 19006-19008 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T430 19260-19265 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T431 19299-19300 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T432 19348-19350 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T433 19368-19369 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T434 19434-19436 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T435 19474-19476 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T436 19489-19490 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T437 19604-19606 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T438 19682-19684 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T439 19694-19696 http://purl.obolibrary.org/obo/CLO_0001000 denotes 35
T440 19737-19739 http://purl.obolibrary.org/obo/CLO_0001313 denotes 36
T441 19797-19799 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T442 19813-19814 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T443 20028-20030 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T444 20037-20039 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T445 20113-20118 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T446 20284-20288 http://purl.obolibrary.org/obo/PR_000001307 denotes CD44
T447 20380-20382 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T448 20383-20385 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T449 20447-20451 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T450 20452-20462 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T451 20550-20552 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T452 20553-20555 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T453 20622-20628 http://purl.obolibrary.org/obo/SO_0000418 denotes signal
T454 20700-20704 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T455 20808-20810 http://purl.obolibrary.org/obo/CLO_0053794 denotes 41
T456 20834-20835 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T457 20969-20977 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T458 21111-21119 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T459 21253-21256 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T460 21380-21384 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T461 21385-21393 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T462 21420-21428 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T463 21488-21496 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T464 21746-21748 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T465 21752-21757 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T466 21789-21797 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T467 21855-21857 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T468 21957-21959 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T469 22009-22011 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T470 22014-22026 http://purl.obolibrary.org/obo/OBI_0000245 denotes organization
T471 22034-22038 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T472 22039-22047 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T473 22235-22237 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T474 22271-22272 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T475 22438-22440 http://purl.obolibrary.org/obo/CLO_0001302 denotes 34
T476 22453-22455 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T477 22561-22563 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T478 22607-22608 http://purl.obolibrary.org/obo/CLO_0001021 denotes b
T479 22657-22659 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T480 22669-22677 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cells
T481 22695-22705 http://purl.obolibrary.org/obo/CL_0000234 denotes phagocytes
T482 22766-22773 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cell
T483 22918-22920 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T484 22930-22932 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T485 22936-22938 http://purl.obolibrary.org/obo/CLO_0053799 denotes 45
T486 23136-23138 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T487 23166-23168 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T488 23178-23180 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T489 23217-23221 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T490 23342-23346 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T491 23347-23357 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T492 23361-23363 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T493 23369-23371 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T494 23471-23480 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T495 23536-23538 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T496 23573-23582 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T497 23599-23605 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T498 23606-23616 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T499 23757-23759 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T500 23778-23782 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T501 23810-23820 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T502 23836-23838 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T503 23843-23845 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T504 23852-23854 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T505 23861-23863 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T506 23906-23908 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T507 23935-23937 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T508 23997-23999 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T509 24092-24096 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T510 24097-24107 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T511 24135-24140 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T512 24169-24171 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T513 24219-24225 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T514 24226-24236 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T515 24385-24387 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T516 24406-24410 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T517 24494-24500 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T518 24561-24562 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T519 24581-24583 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T520 24597-24599 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T521 24600-24602 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T522 24607-24610 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T523 24703-24713 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T524 24719-24721 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T525 24754-24756 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T526 24785-24795 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T527 24812-24813 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T528 24914-24916 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T529 24921-24922 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T530 24994-24996 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T531 25038-25044 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes humans
T532 25098-25105 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes viruses
T533 25299-25301 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T534 25405-25406 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T535 25491-25494 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T536 25543-25545 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T537 25621-25623 http://purl.obolibrary.org/obo/CLO_0001407 denotes 52
T538 25654-25656 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T539 25776-25782 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T540 25798-25800 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T541 25889-25891 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T542 25956-25958 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T543 25959-25961 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T544 26057-26060 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T545 26118-26123 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T546 26124-26126 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T547 26133-26138 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T548 26208-26210 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T549 26379-26384 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T550 26417-26432 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cells
T551 26446-26447 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T552 26474-26475 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T553 26551-26553 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T554 26566-26572 http://purl.obolibrary.org/obo/UBERON_0003891 denotes stroma
T555 26592-26607 http://purl.obolibrary.org/obo/CL_0000451 denotes dendritic cells
T556 26684-26688 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T557 26735-26742 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T558 26777-26779 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T559 26921-26922 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T560 26985-26989 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T561 27004-27006 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T562 27010-27015 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T563 27016-27018 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T564 27032-27037 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T565 27121-27123 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T566 27181-27185 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T567 27197-27198 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T568 27206-27210 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T569 27250-27252 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T570 27275-27277 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T571 27278-27280 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T572 27316-27317 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T573 27325-27329 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T574 27389-27391 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T575 27432-27436 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T576 27513-27514 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T577 27538-27542 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T578 27598-27604 http://purl.obolibrary.org/obo/CL_0000084 denotes T‐cell
T579 27633-27636 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T580 27633-27636 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T581 27652-27655 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T582 27652-27655 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T583 27723-27729 http://purl.obolibrary.org/obo/CL_0000084 denotes T‐cell
T584 27736-27739 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T585 27736-27739 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T586 27751-27759 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T587 27760-27762 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T588 27777-27782 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T589 27800-27809 http://purl.obolibrary.org/obo/CL_0000576 denotes monocytes
T590 27825-27831 http://purl.obolibrary.org/obo/CL_0000084 denotes T‐cell
T591 27885-27895 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T592 27899-27901 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T593 27915-27920 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T594 27937-27939 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T595 28151-28153 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T596 28211-28212 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T597 28220-28224 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T598 28328-28329 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T599 28337-28341 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T600 28453-28458 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T601 28543-28545 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T602 28553-28555 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T603 28556-28558 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T604 28647-28649 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T605 28829-28833 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T606 28868-28870 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T607 28970-28972 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T608 29008-29010 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T609 29054-29056 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T610 29057-29059 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T611 29305-29307 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T612 29570-29572 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T613 29624-29629 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T614 29737-29746 http://purl.obolibrary.org/obo/CLO_0053695 denotes human IgG
T615 29971-29973 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T616 29974-29976 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T617 30147-30149 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T618 30150-30152 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T619 30170-30172 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T620 30219-30221 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T621 30264-30265 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T622 30358-30360 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T623 30429-30431 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T624 30613-30615 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T625 30657-30659 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T626 30712-30714 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T627 30735-30738 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T628 30767-30771 http://purl.obolibrary.org/obo/CLO_0007437 denotes m –1
T629 30767-30771 http://purl.obolibrary.org/obo/CLO_0007448 denotes m –1
T630 30767-30771 http://purl.obolibrary.org/obo/CLO_0007449 denotes m –1
T631 30767-30771 http://purl.obolibrary.org/obo/CLO_0050175 denotes m –1
T632 30767-30771 http://purl.obolibrary.org/obo/CLO_0052399 denotes m –1
T633 30792-30794 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T634 30813-30814 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T635 30840-30842 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T636 30861-30865 http://purl.obolibrary.org/obo/CLO_0007437 denotes m –1
T637 30861-30865 http://purl.obolibrary.org/obo/CLO_0007448 denotes m –1
T638 30861-30865 http://purl.obolibrary.org/obo/CLO_0007449 denotes m –1
T639 30861-30865 http://purl.obolibrary.org/obo/CLO_0050175 denotes m –1
T640 30861-30865 http://purl.obolibrary.org/obo/CLO_0052399 denotes m –1
T641 30882-30883 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T642 30934-30942 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T643 30977-30979 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T644 31019-31023 http://purl.obolibrary.org/obo/CLO_0007437 denotes m –1
T645 31019-31023 http://purl.obolibrary.org/obo/CLO_0007448 denotes m –1
T646 31019-31023 http://purl.obolibrary.org/obo/CLO_0007449 denotes m –1
T647 31019-31023 http://purl.obolibrary.org/obo/CLO_0050175 denotes m –1
T648 31019-31023 http://purl.obolibrary.org/obo/CLO_0052399 denotes m –1
T649 31119-31121 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T650 31203-31206 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T651 31221-31229 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T652 31264-31266 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T653 31399-31401 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T654 31450-31452 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T655 31499-31501 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T656 31504-31507 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T657 31551-31553 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T658 31557-31560 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T659 31561-31562 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T660 31679-31681 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T661 31720-31725 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T662 31916-31918 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T663 31919-31921 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T664 31956-31961 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T665 31967-31969 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T666 31985-31987 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T667 31992-31994 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T668 32002-32004 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T669 32129-32131 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T670 32440-32442 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T671 32533-32535 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T672 32657-32659 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T673 32738-32740 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T674 32816-32818 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T675 32835-32837 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T676 32872-32874 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T677 32883-32885 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T678 33006-33008 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T679 33532-33533 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T680 33930-33933 http://www.ebi.ac.uk/efo/EFO_0001410 denotes arm
T681 34314-34317 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T682 34459-34462 http://purl.obolibrary.org/obo/CLO_0002408 denotes CH1
T683 34488-34489 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T684 34556-34557 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T685 34601-34604 http://purl.obolibrary.org/obo/CLO_0002408 denotes CH1
T686 34674-34676 http://purl.obolibrary.org/obo/CLO_0054055 denotes 71
T687 34742-34744 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T688 34789-34792 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T689 34913-34915 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T690 35005-35008 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T691 35412-35414 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T692 35611-35613 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T693 35653-35654 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T694 35659-35664 http://www.ebi.ac.uk/efo/EFO_0000965 denotes chest
T695 35781-35783 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T696 36034-36035 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T697 36164-36174 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T698 36245-36247 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T699 36263-36272 http://purl.obolibrary.org/obo/CLO_0053695 denotes human IgG
T700 36302-36303 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T701 36429-36431 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T702 36456-36457 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T703 36487-36493 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T704 36554-36555 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T705 36568-36570 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T706 36610-36611 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T707 36638-36640 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T708 36698-36708 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T709 36714-36716 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T710 36717-36719 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T711 36797-36799 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T712 36925-36927 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T713 37294-37296 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T714 37319-37321 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T715 37371-37373 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T716 37579-37581 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T717 37728-37738 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T718 37800-37802 http://purl.obolibrary.org/obo/CLO_0053799 denotes 45
T719 37953-37957 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T720 37978-37982 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T721 38027-38036 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T722 38083-38085 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T723 38266-38267 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T724 38268-38273 http://purl.obolibrary.org/obo/NCBITaxon_9606 denotes human
T725 38304-38314 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T726 38320-38322 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T727 38360-38368 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T728 38504-38514 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T729 38515-38517 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T730 38526-38528 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T731 38555-38557 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T732 38594-38604 http://purl.obolibrary.org/obo/GO_0005623 denotes cells will
T733 38615-38617 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T734 38637-38639 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T735 38644-38646 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T736 38656-38658 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T737 38681-38682 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T738 38747-38751 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T739 38808-38810 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T740 38830-38839 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T741 38847-38857 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T742 38858-38860 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T743 38929-38933 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T744 38965-38969 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T745 39058-39068 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T746 39070-39071 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T747 39092-39094 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T748 39128-39132 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T749 39138-39139 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T750 39223-39231 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T751 39267-39268 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T752 39381-39382 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T753 39523-39525 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T754 39597-39607 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T755 39658-39668 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T756 39674-39676 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T757 39693-39695 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T758 39766-39771 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T759 39831-39833 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T760 39873-39875 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T761 39878-39879 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T762 40002-40004 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T763 40027-40029 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T764 40045-40047 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T765 40294-40297 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T766 40391-40393 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T767 40414-40416 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T768 40544-40546 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T769 40852-40854 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T770 40902-40907 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T771 40945-40947 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T772 41047-41049 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T773 41093-41096 http://www.ebi.ac.uk/efo/EFO_0000826 denotes ear
T774 41097-41101 http://www.ebi.ac.uk/efo/EFO_0000828 denotes nose
T775 41184-41189 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T776 41269-41271 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T777 41426-41430 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T778 41472-41474 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T779 41493-41515 http://purl.obolibrary.org/obo/UBERON_0001017 denotes Central nervous system
T780 41493-41515 http://www.ebi.ac.uk/efo/EFO_0000302 denotes Central nervous system
T781 41493-41515 http://www.ebi.ac.uk/efo/EFO_0000908 denotes Central nervous system
T782 41743-41745 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T783 41877-41879 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T784 41898-41920 http://purl.obolibrary.org/obo/UBERON_0001017 denotes Central nervous system
T785 41898-41920 http://www.ebi.ac.uk/efo/EFO_0000302 denotes Central nervous system
T786 41898-41920 http://www.ebi.ac.uk/efo/EFO_0000908 denotes Central nervous system
T787 41973-41977 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T788 42019-42021 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T789 42211-42213 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T790 42323-42325 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T791 42511-42513 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T792 42626-42628 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T793 42692-42695 http://purl.obolibrary.org/obo/CLO_0052882 denotes CD3
T794 42692-42695 http://purl.obolibrary.org/obo/CLO_0053434 denotes CD3
T795 42724-42726 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T796 42903-42905 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T797 42928-42930 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T798 43131-43133 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T799 43152-43174 http://purl.obolibrary.org/obo/UBERON_0001017 denotes Central nervous system
T800 43152-43174 http://www.ebi.ac.uk/efo/EFO_0000302 denotes Central nervous system
T801 43152-43174 http://www.ebi.ac.uk/efo/EFO_0000908 denotes Central nervous system
T802 43568-43570 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T803 43659-43660 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T804 43756-43758 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T805 43769-43771 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T806 43850-43852 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T807 43955-43957 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T808 44163-44164 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T809 44217-44219 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T810 44328-44330 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T811 44380-44387 http://purl.obolibrary.org/obo/CL_0000623 denotes NK cell
T812 44456-44458 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T813 44472-44474 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T814 44526-44528 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T815 44965-44967 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T816 45033-45035 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T817 45097-45099 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T818 45143-45153 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T819 45154-45156 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T820 45157-45159 http://purl.obolibrary.org/obo/CLO_0008882 denotes Rs
T821 45170-45174 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T822 45327-45329 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T823 45376-45378 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T824 45420-45422 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T825 45466-45468 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T826 45546-45551 http://purl.obolibrary.org/obo/CLO_0007836 denotes mouse
T827 45598-45600 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T828 45800-45802 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T829 45886-45888 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T830 45921-45922 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T831 45928-45930 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T832 46053-46067 http://purl.obolibrary.org/obo/CL_0001034 denotes cells in vitro
T833 46188-46190 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T834 46262-46263 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T835 46346-46348 http://purl.obolibrary.org/obo/CLO_0001527 denotes 94
T836 46353-46355 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T837 46462-46464 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T838 46556-46558 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T839 46589-46591 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T840 46609-46610 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T841 46715-46717 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T842 46786-46788 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T843 46835-46836 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T844 46929-46932 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T845 46960-46962 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T846 47104-47106 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T847 47274-47276 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T848 47309-47311 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T849 47375-47382 http://purl.obolibrary.org/obo/CLO_0009985 denotes focused
T850 47418-47420 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T851 47494-47504 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T852 47505-47507 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T853 47510-47513 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T854 47565-47566 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T855 47603-47613 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T856 47614-47616 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T857 47751-47753 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T858 47951-47957 http://purl.obolibrary.org/obo/PR_000001852 denotes CTLA‐4
T859 47965-47970 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T860 48022-48029 http://purl.obolibrary.org/obo/SO_0000418 denotes signals
T861 48294-48295 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T862 48417-48423 http://purl.obolibrary.org/obo/PR_000001852 denotes CTLA‐4
T863 48505-48510 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T864 48603-48613 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T865 48624-48626 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T866 48641-48643 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T867 48723-48733 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T868 48850-48852 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T869 48869-48877 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T870 48933-48935 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T871 49270-49272 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T872 49276-49277 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T873 49384-49386 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T874 49426-49428 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T875 49442-49444 http://purl.obolibrary.org/obo/CLO_0001313 denotes 36
T876 49455-49458 http://purl.obolibrary.org/obo/CLO_0054060 denotes 102
T877 49486-49491 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T878 49556-49558 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T879 49581-49591 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T880 49615-49617 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T881 49645-49647 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T882 49693-49695 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T883 49707-49708 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T884 49819-49823 http://purl.obolibrary.org/obo/CLO_0007179 denotes L235
T885 49937-49939 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T886 50032-50033 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T887 50052-50055 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T888 50077-50096 http://purl.obolibrary.org/obo/CHEBI_33708 denotes amino acid residues
T889 50077-50096 http://purl.obolibrary.org/obo/PR_000036907 denotes amino acid residues
T890 50106-50108 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T891 50167-50169 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T892 50299-50304 http://purl.obolibrary.org/obo/CLO_0008407 denotes PD‐L1
T893 50526-50528 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T894 50563-50565 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T895 50620-50630 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T896 50711-50713 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T897 50721-50723 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T898 50771-50774 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T899 50783-50785 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T900 50836-50840 http://purl.obolibrary.org/obo/CLO_0007179 denotes L235
T901 50896-50897 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T902 50976-50977 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T903 50984-50986 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T904 51013-51016 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T905 51264-51265 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T906 51286-51288 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T907 51314-51324 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T908 51334-51336 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T909 51379-51381 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T910 51478-51479 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T911 51510-51512 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T912 51602-51604 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T913 51648-51650 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T914 51665-51667 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T915 51682-51692 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T916 51693-51695 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T917 51818-51820 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T918 51949-51951 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T919 51992-51995 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T920 52038-52047 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T921 52119-52128 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T922 52166-52173 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T923 52183-52189 http://purl.obolibrary.org/obo/CLO_0001658 denotes active
T924 52227-52229 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T925 52255-52259 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T926 52288-52298 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T927 52304-52306 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T928 52312-52313 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T929 52412-52421 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T930 52422-52438 http://purl.obolibrary.org/obo/GO_0043235 denotes receptor complex
T931 52507-52511 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T932 52540-52542 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T933 52585-52594 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T934 52641-52643 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T935 52656-52658 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T936 52827-52834 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T937 52899-52903 http://purl.obolibrary.org/obo/CLO_0053432 denotes CD19
T938 52942-52944 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T939 53037-53039 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T940 53125-53134 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T941 53168-53175 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T942 53280-53281 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T943 53294-53296 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T944 53355-53362 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T945 53510-53512 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T946 53545-53549 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T947 53550-53560 http://purl.obolibrary.org/obo/CLO_0001658 denotes activation
T948 53566-53569 http://purl.obolibrary.org/obo/CLO_0053001 denotes 114
T949 53687-53693 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T950 53754-53760 http://purl.obolibrary.org/obo/CL_0000236 denotes B‐cell
T951 53791-53793 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T952 53825-53827 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T953 53903-53910 http://purl.obolibrary.org/obo/CL_0000236 denotes B cells
T954 54223-54225 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T955 54329-54339 http://purl.obolibrary.org/obo/CLO_0001658 denotes activating
T956 54362-54364 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T957 54449-54451 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T958 54471-54472 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T959 54503-54505 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T960 54674-54676 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T961 54766-54768 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T962 54801-54803 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T963 54898-54900 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T964 54984-54987 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T965 55039-55041 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T966 55088-55090 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T967 55288-55291 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T968 55333-55335 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T969 55356-55357 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T970 55497-55499 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T971 55586-55588 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T972 55645-55650 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T973 55666-55675 http://purl.obolibrary.org/obo/SO_0000418 denotes signaling
T974 55817-55822 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T975 55826-55833 http://purl.obolibrary.org/obo/CL_0000084 denotes T cells
T976 55918-55923 http://purl.obolibrary.org/obo/GO_0005623 denotes cells
T977 55945-55948 http://purl.obolibrary.org/obo/CLO_0001046 denotes 116
T978 55961-55963 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T979 56030-56031 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T980 56042-56044 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T981 56174-56176 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T982 56287-56295 http://purl.obolibrary.org/obo/UBERON_0000158 denotes membrane
T983 56484-56486 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T984 56534-56536 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T985 56654-56662 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T986 56873-56875 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T987 56984-56986 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T988 57028-57030 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T989 57092-57100 http://purl.obolibrary.org/obo/CLO_0001658 denotes activity
T990 57237-57238 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T991 57471-57473 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T992 57588-57590 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T993 57606-57609 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T994 57617-57618 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T995 58401-58403 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T996 58942-58943 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T997 59066-59067 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T998 59159-59161 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T999 59299-59301 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T1000 59398-59411 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
T1001 59483-59485 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T9 505-510 Chemical denotes sales http://purl.obolibrary.org/obo/CHEBI_24866
T10 540-545 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T11 958-966 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T12 1746-1754 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T13 1922-1927 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T14 2571-2579 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T15 2880-2887 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T16 2923-2930 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T17 2940-2947 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T18 3323-3331 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T19 3692-3699 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T20 3705-3712 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T21 3738-3745 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T22 3836-3844 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T23 3898-3905 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T24 4178-4186 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T25 4439-4442 Chemical denotes APC http://purl.obolibrary.org/obo/CHEBI_80551
T26 4589-4597 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T27 4967-4969 Chemical denotes Ag http://purl.obolibrary.org/obo/CHEBI_30512|http://purl.obolibrary.org/obo/CHEBI_9141
T29 4971-4978 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T30 5175-5181 Chemical denotes Action http://purl.obolibrary.org/obo/CHEBI_5133
T31 5414-5416 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T33 5491-5493 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T35 5677-5679 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T37 5684-5686 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T39 6042-6044 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T41 6089-6097 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T42 6549-6557 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T43 6886-6895 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T44 7148-7150 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T46 7315-7320 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T47 7567-7576 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T48 7627-7635 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T49 7906-7914 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T50 8099-8107 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T51 8242-8250 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T52 8538-8546 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T53 8850-8852 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T55 8889-8899 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T56 9348-9351 Chemical denotes Phe http://purl.obolibrary.org/obo/CHEBI_17295|http://purl.obolibrary.org/obo/CHEBI_29997
T58 10190-10195 Chemical denotes Light http://purl.obolibrary.org/obo/CHEBI_30212
T59 10288-10293 Chemical denotes Light http://purl.obolibrary.org/obo/CHEBI_30212
T60 10489-10498 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T61 10667-10675 Chemical denotes molecule http://purl.obolibrary.org/obo/CHEBI_25367
T62 10728-10738 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T64 10749-10751 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T66 10884-10892 Chemical denotes molecule http://purl.obolibrary.org/obo/CHEBI_25367
T67 11429-11437 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T68 11977-11979 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T70 12102-12104 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T72 12234-12236 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T74 12297-12307 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T75 12435-12437 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T77 12441-12451 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T78 12873-12881 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T79 13536-13546 Chemical denotes nucleotide http://purl.obolibrary.org/obo/CHEBI_36976
T80 14651-14659 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T81 15105-15112 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T82 15338-15348 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T83 15338-15343 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T84 15344-15348 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T85 15434-15441 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T86 16194-16202 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T87 17324-17338 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T88 17479-17488 Chemical denotes antiviral http://purl.obolibrary.org/obo/CHEBI_22587
T89 17753-17760 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T90 17792-17794 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T92 17815-17817 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T94 18016-18023 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T95 18106-18114 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T96 18439-18447 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T97 18570-18578 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T98 18663-18671 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T99 18689-18697 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T100 18747-18752 Chemical denotes lipid http://purl.obolibrary.org/obo/CHEBI_18059
T101 18756-18763 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T102 18764-18772 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T103 19011-19019 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T104 19142-19150 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T105 19251-19259 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T106 19392-19400 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T107 19544-19551 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T108 19609-19617 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T109 19843-19850 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T110 19893-19900 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T111 19916-19924 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T112 20104-20112 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T113 20188-20205 Chemical denotes glycosaminoglycan http://purl.obolibrary.org/obo/CHEBI_18085
T114 20261-20274 Chemical denotes glycoproteins http://purl.obolibrary.org/obo/CHEBI_17089
T115 20433-20440 Chemical denotes ligands http://purl.obolibrary.org/obo/CHEBI_52214
T116 20602-20608 Chemical denotes ligand http://purl.obolibrary.org/obo/CHEBI_52214
T117 20691-20699 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T118 20749-20756 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T119 20900-20907 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T120 21005-21013 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T121 21088-21096 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T122 21223-21231 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T123 21451-21458 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T124 21530-21537 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T125 22238-22249 Chemical denotes polypeptide http://purl.obolibrary.org/obo/CHEBI_15841
T126 22361-22372 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232
T127 22421-22429 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T128 22576-22584 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T129 22733-22741 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T130 22933-22935 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T132 23181-23183 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T134 23639-23646 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T135 23839-23841 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T137 23909-23911 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T139 23938-23940 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T141 24108-24117 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T142 24285-24292 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T143 25110-25116 Chemical denotes toxins http://purl.obolibrary.org/obo/CHEBI_27026
T144 25251-25265 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T145 25314-25321 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T146 25825-25832 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T147 26001-26009 Chemical denotes antigens http://purl.obolibrary.org/obo/CHEBI_59132
T148 26019-26026 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T149 26127-26129 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T151 26139-26146 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T152 26249-26256 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T153 26333-26341 Chemical denotes antigens http://purl.obolibrary.org/obo/CHEBI_59132
T154 26360-26367 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T155 26529-26536 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T156 26650-26657 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T157 26724-26731 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T158 26901-26908 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T159 27147-27156 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T160 27677-27685 Chemical denotes mitogens http://purl.obolibrary.org/obo/CHEBI_52290
T161 28738-28745 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T162 28820-28828 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T163 28873-28882 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T164 29308-29310 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T166 29573-29575 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T168 29641-29651 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T169 29812-29822 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T170 29812-29817 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T171 29818-29822 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T172 29936-29943 Chemical denotes ligands http://purl.obolibrary.org/obo/CHEBI_52214
T173 30021-30023 Chemical denotes KD http://purl.obolibrary.org/obo/CHEBI_73601
T174 30533-30546 Chemical denotes phenylalanine http://purl.obolibrary.org/obo/CHEBI_28044|http://purl.obolibrary.org/obo/CHEBI_58095
T176 30547-30553 Chemical denotes valine http://purl.obolibrary.org/obo/CHEBI_27266
T177 30829-30835 Chemical denotes ligand http://purl.obolibrary.org/obo/CHEBI_52214
T178 30843-30845 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T180 31063-31072 Chemical denotes histidine http://purl.obolibrary.org/obo/CHEBI_27570
T181 31293-31301 Chemical denotes arginine http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29016|http://purl.obolibrary.org/obo/CHEBI_32696
T184 31554-31556 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T186 31988-31990 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T188 32301-32303 Chemical denotes FG http://purl.obolibrary.org/obo/CHEBI_73635
T189 32346-32356 Chemical denotes asparagine http://purl.obolibrary.org/obo/CHEBI_22653
T190 32717-32723 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T191 32741-32756 Chemical denotes oligosaccharide http://purl.obolibrary.org/obo/CHEBI_50699
T192 33184-33193 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T193 33392-33394 Chemical denotes Eu http://purl.obolibrary.org/obo/CHEBI_32999
T194 33801-33810 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T195 33856-33867 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T196 33856-33861 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T197 33862-33867 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T198 34199-34208 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T199 34256-34264 Chemical denotes molecule http://purl.obolibrary.org/obo/CHEBI_25367
T200 34324-34333 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T201 34831-34838 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T202 34885-34894 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T203 35274-35281 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T204 35910-35917 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T205 36199-36207 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T206 36478-36486 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T207 36573-36579 Chemical denotes ligand http://purl.obolibrary.org/obo/CHEBI_52214
T208 36612-36618 Chemical denotes ligand http://purl.obolibrary.org/obo/CHEBI_52214
T209 36886-36894 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T210 37038-37046 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T211 38088-38096 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T212 38175-38184 Chemical denotes rituximab http://purl.obolibrary.org/obo/CHEBI_64357
T213 38585-38593 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T214 38640-38642 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T216 38920-38928 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T217 39119-39127 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T218 39528-39536 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T219 40352-40362 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T220 40352-40357 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T221 40358-40362 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T222 40751-40756 Chemical denotes alpha http://purl.obolibrary.org/obo/CHEBI_30216
T223 40757-40761 Chemical denotes beta http://purl.obolibrary.org/obo/CHEBI_10545
T224 40902-40904 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T225 41184-41186 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T226 41335-41342 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T227 42071-42073 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T228 42364-42377 Chemical denotes Pembrolizumab http://purl.obolibrary.org/obo/CHEBI_82976
T229 42379-42381 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T230 42591-42593 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T232 42765-42767 Chemical denotes II http://purl.obolibrary.org/obo/CHEBI_74067
T233 42782-42784 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T234 43011-43013 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T235 43666-43672 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T236 43702-43708 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T237 44344-44352 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T238 44825-44831 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T239 44843-44852 Chemical denotes rituximab http://purl.obolibrary.org/obo/CHEBI_64357
T240 45036-45047 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T241 45036-45041 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T242 45042-45047 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T243 45066-45077 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T244 45066-45071 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T245 45072-45077 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T246 45729-45740 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T247 45729-45734 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T248 45735-45740 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T249 47365-47369 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T3637 47916-47926 Chemical denotes inhibitors http://purl.obolibrary.org/obo/CHEBI_35222
T24725 47965-47967 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T35015 47971-47973 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T38212 48132-48145 Chemical denotes Pembrolizumab http://purl.obolibrary.org/obo/CHEBI_82976
T9178 48185-48187 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T92845 48383-48392 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T60873 48644-48646 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T66616 48685-48693 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T93768 48827-48829 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T92385 48853-48855 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T98482 49486-49488 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T9506 49503-49512 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T68471 49618-49628 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T62086 49618-49623 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T40175 49624-49628 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T80744 49765-49772 Chemical denotes leucine http://purl.obolibrary.org/obo/CHEBI_25017
T54623 49840-49847 Chemical denotes alanine http://purl.obolibrary.org/obo/CHEBI_16449
T5000 50077-50087 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T20266 50077-50082 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T44260 50083-50087 Chemical denotes acid http://purl.obolibrary.org/obo/CHEBI_37527
T10443 50253-50264 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T57589 50253-50258 Chemical denotes amino http://purl.obolibrary.org/obo/CHEBI_46882
T8912 50259-50264 Chemical denotes acids http://purl.obolibrary.org/obo/CHEBI_37527
T75315 50299-50301 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T36188 50328-50338 Chemical denotes interferon http://purl.obolibrary.org/obo/CHEBI_52999
T28 50714-50716 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T85014 50744-50746 Chemical denotes PD http://purl.obolibrary.org/obo/CHEBI_74756
T2607 51108-51118 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T70545 51384-51392 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T34 51571-51579 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T62570 51841-51849 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T36 52230-52232 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T38 53513-53515 Chemical denotes RI http://purl.obolibrary.org/obo/CHEBI_73814|http://purl.obolibrary.org/obo/CHEBI_8753
T40 54176-54184 Chemical denotes arginine http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29016|http://purl.obolibrary.org/obo/CHEBI_32696
T32821 55024-55035 Chemical denotes application http://purl.obolibrary.org/obo/CHEBI_33232
T86511 55098-55106 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T45 55159-55168 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T38447 55785-55794 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367
T65735 55798-55805 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T80667 56219-56226 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T94340 56366-56373 Chemical denotes epitope http://purl.obolibrary.org/obo/CHEBI_53000
T17986 56430-56440 Chemical denotes antagonist http://purl.obolibrary.org/obo/CHEBI_48706
T59829 58779-58787 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T54895 58880-58888 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T75881 59363-59371 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224

LitCovid-sample-MedDRA

Id Subject Object Predicate Lexical cue meddra_id
T5 905-919 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T6 921-923 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T7 2799-2822 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes neutralizing antibodies http://purl.bioontology.org/ontology/MEDDRA/10058063
T8 5002-5004 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T9 5006-5020 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T10 9691-9693 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T11 9695-9709 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T12 10902-10904 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T13 10906-10920 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T14 13443-13445 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T15 16448-16462 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes investigations http://purl.bioontology.org/ontology/MEDDRA/10062026
T16 18747-18752 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes lipid http://purl.bioontology.org/ontology/MEDDRA/10024587
T17 31739-31744 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes X‐ray http://purl.bioontology.org/ontology/MEDDRA/10048064
T18 43196-43198 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes Ig http://purl.bioontology.org/ontology/MEDDRA/10021496
T19 43200-43214 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes immunoglobulin http://purl.bioontology.org/ontology/MEDDRA/10021496
T98304 58490-58503 http://purl.bioontology.org/ontology/MEDDRA/10022891 denotes investigation http://purl.bioontology.org/ontology/MEDDRA/10062026

LitCovid-sample-PD-IDO

Id Subject Object Predicate Lexical cue
T13 265-273 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T14 338-346 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T15 842-849 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T16 883-888 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T17 892-901 http://purl.obolibrary.org/obo/IDO_0000586 denotes infection
T18 967-971 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T19 1432-1436 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T20 1693-1702 http://purl.obolibrary.org/obo/IDO_0000528 denotes pathogens
T21 1825-1829 http://purl.obolibrary.org/obo/IDO_0000531 denotes host
T22 2078-2086 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T23 2281-2285 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T24 2308-2312 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T25 2375-2379 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T26 2784-2789 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T27 2865-2870 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T28 2899-2904 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T29 3270-3274 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T30 3332-3341 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T31 3362-3366 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T32 3386-3390 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T33 3450-3454 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T34 3757-3762 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T35 3789-3793 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T36 3893-3897 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T37 3970-3975 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T38 4332-4336 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T39 4456-4472 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T40 4598-4602 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T41 4675-4679 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T42 4724-4728 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T43 4806-4811 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T44 4939-4943 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T45 4987-4991 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T46 5232-5236 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T47 5285-5289 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T48 5319-5323 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T49 5386-5390 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T50 5525-5529 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T51 5554-5558 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T52 5612-5616 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T53 5950-5954 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T54 6010-6014 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T55 6053-6057 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T56 6538-6542 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T57 6558-6567 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T58 6632-6641 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T59 6886-6895 http://purl.obolibrary.org/obo/IDO_0000559 denotes antiviral
T60 7040-7049 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T61 7074-7084 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T62 7490-7494 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T63 7739-7747 http://purl.obolibrary.org/obo/GO_0085030 denotes mutually
T64 7851-7855 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T65 7895-7899 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T66 7915-7927 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions in
T67 8203-8212 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T68 8251-8260 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T69 8547-8555 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T70 8829-8833 http://purl.obolibrary.org/obo/CL_0000000 denotes Cell
T71 8952-8956 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T72 8978-8983 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T73 9079-9089 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T74 9168-9173 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T75 9205-9210 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T76 9283-9288 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T77 9550-9555 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T78 9560-9565 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T79 9686-9690 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T80 9714-9718 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T81 9735-9739 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T82 11285-11290 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T83 11328-11337 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T84 11438-11447 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T85 11596-11600 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T86 11638-11648 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T87 11868-11873 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T88 12178-12187 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocyte
T89 12361-12366 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T90 12391-12396 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T91 12406-12411 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T92 12604-12620 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T93 12813-12823 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T94 12882-12891 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T95 13192-13200 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T96 13210-13220 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T97 13346-13355 http://purl.obolibrary.org/obo/OBI_0100026 denotes organisms
T98 13684-13689 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T99 14203-14211 http://purl.obolibrary.org/obo/IDO_0000607 denotes products
T100 14268-14273 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T101 14449-14457 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T102 14531-14535 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T103 14660-14668 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T104 15077-15081 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T105 15153-15161 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T106 15172-15177 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T107 15429-15433 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T108 15579-15584 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T109 15596-15601 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T110 15844-15849 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T111 15926-15931 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T112 16071-16076 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T113 16103-16108 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T114 16203-16211 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T115 16303-16308 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T116 16412-16416 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T117 16417-16425 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T118 16526-16531 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T119 16588-16596 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T120 16747-16751 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T121 16853-16858 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T122 17004-17012 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T123 17047-17052 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T124 17315-17320 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes virus
T125 17479-17488 http://purl.obolibrary.org/obo/IDO_0000559 denotes antiviral
T126 17576-17585 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T127 17748-17752 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T128 18072-18076 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T129 18279-18283 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T130 18395-18403 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T131 18826-18830 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T132 19114-19121 http://purl.obolibrary.org/obo/BFO_0000019 denotes quality
T133 19260-19265 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T134 20113-20118 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T135 20226-20234 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T136 20447-20451 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T137 20700-20704 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T138 20705-20713 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T139 20795-20803 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T140 21380-21384 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T141 21752-21757 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T142 21860-21868 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T143 22014-22026 http://purl.obolibrary.org/obo/OBI_0100026 denotes organization
T144 22034-22038 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T145 22278-22286 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T146 22480-22490 http://purl.obolibrary.org/obo/IDO_0000607 denotes productive
T147 22585-22594 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T148 22672-22677 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T149 22742-22751 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T150 22769-22773 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T151 23217-23221 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T152 23342-23346 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T153 23510-23518 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T154 23601-23605 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T155 23778-23782 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T156 23794-23804 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T157 24022-24030 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T158 24092-24096 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T159 24135-24140 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T160 24221-24225 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T161 24406-24410 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T162 24796-24804 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T163 25098-25105 http://purl.obolibrary.org/obo/NCBITaxon_10239 denotes viruses
T164 25110-25116 http://purl.obolibrary.org/obo/IDO_0000549 denotes toxins
T165 25358-25373 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T166 26379-26384 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T167 26427-26432 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T168 26602-26607 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T169 26684-26688 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T170 26737-26742 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T171 26951-26967 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T172 26985-26989 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T173 27010-27015 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T174 27032-27037 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T175 27181-27185 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T176 27206-27210 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T177 27325-27329 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T178 27432-27436 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T179 27538-27542 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T180 27600-27604 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T181 27725-27729 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T182 27777-27782 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T183 27827-27831 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T184 27915-27920 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T185 28220-28224 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T186 28337-28341 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T187 28453-28458 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T188 28829-28833 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T189 29624-29629 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T190 29701-29706 http://purl.obolibrary.org/obo/BFO_0000029 denotes sites
T191 29883-29893 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T192 30599-30603 http://purl.obolibrary.org/obo/BFO_0000029 denotes site
T193 30923-30933 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T194 31108-31112 http://purl.obolibrary.org/obo/BFO_0000029 denotes site
T195 31210-31220 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T196 31797-31805 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T197 35145-35159 http://purl.obolibrary.org/obo/IDO_0000467 denotes susceptibility
T198 35245-35255 http://purl.obolibrary.org/obo/IDO_0000607 denotes production
T199 36208-36217 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T200 36895-36903 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T201 37047-37056 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T202 37384-37393 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T203 37857-37864 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T204 37953-37957 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T205 37978-37982 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T206 38097-38106 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T207 38594-38604 http://purl.obolibrary.org/obo/CL_0000000 denotes cells will
T208 38747-38751 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T209 38929-38933 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T210 38965-38969 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T211 39128-39132 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T212 39766-39771 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T213 41109-41118 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T214 41391-41400 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T215 41642-41651 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T216 42112-42130 http://purl.obolibrary.org/obo/IDO_0000436 denotes Infectious disease
T217 42123-42130 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T218 42420-42429 http://purl.obolibrary.org/obo/IDO_0000586 denotes Infection
T219 42546-42555 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T220 42748-42757 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T221 44383-44387 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T222 44512-44521 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T223 45536-45542 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T224 46053-46058 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T225 46728-46737 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T226 48505-48510 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T227 48694-48703 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T228 51393-51402 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T229 51580-51589 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T230 51888-51896 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T231 51937-51945 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T232 52168-52173 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T233 52255-52259 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T234 52260-52267 http://www.geneontology.org/formats/oboInOwl#Subset denotes subsets
T235 52332-52342 http://purl.obolibrary.org/obo/CL_0000738 denotes leukocytes
T236 52507-52511 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T237 52862-52869 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T238 53170-53175 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T239 53261-53270 http://purl.obolibrary.org/obo/OGMS_0000045 denotes disorders
T240 53545-53549 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T241 53689-53693 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T242 53698-53708 http://purl.obolibrary.org/obo/IDO_0000607 denotes production
T243 53756-53760 http://purl.obolibrary.org/obo/CL_0000000 denotes cell
T244 53884-53894 http://purl.obolibrary.org/obo/IDO_0000607 denotes production
T245 53905-53910 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T246 54215-54219 http://purl.obolibrary.org/obo/BFO_0000029 denotes site
T247 55645-55650 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T248 55817-55822 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T249 55828-55833 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T250 55918-55923 http://purl.obolibrary.org/obo/CL_0000000 denotes cells
T251 56572-56580 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T252 56751-56757 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T253 57275-57283 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T254 57476-57484 http://purl.obolibrary.org/obo/BFO_0000034 denotes function
T255 57692-57702 http://purl.obolibrary.org/obo/BFO_0000034 denotes functional
T256 58507-58525 http://purl.obolibrary.org/obo/IDO_0000436 denotes infectious disease
T257 58518-58525 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T258 58633-58651 http://purl.obolibrary.org/obo/IDO_0000436 denotes infectious disease
T259 58644-58651 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T260 58721-58730 http://purl.obolibrary.org/obo/IDO_0000586 denotes infection
T261 58788-58797 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions
T262 58889-58901 http://purl.obolibrary.org/obo/BFO_0000034 denotes functions in
T263 58921-58929 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases
T264 58986-59004 http://purl.obolibrary.org/obo/IDO_0000436 denotes infectious disease
T265 58997-59004 http://purl.obolibrary.org/obo/OGMS_0000031 denotes disease
T266 59607-59615 http://purl.obolibrary.org/obo/OGMS_0000031 denotes diseases

LitCovid-sample-Enju

Id Subject Object Predicate Lexical cue
T20 54995-54997 RP denotes up
T21 54998-55001 JJ denotes new
T22 55002-55015 NNS denotes possibilities
T23 55016-55019 IN denotes for
T24 55020-55023 DT denotes the
T25 55024-55035 NN denotes application
T26 55036-55038 IN denotes of
T27 55039-55056 VBG denotes FcγRIIb‐enhancing
T28 55057-55073 NN denotes modifications.17
T29 55074-55084 NNS denotes Antibodies
T30 55085-55087 CC denotes or
T31 55088-55090 NN denotes Fc
T32 55091-55097 NN denotes fusion
T33 55098-55106 NNS denotes proteins
T34 55106-55107 -COMMA- denotes ,
T35 55108-55113 WP-DOLLAR- denotes whose
T36 55114-55121 JJ denotes primary
T37 55122-55125 NN denotes MOA
T38 55126-55128 VBZ denotes is
T39 55129-55132 DT denotes the
T40 55133-55147 NN denotes neutralization
T41 55148-55150 IN denotes of
T42 55151-55158 JJ denotes soluble
T43 55159-55168 NNS denotes molecules
T44 55169-55173 JJ denotes such
T45 55174-55176 IN denotes as
T46 55177-55180 NN denotes IgE
T47 55181-55183 CC denotes or
T48 55184-55193 NNS denotes cytokines
T49 55193-55194 -COMMA- denotes ,
T50 55195-55198 VBP denotes are
T51 55199-55211 RB denotes particularly
T52 55212-55222 JJ denotes attractive
T53 55223-55233 NNS denotes candidates
T54 55234-55237 IN denotes for
T55 55238-55242 DT denotes this
T56 55243-55251 NN denotes approach
T57 55253-55269 NN denotes Proof‐of‐concept
T58 55270-55273 IN denotes for
T59 55274-55278 DT denotes this
T60 55279-55287 NN denotes strategy
T61 55288-55291 VBZ denotes has
T62 55292-55296 VBN denotes been
T63 55297-55309 VBN denotes demonstrated
T64 55310-55312 IN denotes in
T65 55313-55325 JJ denotes experimental
T66 55326-55335 NN denotes models.48
T67 55336-55342 RB denotes Indeed
T68 55342-55343 -COMMA- denotes ,
T69 55344-55348 DT denotes this
T70 55349-55352 MD denotes may
T71 55353-55355 VB denotes be
T72 55356-55357 DT denotes a
T73 55358-55369 JJ denotes significant
T74 55370-55379 NN denotes component
T75 55380-55382 IN denotes of
T76 55383-55386 DT denotes the
T77 55387-55392 JJ denotes rapid
T78 55393-55406 NN denotes disappearance
T79 55407-55409 IN denotes of
T80 55410-55413 NN denotes IgE
T81 55414-55418 IN denotes from
T82 55419-55422 DT denotes the
T83 55423-55434 NN denotes circulation
T84 55435-55437 IN denotes of
T85 55438-55446 NNS denotes patients
T86 55447-55454 VBN denotes treated
T87 55455-55459 IN denotes with
T88 55460-55463 DT denotes the
T89 55464-55472 NN denotes anti‐IgE
T90 55473-55481 NN denotes XmAb7195
T91 55482-55492 VBG denotes containing
T92 55493-55496 DT denotes the
T93 55497-55504 NN denotes FcγRIIb
T94 55505-55514 VBG denotes enhancing
T95 55515-55521 NNP denotes “SELF”
T96 55522-55535 NNS denotes modifications
T97 55535-55536 -COMMA- denotes ,
T98 55537-55539 IN denotes as
T99 55540-55549 VBN denotes described
T100 55550-55560 RB denotes previously
T101 55563-55569 JJ denotes Immune
T102 55570-55577 NN denotes agonism
T103 55578-55585 IN denotes through
T104 55586-55590 NN denotes FcγR
T105 55591-55602 NN denotes scaffolding
T106 55603-55612 JJ denotes Agonistic
T107 55613-55617 NNS denotes mAbs
T108 55618-55624 VBP denotes induce
T109 55625-55634 NNS denotes responses
T110 55635-55637 IN denotes in
T111 55638-55644 NN denotes target
T112 55645-55650 NNS denotes cells
T113 55651-55653 IN denotes by
T114 55654-55665 VBG denotes stimulating
T115 55666-55675 NN denotes signaling
T116 55676-55678 IN denotes of
T117 55679-55684 PRP-DOLLAR- denotes their
T118 55685-55694 JJ denotes molecular
T119 55695-55701 NN denotes target
T120 55703-55712 RB denotes Typically
T121 55712-55713 -COMMA- denotes ,
T122 55714-55718 DT denotes this
T123 55719-55721 VBZ denotes is
T124 55722-55724 TO denotes to
T125 55725-55731 CC denotes either
T126 55732-55739 VB denotes enhance
T127 55740-55749 NN denotes antitumor
T128 55750-55758 NN denotes immunity
T129 55759-55761 IN denotes by
T130 55762-55770 VBG denotes engaging
T131 55771-55784 JJ denotes costimulatory
T132 55785-55794 NNS denotes molecules
T133 55795-55797 IN denotes on
T134 55798-55816 JJ denotes antigen‐presenting
T135 55817-55822 NNS denotes cells
T136 55823-55825 CC denotes or
T137 55826-55827 NN denotes T
T138 55828-55833 NNS denotes cells
T139 55834-55835 -LRB- denotes (
T140 55835-55839 FW denotes i.e.
T141 55840-55844 NN denotes CD40
T142 55844-55845 -COMMA- denotes ,
T143 55846-55851 NN denotes 4‐1BB
T144 55851-55852 -COMMA- denotes ,
T145 55853-55857 NN denotes OX40
T146 55857-55858 -RRB- denotes )
T147 55859-55861 CC denotes or
T148 55862-55869 VB denotes promote
T149 55870-55879 NN denotes apoptosis
T150 55880-55882 IN denotes by
T151 55883-55891 VBG denotes engaging
T152 55892-55897 NN denotes death
T153 55898-55907 NNS denotes receptors
T154 55908-55910 IN denotes on
T155 55911-55917 NN denotes cancer
T156 55918-55923 NNS denotes cells
T157 55924-55925 -LRB- denotes (
T158 55925-55929 FW denotes i.e.
T159 55930-55933 NN denotes DR4
T160 55933-55934 -COMMA- denotes ,
T161 55935-55938 NN denotes DR5
T162 55938-55939 -COMMA- denotes ,
T163 55940-55943 NN denotes Fas
T164 55943-55944 -RRB- denotes )
T165 55949-55952 DT denotes The
T166 55953-55957 NN denotes role
T167 55958-55960 IN denotes of
T168 55961-55965 NN denotes FcγR
T169 55966-55968 IN denotes in
T170 55969-55972 DT denotes the
T171 55973-55979 NN denotes action
T172 55980-55982 IN denotes of
T173 55983-55988 DT denotes these
T174 55989-55994 NNS denotes types
T175 55995-55997 IN denotes of
T176 55998-56002 NNS denotes mAbs
T177 56003-56010 VBZ denotes appears
T178 56011-56013 TO denotes to
T179 56014-56016 VB denotes be
T180 56017-56026 RB denotes primarily
T181 56027-56029 IN denotes as
T182 56030-56031 DT denotes a
T183 56032-56040 NN denotes scaffold
T184 56042-56049 NN denotes FcγRIIb
T185 56050-56052 VBZ denotes is
T186 56053-56058 RB denotes often
T187 56059-56062 DT denotes the
T188 56063-56074 JJ denotes predominate
T189 56075-56083 NN denotes receptor
T190 56084-56092 VBN denotes involved
T191 56093-56096 CC denotes and
T192 56097-56100 DT denotes the
T193 56101-56107 NN denotes extent
T194 56108-56110 IN denotes of
T195 56111-56114 PRP-DOLLAR- denotes its
T196 56115-56126 NN denotes involvement
T197 56127-56129 VBZ denotes is
T198 56130-56137 JJ denotes complex
T199 56139-56141 IN denotes In
T200 56142-56145 DT denotes the
T201 56146-56150 NN denotes case
T202 56151-56153 IN denotes of
T203 56154-56158 NN denotes CD40
T204 56158-56159 -COMMA- denotes ,
T205 56160-56163 DT denotes the
T206 56164-56170 NN denotes degree
T207 56171-56173 IN denotes of
T208 56174-56181 NN denotes FcγRIIb
T209 56182-56193 NN denotes scaffolding
T210 56194-56201 NN denotes potency
T211 56202-56204 VBZ denotes is
T212 56205-56211 VBN denotes linked
T213 56212-56214 TO denotes to
T214 56215-56218 DT denotes the
T215 56219-56226 NN denotes epitope
T216 56227-56235 NN denotes location
T217 56236-56238 IN denotes of
T218 56239-56242 DT denotes the
T219 56243-56252 VBG denotes targeting
T220 56253-56256 NN denotes mAb
T221 56257-56261 IN denotes with
T222 56262-56269 JJR denotes greater
T223 56270-56277 NN denotes potency
T224 56278-56282 VBN denotes seen
T225 56283-56286 IN denotes for
T226 56287-56295 NN denotes membrane
T227 56296-56304 JJ denotes proximal
T228 56305-56316 NN denotes epitopes.43
T229 56316-56317 -COMMA- denotes ,
T230 56318-56321 CD denotes 117
T231 56322-56324 PRP denotes It
T232 56325-56327 VBZ denotes is
T233 56328-56332 RB denotes also
T234 56333-56343 JJ denotes noteworthy
T235 56344-56348 IN denotes that
T236 56349-56358 VBG denotes depending
T237 56359-56361 IN denotes on
T238 56362-56365 DT denotes the
T239 56366-56373 NN denotes epitope
T240 56374-56382 NN denotes location
T241 56382-56383 -COMMA- denotes ,
T242 56384-56387 DT denotes the
T243 56388-56399 NN denotes scaffolding
T244 56400-56402 IN denotes of
T245 56403-56412 NN denotes anti‐CD40
T246 56413-56417 NNS denotes mAbs
T247 56418-56421 MD denotes may
T248 56422-56429 VB denotes convert
T249 56430-56440 NN denotes antagonist
T250 56441-56445 NNS denotes mAbs
T251 56446-56448 TO denotes to
T252 56449-56458 JJ denotes agonistic
T253 56460-56471 NN denotes Engineering
T254 56472-56474 IN denotes of
T255 56475-56478 DT denotes the
T256 56479-56483 NN denotes IgG1
T257 56484-56486 NN denotes Fc
T258 56487-56493 NN denotes region
T259 56494-56497 IN denotes for
T260 56498-56506 VBN denotes enhanced
T261 56507-56513 CC denotes and/or
T262 56514-56522 JJ denotes specific
T263 56523-56530 NN denotes binding
T264 56531-56533 TO denotes to
T265 56534-56541 NN denotes FcγRIIb
T266 56542-56545 MD denotes can
T267 56546-56553 RB denotes greatly
T268 56554-56561 VB denotes improve
T269 56562-56571 JJ denotes agonistic
T270 56572-56583 NN denotes function.72
T271 56583-56584 -COMMA- denotes ,
T272 56585-56588 CD denotes 118
T273 56588-56589 -COMMA- denotes ,
T274 56590-56593 CD denotes 119
T275 56593-56594 -COMMA- denotes ,
T276 56595-56598 CD denotes 120
T277 56599-56603 JJ denotes Such
T278 56604-56613 NNS denotes mutations
T279 56614-56621 VBD denotes induced
T280 56622-56635 RB denotes significantly
T281 56636-56643 JJR denotes greater
T282 56644-56653 JJ denotes agonistic
T283 56654-56662 NN denotes activity
T284 56663-56665 IN denotes in
T285 56666-56668 DT denotes an
T286 56669-56677 NN denotes anti‐DR5
T287 56678-56683 NN denotes model
T288 56684-56691 IN denotes through
T289 56692-56701 VBN denotes increased
T290 56702-56711 NN denotes induction
T291 56712-56714 IN denotes of
T292 56715-56724 JJ denotes apoptotic
T293 56725-56730 NN denotes death
T294 56731-56734 CC denotes and
T295 56735-56744 VBD denotes decreased
T296 56745-56750 NN denotes tumor
T297 56751-56757 NN denotes growth
T298 56758-56766 VBN denotes compared
T299 56767-56771 IN denotes with
T300 56772-56782 JJ denotes unmodified
T301 56783-56791 NN denotes IgG1.121
T302 56792-56795 DT denotes The
T303 56796-56802 NNP denotes “SELF”
T304 56803-56816 NNS denotes modifications
T305 56817-56821 WDT denotes that
T306 56822-56834 RB denotes dramatically
T307 56835-56838 CC denotes and
T308 56839-56850 RB denotes selectively
T309 56851-56859 VBP denotes increase
T310 56860-56868 NN denotes affinity
T311 56869-56872 IN denotes for
T312 56873-56880 NN denotes FcγRIIb
T313 56881-56885 VBP denotes have
T314 56886-56890 RB denotes also
T315 56891-56895 VBN denotes been
T316 56896-56900 VBN denotes used
T317 56901-56903 TO denotes to
T318 56904-56911 VB denotes enhance
T319 56912-56918 JJ denotes immune
T320 56919-56926 NN denotes agonism
T321 56927-56929 IN denotes in
T322 56930-56932 DT denotes an
T323 56933-56942 NN denotes anti‐OX40
T324 56943-56952 NN denotes model.122
T325 56953-56956 DT denotes The
T326 56957-56973 NN denotes incorporation of
T327 56974-56977 DT denotes the
T328 56978-56979 -DQS- denotes "
T329 56979-56982 NN denotes V12
T330 56982-56983 '' denotes "
T331 56984-56986 NN denotes Fc
T332 56987-56996 NNS denotes mutations
T333 56997-57001 IN denotes into
T334 57002-57006 NN denotes IgG1
T335 57007-57019 RB denotes specifically
T336 57020-57027 VBP denotes enhance
T337 57028-57035 NN denotes FcγRIIb
T338 57036-57047 NN denotes interaction
T339 57048-57056 RB denotes 200‐fold
T340 57056-57057 -COMMA- denotes ,
T341 57058-57068 VBG denotes conferring
T342 57069-57072 DT denotes the
T343 57073-57081 VBN denotes enhanced
T344 57082-57091 JJ denotes agonistic
T345 57092-57100 NN denotes activity
T346 57101-57103 IN denotes of
T347 57104-57106 DT denotes an
T348 57107-57117 NN denotes anti‐CD137
T349 57118-57126 NN denotes antibody
T350 57127-57130 CC denotes and
T351 57131-57133 DT denotes an
T352 57134-57143 NN denotes anti‐OX40
T353 57144-57151 NN denotes mAb.115
T354 57151-57152 -COMMA- denotes ,
T355 57153-57156 CD denotes 122
T356 57158-57164 NNP denotes Future
T357 57165-57176 NNP denotes Engineering
T358 57177-57187 NNPS denotes Strategies
T359 57188-57198 JJ denotes Monoclonal
T360 57199-57209 NNS denotes antibodies
T361 57210-57213 VBP denotes are
T362 57214-57220 JJ denotes potent
T363 57221-57233 NNS denotes therapeutics
T364 57234-57236 IN denotes in
T365 57237-57238 DT denotes a
T366 57239-57245 NN denotes number
T367 57246-57248 IN denotes of
T368 57249-57256 JJ denotes chronic
T369 57257-57259 CC denotes or
T370 57260-57264 RB denotes once
T371 57265-57274 JJ denotes incurable
T372 57275-57283 NNS denotes diseases
T373 57285-57292 RB denotes However
T374 57292-57293 -COMMA- denotes ,
T375 57294-57299 EX denotes there
T376 57300-57302 VBZ denotes is
T377 57303-57308 RB denotes still
T378 57309-57318 JJ denotes extensive
T379 57319-57324 JJ denotes unmet
T380 57325-57333 JJ denotes clinical
T381 57334-57338 NN denotes need
T382 57339-57341 RB denotes as
T383 57342-57346 RB denotes well
T384 57347-57349 IN denotes as
T385 57350-57362 JJ denotes considerable
T386 57363-57367 NN denotes room
T387 57368-57371 IN denotes for
T388 57372-57383 NN denotes improvement
T389 57384-57386 IN denotes in
T390 57387-57391 JJ denotes many
T391 57392-57400 VBG denotes existing
T392 57401-57413 NNS denotes therapeutics
T393 57415-57422 JJ denotes Further
T394 57423-57436 NN denotes understanding
T395 57437-57439 IN denotes of
T396 57440-57443 WRB denotes how
T397 57444-57452 NN denotes antibody
T398 57453-57462 NN denotes structure
T399 57463-57470 VBZ denotes affects
T400 57471-57475 NN denotes FcγR
T401 57476-57484 NN denotes function
T402 57485-57487 VBZ denotes is
T403 57488-57497 JJ denotes essential
T404 57498-57501 IN denotes for
T405 57502-57508 JJ denotes future
T406 57509-57520 NN denotes development
T407 57521-57523 IN denotes of
T408 57524-57528 RBR denotes more
T409 57529-57535 JJ denotes potent
T410 57536-57539 CC denotes and
T411 57540-57549 JJ denotes effective
T412 57550-57554 NNS denotes mAbs
T413 57556-57563 RB denotes Already
T414 57563-57564 -COMMA- denotes ,
T415 57565-57576 NN denotes engineering
T416 57577-57579 IN denotes of
T417 57580-57583 DT denotes the
T418 57584-57587 NN denotes IgG
T419 57588-57590 NN denotes Fc
T420 57591-57594 CC denotes and
T421 57595-57598 PRP-DOLLAR- denotes its
T422 57599-57605 NN denotes glycan
T423 57606-57609 VBZ denotes has
T424 57610-57616 VBN denotes proved
T425 57617-57618 DT denotes a
T426 57619-57625 JJ denotes potent
T427 57626-57629 CC denotes and
T428 57630-57639 JJ denotes effective
T429 57640-57648 NN denotes approach
T430 57649-57652 IN denotes for
T431 57653-57663 VBG denotes increasing
T432 57664-57667 DT denotes the
T433 57668-57676 JJ denotes clinical
T434 57677-57690 NN denotes effectiveness
T435 57690-57691 -COMMA- denotes ,
T436 57692-57702 JJ denotes functional
T437 57703-57714 NN denotes specificity
T438 57715-57718 CC denotes and
T439 57719-57725 NN denotes safety
T440 57726-57728 IN denotes of
T441 57729-57740 JJ denotes therapeutic
T442 57741-57745 NNS denotes mAbs
T443 57746-57749 CC denotes and
T444 57750-57752 VBZ denotes is
T445 57753-57755 DT denotes an
T446 57756-57764 VBG denotes emerging
T447 57765-57772 NN denotes pathway
T448 57773-57775 TO denotes to
T449 57776-57779 DT denotes the
T450 57780-57791 NN denotes development
T451 57792-57794 IN denotes of
T452 57795-57798 DT denotes the
T453 57799-57809 NN denotes “next‐gen”
T454 57810-57822 NNS denotes therapeutics
T455 57824-57830 JJ denotes Future
T456 57831-57841 NNS denotes directions
T457 57842-57844 IN denotes in
T458 57845-57848 DT denotes the
T459 57849-57860 NN denotes development
T460 57861-57864 CC denotes and
T461 57865-57868 NN denotes use
T462 57869-57871 IN denotes of
T463 57872-57883 JJ denotes therapeutic
T464 57884-57894 NNS denotes antibodies
T465 57895-57901 MD denotes should
T466 57902-57914 RB denotes increasingly
T467 57915-57920 VB denotes mimic
T468 57921-57927 JJ denotes normal
T469 57928-57938 JJ denotes protective
T470 57939-57947 NN denotes antibody
T471 57948-57957 NNS denotes responses
T472 57957-57958 -COMMA- denotes ,
T473 57959-57964 WDT denotes which
T474 57965-57968 VBP denotes are
T475 57969-57979 JJ denotes polyclonal
T476 57980-57983 CC denotes and
T477 57984-57992 VBN denotes elicited
T478 57993-57995 IN denotes in
T479 57996-57999 DT denotes the
T480 58000-58007 NN denotes context
T481 58008-58010 IN denotes of
T482 58011-58017 JJ denotes innate
T483 58018-58026 NN denotes receptor
T484 58027-58037 NN denotes engagement
T485 58038-58043 WDT denotes which
T486 58044-58052 VBZ denotes includes
T487 58053-58056 DT denotes the
T488 58057-58060 NNS denotes FcR
T489 58061-58063 RB denotes as
T490 58064-58068 RB denotes well
T491 58069-58071 IN denotes as
T492 58072-58077 JJ denotes other
T493 58078-58088 RB denotes powerfully
T494 58089-58099 JJ denotes responsive
T495 58100-58107 NNS denotes systems
T496 58108-58117 VBG denotes including
T497 58118-58121 DT denotes the
T498 58122-58131 JJ denotes Toll‐like
T499 58132-58141 NNS denotes receptors
T500 58142-58145 CC denotes and
T501 58146-58156 NN denotes complement
T502 58157-58166 NNS denotes receptors
T503 58168-58179 RB denotes Furthermore
T504 58179-58180 -COMMA- denotes ,
T505 58181-58184 DT denotes the
T506 58185-58190 JJ denotes mixed
T507 58191-58199 NN denotes subclass
T508 58200-58206 NN denotes nature
T509 58207-58209 IN denotes of
T510 58210-58215 DT denotes these
T511 58216-58222 JJ denotes normal
T512 58223-58231 NN denotes antibody
T513 58232-58241 NNS denotes responses
T514 58242-58250 VBZ denotes suggests
T515 58251-58255 IN denotes that
T516 58256-58269 NNS denotes circumstances
T517 58270-58273 MD denotes may
T518 58274-58279 VB denotes arise
T519 58280-58282 IN denotes in
T520 58283-58294 JJ denotes therapeutic
T521 58295-58305 NNS denotes strategies
T522 58306-58311 WRB denotes where
T523 58312-58317 EX denotes there
T524 58318-58320 VBZ denotes is
T525 58321-58326 NN denotes value
T526 58327-58329 IN denotes in
T527 58330-58336 VBG denotes having
T528 58337-58347 RB denotes distinctly
T529 58348-58356 VBN denotes modified
T530 58357-58360 NNS denotes Fcs
T531 58361-58364 IN denotes for
T532 58365-58368 DT denotes the
T533 58369-58376 JJ denotes nuanced
T534 58377-58387 NN denotes engagement
T535 58388-58390 IN denotes of
T536 58391-58400 JJ denotes different
T537 58401-58405 NN denotes FcγR
T538 58406-58412 NN denotes family
T539 58413-58420 NNS denotes members
T540 58422-58432 NNS denotes Treatments
T541 58433-58443 VBG denotes comprising
T542 58444-58452 JJ denotes multiple
T543 58453-58457 NNS denotes mAbs
T544 58458-58461 CC denotes and
T545 58462-58468 JJ denotes immune
T546 58469-58479 NNS denotes stimulants
T547 58480-58483 VBP denotes are
T548 58484-58489 IN denotes under
T549 58490-58503 NN denotes investigation
T550 58504-58506 IN denotes in
T551 58507-58517 JJ denotes infectious
T552 58518-58525 NN denotes disease
T0 54880-54883 DT denotes The
T1 54884-54894 NN denotes expression
T2 54895-54897 IN denotes of
T3 54898-54905 NN denotes FcγRIIb
T4 54906-54908 IN denotes on
T5 54909-54913 NNP denotes LSEC
T6 54914-54917 CC denotes and
T7 54918-54921 PRP-DOLLAR- denotes its
T8 54922-54928 NN denotes action
T9 54929-54931 IN denotes in
T10 54932-54935 DT denotes the
T11 54936-54946 NN denotes “sweeping”
T12 54947-54949 CC denotes or
T13 54950-54957 NN denotes removal
T14 54958-54960 IN denotes of
T15 54961-54966 JJ denotes small
T16 54967-54973 JJ denotes immune
T17 54974-54983 NNS denotes complexes
T18 54984-54987 VBZ denotes has
T19 54988-54994 VBN denotes opened
T553 58526-58529 IN denotes for
T554 58530-58544 NN denotes neutralization
T555 58545-58553 NN denotes coverage
T556 58554-58556 IN denotes of
T557 58557-58564 JJ denotes variant
T558 58565-58572 NNS denotes strains
T559 58574-58580 RB denotes Indeed
T560 58580-58581 -COMMA- denotes ,
T561 58582-58586 PDT denotes such
T562 58587-58589 DT denotes an
T563 58590-58598 NN denotes approach
T564 58599-58602 MD denotes may
T565 58603-58605 VB denotes be
T566 58606-58610 RBS denotes most
T567 58611-58620 JJ denotes effective
T568 58621-58623 IN denotes in
T569 58624-58632 VBG denotes emerging
T570 58633-58643 JJ denotes infectious
T571 58644-58651 NN denotes disease
T572 58652-58656 JJ denotes such
T573 58657-58659 IN denotes as
T574 58660-58666 JJ denotes severe
T575 58667-58672 JJ denotes acute
T576 58673-58684 JJ denotes respiratory
T577 58685-58693 NN denotes syndrome
T578 58694-58705 NN denotes coronavirus
T579 58706-58707 CD denotes 2
T580 58708-58709 -LRB- denotes (
T581 58709-58719 NN denotes SARS‐CoV‐2
T582 58719-58720 -RRB- denotes )
T583 58721-58730 NN denotes infection
T584 58732-58735 DT denotes The
T585 58736-58739 NN denotes use
T586 58740-58742 IN denotes of
T587 58743-58751 JJ denotes multiple
T588 58752-58756 NNS denotes mAbs
T589 58757-58765 VBN denotes tailored
T590 58766-58769 IN denotes for
T591 58770-58778 JJ denotes distinct
T592 58779-58787 NN denotes effector
T593 58788-58797 NNS denotes functions
T594 58798-58801 CC denotes and
T595 58802-58811 VBG denotes targeting
T596 58812-58821 JJ denotes different
T597 58822-58830 NNS denotes epitopes
T598 58831-58835 MD denotes will
T599 58836-58844 VB denotes maximize
T600 58845-58848 DT denotes the
T601 58849-58860 NN denotes opportunity
T602 58861-58864 IN denotes for
T603 58865-58876 NN denotes cocktailing
T604 58877-58879 IN denotes of
T605 58880-58888 NN denotes effector
T606 58889-58898 NNS denotes functions
T607 58899-58901 IN denotes in
T608 58902-58911 JJ denotes different
T609 58912-58917 NNS denotes types
T610 58918-58920 IN denotes of
T611 58921-58929 NNS denotes diseases
T612 58931-58937 RB denotes Indeed
T613 58937-58938 -COMMA- denotes ,
T614 58939-58941 IN denotes in
T615 58942-58943 DT denotes a
T616 58944-58949 JJ denotes small
T617 58950-58953 CC denotes but
T618 58954-58966 JJ denotes contemporary
T619 58967-58974 NN denotes example
T620 58975-58982 IN denotes outside
T621 58983-58985 IN denotes of
T622 58986-58996 JJ denotes infectious
T623 58997-59004 NN denotes disease
T624 59004-59005 -COMMA- denotes ,
T625 59006-59009 DT denotes the
T626 59010-59022 NNP denotes FDA‐approved
T627 59023-59034 NN denotes combination
T628 59035-59037 IN denotes in
T629 59038-59052 NN denotes adenocarcinoma
T630 59053-59060 NN denotes therapy
T631 59061-59065 VBZ denotes uses
T632 59066-59067 DT denotes a
T633 59068-59076 NN denotes cocktail
T634 59077-59079 IN denotes of
T635 59080-59083 CD denotes two
T636 59084-59088 NNS denotes mAbs
T637 59088-59089 -COMMA- denotes ,
T638 59090-59100 NN denotes pertuzumab
T639 59101-59104 CC denotes and
T640 59105-59116 NN denotes trastuzumab
T641 59116-59117 -COMMA- denotes ,
T642 59118-59125 IN denotes against
T643 59126-59134 NN denotes Her2.123
T644 59135-59141 RB denotes Rather
T645 59142-59146 IN denotes than
T646 59147-59150 CD denotes one
T647 59151-59155 NN denotes type
T648 59156-59158 IN denotes of
T649 59159-59161 NN denotes Fc
T650 59162-59164 TO denotes to
T651 59165-59172 VB denotes conquer
T652 59173-59176 DT denotes all
T653 59176-59177 -COMMA- denotes ,
T654 59178-59181 DT denotes the
T655 59182-59190 JJ denotes combined
T656 59191-59194 NN denotes use
T657 59195-59197 IN denotes of
T658 59198-59211 RB denotes appropriately
T659 59212-59220 VBN denotes selected
T660 59221-59225 NNS denotes mAbs
T661 59226-59231 WP-DOLLAR- denotes whose
T662 59232-59242 JJ denotes individual
T663 59243-59253 NNS denotes components
T664 59254-59257 VBP denotes are
T665 59258-59266 VBN denotes enhanced
T666 59267-59270 IN denotes for
T667 59271-59274 DT denotes the
T668 59275-59285 NN denotes engagement
T669 59286-59288 IN denotes of
T670 59289-59298 JJ denotes different
T671 59299-59303 NN denotes FcγR
T672 59304-59311 NNS denotes members
T673 59312-59315 MD denotes may
T674 59316-59323 VB denotes utilize
T675 59324-59332 JJ denotes multiple
T676 59333-59343 NNS denotes components
T677 59344-59346 IN denotes of
T678 59347-59350 DT denotes the
T679 59351-59359 NN denotes spectrum
T680 59360-59362 IN denotes of
T681 59363-59371 NN denotes effector
T682 59372-59381 NNS denotes responses
T683 59382-59384 IN denotes on
T684 59385-59390 NN denotes offer
T685 59391-59393 IN denotes by
T686 59394-59397 DT denotes the
T687 59398-59404 JJ denotes immune
T688 59405-59411 NN denotes system
T689 59413-59417 JJ denotes Such
T690 59418-59428 NN denotes “next‐gen”
T691 59429-59438 NNS denotes biologics
T692 59439-59443 MD denotes will
T693 59444-59449 VB denotes begin
T694 59450-59452 TO denotes to
T695 59453-59460 VB denotes realize
T696 59461-59464 DT denotes the
T697 59465-59469 JJ denotes full
T698 59470-59479 NN denotes potential
T699 59480-59482 IN denotes of
T700 59483-59496 JJ denotes FcγR‐mediated
T701 59497-59505 NN denotes antibody
T702 59506-59512 JJ denotes immune
T703 59513-59525 NNS denotes therapeutics
T704 59526-59529 CC denotes and
T705 59530-59535 VB denotes offer
T706 59536-59552 JJ denotes transformational
T707 59553-59559 NN denotes change
T708 59560-59563 IN denotes for
T709 59564-59567 DT denotes the
T710 59568-59577 NN denotes treatment
T711 59578-59580 IN denotes of
T712 59581-59592 JJ denotes intractable
T713 59593-59596 CC denotes and
T714 59597-59606 JJ denotes incurable
T715 59607-59615 NNS denotes diseases
T716 59618-59626 NN denotes Conflict
T717 59627-59629 IN denotes of
T718 59630-59638 NN denotes Interest
T719 59639-59643 NN denotes None
R703 T688 T685 arg2Of system,by
R704 T688 T686 arg1Of system,the
R705 T688 T687 arg1Of system,immune
R706 T691 T689 arg1Of biologics,Such
R707 T691 T690 arg1Of biologics,“next‐gen”
R708 T691 T692 arg1Of biologics,will
R709 T693 T692 arg2Of begin,will
R0 T1 T0 arg1Of expression,The
R1 T1 T2 arg1Of expression,of
R2 T3 T2 arg2Of FcγRIIb,of
R3 T1 T4 arg1Of expression,on
R4 T5 T4 arg2Of LSEC,on
R5 T1 T6 arg1Of expression,and
R6 T8 T6 arg2Of action,and
R7 T8 T7 arg1Of action,its
R8 T8 T9 arg1Of action,in
R9 T12 T9 arg2Of or,in
R10 T12 T10 arg1Of or,the
R11 T11 T12 arg1Of “sweeping”,or
R12 T13 T12 arg2Of removal,or
R13 T12 T14 arg1Of or,of
R14 T17 T14 arg2Of complexes,of
R15 T17 T15 arg1Of complexes,small
R16 T17 T16 arg1Of complexes,immune
R17 T6 T18 arg1Of and,has
R18 T19 T18 arg2Of opened,has
R19 T6 T19 arg1Of and,opened
R20 T22 T19 arg2Of possibilities,opened
R21 T19 T20 arg1Of opened,up
R22 T22 T21 arg1Of possibilities,new
R23 T22 T23 arg1Of possibilities,for
R24 T25 T23 arg2Of application,for
R25 T25 T24 arg1Of application,the
R26 T25 T26 arg1Of application,of
R27 T30 T26 arg2Of or,of
R28 T29 T27 arg1Of Antibodies,FcγRIIb‐enhancing
R29 T29 T28 arg1Of Antibodies,modifications.17
R30 T29 T30 arg1Of Antibodies,or
R31 T33 T30 arg2Of proteins,or
R32 T33 T31 arg1Of proteins,Fc
R33 T33 T32 arg1Of proteins,fusion
R34 T22 T34 arg1Of possibilities,","
R35 T37 T35 arg1Of MOA,whose
R36 T22 T35 arg2Of possibilities,whose
R37 T37 T36 arg1Of MOA,primary
R38 T37 T38 arg1Of MOA,is
R39 T40 T38 arg2Of neutralization,is
R40 T40 T39 arg1Of neutralization,the
R41 T40 T41 arg1Of neutralization,of
R42 T43 T41 arg2Of molecules,of
R43 T43 T42 arg1Of molecules,soluble
R44 T45 T44 arg1Of as,such
R45 T43 T45 arg1Of molecules,as
R46 T47 T45 arg2Of or,as
R47 T46 T47 arg1Of IgE,or
R48 T48 T47 arg2Of cytokines,or
R49 T38 T49 arg1Of is,","
R50 T50 T49 arg2Of are,","
R51 T37 T50 arg1Of MOA,are
R52 T53 T50 arg2Of candidates,are
R53 T52 T51 arg1Of attractive,particularly
R54 T53 T52 arg1Of candidates,attractive
R55 T53 T54 arg1Of candidates,for
R56 T56 T54 arg2Of approach,for
R57 T56 T55 arg1Of approach,this
R58 T57 T58 arg1Of Proof‐of‐concept,for
R59 T60 T58 arg2Of strategy,for
R60 T60 T59 arg1Of strategy,this
R61 T57 T61 arg1Of Proof‐of‐concept,has
R62 T63 T61 arg2Of demonstrated,has
R63 T57 T62 arg1Of Proof‐of‐concept,been
R64 T63 T62 arg2Of demonstrated,been
R65 T57 T63 arg2Of Proof‐of‐concept,demonstrated
R66 T63 T64 arg1Of demonstrated,in
R67 T66 T64 arg2Of models.48,in
R68 T66 T65 arg1Of models.48,experimental
R69 T66 T67 arg1Of models.48,Indeed
R70 T63 T68 arg1Of demonstrated,","
R71 T71 T68 arg2Of be,","
R72 T69 T70 arg1Of this,may
R73 T71 T70 arg2Of be,may
R74 T69 T71 arg1Of this,be
R75 T74 T71 arg2Of component,be
R76 T74 T72 arg1Of component,a
R77 T74 T73 arg1Of component,significant
R78 T74 T75 arg1Of component,of
R79 T78 T75 arg2Of disappearance,of
R80 T78 T76 arg1Of disappearance,the
R81 T78 T77 arg1Of disappearance,rapid
R82 T78 T79 arg1Of disappearance,of
R83 T80 T79 arg2Of IgE,of
R84 T80 T81 arg1Of IgE,from
R85 T83 T81 arg2Of circulation,from
R86 T83 T82 arg1Of circulation,the
R87 T83 T84 arg1Of circulation,of
R88 T85 T84 arg2Of patients,of
R89 T85 T86 arg2Of patients,treated
R90 T86 T87 arg1Of treated,with
R91 T90 T87 arg2Of XmAb7195,with
R92 T90 T88 arg1Of XmAb7195,the
R93 T90 T89 arg1Of XmAb7195,anti‐IgE
R94 T90 T91 arg1Of XmAb7195,containing
R95 T93 T91 arg2Of FcγRIIb,containing
R96 T93 T92 arg1Of FcγRIIb,the
R97 T93 T94 arg1Of FcγRIIb,enhancing
R98 T96 T94 arg2Of modifications,enhancing
R99 T96 T95 arg1Of modifications,“SELF”
R100 T94 T97 arg1Of enhancing,","
R101 T94 T98 arg1Of enhancing,as
R102 T99 T98 arg2Of described,as
R103 T99 T100 arg1Of described,previously
R104 T102 T101 arg1Of agonism,Immune
R105 T102 T103 arg1Of agonism,through
R106 T105 T103 arg2Of scaffolding,through
R107 T105 T104 arg1Of scaffolding,FcγR
R108 T107 T106 arg1Of mAbs,Agonistic
R109 T107 T108 arg1Of mAbs,induce
R110 T109 T108 arg2Of responses,induce
R111 T109 T110 arg1Of responses,in
R112 T112 T110 arg2Of cells,in
R113 T112 T111 arg1Of cells,target
R114 T108 T113 arg1Of induce,by
R115 T114 T113 arg2Of stimulating,by
R116 T107 T114 arg1Of mAbs,stimulating
R117 T115 T114 arg2Of signaling,stimulating
R118 T115 T116 arg1Of signaling,of
R119 T119 T116 arg2Of target,of
R120 T119 T117 arg1Of target,their
R121 T119 T118 arg1Of target,molecular
R122 T123 T120 arg1Of is,Typically
R123 T123 T121 arg1Of is,","
R124 T122 T123 arg1Of this,is
R125 T147 T123 arg2Of or,is
R126 T147 T124 arg1Of or,to
R127 T147 T125 arg1Of or,either
R128 T128 T126 arg2Of immunity,enhance
R129 T128 T127 arg1Of immunity,antitumor
R130 T126 T129 arg1Of enhance,by
R131 T130 T129 arg2Of engaging,by
R132 T132 T130 arg2Of molecules,engaging
R133 T132 T131 arg1Of molecules,costimulatory
R134 T132 T133 arg1Of molecules,on
R135 T136 T133 arg2Of or,on
R136 T135 T134 arg1Of cells,antigen‐presenting
R137 T135 T136 arg1Of cells,or
R138 T138 T136 arg2Of cells,or
R139 T138 T137 arg1Of cells,T
R140 T136 T139 arg1Of or,(
R141 T142 T139 arg2Of ",",(
R142 T146 T139 arg3Of ),(
R143 T142 T140 arg1Of ",",i.e.
R144 T141 T142 arg1Of CD40,","
R145 T143 T142 arg2Of 4‐1BB,","
R146 T142 T144 arg1Of ",",","
R147 T145 T144 arg2Of OX40,","
R148 T126 T147 arg1Of enhance,or
R149 T148 T147 arg2Of promote,or
R150 T149 T148 arg2Of apoptosis,promote
R151 T148 T150 arg1Of promote,by
R152 T151 T150 arg2Of engaging,by
R153 T153 T151 arg2Of receptors,engaging
R154 T153 T152 arg1Of receptors,death
R155 T153 T154 arg1Of receptors,on
R156 T156 T154 arg2Of cells,on
R157 T156 T155 arg1Of cells,cancer
R158 T156 T157 arg1Of cells,(
R159 T159 T157 arg2Of DR4,(
R160 T164 T157 arg3Of ),(
R161 T159 T158 arg1Of DR4,i.e.
R162 T159 T160 arg1Of DR4,","
R163 T161 T160 arg2Of DR5,","
R164 T159 T162 arg1Of DR4,","
R165 T163 T162 arg2Of Fas,","
R166 T166 T165 arg1Of role,The
R167 T166 T167 arg1Of role,of
R168 T168 T167 arg2Of FcγR,of
R169 T166 T169 arg1Of role,in
R170 T171 T169 arg2Of action,in
R171 T171 T170 arg1Of action,the
R172 T171 T172 arg1Of action,of
R173 T174 T172 arg2Of types,of
R174 T174 T173 arg1Of types,these
R175 T174 T175 arg1Of types,of
R176 T176 T175 arg2Of mAbs,of
R177 T166 T177 arg1Of role,appears
R178 T179 T177 arg2Of be,appears
R179 T179 T178 arg1Of be,to
R180 T166 T179 arg1Of role,be
R181 T181 T179 arg2Of as,be
R182 T181 T180 arg1Of as,primarily
R183 T166 T181 arg1Of role,as
R184 T183 T181 arg2Of scaffold,as
R185 T183 T182 arg1Of scaffold,a
R186 T184 T185 arg1Of FcγRIIb,is
R187 T189 T185 arg2Of receptor,is
R188 T185 T186 arg1Of is,often
R189 T189 T187 arg1Of receptor,the
R190 T189 T188 arg1Of receptor,predominate
R191 T189 T190 arg2Of receptor,involved
R192 T185 T191 arg1Of is,and
R193 T197 T191 arg2Of is,and
R194 T193 T192 arg1Of extent,the
R195 T193 T194 arg1Of extent,of
R196 T196 T194 arg2Of involvement,of
R197 T196 T195 arg1Of involvement,its
R198 T193 T197 arg1Of extent,is
R199 T198 T197 arg2Of complex,is
R200 T193 T198 arg1Of extent,complex
R201 T212 T199 arg1Of linked,In
R202 T201 T199 arg2Of case,In
R203 T201 T200 arg1Of case,the
R204 T201 T202 arg1Of case,of
R205 T203 T202 arg2Of CD40,of
R206 T212 T204 arg1Of linked,","
R207 T206 T205 arg1Of degree,the
R208 T206 T207 arg1Of degree,of
R209 T210 T207 arg2Of potency,of
R210 T210 T208 arg1Of potency,FcγRIIb
R211 T210 T209 arg1Of potency,scaffolding
R212 T206 T211 arg1Of degree,is
R213 T212 T211 arg2Of linked,is
R214 T232 T211 modOf is,is
R215 T206 T212 arg2Of degree,linked
R216 T212 T213 arg1Of linked,to
R217 T216 T213 arg2Of location,to
R218 T216 T214 arg1Of location,the
R219 T216 T215 arg1Of location,epitope
R220 T216 T217 arg1Of location,of
R221 T219 T217 arg2Of targeting,of
R222 T219 T218 arg1Of targeting,the
R223 T218 T219 arg1Of the,targeting
R224 T220 T219 arg2Of mAb,targeting
R225 T219 T221 arg1Of targeting,with
R226 T223 T221 arg2Of potency,with
R227 T223 T222 arg1Of potency,greater
R228 T223 T224 arg2Of potency,seen
R229 T224 T225 arg1Of seen,for
R230 T228 T225 arg2Of epitopes.43,for
R231 T228 T226 arg1Of epitopes.43,membrane
R232 T228 T227 arg1Of epitopes.43,proximal
R233 T216 T229 arg1Of location,","
R234 T230 T229 arg2Of 117,","
R235 T248 T231 arg1Of convert,It
R236 T248 T232 arg1Of convert,is
R237 T234 T232 arg2Of noteworthy,is
R238 T232 T233 arg1Of is,also
R239 T248 T234 arg1Of convert,noteworthy
R240 T248 T235 arg1Of convert,that
R241 T248 T236 arg1Of convert,depending
R242 T237 T236 arg2Of on,depending
R243 T240 T237 arg2Of location,on
R244 T240 T238 arg1Of location,the
R245 T240 T239 arg1Of location,epitope
R246 T248 T241 arg1Of convert,","
R247 T243 T242 arg1Of scaffolding,the
R248 T243 T244 arg1Of scaffolding,of
R249 T246 T244 arg2Of mAbs,of
R250 T246 T245 arg1Of mAbs,anti‐CD40
R251 T243 T247 arg1Of scaffolding,may
R252 T248 T247 arg2Of convert,may
R253 T243 T248 arg1Of scaffolding,convert
R254 T250 T248 arg2Of mAbs,convert
R255 T250 T249 arg1Of mAbs,antagonist
R256 T248 T251 arg1Of convert,to
R257 T252 T251 arg2Of agonistic,to
R258 T253 T254 arg1Of Engineering,of
R259 T258 T254 arg2Of region,of
R260 T258 T255 arg1Of region,the
R261 T258 T256 arg1Of region,IgG1
R262 T258 T257 arg1Of region,Fc
R263 T258 T259 arg1Of region,for
R264 T263 T259 arg2Of binding,for
R265 T263 T260 arg1Of binding,enhanced
R266 T260 T261 arg1Of enhanced,and/or
R267 T262 T261 arg2Of specific,and/or
R268 T263 T262 arg1Of binding,specific
R269 T263 T264 arg1Of binding,to
R270 T265 T264 arg2Of FcγRIIb,to
R271 T253 T266 arg1Of Engineering,can
R272 T268 T266 arg2Of improve,can
R273 T268 T267 arg1Of improve,greatly
R274 T253 T268 arg1Of Engineering,improve
R275 T270 T268 arg2Of function.72,improve
R276 T270 T269 arg1Of function.72,agonistic
R277 T270 T271 arg1Of function.72,","
R278 T272 T271 arg2Of 118,","
R279 T270 T273 arg1Of function.72,","
R280 T274 T273 arg2Of 119,","
R281 T268 T275 arg1Of improve,","
R282 T294 T275 arg2Of and,","
R283 T278 T276 arg1Of mutations,120
R284 T278 T277 arg1Of mutations,Such
R285 T278 T279 arg1Of mutations,induced
R286 T283 T279 arg2Of activity,induced
R287 T281 T280 arg1Of greater,significantly
R288 T283 T281 arg1Of activity,greater
R289 T283 T282 arg1Of activity,agonistic
R290 T279 T284 arg1Of induced,in
R291 T287 T284 arg2Of model,in
R292 T287 T285 arg1Of model,an
R293 T287 T286 arg1Of model,anti‐DR5
R294 T279 T288 arg1Of induced,through
R295 T290 T288 arg2Of induction,through
R296 T290 T289 arg2Of induction,increased
R297 T290 T291 arg1Of induction,of
R298 T293 T291 arg2Of death,of
R299 T293 T292 arg1Of death,apoptotic
R300 T279 T294 arg1Of induced,and
R301 T295 T294 arg2Of decreased,and
R302 T278 T295 arg1Of mutations,decreased
R303 T297 T295 arg2Of growth,decreased
R304 T297 T296 arg1Of growth,tumor
R305 T295 T298 arg1Of decreased,compared
R306 T299 T298 arg2Of with,compared
R307 T301 T299 arg2Of IgG1.121,with
R308 T301 T300 arg1Of IgG1.121,unmodified
R309 T304 T302 arg1Of modifications,The
R310 T304 T303 arg1Of modifications,“SELF”
R311 T304 T305 arg1Of modifications,that
R312 T309 T306 arg1Of increase,dramatically
R313 T306 T307 arg1Of dramatically,and
R314 T308 T307 arg2Of selectively,and
R315 T309 T308 arg1Of increase,selectively
R316 T304 T309 arg1Of modifications,increase
R317 T310 T309 arg2Of affinity,increase
R318 T310 T311 arg1Of affinity,for
R319 T312 T311 arg2Of FcγRIIb,for
R320 T304 T313 arg1Of modifications,have
R321 T316 T313 arg2Of used,have
R322 T316 T314 arg1Of used,also
R323 T304 T315 arg1Of modifications,been
R324 T316 T315 arg2Of used,been
R325 T304 T316 arg2Of modifications,used
R326 T318 T316 arg3Of enhance,used
R327 T318 T317 arg1Of enhance,to
R328 T304 T318 arg1Of modifications,enhance
R329 T301 T318 arg2Of IgG1.121,enhance
R330 T320 T319 arg1Of agonism,immune
R331 T299 T320 arg1Of with,agonism
R332 T320 T321 arg1Of agonism,in
R333 T324 T321 arg2Of model.122,in
R334 T324 T322 arg1Of model.122,an
R335 T324 T323 arg1Of model.122,anti‐OX40
R336 T326 T325 arg1Of incorporation of,The
R337 T336 T326 arg1Of enhance,incorporation of
R338 T332 T327 arg1Of mutations,the
R339 T332 T328 arg1Of mutations,""""
R340 T332 T329 arg1Of mutations,V12
R341 T332 T330 arg1Of mutations,""""
R342 T332 T331 arg1Of mutations,Fc
R343 T332 T333 arg1Of mutations,into
R344 T334 T333 arg2Of IgG1,into
R345 T336 T335 arg1Of enhance,specifically
R346 T332 T336 arg1Of mutations,enhance
R347 T338 T336 arg2Of interaction,enhance
R348 T338 T337 arg1Of interaction,FcγRIIb
R349 T336 T339 arg1Of enhance,200‐fold
R350 T336 T340 arg1Of enhance,","
R351 T332 T341 arg1Of mutations,conferring
R352 T350 T341 arg2Of and,conferring
R353 T336 T341 modOf enhance,conferring
R354 T345 T342 arg1Of activity,the
R355 T345 T343 arg2Of activity,enhanced
R356 T345 T344 arg1Of activity,agonistic
R357 T345 T346 arg1Of activity,of
R358 T349 T346 arg2Of antibody,of
R359 T349 T347 arg1Of antibody,an
R360 T349 T348 arg1Of antibody,anti‐CD137
R361 T345 T350 arg1Of activity,and
R362 T353 T350 arg2Of mAb.115,and
R363 T353 T351 arg1Of mAb.115,an
R364 T353 T352 arg1Of mAb.115,anti‐OX40
R365 T353 T354 arg1Of mAb.115,","
R366 T355 T354 arg2Of 122,","
R367 T358 T356 arg1Of Strategies,Future
R368 T358 T357 arg1Of Strategies,Engineering
R369 T360 T359 arg1Of antibodies,Monoclonal
R370 T360 T361 arg1Of antibodies,are
R371 T363 T361 arg2Of therapeutics,are
R372 T363 T362 arg1Of therapeutics,potent
R373 T361 T364 arg1Of are,in
R374 T366 T364 arg2Of number,in
R375 T366 T365 arg1Of number,a
R376 T366 T367 arg1Of number,of
R377 T372 T367 arg2Of diseases,of
R378 T372 T368 arg1Of diseases,chronic
R379 T368 T369 arg1Of chronic,or
R380 T371 T369 arg2Of incurable,or
R381 T371 T370 arg1Of incurable,once
R382 T372 T371 arg1Of diseases,incurable
R383 T376 T373 arg1Of is,However
R384 T376 T374 arg1Of is,","
R385 T375 T376 arg1Of there,is
R386 T384 T376 arg2Of as,is
R387 T376 T377 arg1Of is,still
R388 T380 T378 arg1Of clinical,extensive
R389 T380 T379 arg1Of clinical,unmet
R390 T381 T380 arg1Of need,clinical
R391 T384 T382 arg1Of as,as
R392 T384 T383 arg1Of as,well
R393 T381 T384 arg1Of need,as
R394 T386 T384 arg2Of room,as
R395 T386 T385 arg1Of room,considerable
R396 T386 T387 arg1Of room,for
R397 T388 T387 arg2Of improvement,for
R398 T388 T389 arg1Of improvement,in
R399 T392 T389 arg2Of therapeutics,in
R400 T392 T390 arg1Of therapeutics,many
R401 T392 T391 arg1Of therapeutics,existing
R402 T394 T393 arg1Of understanding,Further
R403 T394 T395 arg1Of understanding,of
R404 T396 T395 arg2Of how,of
R405 T399 T396 arg1Of affects,how
R406 T398 T397 arg1Of structure,antibody
R407 T398 T399 arg1Of structure,affects
R408 T401 T399 arg2Of function,affects
R409 T401 T400 arg1Of function,FcγR
R410 T394 T402 arg1Of understanding,is
R411 T403 T402 arg2Of essential,is
R412 T394 T403 arg1Of understanding,essential
R413 T403 T404 arg1Of essential,for
R414 T406 T404 arg2Of development,for
R415 T406 T405 arg1Of development,future
R416 T406 T407 arg1Of development,of
R417 T412 T407 arg2Of mAbs,of
R418 T412 T408 arg1Of mAbs,more
R419 T412 T409 arg1Of mAbs,potent
R420 T409 T410 arg1Of potent,and
R421 T411 T410 arg2Of effective,and
R422 T412 T411 arg1Of mAbs,effective
R423 T443 T413 arg1Of and,Already
R424 T443 T414 arg1Of and,","
R425 T415 T416 arg1Of engineering,of
R426 T420 T416 arg2Of and,of
R427 T419 T417 arg1Of Fc,the
R428 T419 T418 arg1Of Fc,IgG
R429 T419 T420 arg1Of Fc,and
R430 T422 T420 arg2Of glycan,and
R431 T422 T421 arg1Of glycan,its
R432 T415 T423 arg1Of engineering,has
R433 T424 T423 arg2Of proved,has
R434 T415 T424 arg1Of engineering,proved
R435 T435 T424 arg2Of ",",proved
R436 T429 T425 arg1Of approach,a
R437 T429 T426 arg1Of approach,potent
R438 T426 T427 arg1Of potent,and
R439 T428 T427 arg2Of effective,and
R440 T429 T428 arg1Of approach,effective
R441 T429 T430 arg1Of approach,for
R442 T431 T430 arg2Of increasing,for
R443 T434 T431 arg2Of effectiveness,increasing
R444 T434 T432 arg1Of effectiveness,the
R445 T434 T433 arg1Of effectiveness,clinical
R446 T429 T435 arg1Of approach,","
R447 T438 T435 arg2Of and,","
R448 T438 T436 arg1Of and,functional
R449 T437 T438 arg1Of specificity,and
R450 T439 T438 arg2Of safety,and
R451 T438 T440 arg1Of and,of
R452 T442 T440 arg2Of mAbs,of
R453 T442 T441 arg1Of mAbs,therapeutic
R454 T424 T443 arg1Of proved,and
R455 T444 T443 arg2Of is,and
R456 T415 T444 arg1Of engineering,is
R457 T447 T444 arg2Of pathway,is
R458 T447 T445 arg1Of pathway,an
R459 T447 T446 arg1Of pathway,emerging
R460 T447 T448 arg1Of pathway,to
R461 T450 T448 arg2Of development,to
R462 T450 T449 arg1Of development,the
R463 T450 T451 arg1Of development,of
R464 T454 T451 arg2Of therapeutics,of
R465 T454 T452 arg1Of therapeutics,the
R466 T454 T453 arg1Of therapeutics,“next‐gen”
R467 T456 T455 arg1Of directions,Future
R468 T456 T457 arg1Of directions,in
R469 T460 T457 arg2Of and,in
R470 T460 T458 arg1Of and,the
R471 T459 T460 arg1Of development,and
R472 T461 T460 arg2Of use,and
R473 T460 T462 arg1Of and,of
R474 T464 T462 arg2Of antibodies,of
R475 T464 T463 arg1Of antibodies,therapeutic
R476 T456 T465 arg1Of directions,should
R477 T467 T465 arg2Of mimic,should
R478 T467 T466 arg1Of mimic,increasingly
R479 T456 T467 arg1Of directions,mimic
R480 T471 T467 arg2Of responses,mimic
R481 T471 T468 arg1Of responses,normal
R482 T471 T469 arg1Of responses,protective
R483 T471 T470 arg1Of responses,antibody
R484 T471 T472 arg1Of responses,","
R485 T471 T473 arg1Of responses,which
R486 T471 T474 arg1Of responses,are
R487 T476 T474 arg2Of and,are
R488 T471 T475 arg1Of responses,polyclonal
R489 T475 T476 arg1Of polyclonal,and
R490 T477 T476 arg2Of elicited,and
R491 T471 T477 arg2Of responses,elicited
R492 T477 T478 arg1Of elicited,in
R493 T480 T478 arg2Of context,in
R494 T480 T479 arg1Of context,the
R495 T480 T481 arg1Of context,of
R496 T484 T481 arg2Of engagement,of
R497 T484 T482 arg1Of engagement,innate
R498 T484 T483 arg1Of engagement,receptor
R499 T480 T485 arg1Of context,which
R500 T480 T486 arg1Of context,includes
R501 T491 T486 arg2Of as,includes
R502 T491 T487 arg1Of as,the
R503 T491 T489 arg1Of as,as
R504 T491 T490 arg1Of as,well
R505 T488 T491 arg1Of FcR,as
R506 T495 T491 arg2Of systems,as
R507 T495 T492 arg1Of systems,other
R508 T495 T493 arg1Of systems,powerfully
R509 T495 T494 arg1Of systems,responsive
R510 T495 T496 arg1Of systems,including
R511 T500 T496 arg2Of and,including
R512 T500 T497 arg1Of and,the
R513 T499 T498 arg1Of receptors,Toll‐like
R514 T499 T500 arg1Of receptors,and
R515 T502 T500 arg2Of receptors,and
R516 T502 T501 arg1Of receptors,complement
R517 T514 T503 arg1Of suggests,Furthermore
R518 T514 T504 arg1Of suggests,","
R519 T508 T505 arg1Of nature,the
R520 T508 T506 arg1Of nature,mixed
R521 T508 T507 arg1Of nature,subclass
R522 T508 T509 arg1Of nature,of
R523 T513 T509 arg2Of responses,of
R524 T513 T510 arg1Of responses,these
R525 T513 T511 arg1Of responses,normal
R526 T513 T512 arg1Of responses,antibody
R527 T508 T514 arg1Of nature,suggests
R528 T518 T514 arg2Of arise,suggests
R529 T518 T515 arg1Of arise,that
R530 T516 T517 arg1Of circumstances,may
R531 T518 T517 arg2Of arise,may
R532 T516 T518 arg1Of circumstances,arise
R533 T518 T519 arg1Of arise,in
R534 T521 T519 arg2Of strategies,in
R535 T521 T520 arg1Of strategies,therapeutic
R536 T521 T522 arg1Of strategies,where
R537 T524 T522 arg2Of is,where
R538 T523 T524 arg1Of there,is
R539 T525 T524 arg2Of value,is
R540 T525 T526 arg1Of value,in
R541 T527 T526 arg2Of having,in
R542 T530 T527 arg2Of Fcs,having
R543 T530 T528 arg1Of Fcs,distinctly
R544 T530 T529 arg2Of Fcs,modified
R545 T530 T531 arg1Of Fcs,for
R546 T534 T531 arg2Of engagement,for
R547 T534 T532 arg1Of engagement,the
R548 T534 T533 arg1Of engagement,nuanced
R549 T534 T535 arg1Of engagement,of
R550 T539 T535 arg2Of members,of
R551 T539 T536 arg1Of members,different
R552 T539 T537 arg1Of members,FcγR
R553 T539 T538 arg1Of members,family
R554 T540 T541 arg1Of Treatments,comprising
R555 T544 T541 arg2Of and,comprising
R556 T543 T542 arg1Of mAbs,multiple
R557 T543 T544 arg1Of mAbs,and
R558 T546 T544 arg2Of stimulants,and
R559 T546 T545 arg1Of stimulants,immune
R560 T540 T547 arg1Of Treatments,are
R561 T548 T547 arg2Of under,are
R562 T540 T548 arg1Of Treatments,under
R563 T549 T548 arg2Of investigation,under
R564 T547 T550 arg1Of are,in
R565 T552 T550 arg2Of disease,in
R566 T552 T551 arg1Of disease,infectious
R567 T552 T553 arg1Of disease,for
R568 T555 T553 arg2Of coverage,for
R569 T555 T554 arg1Of coverage,neutralization
R570 T555 T556 arg1Of coverage,of
R571 T558 T556 arg2Of strains,of
R572 T558 T557 arg1Of strains,variant
R573 T565 T559 arg1Of be,Indeed
R574 T565 T560 arg1Of be,","
R575 T563 T561 arg1Of approach,such
R576 T563 T562 arg1Of approach,an
R577 T563 T564 arg1Of approach,may
R578 T565 T564 arg2Of be,may
R579 T563 T565 arg1Of approach,be
R580 T567 T565 arg2Of effective,be
R581 T567 T566 arg1Of effective,most
R582 T563 T567 arg1Of approach,effective
R583 T567 T568 arg1Of effective,in
R584 T569 T568 arg2Of emerging,in
R585 T571 T569 arg2Of disease,emerging
R586 T571 T570 arg1Of disease,infectious
R587 T573 T572 arg1Of as,such
R588 T571 T573 arg1Of disease,as
R589 T583 T573 arg2Of infection,as
R590 T576 T574 arg1Of respiratory,severe
R591 T576 T575 arg1Of respiratory,acute
R592 T583 T576 arg1Of infection,respiratory
R593 T583 T577 arg1Of infection,syndrome
R594 T583 T578 arg1Of infection,coronavirus
R595 T583 T579 arg1Of infection,2
R596 T583 T580 arg1Of infection,(
R597 T581 T580 arg2Of SARS‐CoV‐2,(
R598 T582 T580 arg3Of ),(
R599 T585 T584 arg1Of use,The
R600 T585 T586 arg1Of use,of
R601 T588 T586 arg2Of mAbs,of
R602 T588 T587 arg1Of mAbs,multiple
R603 T588 T589 arg2Of mAbs,tailored
R604 T589 T590 arg1Of tailored,for
R605 T593 T590 arg2Of functions,for
R606 T593 T591 arg1Of functions,distinct
R607 T593 T592 arg1Of functions,effector
R608 T589 T594 arg1Of tailored,and
R609 T595 T594 arg2Of targeting,and
R610 T588 T595 arg1Of mAbs,targeting
R611 T597 T595 arg2Of epitopes,targeting
R612 T597 T596 arg1Of epitopes,different
R613 T585 T598 arg1Of use,will
R614 T599 T598 arg2Of maximize,will
R615 T585 T599 arg1Of use,maximize
R616 T601 T599 arg2Of opportunity,maximize
R617 T601 T600 arg1Of opportunity,the
R618 T601 T602 arg1Of opportunity,for
R619 T603 T602 arg2Of cocktailing,for
R620 T603 T604 arg1Of cocktailing,of
R621 T606 T604 arg2Of functions,of
R622 T606 T605 arg1Of functions,effector
R623 T599 T607 arg1Of maximize,in
R624 T609 T607 arg2Of types,in
R625 T609 T608 arg1Of types,different
R626 T609 T610 arg1Of types,of
R627 T611 T610 arg2Of diseases,of
R628 T631 T612 arg1Of uses,Indeed
R629 T631 T613 arg1Of uses,","
R630 T631 T614 arg1Of uses,in
R631 T619 T614 arg2Of example,in
R632 T619 T615 arg1Of example,a
R633 T619 T616 arg1Of example,small
R634 T616 T617 arg1Of small,but
R635 T618 T617 arg2Of contemporary,but
R636 T619 T618 arg1Of example,contemporary
R637 T619 T620 arg1Of example,outside
R638 T620 T621 arg1Of outside,of
R639 T623 T621 arg2Of disease,of
R640 T623 T622 arg1Of disease,infectious
R641 T631 T624 arg1Of uses,","
R642 T627 T625 arg1Of combination,the
R643 T627 T626 arg1Of combination,FDA‐approved
R644 T627 T628 arg1Of combination,in
R645 T630 T628 arg2Of therapy,in
R646 T630 T629 arg1Of therapy,adenocarcinoma
R647 T627 T631 arg1Of combination,uses
R648 T633 T631 arg2Of cocktail,uses
R649 T633 T632 arg1Of cocktail,a
R650 T633 T634 arg1Of cocktail,of
R651 T636 T634 arg2Of mAbs,of
R652 T636 T635 arg1Of mAbs,two
R653 T633 T637 arg1Of cocktail,","
R654 T639 T637 arg2Of and,","
R655 T638 T639 arg1Of pertuzumab,and
R656 T640 T639 arg2Of trastuzumab,and
R657 T631 T641 arg1Of uses,","
R658 T631 T642 arg1Of uses,against
R659 T643 T642 arg2Of Her2.123,against
R660 T674 T644 arg1Of utilize,Rather
R661 T644 T645 arg1Of Rather,than
R662 T647 T645 arg2Of type,than
R663 T647 T646 arg1Of type,one
R664 T647 T648 arg1Of type,of
R665 T649 T648 arg2Of Fc,of
R666 T651 T650 arg1Of conquer,to
R667 T647 T650 modOf type,to
R668 T652 T651 arg2Of all,conquer
R669 T674 T653 arg1Of utilize,","
R670 T656 T654 arg1Of use,the
R671 T656 T655 arg1Of use,combined
R672 T656 T657 arg1Of use,of
R673 T660 T657 arg2Of mAbs,of
R674 T659 T658 arg1Of selected,appropriately
R675 T660 T659 arg1Of mAbs,selected
R676 T663 T661 arg1Of components,whose
R677 T660 T661 arg2Of mAbs,whose
R678 T663 T662 arg1Of components,individual
R679 T663 T664 arg1Of components,are
R680 T665 T664 arg2Of enhanced,are
R681 T663 T665 arg2Of components,enhanced
R682 T665 T666 arg1Of enhanced,for
R683 T668 T666 arg2Of engagement,for
R684 T668 T667 arg1Of engagement,the
R685 T668 T669 arg1Of engagement,of
R686 T672 T669 arg2Of members,of
R687 T672 T670 arg1Of members,different
R688 T672 T671 arg1Of members,FcγR
R689 T656 T673 arg1Of use,may
R690 T674 T673 arg2Of utilize,may
R691 T656 T674 arg1Of use,utilize
R692 T676 T674 arg2Of components,utilize
R693 T676 T675 arg1Of components,multiple
R694 T676 T677 arg1Of components,of
R695 T679 T677 arg2Of spectrum,of
R696 T679 T678 arg1Of spectrum,the
R697 T679 T680 arg1Of spectrum,of
R698 T682 T680 arg2Of responses,of
R699 T682 T681 arg1Of responses,effector
R700 T679 T683 arg1Of spectrum,on
R701 T684 T683 arg2Of offer,on
R702 T674 T685 arg1Of utilize,by
R710 T691 T693 arg1Of biologics,begin
R711 T704 T693 arg2Of and,begin
R712 T704 T694 arg1Of and,to
R713 T691 T695 arg1Of biologics,realize
R714 T698 T695 arg2Of potential,realize
R715 T698 T696 arg1Of potential,the
R716 T698 T697 arg1Of potential,full
R717 T698 T699 arg1Of potential,of
R718 T703 T699 arg2Of therapeutics,of
R719 T703 T700 arg1Of therapeutics,FcγR‐mediated
R720 T703 T701 arg1Of therapeutics,antibody
R721 T703 T702 arg1Of therapeutics,immune
R722 T695 T704 arg1Of realize,and
R723 T705 T704 arg2Of offer,and
R724 T691 T705 arg1Of biologics,offer
R725 T707 T705 arg2Of change,offer
R726 T707 T706 arg1Of change,transformational
R727 T705 T708 arg1Of offer,for
R728 T710 T708 arg2Of treatment,for
R729 T710 T709 arg1Of treatment,the
R730 T710 T711 arg1Of treatment,of
R731 T715 T711 arg2Of diseases,of
R732 T715 T712 arg1Of diseases,intractable
R733 T712 T713 arg1Of intractable,and
R734 T714 T713 arg2Of incurable,and
R735 T715 T714 arg1Of diseases,incurable
R736 T716 T717 arg1Of Conflict,of
R737 T718 T717 arg2Of Interest,of

LitCovid-sample-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T3 2571-2579 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T4 3836-3844 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T5 4178-4186 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T6 6089-6097 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T7 9348-9351 Chemical denotes Phe http://purl.obolibrary.org/obo/CHEBI_17295|http://purl.obolibrary.org/obo/CHEBI_29997
T9 10489-10498 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T10 10728-10738 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T12 13536-13546 Chemical denotes nucleotide http://purl.obolibrary.org/obo/CHEBI_36976
T13 15338-15348 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T14 17324-17338 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T15 18106-18114 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T16 18439-18447 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T17 18570-18578 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T18 18663-18671 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T19 18689-18697 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T20 18747-18752 Chemical denotes lipid http://purl.obolibrary.org/obo/CHEBI_18059
T21 18756-18763 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T22 18764-18772 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T23 20188-20205 Chemical denotes glycosaminoglycan http://purl.obolibrary.org/obo/CHEBI_18085
T24 20261-20274 Chemical denotes glycoproteins http://purl.obolibrary.org/obo/CHEBI_17089
T25 21088-21096 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T26 21223-21231 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080
T27 22238-22249 Chemical denotes polypeptide http://purl.obolibrary.org/obo/CHEBI_15841
T28 25251-25265 Chemical denotes macromolecules http://purl.obolibrary.org/obo/CHEBI_33839
T29 29812-29822 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T30 30533-30546 Chemical denotes phenylalanine http://purl.obolibrary.org/obo/CHEBI_28044|http://purl.obolibrary.org/obo/CHEBI_58095
T32 30547-30553 Chemical denotes valine http://purl.obolibrary.org/obo/CHEBI_27266
T33 31063-31072 Chemical denotes histidine http://purl.obolibrary.org/obo/CHEBI_27570
T34 31293-31301 Chemical denotes arginine http://purl.obolibrary.org/obo/CHEBI_32696|http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29016
T37 32346-32356 Chemical denotes asparagine http://purl.obolibrary.org/obo/CHEBI_22653
T38 32717-32723 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T39 32741-32756 Chemical denotes oligosaccharide http://purl.obolibrary.org/obo/CHEBI_50699
T40 33184-33193 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T41 33801-33810 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T42 33856-33867 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T43 34199-34208 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T44 34324-34333 Chemical denotes disulfide http://purl.obolibrary.org/obo/CHEBI_48343
T45 35274-35281 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T46 40352-40362 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T47 41335-41342 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T48 43666-43672 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T49 43702-43708 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T50 44825-44831 Chemical denotes fucose http://purl.obolibrary.org/obo/CHEBI_33984
T51 45036-45047 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T52 45066-45077 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T53 45729-45740 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T54 49618-49628 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T55 49765-49772 Chemical denotes leucine http://purl.obolibrary.org/obo/CHEBI_25017
T56 49840-49847 Chemical denotes alanine http://purl.obolibrary.org/obo/CHEBI_16449
T57 50077-50087 Chemical denotes amino acid http://purl.obolibrary.org/obo/CHEBI_33709
T58 50253-50264 Chemical denotes amino acids http://purl.obolibrary.org/obo/CHEBI_33709
T59 51108-51118 Chemical denotes disulfides http://purl.obolibrary.org/obo/CHEBI_35489|http://purl.obolibrary.org/obo/CHEBI_48343
T61 51841-51849 Chemical denotes tyrosine http://purl.obolibrary.org/obo/CHEBI_18186
T62 54176-54184 Chemical denotes arginine http://purl.obolibrary.org/obo/CHEBI_32696|http://purl.obolibrary.org/obo/CHEBI_16467|http://purl.obolibrary.org/obo/CHEBI_29016
T65 55098-55106 Chemical denotes proteins http://purl.obolibrary.org/obo/CHEBI_36080

LitCovid-sample-Pubtator

Id Subject Object Predicate Lexical cue pubann:denotes pubann:has_HGVS_notation
100 4439-4442 Disease denotes APC MESH:D011125
1003 47951-47957 Gene denotes CTLA‐4 Gene:1493
1004 47965-47970 Gene denotes PD‐L1 Gene:29126
1005 47971-47975 Gene denotes PD‐1 Gene:5133
1006 48185-48189 Gene denotes PD‐1 Gene:5133
1007 48417-48423 Gene denotes CTLA‐4 Gene:1493
1008 47751-47755 Gene denotes FcγR Gene:2213
1009 47614-47618 Gene denotes FcγR Gene:2213
101 4953-4965 Disease denotes cytotoxicity MESH:D064420
1010 47505-47509 Gene denotes FcγR Gene:2213
1011 48132-48145 Chemical denotes Pembrolizumab MESH:C582435
1012 48147-48156 Chemical denotes nivolumab MESH:D000077594
1013 48161-48171 Chemical denotes cemiplimab MESH:C000627974
1014 48393-48405 Chemical denotes tremelimumab MESH:C520704
1015 48073-48078 Disease denotes tumor MESH:D009369
1016 48220-48226 Disease denotes cancer MESH:D009369
1017 48319-48324 Mutation denotes S228P rs1469294455
1022 48641-48646 Gene denotes FcγRI Gene:2214
1023 48850-48855 Gene denotes FcγRI Gene:2214
1024 48933-48940 Gene denotes FcγRIIb Gene:2213
1025 48827-48831 Gene denotes PD‐1 Gene:5133
1031 49486-49491 Gene denotes PD‐L1 Gene:29126
1032 49556-49560 Gene denotes FcγR Gene:2213
1033 49384-49388 Gene denotes FcγR Gene:2213
1034 49340-49355 Chemical denotes N‐linked glycan
1035 49459-49471 Chemical denotes Atezolizumab MESH:C000594389
1044 49937-49941 Gene denotes FcγR Gene:2213
1045 49693-49697 Gene denotes FcγR Gene:2213
1046 49645-49649 Gene denotes FcγR Gene:2213
1047 49765-49772 Chemical denotes leucine MESH:D007930
1048 49840-49847 Chemical denotes alanine MESH:D000409
1049 49995-50005 Chemical denotes teplizumab MESH:C502540
1050 50010-50020 Chemical denotes spesolimab
1051 49849-49860 Mutation denotes L234A L235A p.L234,235A,A
1063 50299-50304 Gene denotes PD‐L1 Gene:29126
1064 50616-50619 Gene denotes C1q Gene:712
1065 50563-50567 Gene denotes FcγR Gene:2213
1066 50167-50171 Gene denotes FcγR Gene:2213
1067 50526-50530 Gene denotes FcγR Gene:2213
1068 50106-50110 Gene denotes FcγR Gene:2213
1069 50282-50292 Chemical denotes durvalumab MESH:C000613593
1070 50310-50321 Chemical denotes anifrolumab MESH:C582345
1071 50408-50413 Mutation denotes L234F p.L234F
1072 50447-50452 Mutation denotes L235E p.L235E
1073 50476-50481 Mutation denotes P331S p.P331S
1088 50711-50716 Gene denotes FcγRI Gene:2214
1089 50721-50728 Gene denotes FcγRIIb Gene:2213
1090 50984-50988 Gene denotes FcγR Gene:2213
1091 50783-50787 Gene denotes FcγR Gene:2213
1092 51286-51290 Gene denotes FcγR Gene:2213
1093 51108-51118 Chemical denotes disulfides MESH:D004220
1094 50744-50770 Disease denotes PD‐1 antibody tislelizumab MESH:D010300
1095 50899-50904 Mutation denotes E233P p.E233P
1096 50906-50911 Mutation denotes F234V rs755807976
1097 50913-50918 Mutation denotes L235A p.L235A
1098 50946-50951 Mutation denotes D265A p.D265A
1099 51049-51054 Mutation denotes S228P rs1469294455
1100 51067-51072 Mutation denotes L309V p.L309V
1101 51077-51082 Mutation denotes R409K p.R409K
1104 51510-51514 Gene denotes FcγR Gene:2213
1105 51379-51383 Gene denotes FcγR Gene:2213
1110 51665-51672 Gene denotes FcγRIIb Gene:2213
1111 51693-51697 Gene denotes FcγR Gene:2213
1113 51841-51849 Chemical denotes tyrosine MESH:D014443
1122 51949-51956 Gene denotes FcγRIIb Gene:2213
1123 52151-52154 Gene denotes BCR Gene:613
1124 52540-52547 Gene denotes FcγRIIb Gene:2213
1125 52641-52648 Gene denotes FcγRIIb Gene:2213
1126 52304-52308 Gene denotes FcγR Gene:2213
1127 52656-52658 Chemical denotes Fc
1128 52193-52221 Disease denotes systemic lupus erythematosus MESH:D008180
1129 52271-52280 Disease denotes allergies MESH:D004342
1136 52911-52914 Gene denotes BCR Gene:613
1137 53037-53044 Gene denotes FcγRIIb Gene:2213
1138 53121-53124 Gene denotes BCR Gene:613
1139 52851-52869 Disease denotes autoimmune disease MESH:D001327
1140 52960-52965 Mutation denotes S267E p.S267E
1141 52970-52975 Mutation denotes L328F p.L328F
1147 53791-53798 Gene denotes FcγRIIb Gene:2213
1148 53743-53746 Gene denotes BCR Gene:613
1149 53188-53206 Disease denotes IgE mAb omalizumab MESH:D007589
1150 53252-53270 Disease denotes allergic disorders MESH:D004342
1151 54013-54020 Disease denotes allergy MESH:D004342
1162 54223-54230 Gene denotes FcγRIIb Gene:2213
1163 54766-54773 Gene denotes FcγRIIb Gene:2213
1164 54503-54510 Gene denotes FcγRIIa Gene:2212
1165 54538-54546 Species denotes patients Tax:9606
1166 54176-54184 Chemical denotes arginine MESH:D001120
1167 54702-54707 Mutation denotes P238D p.P238D
1168 54709-54714 Mutation denotes E233D p.E233D
1169 54716-54721 Mutation denotes G237D p.G237D
1170 54730-54735 Mutation denotes P271G p.P271G
1171 54740-54745 Mutation denotes A330R p.A330R
1176 54898-54905 Gene denotes FcγRIIb Gene:2213
1177 55039-55046 Gene denotes FcγRIIb Gene:2213
1178 55497-55504 Gene denotes FcγRIIb Gene:2213
1179 55438-55446 Species denotes patients Tax:9606
1181 55586-55590 Gene denotes FcγR Gene:2213
1188 55853-55857 Gene denotes OX40 Gene:7293
1189 55930-55933 Gene denotes DR4 Gene:3126
119 5291-5299 Gene denotes FcγRIIIa Gene:2214
1190 55935-55938 Gene denotes DR5 Gene:8795
1191 55846-55851 Gene denotes 4‐1BB Gene:3604
1192 55892-55897 Disease denotes death MESH:D003643
1193 55911-55917 Disease denotes cancer MESH:D009369
1197 56042-56049 Gene denotes FcγRIIb Gene:2213
1198 56174-56181 Gene denotes FcγRIIb Gene:2213
1199 55961-55965 Gene denotes FcγR Gene:2213
120 5392-5400 Gene denotes FcγRIIIa Gene:2214
1206 56534-56541 Gene denotes FcγRIIb Gene:2213
1207 56674-56677 Gene denotes DR5 Gene:8795
1208 56873-56880 Gene denotes FcγRIIb Gene:2213
1209 56938-56942 Gene denotes OX40 Gene:7293
121 5402-5409 Gene denotes FcγRIIa Gene:2212
1210 56725-56730 Disease denotes death MESH:D003643
1211 56735-56757 Disease denotes decreased tumor growth MESH:D006130
1215 57028-57035 Gene denotes FcγRIIb Gene:2213
1216 57112-57117 Gene denotes CD137 Gene:3604
1217 57139-57143 Gene denotes OX40 Gene:7293
122 5411-5416 Gene denotes FcγRI Gene:2214
1220 57471-57475 Gene denotes FcγR Gene:2213
1221 57599-57605 Chemical denotes glycan MESH:D011134
123 5488-5493 Gene denotes FcγRI Gene:2214
1233 58401-58405 Gene denotes FcγR Gene:2213
1234 59126-59130 Gene denotes Her2 Gene:2064
1235 58660-58707 Species denotes severe acute respiratory syndrome coronavirus 2 Tax:2697049
1236 58709-58719 Species denotes SARS‐CoV‐2 Tax:2697049
1237 59090-59100 Chemical denotes pertuzumab MESH:C485206
1238 59105-59116 Chemical denotes trastuzumab MESH:D000068878
1239 58507-58525 Disease denotes infectious disease MESH:D003141
124 5495-5503 Gene denotes FcγRIIIa Gene:2214
1240 58633-58651 Disease denotes infectious disease MESH:D003141
1241 58721-58730 Disease denotes infection MESH:D007239
1242 58986-59004 Disease denotes infectious disease MESH:D003141
1243 59038-59052 Disease denotes adenocarcinoma MESH:D000230
1246 59299-59303 Gene denotes FcγR Gene:2213
1247 59483-59487 Gene denotes FcγR Gene:2213
125 5634-5637 Gene denotes BCR Gene:613
126 5703-5710 Gene denotes FcγRIIb Gene:2213
127 5771-5778 Gene denotes FcγRIIb Gene:2213
128 6016-6023 Gene denotes FcγRIIb Gene:2213
129 6030-6037 Gene denotes FcγRIIa Gene:2212
131 5990-5994 Gene denotes FcγR Gene:2213
132 5668-5672 Gene denotes FcγR Gene:2213
134 5479-5486 Gene denotes FcγRIIa Gene:2212
135 5246-5258 Disease denotes cytotoxicity MESH:D064420
141 6089-6097 Chemical denotes tyrosine MESH:D014443
145 6285-6293 Disease denotes COVID-19 MESH:C000657245
150 6843-6847 Gene denotes FcRn Gene:2217
151 6972-6988 Gene denotes Fc receptor‐like Gene:84824
152 6642-6646 Gene denotes FcγR Gene:2213
153 6626-6631 Species denotes human Tax:9606
170 7145-7150 Gene denotes FcγRI Gene:2214
171 7161-7168 Gene denotes FcγRIIc Gene:9103
172 7170-7178 Gene denotes FcγRIIIa Gene:2214
173 7223-7228 Gene denotes CD32a Gene:2212
174 7230-7235 Gene denotes CD32c Gene:9103
175 7237-7242 Gene denotes CD16a Gene:2214
176 7247-7252 Gene denotes CD16b Gene:2215
177 7322-7329 Gene denotes FcγRIIb Gene:2213
178 7342-7347 Gene denotes CD32b Gene:2213
179 7152-7159 Gene denotes FcγRIIa Gene:2212
180 7034-7039 Species denotes human Tax:9606
181 7183-7191 Gene denotes FcγRIIIb Gene:2215
189 8213-8217 Gene denotes FcγR Gene:2213
190 8697-8701 Gene denotes FcγR Gene:2213
191 8475-8479 Gene denotes FcγR Gene:2213
192 8317-8321 Gene denotes FcγR Gene:2213
193 7984-7988 Gene denotes FcγR Gene:2213
194 8197-8202 Species denotes human Tax:9606
195 8469-8474 Species denotes human Tax:9606
213 8847-8852 Gene denotes FcγRI Gene:2214
214 8866-8870 Gene denotes IgG3 Gene:3502
215 8889-8901 Gene denotes interferon‐γ Gene:3458
216 9004-9008 Gene denotes IgG3 Gene:3502
217 9153-9157 Gene denotes IgG3 Gene:3502
218 9174-9182 Gene denotes FcγRIIIa Gene:2214
219 9195-9199 Gene denotes IgG3 Gene:3502
220 9389-9393 Gene denotes IgG3 Gene:3502
221 9407-9414 Gene denotes FcγRIIb Gene:2213
222 9427-9431 Gene denotes IgG3 Gene:3502
223 9591-9599 Gene denotes FcγRIIIb Gene:2215
224 9066-9072 Species denotes people Tax:9606
225 9368-9376 Gene denotes FcγRIIIb Gene:2215
226 8984-8991 Gene denotes FcγRIIa Gene:2212
227 9348-9351 Chemical denotes Phe MESH:D010649
228 9265-9282 Disease denotes myeloid dendritic MESH:D007635
229 9532-9549 Disease denotes myeloid dendritic MESH:D007635
233 9764-9770 Species denotes people Tax:9606
235 6285-6293 Disease denotes COVID-19 MESH:C000657245
246 10746-10751 Gene denotes FcγRI Gene:2214
247 10753-10760 Gene denotes FcγRIIb Gene:2213
248 10771-10774 Gene denotes CH1 Gene:51430
249 10410-10413 Gene denotes CH1 Gene:51430
250 10269-10273 Gene denotes FcγR Gene:2213
252 10762-10769 Gene denotes FcγRIIc Gene:9103
253 10394-10401 Gene denotes FcγRIIa Gene:2212
254 10489-10498 Chemical denotes disulfide MESH:D004220
255 10728-10738 Chemical denotes disulfides MESH:D004220
257 6285-6293 Disease denotes COVID-19 MESH:C000657245
262 11338-11342 Gene denotes FcγR Gene:2213
263 11322-11327 Species denotes human Tax:9606
275 11974-11979 Gene denotes FcγRI Gene:2214
276 11984-11991 Gene denotes FcγRIIb Gene:2213
277 12099-12104 Gene denotes FcγRI Gene:2214
278 12106-12113 Gene denotes FcγRIIa Gene:2212
279 12118-12126 Gene denotes FcγRIIIa Gene:2214
280 12134-12141 Gene denotes FcγRIIb Gene:2213
281 12057-12064 Gene denotes FcγRIIa Gene:2212
282 11940-11944 Gene denotes FcγR Gene:2213
283 11686-11690 Gene denotes FcγR Gene:2213
285 11632-11637 Species denotes human Tax:9606
287 12188-12192 Gene denotes FcγR Gene:2213
294 12297-12309 Gene denotes interferon‐γ Gene:3458
295 12432-12437 Gene denotes FcγRI Gene:14129
296 12441-12453 Gene denotes interferon‐γ Gene:15978
297 12538-12543 Species denotes mouse Tax:10090
306 13016-13021 Species denotes human Tax:9606
307 13204-13209 Species denotes human Tax:9606
308 13035-13040 Species denotes human Tax:9606
309 12949-12966 Disease denotes thrombocytopenias MESH:D013921
310 13285-13313 Disease denotes systemic lupus erythematosus MESH:D008180
311 13367-13383 Disease denotes hyper‐responsive MESH:D012130
318 13793-13800 Gene denotes FcγRIIb Gene:2213
319 13914-13921 Gene denotes FcγRIIc Gene:9103
320 13494-13498 Gene denotes FcγR Gene:2213
322 13608-13614 Species denotes humans Tax:9606
323 13900-13907 Gene denotes FcγRIIa Gene:2212
335 14161-14168 Gene denotes FcγRIII Gene:2214
336 14213-14221 Gene denotes FcγRIIIa Gene:2214
337 14226-14234 Gene denotes FcγRIIIb Gene:2215
338 14240-14248 Gene denotes FcγRIIIa Gene:2214
339 14363-14371 Gene denotes FcγRIIIa Gene:2214
340 14811-14818 Gene denotes FcγRIIa Gene:2212
341 14483-14489 Species denotes humans Tax:9606
342 14627-14632 Species denotes human Tax:9606
343 14731-14739 Gene denotes FcγRIIIb Gene:2215
344 14461-14469 Gene denotes FcγRIIIb Gene:2215
345 14710-14717 Gene denotes FcγRIIa Gene:2212
35 325-346 Disease denotes inflammatory diseases MESH:D007249
354 15213-15220 Gene denotes FcγRIIb Gene:2213
355 15273-15281 Gene denotes FcγRIIb1 Gene:1555
356 15427-15450 Gene denotes B‐cell antigen receptor Gene:613
357 15452-15455 Gene denotes BCR Gene:613
358 15678-15686 Gene denotes FcγRIIb1 Gene:1555
359 15148-15152 Gene denotes FcγR Gene:2213
36 359-366 Disease denotes cancers MESH:D009369
360 14866-14870 Gene denotes FcγR Gene:2213
361 15836-15841 Species denotes human Tax:9606
369 16085-16093 Gene denotes FcγRIIIa Gene:2214
37 397-409 Disease denotes malignancies MESH:D009369
370 16128-16135 Gene denotes FcγRIIa Gene:2212
371 16137-16144 Gene denotes FcγRIIb Gene:2213
372 16148-16156 Gene denotes FcγRIIIa Gene:2214
373 15905-15909 Gene denotes FcγR Gene:2213
374 16055-16059 Gene denotes FcγR Gene:2213
375 16098-16102 Disease denotes αβ T MESH:D001260
382 16492-16496 Gene denotes FcγR Gene:2213
383 16696-16703 Gene denotes FcγRIIb Gene:2213
384 16917-16924 Gene denotes FcγRIIb Gene:2213
385 16954-16961 Gene denotes FcγRIIb Gene:2213
386 17366-17373 Gene denotes FcγRIIb Gene:2213
395 18043-18046 Gene denotes BCR Gene:613
396 17738-17741 Gene denotes BCR Gene:613
397 17984-17988 Gene denotes FcγR Gene:2213
398 17629-17633 Gene denotes FcγR Gene:2213
399 18106-18114 Chemical denotes tyrosine MESH:D014443
403 18339-18342 Gene denotes BCR Gene:613
405 19006-19010 Gene denotes FcγR Gene:2213
410 19348-19352 Gene denotes FcγR Gene:2213
411 20037-20041 Gene denotes FcγR Gene:2213
412 19604-19608 Gene denotes FcγR Gene:2213
413 19474-19478 Gene denotes FcγR Gene:2213
418 20937-20942 Disease denotes flush MESH:D005483
419 21177-21189 Disease denotes cytotoxicity MESH:D064420
42 1463-1467 Gene denotes FcγR Gene:2213
420 21240-21252 Disease denotes cytotoxicity MESH:D064420
421 21359-21364 Disease denotes flush MESH:D005483
426 21855-21859 Gene denotes FcγR Gene:2213
427 21746-21750 Gene denotes FcγR Gene:2213
428 21696-21700 Chemical denotes ADCP
429 21679-21691 Disease denotes cytotoxicity MESH:D064420
43 831-849 Disease denotes autoimmune disease MESH:D001327
432 22009-22013 Gene denotes FcγR Gene:2213
433 22257-22263 Chemical denotes glycan MESH:D011134
44 892-901 Disease denotes infection MESH:D007239
443 22657-22665 Gene denotes FcγRIIIa Gene:2214
444 22918-22925 Gene denotes FcγRIIa Gene:2212
445 22930-22935 Gene denotes FcγRI Gene:2214
446 23136-23143 Gene denotes FcγRIII Gene:2214
447 23166-23173 Gene denotes FcγRIIa Gene:2212
448 23178-23183 Gene denotes FcγRI Gene:2214
449 22561-22565 Gene denotes FcγR Gene:2213
45 929-936 Disease denotes allergy MESH:D004342
450 23034-23042 Species denotes patients Tax:9606
451 22865-22871 Disease denotes cancer MESH:D009369
464 23536-23543 Gene denotes FcγRIIb Gene:2213
465 23676-23679 Gene denotes BCR Gene:613
466 23757-23765 Gene denotes FcγRIIb1 Gene:1555
467 23836-23841 Gene denotes FcγRI Gene:2214
468 23843-23850 Gene denotes FcγRIIa Gene:2212
469 23861-23868 Gene denotes FcγRIII Gene:2214
470 24190-24193 Gene denotes BCR Gene:613
471 24322-24325 Gene denotes BCR Gene:613
472 24385-24393 Gene denotes FcγRIIB1 Gene:1555
473 23852-23859 Gene denotes FcγRIIc Gene:9103
48 2000-2004 Gene denotes FcγR Gene:2213
481 24754-24761 Gene denotes FcγRIIb Gene:14130
482 24994-25001 Gene denotes FcγRIIb Gene:14130
483 24719-24723 Gene denotes FcγR Gene:2213
484 24581-24585 Gene denotes FcγR Gene:2213
485 24494-24500 Species denotes humans Tax:9606
486 25029-25033 Species denotes mice Tax:10090
487 25038-25044 Species denotes humans Tax:9606
49 1788-1792 Gene denotes FcγR Gene:2213
493 25654-25658 Gene denotes FcγR Gene:2213
494 25534-25538 Species denotes mice Tax:10090
495 25612-25620 Species denotes patients Tax:9606
496 25570-25583 Disease denotes recall memory MESH:D008569
497 25712-25717 Disease denotes tumor MESH:D009369
504 26124-26129 Gene denotes FcγRI Gene:2214
505 25889-25893 Gene denotes FcγR Gene:2213
506 25798-25802 Gene denotes FcγR Gene:2213
507 26118-26123 Species denotes human Tax:9606
508 26173-26177 Species denotes mice Tax:10090
509 26133-26138 Species denotes human Tax:9606
511 26551-26558 Gene denotes FcγRIIb Gene:2213
513 26777-26784 Gene denotes FcγRIIb Gene:2213
515 27004-27008 Gene denotes FcγR Gene:2213
524 28100-28105 Gene denotes CD357 Gene:8784
525 27937-27941 Gene denotes FcγR Gene:2213
526 27899-27903 Gene denotes FcγR Gene:2213
527 27760-27764 Gene denotes FcγR Gene:2213
528 27389-27393 Gene denotes FcγR Gene:2213
529 27121-27125 Gene denotes FcγR Gene:2213
530 26992-27008 Gene denotes und mAbs by FcγR Gene:2213
531 27068-27080 Species denotes participants Tax:9606
535 28151-28155 Gene denotes FcγR Gene:2213
536 28378-28389 Chemical denotes daratumumab MESH:C556306
537 28319-28324 Disease denotes death MESH:D003643
544 29305-29310 Gene denotes FcγRI Gene:2214
545 29570-29575 Gene denotes FcγRI Gene:2214
546 29641-29653 Gene denotes interferon‐γ Gene:3458
547 29008-29012 Gene denotes FcγR Gene:2213
548 28868-28872 Gene denotes FcγR Gene:2213
549 29710-29722 Disease denotes inflammation MESH:D007249
554 29915-29919 Gene denotes IgG3 Gene:3502
555 30170-30177 Gene denotes FcγRIIb Gene:2213
556 30219-30226 Gene denotes FcγRIII Gene:2214
557 29737-29742 Species denotes human Tax:9606
562 30429-30437 Gene denotes FcγRIIIa Gene:2214
563 30358-30362 Gene denotes FcγR Gene:2213
564 30533-30546 Chemical denotes phenylalanine MESH:D010649
565 30547-30553 Chemical denotes valine MESH:D014633
572 30792-30799 Gene denotes FcγRIIb Gene:2213
573 30840-30845 Gene denotes FcγRI Gene:2214
574 30977-30984 Gene denotes FcγRIIa Gene:2212
575 30712-30716 Gene denotes FcγR Gene:2213
576 31063-31072 Chemical denotes histidine MESH:D006639
577 31293-31301 Chemical denotes arginine MESH:D001120
579 31399-31403 Gene denotes FcγR Gene:2213
58 2503-2510 Gene denotes FcγRIIb Gene:2213
583 31551-31556 Gene denotes FcγRI Gene:2214
584 31499-31503 Gene denotes FcγR Gene:2213
585 31450-31454 Gene denotes FcγR Gene:2213
588 31679-31683 Gene denotes FcγR Gene:2213
589 31720-31725 Species denotes human Tax:9606
59 3016-3023 Gene denotes FcγRIIb Gene:2213
60 2672-2676 Gene denotes FcγR Gene:2213
602 31985-31990 Gene denotes FcγRI Gene:2214
603 32002-32009 Gene denotes FcγRIII Gene:2214
604 32657-32665 Gene denotes FcγRIIIa Gene:2214
605 31992-31998 Gene denotes FcγRII Gene:2214
606 32533-32537 Gene denotes FcγR Gene:2213
607 32129-32133 Gene denotes FcγR Gene:2213
608 31956-31961 Species denotes human Tax:9606
609 32327-32342 Chemical denotes N‐linked glycan
61 2215-2219 Gene denotes FcγR Gene:2213
610 32346-32356 Chemical denotes asparagine MESH:D001216
611 32362-32366 Chemical denotes N297
612 32717-32723 Chemical denotes fucose MESH:D005643
613 32741-32756 Chemical denotes oligosaccharide MESH:D009844
617 32835-32839 Gene denotes FcγR Gene:2213
618 33006-33010 Gene denotes FcγR Gene:2213
619 32883-32887 Gene denotes FcγR Gene:2213
62 2073-2077 Gene denotes FcγR Gene:2213
621 33184-33193 Chemical denotes disulfide MESH:D004220
624 33801-33810 Chemical denotes disulfide MESH:D004220
625 34199-34208 Chemical denotes disulfide MESH:D004220
63 3050-3062 Species denotes participants Tax:9606
630 34459-34462 Gene denotes CH1 Gene:51430
631 34601-34604 Gene denotes CH1 Gene:51430
632 34913-34917 Gene denotes FcγR Gene:2213
633 34324-34333 Chemical denotes disulfide MESH:D004220
635 35000-35004 Gene denotes IgG3 Gene:3502
639 35412-35416 Gene denotes FcγR Gene:2213
64 2571-2579 Chemical denotes tyrosine MESH:D014443
641 35611-35615 Gene denotes FcγR Gene:2213
645 36638-36645 Gene denotes FcγRIIb Gene:2213
646 36568-36572 Gene denotes FcγR Gene:2213
647 36263-36268 Species denotes human Tax:9606
65 2322-2334 Disease denotes cytotoxicity MESH:D064420
652 36797-36801 Gene denotes FcγR Gene:2213
653 37371-37375 Gene denotes FcγR Gene:2213
654 37319-37323 Gene denotes FcγR Gene:2213
655 37028-37036 Species denotes patients Tax:9606
680 38043-38047 Gene denotes HER2 Gene:2064
681 38054-38058 Gene denotes EGFR Gene:1956
682 38216-38220 Gene denotes HER2 Gene:2064
683 38242-38246 Gene denotes EGFR Gene:1956
684 38526-38534 Gene denotes FcγRIIIa Gene:2214
685 38555-38562 Gene denotes FcγRIIb Gene:2213
686 38615-38622 Gene denotes FcγRIIb Gene:2213
687 38637-38642 Gene denotes FcγRI Gene:2214
688 38644-38651 Gene denotes FcγRIIa Gene:2212
689 38808-38815 Gene denotes FcγRIIb Gene:2213
690 39092-39096 Gene denotes FcγR Gene:2213
691 38858-38862 Gene denotes FcγR Gene:2213
692 38515-38519 Gene denotes FcγR Gene:2213
693 38320-38324 Gene denotes FcγR Gene:2213
694 38083-38087 Gene denotes FcγR Gene:2213
695 38268-38273 Species denotes human Tax:9606
696 38175-38184 Chemical denotes rituximab MESH:D000069283
697 38198-38209 Chemical denotes trastuzumab MESH:D000068878
698 38226-38235 Chemical denotes cetuximab MESH:D000068818
699 37811-37831 Disease denotes Cytotoxic mAb cancer MESH:D064420
700 37958-37977 Disease denotes death of the cancer MESH:D009369
701 38130-38135 Disease denotes tumor MESH:D009369
702 38683-38688 Disease denotes tumor MESH:D009369
703 38740-38746 Disease denotes cancer MESH:D009369
714 39693-39701 Gene denotes FcγRIIIa Gene:2214
715 39831-39838 Gene denotes FcγRIIb Gene:2213
716 40002-40009 Gene denotes FcγRIII Gene:2214
717 40045-40053 Gene denotes FcγRIIIa Gene:2214
718 39873-39877 Gene denotes FcγR Gene:2213
719 39674-39678 Gene denotes FcγR Gene:2213
720 39523-39527 Gene denotes FcγR Gene:2213
721 40113-40120 Species denotes patient Tax:9606
722 39760-39765 Disease denotes tumor MESH:D009369
723 40178-40184 Disease denotes cancer MESH:D009369
725 40329-40344 Chemical denotes N‐linked glycan
793 40637-40663 Gene denotes Matrix Metalloproteinase 9 Gene:4318
794 40665-40669 Gene denotes MMP9 Gene:4318
795 41047-41054 Gene denotes FcγRIII Gene:2214
796 41472-41479 Gene denotes FcγRIII Gene:2214
798 41743-41750 Gene denotes FcγRIII Gene:2214
799 41799-41828 Gene denotes C–C chemokine receptor type 4 Gene:1233
800 41830-41834 Gene denotes CCR4 Gene:1233
801 41877-41884 Gene denotes FcγRIII Gene:2214
802 42019-42026 Gene denotes FcγRIII Gene:2214
803 42071-42075 Gene denotes PD‐1 Gene:5133
804 42211-42218 Gene denotes FcγRIII Gene:2214
805 42323-42330 Gene denotes FcγRIII Gene:2214
806 42379-42383 Gene denotes PD‐1 Gene:5133
807 42511-42518 Gene denotes FcγRIII Gene:2214
808 43131-43138 Gene denotes FcγRIII Gene:2214
809 42928-42932 Gene denotes FcγR Gene:2213
810 42903-42907 Gene denotes FcγR Gene:2213
811 42724-42728 Gene denotes FcγR Gene:2213
812 42626-42630 Gene denotes FcγR Gene:2213
813 41269-41273 Gene denotes FcγR Gene:2213
814 40945-40949 Gene denotes FcγR Gene:2213
815 40852-40856 Gene denotes FcγR Gene:2213
816 43011-43015 Gene denotes PD‐1 Gene:5133
817 42782-42786 Gene denotes PD‐1 Gene:5133
818 41184-41189 Gene denotes PD‐L1 Gene:29126
819 40902-40907 Gene denotes PD‐L1 Gene:29126
820 41093-41118 Disease denotes ear nose throat disorders MESH:D004427
821 41381-41400 Disease denotes Metabolic disorders MESH:D008659
822 41626-41651 Disease denotes musculoskeletal disorders MESH:D009140
823 42112-42130 Disease denotes Infectious disease MESH:D003141
824 42420-42429 Disease denotes Infection MESH:D007239
825 42532-42555 Disease denotes Hematological disorders MESH:D006402
826 42738-42757 Disease denotes Metabolic disorders MESH:D008659
827 43023-43028 Mutation denotes S228P rs1469294455
828 41197-41202 Mutation denotes L234F p.L234F
829 41204-41209 Mutation denotes L235E p.L235E
830 41211-41216 Mutation denotes P331S p.P331S
831 40930-40935 Mutation denotes N297A p.N297A
832 40780-40785 Mutation denotes L234F p.L234F
833 40787-40792 Mutation denotes L235E p.L235E
834 40794-40799 Mutation denotes P331S p.P331S
835 42794-42799 Mutation denotes S228P rs1469294455
836 42391-42396 Mutation denotes S228P rs1469294455
837 41688-41693 Mutation denotes F243L p.F243L
838 41695-41700 Mutation denotes L235V p.L235V
839 41702-41707 Mutation denotes R292P p.R292P
84 3417-3425 Gene denotes FcγRIIIa Gene:2214
840 41709-41714 Mutation denotes Y300L p.Y300L
841 41716-41721 Mutation denotes P396L p.P396L
842 41985-41990 Mutation denotes S239D p.S239D
843 41992-41997 Mutation denotes I332E p.I332E
844 42083-42088 Mutation denotes S228P rs1469294455
845 42289-42294 Mutation denotes P247I p.P247I
846 42296-42301 Mutation denotes A339Q p.A339Q
848 42703-42708 Mutation denotes L234A p.L234A
849 42815-42820 Mutation denotes L235A p.L235A
85 3580-3588 Gene denotes FcγRIIIa Gene:2214
850 42605-42610 Mutation denotes L234A p.L234A
851 42710-42715 Mutation denotes L235A p.L235A
853 42801-42806 Mutation denotes E233P p.E233P
854 42808-42813 Mutation denotes F234V rs755807976
855 42612-42617 Mutation denotes L235A p.L235A
856 42822-42827 Mutation denotes D265A p.D265A
857 42829-42834 Mutation denotes L309V p.L309V
858 42836-42841 Mutation denotes R409K p.R409K
86 3808-3815 Gene denotes FcγRIIb Gene:2213
861 6285-6293 Disease denotes COVID-19 MESH:C000657245
863 43571-43577 Chemical denotes glycan MESH:D011134
87 4109-4116 Gene denotes FcγRIIb Gene:2213
879 43756-43764 Gene denotes FcγRIIIa Gene:2214
88 4550-4557 Gene denotes FcγRIIb Gene:2213
880 43769-43777 Gene denotes FcγRIIIb Gene:2215
881 43850-43857 Gene denotes FcγRIIb Gene:2213
882 43955-43963 Gene denotes FcγRIIIa Gene:2214
883 44060-44064 Gene denotes HER2 Gene:2064
884 44071-44075 Gene denotes EGFR Gene:1956
885 44217-44224 Gene denotes FcγRIII Gene:2214
886 44328-44335 Gene denotes FcγRIII Gene:2214
887 44472-44480 Gene denotes FcγRIIIa Gene:2214
888 44526-44533 Gene denotes FcγRIIa Gene:2212
889 44456-44464 Gene denotes FcγRIIIb Gene:2215
89 3940-3944 Gene denotes FcγR Gene:2213
890 43598-43613 Chemical denotes N‐linked glycan
891 43666-43672 Chemical denotes fucose MESH:D005643
892 43702-43708 Chemical denotes fucose MESH:D005643
893 44026-44031 Disease denotes tumor MESH:D009369
90 3567-3571 Gene denotes FcγR Gene:2213
900 44795-44803 Species denotes patients Tax:9606
901 44676-44688 Chemical denotes obinutuzumab MESH:C543332
902 44825-44831 Chemical denotes fucose MESH:D005643
903 44843-44852 Chemical denotes rituximab MESH:D000069283
904 44926-44932 Chemical denotes glycan MESH:D011134
905 44766-44794 Disease denotes chronic lymphocytic leukemia MESH:D015451
91 3318-3322 Gene denotes FcγR Gene:2213
914 45376-45384 Gene denotes FcγRIIIa Gene:2214
915 45420-45428 Gene denotes FcγRIIIa Gene:2214
916 45466-45473 Gene denotes FcγRIII Gene:14131
917 45546-45551 Species denotes mouse Tax:10090
918 45257-45285 Disease denotes chronic lymphocytic leukemia MESH:D015451
919 45519-45542 Disease denotes reduced lymphoma growth MESH:D006130
92 4663-4667 Gene denotes FcγR Gene:2213
920 45331-45336 Mutation denotes S329D p.S329D
921 45341-45346 Mutation denotes I332E p.I332E
93 4155-4162 Gene denotes FcγRIIb Gene:2213
94 4980-4983 Gene denotes BCR Gene:613
941 45641-45645 Gene denotes HER2 Gene:2064
942 45679-45683 Gene denotes HER2 Gene:2064
943 45800-45808 Gene denotes FcγRIIIa Gene:2214
944 45886-45893 Gene denotes FcγRIIb Gene:2213
945 46047-46051 Gene denotes HER2 Gene:13866
946 46118-46122 Gene denotes HER2 Gene:13866
947 45928-45932 Gene denotes FcγR Gene:2213
948 46149-46153 Species denotes mice Tax:10090
949 45560-45572 Chemical denotes Margetuximab MESH:C000617981
95 3593-3600 Gene denotes FcγRIIa Gene:2212
950 45650-45661 Chemical denotes trastuzumab MESH:D000068878
951 45988-45999 Chemical denotes trastuzumab MESH:D000068878
952 46005-46017 Chemical denotes margetuximab MESH:C000617981
953 45695-45702 Disease denotes cancers MESH:D009369
954 46134-46139 Disease denotes tumor MESH:D009369
955 45742-45747 Mutation denotes L235V p.L235V
956 45749-45754 Mutation denotes F243L p.F243L
957 45756-45761 Mutation denotes R292P p.R292P
958 45763-45768 Mutation denotes Y300L p.Y300L
959 45773-45778 Mutation denotes P396L p.P396L
96 3836-3844 Chemical denotes tyrosine MESH:D014443
967 46462-46470 Gene denotes FcγRIIIa Gene:2214
968 46169-46181 Chemical denotes ocaratuzumab MESH:C550337
969 46273-46280 Disease denotes cancers MESH:D009369
97 4178-4186 Chemical denotes tyrosine MESH:D014443
970 46292-46312 Disease denotes non‐Hodgkin lymphoma MESH:D008228
971 46317-46345 Disease denotes chronic lymphocytic leukemia MESH:D015451
972 46367-46372 Mutation denotes P247I p.P247I
973 46377-46382 Mutation denotes A339Q p.A339Q
976 46589-46597 Gene denotes FcγRIIIa Gene:2214
977 46569-46575 Chemical denotes glycan MESH:D011134
979 37371-37375 Gene denotes FcγR Gene:2213
98 4278-4282 Chemical denotes ITAM
984 47418-47422 Gene denotes FcγR Gene:2213
985 47104-47108 Gene denotes FcγR Gene:2213
986 46960-46964 Gene denotes FcγR Gene:2213
987 46786-46790 Gene denotes FcγR Gene:2213
99 3400-3412 Disease denotes cytotoxicity MESH:D064420

LitCovid-sample-PD-NCBITaxon

Id Subject Object Predicate Lexical cue ncbi_taxonomy_id
T4 6285-6293 Species denotes COVID-19 NCBItxid:2697049
T5 6626-6631 Species denotes human NCBItxid:9606
T6 7000-7005 Species denotes Human NCBItxid:9606
T7 7034-7039 Species denotes human NCBItxid:9606
T8 8197-8202 Species denotes human NCBItxid:9606
T9 8469-8474 Species denotes human NCBItxid:9606
T10 8487-8494 Species denotes rodents NCBItxid:9989
T11 8507-8515 Species denotes primates NCBItxid:9443
T12 9877-9885 Species denotes COVID-19 NCBItxid:2697049
T13 11027-11035 Species denotes COVID-19 NCBItxid:2697049
T14 11322-11327 Species denotes human NCBItxid:9606
T15 11632-11637 Species denotes human NCBItxid:9606
T16 12538-12543 Species denotes mouse NCBItxid:10090|NCBItxid:10088
T18 12728-12736 Species denotes primates NCBItxid:9443
T19 13016-13021 Species denotes human NCBItxid:9606
T20 13035-13040 Species denotes human NCBItxid:9606
T21 13204-13209 Species denotes human NCBItxid:9606
T22 13608-13614 Species denotes humans NCBItxid:9605
T23 14483-14489 Species denotes humans NCBItxid:9605
T24 14627-14632 Species denotes human NCBItxid:9606
T25 14743-14750 Species denotes macaque NCBItxid:9539
T26 15836-15841 Species denotes human NCBItxid:9606
T27 24494-24500 Species denotes humans NCBItxid:9605
T28 25029-25033 Species denotes mice NCBItxid:10095|NCBItxid:10088
T30 25038-25044 Species denotes humans NCBItxid:9605
T31 25098-25105 Species denotes viruses NCBItxid:10239
T32 25534-25538 Species denotes mice NCBItxid:10095|NCBItxid:10088
T34 26118-26123 Species denotes human NCBItxid:9606
T35 26133-26138 Species denotes human NCBItxid:9606
T36 26173-26177 Species denotes mice NCBItxid:10095|NCBItxid:10088
T38 29737-29742 Species denotes human NCBItxid:9606
T39 31720-31725 Species denotes human NCBItxid:9606
T40 31956-31961 Species denotes human NCBItxid:9606
T41 36263-36268 Species denotes human NCBItxid:9606
T42 38268-38273 Species denotes human NCBItxid:9606
T43 43321-43329 Species denotes COVID-19 NCBItxid:2697049
T44 45546-45551 Species denotes mouse NCBItxid:10090|NCBItxid:10088
T46 46149-46153 Species denotes mice NCBItxid:10095|NCBItxid:10088
T48 58660-58707 Species denotes severe acute respiratory syndrome coronavirus 2 NCBItxid:2697049
T49 58709-58719 Species denotes SARS‐CoV‐2 NCBItxid:2697049

LitCovid-sample-sentences

Id Subject Object Predicate Lexical cue
T17 0-12 Sentence denotes Introduction
T18 13-148 Sentence denotes The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy.
T19 149-274 Sentence denotes Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of diseases.
T20 275-728 Sentence denotes They have revolutionized the treatment of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is expanding rapidly with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1
T21 729-1103 Sentence denotes The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity.
T22 1104-1496 Sentence denotes Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review.
T23 1497-1830 Sentence denotes In normal homeostatic immunity, there is a balance between IgG immune complex activation of proinflammatory responses through the activating‐type FcγRs—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host.
T24 1831-2019 Sentence denotes Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7
T25 2020-2183 Sentence denotes Many therapeutic mAbs depend, to varying degrees, on FcγR function (Figure 1, Table 1) for their mechanism of action (MOA) and/or their pharmacokinetic properties.
T26 2184-2436 Sentence denotes For some mAbs interaction with FcγR is central to their MOA, such as the destruction of a target cell by antibody‐dependent cell‐mediated cytotoxicity (ADCC; Figure 1a) or antibody‐dependent cell‐mediated phagocytosis (phagocytosis or ADCP; Figure 1b).
T27 2437-2655 Sentence denotes This also includes mAbs that may harness the inhibitory action of FcγRIIb to modulate the proinflammatory responses of immunoreceptor tyrosine activation motif (ITAM)‐dependent receptor signaling complexes (Figure 1c).
T28 2656-2982 Sentence denotes For other mAbs, FcγR may play a secondary role, such as the removal or “sweeping” of all immune complexes formed by cytokine or virus‐specific neutralizing antibodies or of opsonized fragments of lysed target cells which in antigen‐presenting cells may also feed the antigen into the antigen‐presentation pathways (Figure 1d).
T29 2983-3275 Sentence denotes In addition, FcγRs, particularly FcγRIIb (Figure 1e), are also key participants in the MOA of immune‐stimulating agonistic mAbs or apoptotic mAbs by acting as a scaffold for the additional cross‐linking of mAbs already bound to a cellular target, thereby inducing a signal in the target cell.
T30 3276-3601 Sentence denotes Figure 1 Graphical representation of the FcγR effector functions. (a) Natural killer cell antibody‐dependent cell‐mediated cytotoxicity via FcγRIIIa. (b) Antibody‐dependent cell‐mediated phagocytosis, and/or trogocytosis of large immune complexes, by professional phagocytes via activating FcγR such as FcγRIIIa and FcγRIIa.
T31 3602-3816 Sentence denotes Biological sequelae include the destruction of the ingested complexes which may also feed antigen into antigen‐presentation pathways of antigen‐presenting cells (APCs). (c) Inhibition of cell activation by FcγRIIb.
T32 3817-4117 Sentence denotes The immunoreceptor tyrosine activation motif (ITAM)‐mediated signaling of B‐cell antigen receptors (left) or of activating FcγR (right) on innate immune cells such as macrophages and basophils is inhibited by IgG Fc‐mediated co‐cross‐linking of these activating receptors with the inhibitory FcγRIIb.
T33 4118-4529 Sentence denotes This leads to phosphorylation of the FcγRIIb immunoreceptor tyrosine‐based inhibitory motif (ITIM) and consequently recruits the phosphatases that modulate the ITAM‐driven signaling responses leading to diminished cell responses. (d) Sweeping or internalization of small immune complexes leading to their removal and, in APC, to enhanced immune responses. (e) Scaffolding in which the FcγRs play a passive role.
T34 4530-4848 Sentence denotes Typically involving FcγRIIb, no signal is generated in the effector cell but “super‐cross‐linking” of the opsonizing antibody by the FcγR on one cell generates a signal in the conjugated target cell, for example, induction of apoptosis or activation in agonistic expansion of cells and/or their secretion of cytokines.
T35 4849-4913 Sentence denotes In extreme cases, this leads to life‐threatening cytokine storm.
T36 4914-5041 Sentence denotes ADCC, antibody‐dependent cell‐mediated cytotoxicity; Ag, antigen; BCR, B‐cell receptor; Ig, immunoglobulin; NK, natural killer.
T37 5042-5119 Sentence denotes Table 1 FcγR responses relevant to therapeutic monoclonal antibodies (mAbs).
T38 5120-5200 Sentence denotes FcγR‐mediated mechanism of action Effector responses Action Dominant receptor
T39 5201-5299 Sentence denotes Activation Antibody‐dependent cell‐mediated cytotoxicity Direct killing of target cell FcγRIIIa
T40 5300-5416 Sentence denotes Antibody‐dependent cell‐mediated phagocytosis, trogocytosis Direct killing of target cell FcγRIIIa, FcγRIIa, FcγRI
T41 5417-5503 Sentence denotes Antigen presentation Vaccine‐like immunity post‐mAb therapy FcγRIIa, FcγRI, FcγRIIIa
T42 5504-5688 Sentence denotes Inhibition Reduce B‐cell proliferation or innate cell activation by antibody complexes Inhibition of ITAM cell activation (i.e. BCR) or activating‐type FcR (i.e. FcγR, FcεRI, FcαRI).
T43 5689-5769 Sentence denotes Note that the FcγRIIb must be co‐cross‐linked with the ITAM activating receptor.
T44 5771-5778 Sentence denotes FcγRIIb
T45 5779-5850 Sentence denotes Sweeping Internalization Removal of small immune complexes FcγRIIb a
T46 5851-6045 Sentence denotes Scaffolding Target agonism or apoptosis Passive “super‐cross‐linking” of mAb on opsonized target cell, for example, CD40, CD28, CD20, by FcγR on an adjacent cell FcγRIIb; also FcγRIIa, FcγRI?
T47 6046-6115 Sentence denotes BCR, B‐cell receptor; ITAM, immunoreceptor tyrosine activation motif.
T48 6116-6179 Sentence denotes a Activating FcγR can also contribute to removal of complexes.
T49 6180-6327 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T50 6328-6510 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T51 6511-6998 Sentence denotes This review focuses on the cell‐based effector functions that arise from the interaction of IgG with the classical human leukocyte FcγR.7 Although beyond the scope of this review, it should be noted that the IgG‐Fc portion dictates other aspects of an antibody’s biology, including its serum half‐life mediated by the neonatal FcR (FcRn), 3 the activation of complement C1,8 antiviral protection via the intracellular receptor TRIM219 and interactions with the Fc receptor‐like family.10
T52 7000-7029 Sentence denotes Human FcγR General Properties
T53 7030-7397 Sentence denotes The human leukocyte receptors fall into two functional groups, namely, proinflammatory, activating‐type receptors (FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa and FcγRIIIb, which are also known as CD64, CD32a, CD32c, CD16a and CD16b, respectively) and the anti‐inflammatory, inhibitory‐receptor group (FcγRIIb also called CD32b) which was the first immune checkpoint described.
T54 7398-7505 Sentence denotes These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses.
T55 7506-7714 Sentence denotes In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1).
T56 7715-7862 Sentence denotes These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types.
T57 7863-8118 Sentence denotes Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses.
T58 8119-8261 Sentence denotes In this review, we address only key aspects of the extensive knowledge of the human leukocyte FcγR family as it relates to effector functions.
T59 8262-8762 Sentence denotes A number of other reviews more comprehensively explore FcγR biology physiology, biochemistry, genetics and structure.7, 11, 12, 13, 14 Notwithstanding the recognized differences between the immunobiology of human FcγR and of rodents or nonhuman primates, animal models of FcR effector function in vivo have helped shape the strategies for the development of current therapeutic mAbs and are well reviewed.12, 15 Furthermore, humanized FcγR models will provide even greater insights into the future.16
T60 8763-8791 Sentence denotes Table 2 Properties of FcγR.
T61 8792-8846 Sentence denotes Receptor Affinity IgG specificity Cell distribution
T62 8847-8983 Sentence denotes FcγRI High IgG1, IgG3, IgG4 Induced by interferon‐γ on monocytes, neutrophils, macrophages, dendritic cell subpopulations; mast cells
T63 8984-9130 Sentence denotes FcγRIIa Low IgG1, IgG3, but IgG2 binding limited to the FcγRIIa‐H131 form, ~70% people) All leukocytes and platelets except T and B lymphocytes
T64 9131-9173 Sentence denotes FcγRIIc a Low IgG1, IgG3, IgG4 NK cells
T65 9174-9200 Sentence denotes FcγRIIIa Low IgG1, IgG3.
T66 9202-9320 Sentence denotes NK cells, macrophages, subpopulation of circulating monocytes, myeloid dendritic cells, neutrophils at very low levels
T67 9321-9367 Sentence denotes Binding avidity reduced by Phe at position 158
T68 9368-9406 Sentence denotes FcγRIIIb Low IgG1, IgG3 Neutrophils
T69 9407-9514 Sentence denotes FcγRIIb Low IgG1, IgG3, IgG4 B lymphocytes, some monocytes (can be upregulated); basophils; eosinophils?
T70 9515-9626 Sentence denotes Plasmacytoid and myeloid dendritic cells; NK cells only of individuals with FcγRIIIb gene copy number variation
T71 9627-9690 Sentence denotes Airway smooth muscle, LSEC, placenta, follicular dendritic cell
T72 9691-9740 Sentence denotes Ig, immunoglobulin; NK cell, natural killer cell.
T73 9741-9771 Sentence denotes a Expressed in 20% of people.
T74 9772-9919 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T75 9920-10102 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T76 10103-10157 Sentence denotes Table 3 Unique features of IgG subclass Fc and hinge.
T77 10158-10258 Sentence denotes IgG subclass FcγR specificity Light‐chain attachment Hinge characteristics Fc stability Comment
T78 10259-10369 Sentence denotes IgG1 All FcγR Upper hinge Light‐chain attachment Stable Fc is >100× times more stable than IgG4 and IgG2.
T79 10370-10387 Sentence denotes Stable core hinge
T80 10388-10524 Sentence denotes IgG2 FcγRIIa His131 CH1 of Fab and/or upper hinge Stable core hinge with additional inter H‐chain disulfide bonds in the upper hinge.
T81 10526-10607 Sentence denotes Unstable CH3:CH3 Alternative light‐chain attachment creates distinct conformers.
T82 10608-10739 Sentence denotes Unlike IgG4, the CH3:CH3 instability does not lead to half‐molecule exchange as a result of stable core and upper hinge disulfides.
T83 10740-10901 Sentence denotes IgG4 FcγRI, FcγRIIb, FcγRIIc CH1 of Fab Labile core hinge Unstable CH3:CH3 Combined instability of core hinge and CH3:CH3 permits half‐IgG molecule exchange
T84 10902-10921 Sentence denotes Ig, immunoglobulin.
T85 10922-11069 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T86 11070-11252 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T87 11254-11290 Sentence denotes FcγR expression on hemopoietic cells
T88 11291-11555 Sentence denotes The tissue distribution of the human leukocyte FcγR is well documented and reviewed comprehensively elsewhere.7, 11, 17 In the context of effector functions harnessed by therapeutic mAbs, several aspects of the cellular distribution (Table 2) should be emphasized.
T89 11556-11701 Sentence denotes FcγR expression profiles differ between cell lineages but almost all mature human leukocytes, and platelets, express at least one FcγR (Table 2).
T90 11702-12143 Sentence denotes It should also be appreciated that the cellular expression levels and receptor diversity as will be described later is also influenced by the activation state of the cells, anatomical location and the cytokine environment which modulates FcγR expression, particularly for FcγRI and FcγRIIb.18 For example, resting monocyte subpopulations may express only FcγRIIa but activated macrophages express FcγRI, FcγRIIa and FcγRIIIa and/or FcγRIIb.7
T91 12144-12230 Sentence denotes Thus, specific characteristics of leukocyte FcγR expression are summarized as follows:
T92 12231-12412 Sentence denotes FcγRI is not usually expressed until induced by cytokines such as interferon‐γ on monocytes, neutrophils, macrophages, microglial cells in the brain, dendritic cells and mast cells.
T93 12413-12698 Sentence denotes The sensitivity of FcγRI to interferon‐γ suggests that its in vivo activity is closely tied to immune activation events, and mouse studies have suggested that it has a critical role early in immune responses.19, 20 Its role in the MOA of antibodies may vary with anatomical location.21
T94 12699-12824 Sentence denotes FcγRIIa is expressed only in primates and shows the broadest expression of all FcγRs, being present on all innate leukocytes.
T95 12825-12967 Sentence denotes It is also present on platelets but its role in effector functions is not established but it is important in certain immune thrombocytopenias.
T96 12968-13046 Sentence denotes A polymorphic form of this receptor is the only human receptor for human IgG2.
T97 13047-13221 Sentence denotes This, together with its limited species expression and unique ITAM‐containing cytoplasmic tail (reviewed by Anania et al. 11), suggests a unique function in human leukocytes.
T98 13222-13468 Sentence denotes Interestingly, polymorphism of the receptor is associated with systemic lupus erythematosus and resistance to Gram‐negative organisms.11 A rare, hyper‐responsive form is a risk factor for neutrophil‐driven anaphylaxis in Ig replacement therapy.22
T99 13469-13908 Sentence denotes FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa.
T100 13909-14027 Sentence denotes Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals.
T101 14028-14160 Sentence denotes Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this.
T102 14161-14235 Sentence denotes FcγRIII forms are two highly related gene products, FcγRIIIa and FcγRIIIb.
T103 14236-14328 Sentence denotes The FcγRIIIa is expressed on NK cells and professional phagocytes, particularly macrophages.
T104 14329-14576 Sentence denotes It is only recently apparent that FcγRIIIa is expressed on neutrophils, albeit at low levels, but plays a role in their function.23 FcγRIIIb is unique to humans and unlike other FcγRs it is attached to cell membrane via a glycophosphatidyl anchor.
T105 14577-14718 Sentence denotes It is expressed, predominantly and abundantly, on human neutrophils.7 Its effector function depends in part on its coexpression with FcγRIIa.
T106 14719-14832 Sentence denotes The lack of FcγRIIIb on macaque neutrophils appears to be compensated for by an increase in FcγRIIa expression.15
T107 14833-14900 Sentence denotes FcγRIIbs are the inhibitory‐type FcγR and arise from a single gene.
T108 14901-14982 Sentence denotes They lack intrinsic proinflammatory signaling and are instead immune checkpoints.
T109 14983-15113 Sentence denotes They provide feedback regulation by antibodies, in the form of immune complexes, to inhibit B‐cell activation by specific antigen.
T110 15114-15178 Sentence denotes They also control activating‐type FcγR function on innate cells.
T111 15179-15272 Sentence denotes Two major splice variant forms of FcγRIIb exist with differential tissue expression profiles.
T112 15273-15457 Sentence denotes FcγRIIb1 preferentially expressed on B lymphocytes contains a 20‐amino acid cytoplasmic insertion necessary for membrane retention and cocapping with the B‐cell antigen receptor (BCR).
T113 15458-15633 Sentence denotes FcγRIIb2 is the predominant inhibitory receptor found on basophils and neutrophils, as well as on subpopulations of mast cells, dendritic cells and some monocytes/macrophages.
T114 15634-15850 Sentence denotes FcγRIIb2 lacks the cytoplasmic insertion of FcγRIIb1 and consequently can internalize rapidly including with the activating FcR when they are co‐cross‐linked.11 It is not clear which form is present on human T cells.
T115 15851-15978 Sentence denotes One additional comment on tissue distribution is that FcγR expression on T cells has been difficult to establish unequivocally.
T116 15979-16060 Sentence denotes However, there is increasing evidence that T‐lymphocyte populations express FcγR.
T117 16061-16272 Sentence denotes Some γδ T cells express FcγRIIIa and αβ T cells reportedly express FcγRIIa, FcγRIIb or FcγRIIIa but the significance with respect to effector function mediated by antibody is presently unclear.24, 25, 26, 27, 28
T118 16274-16308 Sentence denotes Expression on nonhemopoietic cells
T119 16309-16532 Sentence denotes The immunobiology of FcγR is studied and understood almost exclusively in the context of hematopoietic cell function but relatively recent investigations have identified and explored FcγR expression on nonhemopoietic cells.
T120 16533-16637 Sentence denotes These studies suggest important roles in normal immune function and in the MOA of some therapeutic mAbs.
T121 16638-16796 Sentence denotes The most extensively characterized receptor expression is FcγRIIb which is expressed on follicular dendritic cell, airway smooth muscle and liver endothelium.
T122 16797-17187 Sentence denotes Its abundant expression on liver sinusoidal endothelial cells (LSECs) is estimated to represent the majority of in vivo FcγRIIb expression.17, 29, 30, 31 As FcγRIIb lacks intrinsic proinflammatory signaling function, its role on these nonhemopoietic cells involves immune complex handling without the danger of, or the need for, induction of local tissue destructive inflammatory responses.
T123 17188-17525 Sentence denotes On LSEC its major role appears to be immune complex sweeping, a process of removal of small immune complexes such as opsonized virus or macromolecules.17 This scavenging role by FcγRIIb on LSEC can be exploited in principle by mAbs forming small soluble complexes with their targets such as antiviral, anticytokine or similar antibodies.
T124 17527-17566 Sentence denotes FcγR activating or inhibitory signaling
T125 17567-17694 Sentence denotes Effector functions that are initiated via the activating‐type FcγR occur by signaling via the ITAM pathway of immune receptors.
T126 17695-17879 Sentence denotes This well‐characterized pathway is used by BCR and T‐cell antigen receptors, the IgE receptor FcεRI and IgA receptor FcαRI (reviewed extensively by Hogarth and Pietersz 7 Anania et al.
T127 17880-18047 Sentence denotes 11 and Getahun and Cambier 32) Induction of an activating signal requires the aggregation of activating FcγR by immune complexes, or by antigen in the case of the BCR.
T128 18048-18208 Sentence denotes This aggregation at the cell membrane results in specific tyrosine phosphorylation of the ITAM by Src kinases, thus initiating the activation cascade.32, 33, 34
T129 18209-18842 Sentence denotes The inhibitory‐type FcγRs, FcγRIIb1 and FcγRIIb2, whose expression is cell lineage restricted, modulate the ITAM signaling of the BCR or the activating‐type FcγRs, respectively.11 Their function is dependent on the immunoreceptor tyrosine inhibition motif in their cytoplasmic tail.32, 33 This checkpoint action requires that FcγRIIbs are coaggregated with the tyrosine‐phosphorylated ITAM‐signaling receptor complex which results also in immunoreceptor tyrosine inhibition motif tyrosine phosphorylation and consequential recruitment of lipid or protein tyrosine phosphatases that powerfully dampen the ITAM‐induced cell activation.
T130 18844-18877 Sentence denotes FcγR‐Dependent Effector Responses
T131 18879-18970 Sentence denotes Not all opsonized targets are equal: size, distance, valency and Fc geometry affect potency
T132 18971-19266 Sentence denotes To understand the immunobiology of FcγR effector responses particularly in the therapeutic mAb context, it is important to appreciate that the quality and potency of such effector responses is greatly affected by the nature of the IgG immune complex and/or the state of potential effector cells.
T133 19267-19410 Sentence denotes First, opsonization, per se, of a target is not necessarily sufficient to ensure FcγR interaction in a way that initiates an effector response.
T134 19411-20085 Sentence denotes Although it is the IgG Fc that interacts with and clusters the FcγR to induce a response, the nature of the Fab interaction with its epitope can strongly influence the likelihood or potency of FcγR effector responses by influencing the density of appropriately presented Fc portions.35 and also the size of the immune complex.36 Furthermore, the display/orientation and geometry of the Fc portions, as a consequence of the fragment antigen‐binding (Fab) interaction with the target epitope, can result in effector responses such as ADCC that differ substantially in potency, presumably because the orientation of the Fc makes FcγR engagement more, or less, accessible.37, 38
T135 20086-20441 Sentence denotes Second, in innate effector cells at rest, the largely linear actin cytoskeleton and the extracellular glycosaminoglycan glycocalyx regulate function by interacting with large glycoproteins, such as CD44, arranging these into ordered “picket” fences.39, 40 These corral receptors, including the FcγRs, and sterically inhibit their interaction with ligands.
T136 20442-21140 Sentence denotes Upon cell activation, cytoskeletal remodeling is associated with the loss of the receptor corrals, allowing FcγRs and other receptors to freely diffuse, engage ligand, cluster and signal.39 The influence of such surface constraints on receptors and effector cell function helps explain some of the observed epitope distance requirements for optimal mAb function,39, 41 which were apparent in a comparative study of ADCC and ADCP.42 ADCC was optimal when the epitope was displayed close, 0.3 nm “flush” or 1.5 nm, to the target membrane where close conjugation of effector and target by the mAb presumably facilitates the delivery of pore‐forming proteins to the target membrane as required by ADCC.
T137 21141-21286 Sentence denotes Interestingly, complement‐dependent cytotoxicity which also utilizes pore‐forming proteins for its cytotoxicity has similar distance constraints.
T138 21287-21580 Sentence denotes By contrast, ADCP was poor  when targeting epitopes displayed close or "flush" to the target cell membrane (within ~0.3 nm) but ADCP activity was restored when the epitope was displayed 1.5 nm off the membrane, demonstrating different optimal epitope distance requirements for ADCC and ADCP.42
T139 21581-21776 Sentence denotes Although the action of agonistic/antagonistic mAbs is mechanistically distinct to those eliciting cytotoxicity and ADCP, the distance segregation between target and FcγR+ cells is also important.
T140 21777-21908 Sentence denotes Indeed, the membrane proximal epitopes of CD28 and CD40 are important for the FcγR function in the complex MOA of these mAbs.43, 44
T141 21909-22153 Sentence denotes Clearly, the effects of immune complex valency, Fc density, presentation and geometry together with FcγR organization in the cell membrane suggest that the development of mAbs to certain targets will be heavily influenced by the context of use.
T142 22154-22270 Sentence denotes Thus, improved mAb potency may not necessarily be achieved by engineering of the Fc polypeptide or its glycan alone.
T143 22271-22491 Sentence denotes A more function‐oriented approach early in mAb selection and development by, for example, application of rapid screening technologies that select for effector potency,34 followed by Fc engineering may be more productive.
T144 22493-22514 Sentence denotes ADCC and phagocytosis
T145 22515-22726 Sentence denotes ADCC and ADCP are the most widely appreciated FcγR‐dependent effector functions (Figure 1a, b) and are, respectively, mediated primarily via  FcγRIIIa on NK cells and professional phagocytes such as macrophages.
T146 22727-22880 Sentence denotes These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy.
T147 22881-23054 Sentence denotes In addition, ADCP can also occur via FcγRIIa and FcγRI,45 but the extent to which cytotoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear.
T148 23055-23326 Sentence denotes The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later.
T149 23328-23368 Sentence denotes Inhibition of cell activation by FcγRIIb
T150 23369-23493 Sentence denotes FcγRIIb is an immune checkpoint46, 47 and its splice variants are potent modulators of ITAM‐dependent signaling (Figure 1c).
T151 23494-23592 Sentence denotes This modulatory function occurs only when FcγRIIb is coaggregated with an ITAM signaling receptor.
T152 23593-24006 Sentence denotes Thus, B‐cell activation by the binding of the antigen in the immune complex to the BCR is regulated by the simultaneous binding of the Fcs of the immune complex to FcγRIIb1 on the same cell. In innate leukocytes, the activating‐type FcR (i.e. FcγRI, FcγRIIa, FcγRIIc, FcγRIII) and the high‐affinity IgE receptor, FcεRI, and the IgA receptor, FcαRI, are all modulated by immune complex co‐engagement with FcγRIIb2.
T153 24007-24212 Sentence denotes The inhibitory function contributes to the MOA of therapeutic antibodies that target cell‐activating molecules where the target cells also express the inhibitory FcγRIIbs such as the BCR (discussed later).
T154 24213-24411 Sentence denotes Thus, B‐cell activation is modulated by the simulatenous binding of the antigen in the immune complex to the BCR and the binding of the Fcs, also in the immune complex, to FcγRIIB1 on the same cell.
T155 24413-24458 Sentence denotes Sweeping: clearance of small immune complexes
T156 24459-24586 Sentence denotes The removal of immune complexes in humans depends primarily on the complement receptor pathway and to a lesser degree the FcγR.
T157 24587-24724 Sentence denotes Among the FcγRs, it has been widely believed that immune complex removal only occurs by phagocytosis/endocytosis of activating‐type FcγR.
T158 24725-25045 Sentence denotes Surprisingly, the inhibitory FcγRIIb, which lacks intrinsic activating function, plays a major role in clearance, and rapidly “sweeps” away small complexes from the circulation (Figure 1d).48, 49 A major tissue involved in the clearance is likely to be the LSEC, where FcγRIIb is expressed abundantly in mice and humans.
T159 25046-25297 Sentence denotes This role is potentially important in resistance to viruses and toxins but may also be key to optimal performance of therapeutic IgG mAbs whose primary MOA is believed to be only neutralization of soluble macromolecules, for example, cytokines or IgE.
T160 25299-25373 Sentence denotes FcγR uptake of antigen: antibody complexes and shaping the immune response
T161 25374-25436 Sentence denotes Monoclonal antibody therapy is a form of passive immunization.
T162 25437-25758 Sentence denotes Indeed, longer‐term vaccine‐like or vaccinal immunity has been demonstrated in anti‐CD20‐treated mice via FcγRIIa50, 51 and in vitro recall memory responses from CD20‐treated patients.52 Although this is dependent on FcγR and anti‐CD20, the mechanism by which long‐term anti‐tumor response is established remains unclear.
T163 25759-26460 Sentence denotes Nonetheless, the active involvement of FcγR in the enhancement of antigen‐specific immunity by uptake of immune complexes through FcγR is historically well documented in experimental systems where FcγRs bind immune complexes and thereby feed antigens into the antigen‐presentation pathways.53 This has been demonstrated in vivo for small immune complexes via human FcγRI on human antigen‐presenting cells54 and in mice.19 Similarly, the capacity of FcγRIIbs to bind and rapidly internalize antigen–antibody complexes suggests that it too may significantly influence feeding antigens into professional antigen‐presenting cells of hematopoietic origin such as dendritic cells and possibly B lymphocytes.
T164 26461-26745 Sentence denotes Although not a classical major histocompatibility complex‐dependent antigen presentation, FcγRIIb on the stroma‐derived follicular dendritic cells influences antibody immunity by recycling antigen–antibody complexes to the cell surface for presentation of intact antigen to B cells.55
T165 26746-26968 Sentence denotes Although somewhat speculative, FcγRIIb’s rapid internalization/sweeping of complexes by the abundant LSEC, which interact with lymphocytes and can present antigen,56 may have a significant role in shaping immune responses.
T166 26970-27015 Sentence denotes Scaffolding of cell‐bound mAbs by FcγR+ cells
T167 27016-27117 Sentence denotes FcγR‐expressing cells can be critical, but passive, participants in the MOA of some mAbs (Figure 1e).
T168 27118-27330 Sentence denotes In FcγR scaffolding, IgG mAb molecules that have opsonized the cell surface of a target cell are additionally cross‐linked by their Fc portions engaging the FcγRs that are arrayed on the surface of a second cell.
T169 27331-27543 Sentence denotes This “super‐cross‐linking” of the target‐bound mAb by the FcγR lattice or “scaffold” on the adjacent cell greatly exceeds the target cross‐linking by the mAb alone, thereby inducing a response in the target cell.
T170 27544-28137 Sentence denotes Scaffolding was originally identified as the basis of T‐cell mitogenesis induced by anti‐CD3 mAb.57, 58 The CD3 mAbs alone were poor mitogens but the “super‐cross‐linking” of the T‐cell‐bound CD3 mAb by the membrane FcγR on adjacent cells, particularly by monocytes, induced rapid T‐cell expansion and cytokine secretion but did not require activation of FcγR‐expressing cells.57 Regrettably, FcγR scaffolding came to prominence and clinical relevance because of its causal role in the catastrophic adverse events resulting from the administration of anti‐CD357 and anti‐CD28 (TGN1412)59 mAbs.
T171 28138-28273 Sentence denotes Nonetheless, FcγR scaffold‐based induction of intracellular responses in a target cell can also lead to beneficial therapeutic effects.
T172 28274-28496 Sentence denotes Such examples are the induction of apoptotic death in a target cell, which is likely part of the MOA of daratumumab in multiple myeloma60 or the controlled agonistic expansion of cells, for example, via CD40 mAb agonism.43
T173 28498-28547 Sentence denotes IgG subclasses: specificity and affinity for FcγR
T174 28548-28771 Sentence denotes Most FcγRs (Table 2) are weak, low‐affinity receptors (affinities in the micromolar range) for IgG‐Fc, irrespective of whether the IgG is uncomplexed, monomeric or when it is complexed with antigen (i.e. an immune complex).
T175 28772-29013 Sentence denotes The very avid binding of immune complexes to an effector cell surface that displays an array of FcγR molecules is the result of the collective contributions of the low‐affinity interactions of each Fc of the IgGs in the complex with an FcγR.
T176 29014-29166 Sentence denotes This avidity effect is necessary as the FcγRs operate in vivo in environments of high concentrations of uncomplexed monomeric IgG (normally 3–12 g L–1).
T177 29167-29257 Sentence denotes Thus, the avid multivalent binding of the complex out competes uncomplexed, monomeric IgG.
T178 29258-29311 Sentence denotes The notable exception to this is the enigmatic FcγRI.
T179 29312-29488 Sentence denotes This receptor shows high, nanomolar affinity for uncomplexed monomeric IgG and thus would be expected to be constantly occupied in vivo by the normal circulating monomeric IgG.
T180 29489-29556 Sentence denotes However, IgG dissociation permits engagement with immune complexes.
T181 29557-29723 Sentence denotes Furthermore, FcγRI is not expressed or expressed poorly on resting cells, requiring interferon‐γ for induction of its expression, presumably at sites of inflammation.
T182 29724-29905 Sentence denotes Although the human IgG heavy‐chain constant domains have greater than 90% identity, key amino acid differences confer each subclass with unique structural and functional properties.
T183 29906-29977 Sentence denotes IgG1 and IgG3 are “universal” ligands, that is, they bind to all FcγRs.
T184 29978-30300 Sentence denotes Formal measurement of the weak, micromolar KD interactions of the low‐affinity receptors with monomeric IgG1 also revealed differing affinities between the low‐affinity FcγRs, with inhibitory FcγRIIb generally having the lowest affinity and FcγRIII the higher, sometimes referred to as a “moderate” affinity receptor.7, 61
T185 30301-30464 Sentence denotes The strength of IgG1 interaction can also be affected by FcγR polymorphism and in the context of therapeutic mAbs, variation in FcγRIIIa is particularly important.
T186 30465-30676 Sentence denotes The most common and possibly clinically significant polymorphism is phenylalanine/valine variation at position 158 in the IgG‐binding site, wherein FcγRIIIa‐F158 binds IgG1 less well than the FcγRIIIa‐V158 form.
T187 30677-30729 Sentence denotes IgG4 and IgG2 have more restricted FcγR specificity.
T188 30730-30867 Sentence denotes IgG4 has low affinity (KA = ~2 × 105 m –1) for the inhibitory FcγRIIb, but is also a high‐affinity ligand for FcγRI (KA = ~4 × 108 m –1).
T189 30868-31113 Sentence denotes IgG2 exhibits a highly restricted specificity, showing functional activity with only one polymorphic form of FcγRIIa (binding affinity KA = ~4.5 × 105 m –1) which is permitted by the presence of histidine at position 131 of its IgG‐binding site.
T190 31114-31324 Sentence denotes This FcγRIIa–H131 form is expressed in approximately 70% of the population, whereas IgG2 has no functional activity on the other common allelic form, FcγRIIa‐R131, which contains arginine at position 131.11, 61
T191 31326-31341 Sentence denotes IgG Subclasses:
T192 31342-31366 Sentence denotes Structure and Properties
T193 31368-31416 Sentence denotes The molecular basis of IgG and FcγR interactions
T194 31417-31480 Sentence denotes The extracellular regions of the FcγR are structurally similar.
T195 31481-31627 Sentence denotes Each low‐affinity FcγR has two ectodomains, whereas the high‐affinity FcγRI has a third domain but this is not directly involved in IgG binding.62
T196 31628-31922 Sentence denotes The interaction between the IgG subclasses and the FcγR is most comprehensively defined for human IgG1 by both X‐ray crystallographic7, 62, 63 and mutagenesis structure/function analyses.64, 65, 66 These studies defined key regions of the IgG sequence required for interaction with their FcγRs.
T197 31923-32089 Sentence denotes Crystallographic analyses of the human IgG1‐Fc complexed with FcγRI, FcγRII or FcγRIII show that these interactions are similar in topology, and asymmetric in nature.
T198 32090-32171 Sentence denotes The second extracellular domain of the FcγR inserts between the two heavy chains.
T199 32172-32322 Sentence denotes Here it makes contacts with the lower hinge of both H chains and with residues of the adjacent BC loop of one CH2 domain and the FG loop of the other.
T200 32323-32504 Sentence denotes The N‐linked glycan at asparagine 297 (N297) of the heavy chain is essential for the structural integrity of the IgG‐Fc by affecting the spacing and conformation of the CH2 domains.
T201 32505-32759 Sentence denotes Indeed, its removal ablates FcγR binding.67 Of particular relevance to therapeutic mAb development is that the normal low‐affinity IgG interaction with FcγRIIIa is profoundly increased by the removal of the core fucose from the N297 Fc oligosaccharide.68
T202 32760-33011 Sentence denotes No crystallographic data are available for IgG2 or IgG4 Fc in complex with FcγR, but mutagenesis studies of the Fc and the FcγR revealed general similarity, but with critical differences, in the interaction of these subclasses with their cognate FcγR.
T203 33013-33060 Sentence denotes Unique features of the IgG2 and IgG4 subclasses
T204 33061-33268 Sentence denotes In IgG1, the stable interaction of the two heavy chains results from the combined effects of stable covalent inter H‐chain disulfide bonds and strong noncovalent interaction of the two CH3 domains (Table 3).
T205 33269-33364 Sentence denotes In stark contrast, in IgG2 and IgG4 the interaction of the CH3 domains of each H‐chain is weak.
T206 33365-33460 Sentence denotes Residues 392, 397 and 409 (Eu numbering) profoundly affect the stability of these interactions.
T207 33461-33657 Sentence denotes The difference at position 409 (R409 in IgG4 and K409 in IgG1) confers a 100‐fold decrease in stability of the interface between the two CH3 domains of IgG4 compared with that of IgG1 (Table 3).69
T208 33658-33817 Sentence denotes Furthermore, the core hinge of IgG4 differs from IgG1 at position 228 (P228 in IgG1 and S228 in IgG4), resulting in unstable inter‐heavy‐chain disulfide bonds.
T209 33818-34286 Sentence denotes This, together with the destabilizing amino acids in the CH3, confers the unique property of half‐antibody (Fab arm) exchange between different IgG4 antibodies,69 thereby creating monovalent, bispecific IgG4 antibodies in vivo.69, 70 The similarly unstable interactions between the CH3 domains in IgG2 are conferred by the interface residue M397; however, the stable inter‐H‐chain disulfide bonds of the core and upper hinge prevent half‐molecule exchange (Table 3).69
T210 34287-34360 Sentence denotes In addition, IgG2 uniquely has three disulfide bond conformers (Table 3).
T211 34361-34970 Sentence denotes The distinct conformers are formed when (1) each light chain is attached to the Cys131 residue of CH1 in the heavy chain (IgG2‐A conformer), (2) both light chains attach to the upper hinge (IgG2‐B) or (3) one light chain is attached to the CH1 Cys131 and one to the upper hinge of the other heavy chain (IgG2‐AB).71 This results in distinct positioning of the Fabs relative to the Fc portions in the different conformers, which has implications for the interaction with antigen and the capacity of IgG2 to cross‐link target molecules in the absence of FcγR binding, for example, in an agonistic mAb setting.72
T212 34971-35070 Sentence denotes It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology.
T213 35071-35336 Sentence denotes The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73
T214 35338-35388 Sentence denotes Therapeutic antibody design: improving mAb potency
T215 35389-35479 Sentence denotes Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy.
T216 35480-35786 Sentence denotes The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.
T217 35787-36085 Sentence denotes Therapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical.
T218 36087-36116 Sentence denotes The nature of the IgG isotype
T219 36117-36284 Sentence denotes Different capabilities for the recruitment and activation of the different immune effector functions are naturally found in the Fc regions of the human IgG subclasses.
T220 36285-36432 Sentence denotes Thus, to achieve a desired MOA, the different IgG subclasses are important starting points for the selection and engineering of the optimal mAb Fc.
T221 36433-36763 Sentence denotes IgG1 is, in many ways, a proinflammatory or “effector‐active” subclass, as it can initiate the complement cascade and is a “universal” FcγR ligand.74 Notwithstanding it is also a ligand for the inhibitory FcγRIIb, IgG1 elicits proinflammatory responses through all activating‐type FcγRs, including ADCC, ADCP and cytokine release.
T222 36764-36940 Sentence denotes Because of their more restricted FcγR‐binding profile, IgG2 and IgG4 have offered some choice in potentially avoiding FcR effector function without the need for Fc engineering.
T223 36941-37410 Sentence denotes They have been used as the backbone for therapeutic mAbs either because recruitment of patients’ effector functions was unlikely to be necessary for the primary MOA of the mAb or is possibly detrimental to the desired therapeutic effect.75 However, the use of these unmodified “inert” subclasses is not without consequences and underscores the need for Fc engineering to modify FcγR interactions—See the “Attenuating and ablating FcγR related functions of IgG” section.
T224 37411-37577 Sentence denotes Thus, the choice of IgG subclass for therapeutic mAb engineering is an important first step for engineering of novel mAbs of improved specificity, potency and safety.
T225 37579-37630 Sentence denotes Fc engineering for enhanced anticancer therapeutics
T226 37631-37810 Sentence denotes IgG1 is the predominant subclass used in the development of cytotoxic mAbs where induction of an activation‐type response, ADCC or phagocytosis, is considered desirable.45, 76, 77
T227 37811-37903 Sentence denotes Cytotoxic mAb cancer therapeutics can control disease progression by one or more mechanisms.
T228 37904-38060 Sentence denotes Their MOAs include direct induction of apoptotic cell death of the cancer cell (anti‐CD20, anti‐CD52) or blocking receptor signaling (anti‐HER2, anti‐EGFR).
T229 38061-38473 Sentence denotes They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design.
T230 38474-38563 Sentence denotes IgG1 antibodies bind both the activating FcγR (e.g. FcγRIIIa) and the inhibitory FcγRIIb.
T231 38564-38713 Sentence denotes In some environments effector cells will coexpress FcγRIIb together with FcγRI, FcγRIIa and FcγIIIa, as may occur on a tumor‐infiltrating macrophage.
T232 38714-38970 Sentence denotes Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell.
T233 38971-39017 Sentence denotes This leads to reduced therapeutic mAb potency.
T234 39018-39467 Sentence denotes Thus, the relative contributions of the activating (A) and inhibitory (I) FcγR to the response by an effector cell, the A‐to‐I ratio, may be an important determinant in clinical outcome of therapeutic mAb activity,76, 81, 82 that is, the higher the A‐to‐I ratio, the greater the proinflammatory response induced by the therapeutic mAb or conversely the lower the A‐to‐I ratio, the greater the inhibition or dampening of the proinflammatory response.
T235 39468-39579 Sentence denotes Thus, the challenge for the development of more potent FcγR effector mAbs is to overcome three major obstacles.
T236 39580-39772 Sentence denotes First, improving activation potency by selectively enhancing interaction with activating‐type FcγR, particularly FcγRIIIa owing to its predominant role in ADCC‐mediated killing of tumor cells.
T237 39773-39839 Sentence denotes Second, reducing binding interactions with the inhibitory FcγRIIb.
T238 39840-39914 Sentence denotes These two approaches improve the FcγR A‐to‐I ratio of cytotoxic IgG1 mAbs.
T239 39915-40185 Sentence denotes Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer.
T240 40186-40271 Sentence denotes At the time of writing, some mAbs with improved potency are coming into clinical use.
T241 40272-40404 Sentence denotes Their improved action has been achieved by modifying the N‐linked glycan or the amino acid sequence of the heavy‐chain Fc (Table 4).
T242 40405-40511 Sentence denotes Table 4 Fc or hinge‐engineered monoclonal antibodies (mAbs) approved or in advanced clinical development.
T243 40512-40621 Sentence denotes mAb name Target IgG backbone Fc modification Effect on mAb Therapy area Most advanced development stage
T244 40622-40726 Sentence denotes Andecaliximab Matrix Metalloproteinase 9 (MMP9) IgG4 S228P Stabilize core hinge Oncology Phase III
T245 40727-40887 Sentence denotes Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III
T246 40888-40977 Sentence denotes Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed
T247 40978-41171 Sentence denotes Benralizumab Interleukin 5 IgG1 Afucosylated Selectively enhance FcγRIII interaction Respiratory dermatology; ear nose throat disorders; gastrointestinal; hematology; immunology; Marketed
T248 41172-41301 Sentence denotes Durvalumab PD‐L1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2 F/G loop; plus ablate FcγR binding Oncology Marketed
T249 41302-41411 Sentence denotes Evinacumab Angiopoietin‐related protein 3 IgG4 S228P Stabilize core hinge Metabolic disorders Phase III
T250 41412-41536 Sentence denotes Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III
T251 41537-41661 Sentence denotes Ixekizumab Interleukin 17A IgG4 S228P Stabilize core hinge Dermatology; immunology; musculoskeletal disorders Marketed
T252 41662-41783 Sentence denotes Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III
T253 41784-41940 Sentence denotes Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed
T254 41941-42059 Sentence denotes Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III
T255 42060-42150 Sentence denotes Nivolumab PD‐1 IgG4 S228P Stabilize core hinge Infectious disease; oncology Marketed
T256 42151-42262 Sentence denotes Obinutuzumab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Immunology; oncology Marketed
T257 42263-42363 Sentence denotes Ocaratuzumab CD20 IgG1 P247I; A339Q Selectively enhance FcγRIII interaction Oncology Phase III
T258 42364-42449 Sentence denotes Pembrolizumab PD‐1 IgG4 S228P Stabilize core hinge Infection; oncology Marketed
T259 42450-42566 Sentence denotes Roledumab Rhesus D IgG1 Afucosylated Selectively enhance FcγRIII interaction Hematological disorders Phase III
T260 42567-42679 Sentence denotes Spesolimab (BI‐655130) IL‐36R IgG1 L234A; L235A Ablate FcγR binding Gastrointestinal; immunology Phase III
T261 42680-42767 Sentence denotes Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II
T262 42768-42988 Sentence denotes Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III
T263 42989-43071 Sentence denotes Toripalimab (JS 001) PD‐1 IgG4 S228P Stabilize core hinge Oncology Phase III
T264 43072-43195 Sentence denotes Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III
T265 43196-43215 Sentence denotes Ig, immunoglobulin.
T266 43216-43363 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T267 43364-43546 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T268 43548-43577 Sentence denotes Modification of the Fc glycan
T269 43578-43858 Sentence denotes The typical complex N‐linked glycan attached to N297 of the heavy chain includes a core fucose.85 Antibodies that lack this fucose have approximately 50‐fold improved binding to FcγRIIIa and FcγRIIIb and importantly retain the weak, low‐affinity binding to the inhibitory FcγRIIb.
T270 43859-44233 Sentence denotes Furthermore, this glycoengineering increased binding affinity of the modified IgG1 mAb for both FcγRIIIa V158 and F158 allelotypes.86, 87, 88 Afucosyl versions of the tumor targeting mAbs such as anti‐HER2, anti‐EGFR and anti‐CD20 had greater antitumor effects and increased survival,68, 88, 89 which is a reflection of the greatly increased, and selective, FcγRIII binding.
T271 44234-44559 Sentence denotes Compared with their unmodified counterparts, the afucosyl mAbs showed dramatic improvement of FcγRIII‐related effector responses such as stronger NK cell‐mediated ADCC, or enhanced neutrophil‐mediated phagocytosis through FcγRIIIb and/or FcγRIIIa.23 However, certain neutrophil functions via FcγRIIa may be compromised.90, 91
T272 44560-44664 Sentence denotes There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4).
T273 44665-45015 Sentence denotes Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments.
T274 45017-45047 Sentence denotes Mutation of the Fc amino acids
T275 45048-45160 Sentence denotes Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs.
T276 45161-45441 Sentence denotes The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele.
T277 45442-45559 Sentence denotes The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models.
T278 45560-45939 Sentence denotes Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio.
T279 45940-46154 Sentence denotes This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice.
T280 46155-46526 Sentence denotes The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1.
T281 46527-46688 Sentence denotes Thus, the engineering of the Fc domain or glycan for improved FcγRIIIa binding is a powerful tool to create more potent and clinically effective anticancer mAbs.
T282 46690-46744 Sentence denotes Attenuating and ablating FcγR‐related functions of IgG
T283 46745-46853 Sentence denotes There are circumstances where binding to FcγR is unnecessary or undesirable in the MOA of a therapeutic mAb.
T284 46854-47191 Sentence denotes Unmodified IgG irrespective of its subclass or intended therapeutic effect has the potential to engage an FcγR which may lead to suboptimal therapeutic performance or to unexpected and catastrophic consequences.57, 59 Clearly reducing or eliminating FcγR interactions, when they are not required for therapeutic effect, may be desirable.
T285 47192-47284 Sentence denotes Indeed, this had been addressed by the choice of IgG subclass or by modifying the Fc region.
T286 47285-47446 Sentence denotes Indeed, most efforts in Fc engineering mAbs that have translated to an approved drug have focused on the reduction or elimination of FcγR interactions (Table 4).
T287 47447-47714 Sentence denotes One approach to minimize interactions with the activating FcγR has been the use of IgG4 or IgG2 backbones, which show a more restricted specificity for the activating FcγR and consequently have been traditionally, and simplistically, viewed as “inert” IgG subclasses.
T288 47715-47896 Sentence denotes Notwithstanding the unexpected, and FcγR‐dependent, severe adverse reaction induced by the IgG4 TGN1412 mAb, the IgG4 or IgG2 backbones have been successfully used in many settings.
T289 47897-48131 Sentence denotes Indeed, checkpoint inhibitors, such as mAbs targeting CTLA‐4 or the PD‐L1/PD‐1 interaction for the suppression of inhibitory signals that contribute to immune tolerance in the tumor microenvironment, are formatted on an IgG4 backbone.
T290 48132-48356 Sentence denotes Pembrolizumab, nivolumab and cemiplimab are all anti‐PD‐1 antibodies currently used for cancer therapy and have been formatted on an IgG4 backbone95, 96, 97 with a stabilized core hinge (S228P) to prevent half‐IgG4 exchange.
T291 48357-48513 Sentence denotes Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98
T292 48514-48585 Sentence denotes However, the use of IgG2 and IgG4 as “inert” subclasses is problematic.
T293 48586-48981 Sentence denotes Both bind to the activating receptors FcγRIIa‐H131 and FcγRI, respectively (Table 2), and initiate effector functions such as neutrophil activation and apoptosis induction.75, 99 Interestingly, in experimental systems, cross‐linking of anti‐PD‐1 IgG4‐based mAb by FcγRI switched its activity from blocking to activatory.10 Moreover, IgG4 binds to FcγRIIb, which may scaffold the therapeutic mAb.
T294 48982-49299 Sentence denotes Although scaffolding may be beneficial in some contexts, for example, in immune agonism,43 it can be disastrous and unexpected in others as it was for the anti‐CD28 TGN1412 mAb.59 Thus, the IgG2 and IgG4 subclasses are not the optimum choice for “FcR‐inactive” mAbs, and so modifying the Fc is a more direct approach.
T295 49300-49594 Sentence denotes The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13
T296 49595-49706 Sentence denotes Modification to the Fc amino acid sequence of the FcγR‐contact regions can also be used to reduce FcγR binding.
T297 49707-49862 Sentence denotes A widely used modification of IgG1 is the substitution of leucine 234 and 235 in the lower hinge sequence (L234 L235 G236 G237) with alanine (L234A L235A).
T298 49863-50031 Sentence denotes It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4).
T299 50032-50236 Sentence denotes A separate strategy has used combinations of amino acid residues from the FcγR‐binding regions of IgG2 and IgG4, which have restricted FcγR specificity, together with other binding‐inactivating mutations.
T300 50237-50415 Sentence denotes The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F).
T301 50416-50633 Sentence denotes They additionally incorporated L235E in the lower hinge and P331S in the F/G loop of the CH2 domain to ablate FcγR binding by disrupting two major FcγR contact sites7 and also coincidently decreasing C1q activation.16
T302 50634-50729 Sentence denotes IgG4 mAbs have been similarly engineered to eliminate their interaction with FcγRI and FcγRIIb.
T303 50730-51004 Sentence denotes The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2.
T304 51005-51222 Sentence denotes It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4.
T305 51223-51327 Sentence denotes Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17
T306 51328-51590 Sentence denotes Thus, Fc engineering is an effective way to remove FcγR effector functions and may be preferable to using unmodified IgG2 or IgG4 backbones that have a more restricted repertoire of FcγR interactions but which are still able to induce certain effector functions.
T307 51592-51622 Sentence denotes Improving FcγRIIb interactions
T308 51623-51792 Sentence denotes Preferential or specific Fc engagement of FcγRIIb over the activating FcγR offers several potential therapeutic advantages for new mAbs in distinct therapeutic settings.
T309 51794-51896 Sentence denotes Improved recruitment of FcγRIIb immunoreceptor tyrosine inhibition motif‐dependent inhibitory function
T310 51897-52383 Sentence denotes Harnessing the physiological inhibitory function of FcγRIIb by mAbs that target ITAM receptors has the potential to shut down ITAM‐dependent signaling pathways of major importance in antibody pathologies.32, 108 Such ITAM signaling receptors include the BCR complex on B cells which is active in systemic lupus erythematosus, the FcεRI on basophils and mast cell subsets in allergies or the activating‐type FcγR on a variety of innate leukocytes in antibody‐mediated tissue destruction.
T311 52384-52548 Sentence denotes In such scenarios, the ITAM signaling receptor complex that is targeted by the therapeutic mAb must be co‐expressed on the cell surface with the inhibitory FcγRIIb.
T312 52549-52752 Sentence denotes This permits coengagement with ITAM signaling receptor by the Fab of the mAb and inhibitory FcγRIIb by its Fc which is the critical requirement in the inhibitory MOA for such therapeutic mAbs (Figure 1).
T313 52753-53178 Sentence denotes Obexelimab (also known as XmAb5871; Table 4), currently in early clinical testing in inflammatory autoimmune disease, is an IgG1 mAb that targets CD19 of the BCR complex.19 It contains two Fc modifications, S267E and L328F (also known as “SELF” mutations), that selectively increased FcγRIIb binding by 400‐fold to about 1 nm, which results in powerful suppression of BCR signaling and the proliferation of primary B cells.19
T314 53179-54143 Sentence denotes The anti‐IgE mAb omalizumab is an IgG1 mAb approved for the treatment of allergic disorders.110, 111 A similar but Fc‐engineered IgG1 mAb XmAb7195, currently in early clinical testing, contains the affinity‐enhancing SELF modifications.112 Both mAbs sterically neutralize the interaction between IgE and its high‐affinity receptor FcεRI to prevent basophil and mast cell activation.113, 114 However, XmAb7195 exhibited more efficient removal (sweeping; discussed later) of circulating IgE and also inhibited B‐cell IgE production, presumably by binding to the IgE BCR on the B‐cell surface and coclustering with FcγRIIb via its affinity‐enhanced Fc domain.112 Thus, XmAb7195’s selective modulation of IgE production by IgE+ B cells in addition to its enhanced clearance of IgE may offer significantly improved therapeutic benefits in allergy therapy beyond simple IgE neutralization.112 The “SELF” mutations have also been used in agonistic mAbs (discussed later).
T315 54144-54375 Sentence denotes One cautionary note is that the arginine 131 (R131) of the IgG‐binding site in FcγRIIb is critical for the enhanced affinity binding of “SELF”‐mutated Fcs but it is also present in the activating‐type “high responder” FcγRIIa‐R131.
T316 54376-54638 Sentence denotes Thus, antibodies modified with “SELF” have very‐high‐affinity binding to FcγRIIa‐R131 115 with a potentially increased risk of FcγRIIa‐dependent complications in patients expressing this allelic form, although, so far, none have been reported in clinical trials.
T317 54639-54829 Sentence denotes However, an alternative set of six Fc mutations, termed “V12” (P238D, E233D, G237D, H268D, P271G and A330R), potently enhanced FcγRIIb binding without increasing FcγRIIa–R131 interaction.115
T318 54831-54879 Sentence denotes Enhancing the sweeping of small immune complexes
T319 54880-55252 Sentence denotes The expression of FcγRIIb on LSEC and its action in the “sweeping” or removal of small immune complexes has opened up new possibilities for the application of FcγRIIb‐enhancing modifications.17 Antibodies or Fc fusion proteins, whose primary MOA is the neutralization of soluble molecules such as IgE or cytokines, are particularly attractive candidates for this approach.
T320 55253-55561 Sentence denotes Proof‐of‐concept for this strategy has been demonstrated in experimental models.48 Indeed, this may be a significant component of the rapid disappearance of IgE from the circulation of patients treated with the anti‐IgE XmAb7195 containing the FcγRIIb enhancing “SELF” modifications, as described previously.
T321 55563-55602 Sentence denotes Immune agonism through FcγR scaffolding
T322 55603-55702 Sentence denotes Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target.
T323 55703-55948 Sentence denotes Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116
T324 55949-56041 Sentence denotes The role of FcγR in the action of these types of mAbs appears to be primarily as a scaffold.
T325 56042-56138 Sentence denotes FcγRIIb is often the predominate receptor involved and the extent of its involvement is complex.
T326 56139-56459 Sentence denotes In the case of CD40, the degree of FcγRIIb scaffolding potency is linked to the epitope location of the targeting mAb with greater potency seen for membrane proximal epitopes.43, 117 It is also noteworthy that depending on the epitope location, the scaffolding of anti‐CD40 mAbs may convert antagonist mAbs to agonistic.
T327 56460-56952 Sentence denotes Engineering of the IgG1 Fc region for enhanced and/or specific binding to FcγRIIb can greatly improve agonistic function.72, 118, 119, 120 Such mutations induced significantly greater agonistic activity in an anti‐DR5 model through increased induction of apoptotic death and decreased tumor growth compared with unmodified IgG1.121 The “SELF” modifications that dramatically and selectively increase affinity for FcγRIIb have also been used to enhance immune agonism in an anti‐OX40 model.122
T328 56953-57156 Sentence denotes The incorporation of the "V12" Fc mutations into IgG1 specifically enhance FcγRIIb interaction 200‐fold, conferring the enhanced agonistic activity of an anti‐CD137 antibody and an anti‐OX40 mAb.115, 122
T329 57158-57187 Sentence denotes Future Engineering Strategies
T330 57188-57284 Sentence denotes Monoclonal antibodies are potent therapeutics in a number of chronic or once incurable diseases.
T331 57285-57414 Sentence denotes However, there is still extensive unmet clinical need as well as considerable room for improvement in many existing therapeutics.
T332 57415-57555 Sentence denotes Further understanding of how antibody structure affects FcγR function is essential for future development of more potent and effective mAbs.
T333 57556-57823 Sentence denotes Already, engineering of the IgG Fc and its glycan has proved a potent and effective approach for increasing the clinical effectiveness, functional specificity and safety of therapeutic mAbs and is an emerging pathway to the development of the “next‐gen” therapeutics.
T334 57824-58167 Sentence denotes Future directions in the development and use of therapeutic antibodies should increasingly mimic normal protective antibody responses, which are polyclonal and elicited in the context of innate receptor engagement which includes the FcR as well as other powerfully responsive systems including the Toll‐like receptors and complement receptors.
T335 58168-58421 Sentence denotes Furthermore, the mixed subclass nature of these normal antibody responses suggests that circumstances may arise in therapeutic strategies where there is value in having distinctly modified Fcs for the nuanced engagement of different FcγR family members.
T336 58422-58573 Sentence denotes Treatments comprising multiple mAbs and immune stimulants are under investigation in infectious disease for neutralization coverage of variant strains.
T337 58574-58731 Sentence denotes Indeed, such an approach may be most effective in emerging infectious disease such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection.
T338 58732-58930 Sentence denotes The use of multiple mAbs tailored for distinct effector functions and targeting different epitopes will maximize the opportunity for cocktailing of effector functions in different types of diseases.
T339 58931-59134 Sentence denotes Indeed, in a small but contemporary example outside of infectious disease, the FDA‐approved combination in adenocarcinoma therapy uses a cocktail of two mAbs, pertuzumab and trastuzumab, against Her2.123
T340 59135-59412 Sentence denotes Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system.
T341 59413-59616 Sentence denotes Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases.
T342 59618-59638 Sentence denotes Conflict of Interest
T343 59639-59644 Sentence denotes None.

LitCovid-sample-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T2 6797-6802 Body_part denotes serum http://purl.obolibrary.org/obo/UBERON_0001977
T3 9655-9663 Body_part denotes placenta http://purl.obolibrary.org/obo/UBERON_0001987
T4 11295-11301 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T5 12374-12379 Body_part denotes brain http://purl.obolibrary.org/obo/UBERON_0000955
T6 13137-13141 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T7 13860-13864 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T8 15245-15251 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T9 15877-15883 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T10 16778-16783 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T11 16784-16795 Body_part denotes endothelium http://purl.obolibrary.org/obo/UBERON_0001986
T12 16824-16829 Body_part denotes liver http://purl.obolibrary.org/obo/UBERON_0002107
T13 17145-17151 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T14 18486-18490 Body_part denotes tail http://purl.obolibrary.org/obo/UBERON_0002415
T15 21075-21079 Body_part denotes pore http://purl.obolibrary.org/obo/UBERON_0008915
T16 21210-21214 Body_part denotes pore http://purl.obolibrary.org/obo/UBERON_0008915
T17 24929-24935 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T18 26566-26572 Body_part denotes stroma http://purl.obolibrary.org/obo/UBERON_0003891
T19 33930-33933 Body_part denotes arm http://purl.obolibrary.org/obo/UBERON_0001460
T20 35239-35244 Body_part denotes scale http://purl.obolibrary.org/obo/UBERON_0002542
T21 35659-35664 Body_part denotes chest http://purl.obolibrary.org/obo/UBERON_0001443
T22 41093-41096 Body_part denotes ear http://purl.obolibrary.org/obo/UBERON_0001690
T23 41097-41101 Body_part denotes nose http://purl.obolibrary.org/obo/UBERON_0000004
T24 41102-41108 Body_part denotes throat http://purl.obolibrary.org/obo/UBERON_0000341
T25 41493-41515 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T26 41898-41920 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T27 43152-43174 Body_part denotes Central nervous system http://purl.obolibrary.org/obo/UBERON_0001017
T28 52364-52370 Body_part denotes tissue http://purl.obolibrary.org/obo/UBERON_0000479
T29 59398-59411 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405

LitCovid-sample-UniProt

Id Subject Object Predicate Lexical cue uniprot_id
T1 4439-4442 Protein denotes APC https://www.uniprot.org/uniprot/P0C1F2|https://www.uniprot.org/uniprot/P01532
T3 5969-5973 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T29 5975-5979 Protein denotes CD28 https://www.uniprot.org/uniprot/Q9BYV0|https://www.uniprot.org/uniprot/Q8WXJ2|https://www.uniprot.org/uniprot/Q8NI56|https://www.uniprot.org/uniprot/Q8NI55|https://www.uniprot.org/uniprot/Q8NI54|https://www.uniprot.org/uniprot/Q70WG0|https://www.uniprot.org/uniprot/Q6GSH7|https://www.uniprot.org/uniprot/Q52M23|https://www.uniprot.org/uniprot/Q28071|https://www.uniprot.org/uniprot/Q13964|https://www.uniprot.org/uniprot/P42069|https://www.uniprot.org/uniprot/P31042|https://www.uniprot.org/uniprot/P31041|https://www.uniprot.org/uniprot/P10747|https://www.uniprot.org/uniprot/O02757|https://www.uniprot.org/uniprot/A8KAC1
T45 5981-5985 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4|https://www.uniprot.org/uniprot/P11836
T52 6843-6847 Protein denotes FcRn https://www.uniprot.org/uniprot/Q9R2A5|https://www.uniprot.org/uniprot/Q9QUR0|https://www.uniprot.org/uniprot/Q9NZ19|https://www.uniprot.org/uniprot/Q9HBV7|https://www.uniprot.org/uniprot/Q8SPV9|https://www.uniprot.org/uniprot/Q61559|https://www.uniprot.org/uniprot/Q5HYM5|https://www.uniprot.org/uniprot/Q2KN22|https://www.uniprot.org/uniprot/P55899|https://www.uniprot.org/uniprot/P13599
T62 7217-7221 Protein denotes CD64 https://www.uniprot.org/uniprot/Q92663|https://www.uniprot.org/uniprot/Q92495|https://www.uniprot.org/uniprot/Q5QNW7|https://www.uniprot.org/uniprot/P26151|https://www.uniprot.org/uniprot/P12315|https://www.uniprot.org/uniprot/P12314
T68 7237-7242 Protein denotes CD16a https://www.uniprot.org/uniprot/Q6PIJ0|https://www.uniprot.org/uniprot/Q65ZM6|https://www.uniprot.org/uniprot/Q5EBR4|https://www.uniprot.org/uniprot/Q53FL6|https://www.uniprot.org/uniprot/Q53FJ0|https://www.uniprot.org/uniprot/P08637|https://www.uniprot.org/uniprot/A2N6W9
T75 7247-7252 Protein denotes CD16b https://www.uniprot.org/uniprot/O75015
T76 8889-8899 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T78 8973-8977 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T81 9634-9640 Protein denotes smooth https://www.uniprot.org/uniprot/Q9VPM8|https://www.uniprot.org/uniprot/P91682|https://www.uniprot.org/uniprot/B7FNK1
T84 12297-12307 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T86 12401-12405 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T89 12441-12451 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T91 15574-15578 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T94 16760-16766 Protein denotes smooth https://www.uniprot.org/uniprot/Q9VPM8|https://www.uniprot.org/uniprot/P91682|https://www.uniprot.org/uniprot/B7FNK1
T97 20147-20152 Protein denotes actin https://www.uniprot.org/uniprot/Q92193|https://www.uniprot.org/uniprot/Q92192|https://www.uniprot.org/uniprot/Q24733|https://www.uniprot.org/uniprot/Q11212|https://www.uniprot.org/uniprot/P91754|https://www.uniprot.org/uniprot/P90689|https://www.uniprot.org/uniprot/P80709|https://www.uniprot.org/uniprot/P68555|https://www.uniprot.org/uniprot/P45521|https://www.uniprot.org/uniprot/P38136|https://www.uniprot.org/uniprot/P14227|https://www.uniprot.org/uniprot/O17320|https://www.uniprot.org/uniprot/O16808
T110 20261-20274 Protein denotes glycoproteins https://www.uniprot.org/uniprot/Q9QSP1|https://www.uniprot.org/uniprot/Q9QJT6|https://www.uniprot.org/uniprot/Q9JGT4|https://www.uniprot.org/uniprot/Q9IPJ6|https://www.uniprot.org/uniprot/Q9DIC6|https://www.uniprot.org/uniprot/Q91DS0|https://www.uniprot.org/uniprot/Q91C28|https://www.uniprot.org/uniprot/Q8QQA2|https://www.uniprot.org/uniprot/Q8QPE5|https://www.uniprot.org/uniprot/Q8QPE4|https://www.uniprot.org/uniprot/Q8QPE3|https://www.uniprot.org/uniprot/Q8JTH0|https://www.uniprot.org/uniprot/Q8BDV6|https://www.uniprot.org/uniprot/Q8B6J6|https://www.uniprot.org/uniprot/Q8B0I1|https://www.uniprot.org/uniprot/Q8B0H6|https://www.uniprot.org/uniprot/Q8B0H1|https://www.uniprot.org/uniprot/Q89669|https://www.uniprot.org/uniprot/Q85213|https://www.uniprot.org/uniprot/Q82706|https://www.uniprot.org/uniprot/Q82683|https://www.uniprot.org/uniprot/Q82020|https://www.uniprot.org/uniprot/Q787B5|https://www.uniprot.org/uniprot/Q77SK0|https://www.uniprot.org/uniprot/Q77N36|https://www.uniprot.org/uniprot/Q76G52|https://www.uniprot.org/uniprot/Q75T09|https://www.uniprot.org/uniprot/Q6X1D5|https://www.uniprot.org/uniprot/Q6X1D1|https://www.uniprot.org/uniprot/Q6TYA0|https://www.uniprot.org/uniprot/Q6E0W7|https://www.uniprot.org/uniprot/Q66T62|https://www.uniprot.org/uniprot/Q5VKP3|https://www.uniprot.org/uniprot/Q5VKN9|https://www.uniprot.org/uniprot/Q5K2K4|https://www.uniprot.org/uniprot/Q5IX93|https://www.uniprot.org/uniprot/Q5IX92|https://www.uniprot.org/uniprot/Q5IX91|https://www.uniprot.org/uniprot/Q5IX90|https://www.uniprot.org/uniprot/Q5IX89|https://www.uniprot.org/uniprot/Q5IX88|https://www.uniprot.org/uniprot/Q5IX87|https://www.uniprot.org/uniprot/Q5GA86|https://www.uniprot.org/uniprot/Q58FH1|https://www.uniprot.org/uniprot/Q4VKV3|https://www.uniprot.org/uniprot/Q4F900|https://www.uniprot.org/uniprot/Q49LL3|https://www.uniprot.org/uniprot/Q49IU2|https://www.uniprot.org/uniprot/Q49IU1|https://www.uniprot.org/uniprot/Q49IT9|https://www.uniprot.org/uniprot/Q49IT8|https://www.uniprot.org/uniprot/Q49AV0|https://www.uniprot.org/uniprot/Q0GBY1|https://www.uniprot.org/uniprot/Q0GBX6|https://www.uniprot.org/uniprot/Q08089|https://www.uniprot.org/uniprot/P32595|https://www.uniprot.org/uniprot/P32550|https://www.uniprot.org/uniprot/P19462|https://www.uniprot.org/uniprot/P16288|https://www.uniprot.org/uniprot/P15199|https://www.uniprot.org/uniprot/P13180|https://www.uniprot.org/uniprot/P0C572|https://www.uniprot.org/uniprot/P08667|https://www.uniprot.org/uniprot/P08163|https://www.uniprot.org/uniprot/P07923|https://www.uniprot.org/uniprot/P04884|https://www.uniprot.org/uniprot/P04883|https://www.uniprot.org/uniprot/P04882|https://www.uniprot.org/uniprot/P03524|https://www.uniprot.org/uniprot/P03522|https://www.uniprot.org/uniprot/O92284|https://www.uniprot.org/uniprot/O56677|https://www.uniprot.org/uniprot/O10236|https://www.uniprot.org/uniprot/J7HBH4|https://www.uniprot.org/uniprot/D8V075|https://www.uniprot.org/uniprot/A7WNB3|https://www.uniprot.org/uniprot/A4UHQ6|https://www.uniprot.org/uniprot/A4UHQ1|https://www.uniprot.org/uniprot/A3RM22|https://www.uniprot.org/uniprot/A3F5R8|https://www.uniprot.org/uniprot/A3F5R3|https://www.uniprot.org/uniprot/A3F5Q8|https://www.uniprot.org/uniprot/A3F5N3|https://www.uniprot.org/uniprot/A3F5M3|https://www.uniprot.org/uniprot/A3F5L8
T195 20284-20288 Protein denotes CD44 https://www.uniprot.org/uniprot/Q9UJ36|https://www.uniprot.org/uniprot/Q9UCB0|https://www.uniprot.org/uniprot/Q9UC30|https://www.uniprot.org/uniprot/Q9UC29|https://www.uniprot.org/uniprot/Q9UC28|https://www.uniprot.org/uniprot/Q9QYX8|https://www.uniprot.org/uniprot/Q9H5A5|https://www.uniprot.org/uniprot/Q99J14|https://www.uniprot.org/uniprot/Q99021|https://www.uniprot.org/uniprot/Q96J24|https://www.uniprot.org/uniprot/Q92493|https://www.uniprot.org/uniprot/Q8N694|https://www.uniprot.org/uniprot/Q86Z27|https://www.uniprot.org/uniprot/Q86T72|https://www.uniprot.org/uniprot/Q64296|https://www.uniprot.org/uniprot/Q62409|https://www.uniprot.org/uniprot/Q62408|https://www.uniprot.org/uniprot/Q62063|https://www.uniprot.org/uniprot/Q62062|https://www.uniprot.org/uniprot/Q62061|https://www.uniprot.org/uniprot/Q62060|https://www.uniprot.org/uniprot/Q61395|https://www.uniprot.org/uniprot/Q60523|https://www.uniprot.org/uniprot/Q60522|https://www.uniprot.org/uniprot/Q29423|https://www.uniprot.org/uniprot/Q28284|https://www.uniprot.org/uniprot/Q16522|https://www.uniprot.org/uniprot/Q16208|https://www.uniprot.org/uniprot/Q16066|https://www.uniprot.org/uniprot/Q16065|https://www.uniprot.org/uniprot/Q16064|https://www.uniprot.org/uniprot/Q15861|https://www.uniprot.org/uniprot/Q13980|https://www.uniprot.org/uniprot/Q13968|https://www.uniprot.org/uniprot/Q13967|https://www.uniprot.org/uniprot/Q13961|https://www.uniprot.org/uniprot/Q13960|https://www.uniprot.org/uniprot/Q13959|https://www.uniprot.org/uniprot/Q13958|https://www.uniprot.org/uniprot/Q13957|https://www.uniprot.org/uniprot/Q13419|https://www.uniprot.org/uniprot/Q05732|https://www.uniprot.org/uniprot/Q05078|https://www.uniprot.org/uniprot/Q04858|https://www.uniprot.org/uniprot/P26051|https://www.uniprot.org/uniprot/P22511|https://www.uniprot.org/uniprot/P20944|https://www.uniprot.org/uniprot/P16070|https://www.uniprot.org/uniprot/P15379|https://www.uniprot.org/uniprot/P14745|https://www.uniprot.org/uniprot/O95370|https://www.uniprot.org/uniprot/D3DR13|https://www.uniprot.org/uniprot/D3DR12|https://www.uniprot.org/uniprot/B6EAT9|https://www.uniprot.org/uniprot/A5YRN9
T250 21819-21823 Protein denotes CD28 https://www.uniprot.org/uniprot/Q9BYV0|https://www.uniprot.org/uniprot/Q8WXJ2|https://www.uniprot.org/uniprot/Q8NI56|https://www.uniprot.org/uniprot/Q8NI55|https://www.uniprot.org/uniprot/Q8NI54|https://www.uniprot.org/uniprot/Q70WG0|https://www.uniprot.org/uniprot/Q6GSH7|https://www.uniprot.org/uniprot/Q52M23|https://www.uniprot.org/uniprot/Q28071|https://www.uniprot.org/uniprot/Q13964|https://www.uniprot.org/uniprot/P42069|https://www.uniprot.org/uniprot/P31042|https://www.uniprot.org/uniprot/P31041|https://www.uniprot.org/uniprot/P10747|https://www.uniprot.org/uniprot/O02757|https://www.uniprot.org/uniprot/A8KAC1
T266 21828-21832 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T292 25521-25525 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T299 25599-25603 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T306 25668-25672 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T313 28100-28105 Protein denotes CD357 https://www.uniprot.org/uniprot/Q9Y5U5|https://www.uniprot.org/uniprot/Q9NYJ9|https://www.uniprot.org/uniprot/Q9JKR3|https://www.uniprot.org/uniprot/Q9JKR2|https://www.uniprot.org/uniprot/Q9JKR1|https://www.uniprot.org/uniprot/Q5U0I4|https://www.uniprot.org/uniprot/O95851|https://www.uniprot.org/uniprot/O35714|https://www.uniprot.org/uniprot/B1AME1
T322 28115-28119 Protein denotes CD28 https://www.uniprot.org/uniprot/Q9BYV0|https://www.uniprot.org/uniprot/Q8WXJ2|https://www.uniprot.org/uniprot/Q8NI56|https://www.uniprot.org/uniprot/Q8NI55|https://www.uniprot.org/uniprot/Q8NI54|https://www.uniprot.org/uniprot/Q70WG0|https://www.uniprot.org/uniprot/Q6GSH7|https://www.uniprot.org/uniprot/Q52M23|https://www.uniprot.org/uniprot/Q28071|https://www.uniprot.org/uniprot/Q13964|https://www.uniprot.org/uniprot/P42069|https://www.uniprot.org/uniprot/P31042|https://www.uniprot.org/uniprot/P31041|https://www.uniprot.org/uniprot/P10747|https://www.uniprot.org/uniprot/O02757|https://www.uniprot.org/uniprot/A8KAC1
T338 28477-28481 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T364 29641-29651 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T366 30753-30760 Protein denotes KA = ~2 https://www.uniprot.org/uniprot/Q8WWG8|https://www.uniprot.org/uniprot/Q63273|https://www.uniprot.org/uniprot/Q62643|https://www.uniprot.org/uniprot/Q61626|https://www.uniprot.org/uniprot/Q16478|https://www.uniprot.org/uniprot/G5E822
T372 37989-37993 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T379 38000-38004 Protein denotes CD52 https://www.uniprot.org/uniprot/Q9BW46|https://www.uniprot.org/uniprot/Q64389|https://www.uniprot.org/uniprot/Q63064|https://www.uniprot.org/uniprot/Q5T138|https://www.uniprot.org/uniprot/Q28896|https://www.uniprot.org/uniprot/P32763|https://www.uniprot.org/uniprot/P31358
T386 38191-38195 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T393 40637-40663 Protein denotes Matrix Metalloproteinase 9 https://www.uniprot.org/uniprot/Q9UDK2|https://www.uniprot.org/uniprot/Q9UCL1|https://www.uniprot.org/uniprot/Q9UCJ9|https://www.uniprot.org/uniprot/Q9H4Z1|https://www.uniprot.org/uniprot/Q9DC02|https://www.uniprot.org/uniprot/Q8N725|https://www.uniprot.org/uniprot/Q80XI8|https://www.uniprot.org/uniprot/Q3LR70|https://www.uniprot.org/uniprot/Q06788|https://www.uniprot.org/uniprot/P52176|https://www.uniprot.org/uniprot/P50282|https://www.uniprot.org/uniprot/P41246|https://www.uniprot.org/uniprot/P41245|https://www.uniprot.org/uniprot/P14780|https://www.uniprot.org/uniprot/O19130|https://www.uniprot.org/uniprot/O18733|https://www.uniprot.org/uniprot/B2R7V9|https://www.uniprot.org/uniprot/A5PKB8
T411 40665-40669 Protein denotes MMP9 https://www.uniprot.org/uniprot/Q9UDK2|https://www.uniprot.org/uniprot/Q9UCL1|https://www.uniprot.org/uniprot/Q9UCJ9|https://www.uniprot.org/uniprot/Q9H4Z1|https://www.uniprot.org/uniprot/Q9DC02|https://www.uniprot.org/uniprot/Q8N725|https://www.uniprot.org/uniprot/Q80XI8|https://www.uniprot.org/uniprot/Q3LR70|https://www.uniprot.org/uniprot/Q06788|https://www.uniprot.org/uniprot/P52176|https://www.uniprot.org/uniprot/P50282|https://www.uniprot.org/uniprot/P41246|https://www.uniprot.org/uniprot/P41245|https://www.uniprot.org/uniprot/P14780|https://www.uniprot.org/uniprot/O19130|https://www.uniprot.org/uniprot/O18733|https://www.uniprot.org/uniprot/B2R7V9|https://www.uniprot.org/uniprot/A5PKB8
T429 40740-40772 Protein denotes Interferon alpha/beta receptor 1 https://www.uniprot.org/uniprot/Q95206|https://www.uniprot.org/uniprot/Q8WTZ2|https://www.uniprot.org/uniprot/Q80UJ3|https://www.uniprot.org/uniprot/Q7M4L2|https://www.uniprot.org/uniprot/Q764M8|https://www.uniprot.org/uniprot/Q6PKD7|https://www.uniprot.org/uniprot/Q53H11|https://www.uniprot.org/uniprot/Q53GW9|https://www.uniprot.org/uniprot/Q28589|https://www.uniprot.org/uniprot/Q04790|https://www.uniprot.org/uniprot/P33896|https://www.uniprot.org/uniprot/P17181|https://www.uniprot.org/uniprot/D3DSF0|https://www.uniprot.org/uniprot/B4DNT3|https://www.uniprot.org/uniprot/B2R6L9
T444 40902-40907 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T453 40992-41005 Protein denotes Interleukin 5 https://www.uniprot.org/uniprot/Q9XT91|https://www.uniprot.org/uniprot/Q9MYM5|https://www.uniprot.org/uniprot/Q9ESI9|https://www.uniprot.org/uniprot/Q95J76|https://www.uniprot.org/uniprot/Q62575|https://www.uniprot.org/uniprot/Q28586|https://www.uniprot.org/uniprot/Q13840|https://www.uniprot.org/uniprot/Q08125|https://www.uniprot.org/uniprot/P52173|https://www.uniprot.org/uniprot/P48093|https://www.uniprot.org/uniprot/P46685|https://www.uniprot.org/uniprot/P05113|https://www.uniprot.org/uniprot/P04401|https://www.uniprot.org/uniprot/O77515|https://www.uniprot.org/uniprot/O62740|https://www.uniprot.org/uniprot/O08987|https://www.uniprot.org/uniprot/O02699|https://www.uniprot.org/uniprot/A9QWQ8
T471 41184-41189 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T480 41314-41344 Protein denotes Angiopoietin‐related protein 3 https://www.uniprot.org/uniprot/Q9Y5C1|https://www.uniprot.org/uniprot/Q9R182|https://www.uniprot.org/uniprot/B2RCW1|https://www.uniprot.org/uniprot/B1ALJ0|https://www.uniprot.org/uniprot/A0JLS0
T485 41426-41430 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T494 41549-41564 Protein denotes Interleukin 17A https://www.uniprot.org/uniprot/Q95L56|https://www.uniprot.org/uniprot/Q687Y7|https://www.uniprot.org/uniprot/Q62386|https://www.uniprot.org/uniprot/Q61453|https://www.uniprot.org/uniprot/Q60I29|https://www.uniprot.org/uniprot/Q60971|https://www.uniprot.org/uniprot/Q5T2P0|https://www.uniprot.org/uniprot/Q16552
T502 41801-41828 Protein denotes C chemokine receptor type 4 https://www.uniprot.org/uniprot/Q9ULY7|https://www.uniprot.org/uniprot/Q9ULY6|https://www.uniprot.org/uniprot/Q8MJW8|https://www.uniprot.org/uniprot/Q14A03|https://www.uniprot.org/uniprot/P51680|https://www.uniprot.org/uniprot/P51679
T508 41830-41834 Protein denotes CCR4 https://www.uniprot.org/uniprot/Q9ULY7|https://www.uniprot.org/uniprot/Q9ULY6|https://www.uniprot.org/uniprot/Q8MJW8|https://www.uniprot.org/uniprot/Q14A03|https://www.uniprot.org/uniprot/P51680|https://www.uniprot.org/uniprot/P51679
T514 41973-41977 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T523 42071-42075 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T531 42165-42169 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T538 42277-42281 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T545 42379-42383 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T553 42591-42597 Protein denotes IL‐36R https://www.uniprot.org/uniprot/Q9HB29|https://www.uniprot.org/uniprot/Q587I8|https://www.uniprot.org/uniprot/Q53TU8|https://www.uniprot.org/uniprot/Q45H74|https://www.uniprot.org/uniprot/Q13525|https://www.uniprot.org/uniprot/A4FU63
T559 42782-42786 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T567 43011-43015 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T575 43085-43089 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T582 44085-44089 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T589 44707-44711 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T596 45170-45174 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T605 46164-46168 Protein denotes CD20 https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4
T612 47951-47957 Protein denotes CTLA‐4 https://www.uniprot.org/uniprot/Q9XSI1|https://www.uniprot.org/uniprot/Q9UKN9|https://www.uniprot.org/uniprot/Q9TT02|https://www.uniprot.org/uniprot/Q9QZZ7|https://www.uniprot.org/uniprot/Q9MYX7|https://www.uniprot.org/uniprot/Q96P43|https://www.uniprot.org/uniprot/Q8WXJ1|https://www.uniprot.org/uniprot/Q5S005|https://www.uniprot.org/uniprot/Q53TD5|https://www.uniprot.org/uniprot/Q52MC1|https://www.uniprot.org/uniprot/Q0PP65|https://www.uniprot.org/uniprot/P42072|https://www.uniprot.org/uniprot/P16410|https://www.uniprot.org/uniprot/P09793|https://www.uniprot.org/uniprot/O95653|https://www.uniprot.org/uniprot/E9PDH0|https://www.uniprot.org/uniprot/A0N1S0
T629 47965-47970 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T638 47971-47975 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T646 48185-48189 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T654 48417-48423 Protein denotes CTLA‐4 https://www.uniprot.org/uniprot/Q9XSI1|https://www.uniprot.org/uniprot/Q9UKN9|https://www.uniprot.org/uniprot/Q9TT02|https://www.uniprot.org/uniprot/Q9QZZ7|https://www.uniprot.org/uniprot/Q9MYX7|https://www.uniprot.org/uniprot/Q96P43|https://www.uniprot.org/uniprot/Q8WXJ1|https://www.uniprot.org/uniprot/Q5S005|https://www.uniprot.org/uniprot/Q53TD5|https://www.uniprot.org/uniprot/Q52MC1|https://www.uniprot.org/uniprot/Q0PP65|https://www.uniprot.org/uniprot/P42072|https://www.uniprot.org/uniprot/P16410|https://www.uniprot.org/uniprot/P09793|https://www.uniprot.org/uniprot/O95653|https://www.uniprot.org/uniprot/E9PDH0|https://www.uniprot.org/uniprot/A0N1S0
T671 48827-48831 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T679 49142-49146 Protein denotes CD28 https://www.uniprot.org/uniprot/Q9BYV0|https://www.uniprot.org/uniprot/Q8WXJ2|https://www.uniprot.org/uniprot/Q8NI56|https://www.uniprot.org/uniprot/Q8NI55|https://www.uniprot.org/uniprot/Q8NI54|https://www.uniprot.org/uniprot/Q70WG0|https://www.uniprot.org/uniprot/Q6GSH7|https://www.uniprot.org/uniprot/Q52M23|https://www.uniprot.org/uniprot/Q28071|https://www.uniprot.org/uniprot/Q13964|https://www.uniprot.org/uniprot/P42069|https://www.uniprot.org/uniprot/P31042|https://www.uniprot.org/uniprot/P31041|https://www.uniprot.org/uniprot/P10747|https://www.uniprot.org/uniprot/O02757|https://www.uniprot.org/uniprot/A8KAC1
T695 49486-49491 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T704 50299-50304 Protein denotes PD‐L1 https://www.uniprot.org/uniprot/Q9NZQ7|https://www.uniprot.org/uniprot/Q9NUZ5|https://www.uniprot.org/uniprot/Q9EP73|https://www.uniprot.org/uniprot/Q6WEX4|https://www.uniprot.org/uniprot/Q66RK1|https://www.uniprot.org/uniprot/Q2V8D5|https://www.uniprot.org/uniprot/Q14CJ2|https://www.uniprot.org/uniprot/B4DU27|https://www.uniprot.org/uniprot/B2RBA2
T713 50328-50338 Protein denotes interferon https://www.uniprot.org/uniprot/P51527|https://www.uniprot.org/uniprot/P51526
T715 50744-50748 Protein denotes PD‐1 https://www.uniprot.org/uniprot/Q7M4M5|https://www.uniprot.org/uniprot/Q6NZ54|https://www.uniprot.org/uniprot/Q3KQW2|https://www.uniprot.org/uniprot/P18621|https://www.uniprot.org/uniprot/J3QL51|https://www.uniprot.org/uniprot/B5ME31|https://www.uniprot.org/uniprot/B4E3C2|https://www.uniprot.org/uniprot/B2R4H3
T723 52250-52254 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T726 52899-52903 Protein denotes CD19 https://www.uniprot.org/uniprot/Q9BRD6|https://www.uniprot.org/uniprot/Q96S68|https://www.uniprot.org/uniprot/Q542B2|https://www.uniprot.org/uniprot/Q3LRP3|https://www.uniprot.org/uniprot/P25918|https://www.uniprot.org/uniprot/P25917|https://www.uniprot.org/uniprot/P15391|https://www.uniprot.org/uniprot/F5H635|https://www.uniprot.org/uniprot/A0N0P9
T735 53540-53544 Protein denotes mast https://www.uniprot.org/uniprot/Q9NL57|https://www.uniprot.org/uniprot/Q9NBD7|https://www.uniprot.org/uniprot/A4V279
T738 55771-55794 Protein denotes costimulatory molecules https://www.uniprot.org/uniprot/Q9BXR1|https://www.uniprot.org/uniprot/Q8VE98|https://www.uniprot.org/uniprot/Q8NCB6|https://www.uniprot.org/uniprot/Q8NC34|https://www.uniprot.org/uniprot/Q8NBI8|https://www.uniprot.org/uniprot/Q7TPB4|https://www.uniprot.org/uniprot/Q6UXI2|https://www.uniprot.org/uniprot/Q6P5Y4|https://www.uniprot.org/uniprot/Q5ZPR3
T747 55840-55844 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T773 56154-56158 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T799 56408-56412 Protein denotes CD40 https://www.uniprot.org/uniprot/Q9BYU0|https://www.uniprot.org/uniprot/Q99NE3|https://www.uniprot.org/uniprot/Q99NE2|https://www.uniprot.org/uniprot/Q99NE1|https://www.uniprot.org/uniprot/Q99NE0|https://www.uniprot.org/uniprot/Q8SQ34|https://www.uniprot.org/uniprot/Q8K2X6|https://www.uniprot.org/uniprot/Q86YK5|https://www.uniprot.org/uniprot/Q7YRL5|https://www.uniprot.org/uniprot/Q7M4Q8|https://www.uniprot.org/uniprot/Q5U007|https://www.uniprot.org/uniprot/Q5JY15|https://www.uniprot.org/uniprot/Q542B1|https://www.uniprot.org/uniprot/Q53GN5|https://www.uniprot.org/uniprot/Q3ZTK5|https://www.uniprot.org/uniprot/Q3UBH3|https://www.uniprot.org/uniprot/Q3U7C9|https://www.uniprot.org/uniprot/Q3U799|https://www.uniprot.org/uniprot/Q3TSL2|https://www.uniprot.org/uniprot/Q3TS33|https://www.uniprot.org/uniprot/Q3LRP1|https://www.uniprot.org/uniprot/Q28203|https://www.uniprot.org/uniprot/P27512|https://www.uniprot.org/uniprot/P25942|https://www.uniprot.org/uniprot/E1P5S9|https://www.uniprot.org/uniprot/A7YWS9
T825 57112-57117 Protein denotes CD137 https://www.uniprot.org/uniprot/Q07011|https://www.uniprot.org/uniprot/P20334
T827 59465-59469 Protein denotes full https://www.uniprot.org/uniprot/Q8N1N2

LitCovid-sample-PD-FMA

Id Subject Object Predicate Lexical cue fma_id
T14 818-827 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T15 905-919 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T16 920-925 Body_part denotes (Ig)E http://purl.org/sig/ont/fma/fma62875
T17 921-923 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T18 967-971 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T19 1130-1133 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T20 1241-1247 Body_part denotes plasma http://purl.org/sig/ont/fma/fma62970
T21 1432-1444 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T22 1432-1436 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T23 1556-1559 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T24 2281-2285 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T25 2289-2297 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T26 2308-2312 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T27 2356-2364 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T28 2375-2379 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T29 2571-2579 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T30 2772-2780 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T31 2865-2870 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T32 2880-2904 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T33 2899-2904 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T34 3270-3274 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T35 3347-3366 Body_part denotes Natural killer cell http://purl.org/sig/ont/fma/fma63147
T36 3362-3366 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T37 3367-3375 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T38 3386-3390 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T39 3431-3439 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T40 3450-3454 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T41 3738-3762 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T42 3757-3762 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T43 3789-3793 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T44 3836-3844 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T45 3893-3897 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T46 3970-3975 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T47 3984-3995 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T48 4000-4009 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T49 4026-4029 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T50 4178-4186 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T51 4332-4336 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T52 4598-4602 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T53 4647-4655 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T54 4675-4679 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T55 4724-4728 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T56 4806-4811 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T57 4838-4847 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T58 4898-4906 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T59 4920-4928 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T60 4939-4943 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T61 4987-4991 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T62 5002-5004 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T63 5006-5020 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T64 5213-5221 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T65 5232-5236 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T66 5285-5289 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T67 5300-5308 Body_part denotes Antibody http://purl.org/sig/ont/fma/fma62871
T68 5319-5323 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T69 5386-5390 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T70 5525-5529 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T71 5554-5558 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T72 5573-5581 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T73 5612-5616 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T74 5950-5954 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T75 6010-6014 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T76 6053-6057 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T77 6089-6097 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T78 6538-6542 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T79 6603-6606 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T80 6632-6641 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T81 6719-6722 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T82 6763-6773 Body_part denotes antibody’s http://purl.org/sig/ont/fma/fma62871
T83 6797-6802 Body_part denotes serum http://purl.org/sig/ont/fma/fma63083
T84 7040-7049 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T85 7490-7494 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T86 7851-7855 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T87 7895-7899 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T88 8203-8212 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T89 8812-8815 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T90 8829-8833 Body_part denotes Cell http://purl.org/sig/ont/fma/fma68646
T91 8905-8914 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T92 8916-8927 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T93 8929-8940 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T94 8942-8956 Body_part denotes dendritic cell http://purl.org/sig/ont/fma/fma273565
T95 8952-8956 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T96 8973-8983 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T97 8978-8983 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T98 9079-9089 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T99 9094-9103 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T100 9117-9130 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T101 9165-9173 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T102 9168-9173 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T103 9202-9210 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T104 9205-9210 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T105 9212-9223 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T106 9254-9263 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T107 9273-9288 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T108 9283-9288 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T109 9290-9301 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T110 9395-9406 Body_part denotes Neutrophils http://purl.org/sig/ont/fma/fma62860
T111 9439-9452 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T112 9459-9468 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T113 9491-9500 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T114 9502-9513 Body_part denotes eosinophils http://purl.org/sig/ont/fma/fma62861
T115 9540-9555 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T116 9550-9555 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T117 9557-9565 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T118 9560-9565 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T119 9600-9604 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T120 9641-9647 Body_part denotes muscle http://purl.org/sig/ont/fma/fma32558
T121 9655-9663 Body_part denotes placenta http://purl.org/sig/ont/fma/fma63934
T122 9665-9690 Body_part denotes follicular dendritic cell http://purl.org/sig/ont/fma/fma83037
T123 9686-9690 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T124 9691-9693 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T125 9695-9709 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T126 9711-9718 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T127 9714-9718 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T128 9720-9739 Body_part denotes natural killer cell http://purl.org/sig/ont/fma/fma63147
T129 9735-9739 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T130 10131-10134 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T131 10158-10161 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T132 10880-10883 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T133 10902-10904 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T134 10906-10920 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T135 11273-11290 Body_part denotes hemopoietic cells http://purl.org/sig/ont/fma/fma83598
T136 11285-11290 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T137 11295-11301 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T138 11328-11337 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T139 11596-11600 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T140 11638-11648 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T141 11654-11663 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T142 11868-11873 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T143 11903-11911 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T144 12016-12024 Body_part denotes monocyte http://purl.org/sig/ont/fma/fma62864
T145 12079-12090 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T146 12178-12187 Body_part denotes leukocyte http://purl.org/sig/ont/fma/fma62852
T147 12279-12288 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T148 12313-12322 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T149 12324-12335 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T150 12337-12348 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T151 12350-12366 Body_part denotes microglial cells http://purl.org/sig/ont/fma/fma54539
T152 12361-12366 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T153 12374-12379 Body_part denotes brain http://purl.org/sig/ont/fma/fma50801
T154 12381-12396 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T155 12391-12396 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T156 12401-12411 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T157 12406-12411 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T158 12813-12823 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T159 12847-12856 Body_part denotes platelets http://purl.org/sig/ont/fma/fma62851
T160 13125-13136 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T161 13210-13220 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T162 13410-13420 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T163 13443-13445 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T164 13536-13546 Body_part denotes nucleotide http://purl.org/sig/ont/fma/fma82740
T165 13684-13689 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T166 13710-13714 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T167 13848-13859 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T168 14198-14202 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T169 14265-14273 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T170 14268-14273 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T171 14316-14327 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T172 14388-14399 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T173 14531-14544 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T174 14531-14535 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T175 14633-14644 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T176 14751-14762 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T177 14895-14899 Body_part denotes gene http://purl.org/sig/ont/fma/fma74402
T178 15077-15081 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T179 15172-15177 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T180 15245-15251 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T181 15310-15323 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T182 15338-15348 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T183 15349-15360 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T184 15429-15433 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T185 15515-15524 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T186 15529-15540 Body_part denotes neutrophils http://purl.org/sig/ont/fma/fma62860
T187 15574-15584 Body_part denotes mast cells http://purl.org/sig/ont/fma/fma66784
T188 15579-15584 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T189 15586-15601 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T190 15596-15601 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T191 15611-15620 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T192 15621-15632 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T193 15653-15664 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T194 15844-15849 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T195 15877-15883 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T196 15926-15931 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T197 16022-16034 Body_part denotes T‐lymphocyte http://purl.org/sig/ont/fma/fma62870
T198 16071-16076 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T199 16103-16108 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T200 16224-16232 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T201 16303-16308 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T202 16398-16416 Body_part denotes hematopoietic cell http://purl.org/sig/ont/fma/fma83598
T203 16412-16416 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T204 16526-16531 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T205 16726-16751 Body_part denotes follicular dendritic cell http://purl.org/sig/ont/fma/fma83037
T206 16747-16751 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T207 16767-16773 Body_part denotes muscle http://purl.org/sig/ont/fma/fma32558
T208 16778-16783 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T209 16784-16795 Body_part denotes endothelium http://purl.org/sig/ont/fma/fma63916
T210 16824-16829 Body_part denotes liver http://purl.org/sig/ont/fma/fma7197
T211 16830-16840 Body_part denotes sinusoidal http://purl.org/sig/ont/fma/fma63131
T212 16841-16858 Body_part denotes endothelial cells http://purl.org/sig/ont/fma/fma66772
T213 16853-16858 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T214 17047-17052 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T215 17145-17151 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T216 17748-17752 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T217 17776-17779 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T218 17799-17802 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T219 18072-18085 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T220 18072-18076 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T221 18106-18114 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T222 18279-18283 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T223 18439-18447 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T224 18474-18485 Body_part denotes cytoplasmic http://purl.org/sig/ont/fma/fma66835
T225 18570-18578 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T226 18663-18671 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T227 18689-18697 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T228 18747-18752 Body_part denotes lipid http://purl.org/sig/ont/fma/fma67264
T229 18756-18763 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T230 18764-18772 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T231 18826-18830 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T232 19202-19205 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T233 19260-19265 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T234 19430-19433 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T235 20113-20118 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T236 20147-20165 Body_part denotes actin cytoskeleton http://purl.org/sig/ont/fma/fma84684
T237 20188-20205 Body_part denotes glycosaminoglycan http://purl.org/sig/ont/fma/fma63011
T238 20206-20216 Body_part denotes glycocalyx http://purl.org/sig/ont/fma/fma66838
T239 20261-20274 Body_part denotes glycoproteins http://purl.org/sig/ont/fma/fma62925
T240 20447-20451 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T241 20700-20704 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T242 21088-21096 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T243 21223-21231 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T244 21380-21393 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T245 21380-21384 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T246 21752-21757 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T247 22034-22047 Body_part denotes cell membrane http://purl.org/sig/ont/fma/fma63841
T248 22034-22038 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T249 22669-22677 Body_part denotes NK cells http://purl.org/sig/ont/fma/fma63147
T250 22672-22677 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T251 22714-22725 Body_part denotes macrophages http://purl.org/sig/ont/fma/fma63261
T252 22766-22773 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T253 22769-22773 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T254 23217-23221 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T255 23342-23346 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T256 23601-23605 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T257 23778-23782 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T258 23794-23804 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T259 23892-23895 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T260 23921-23924 Body_part denotes IgA http://purl.org/sig/ont/fma/fma62874
T261 24092-24096 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T262 24135-24140 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T263 24221-24225 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T264 24406-24410 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T265 24929-24935 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T266 25175-25178 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T267 25280-25289 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T268 25293-25296 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T269 25323-25331 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T270 25385-25393 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T271 26257-26265 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T272 26360-26384 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T273 26379-26384 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T274 26417-26432 Body_part denotes dendritic cells http://purl.org/sig/ont/fma/fma273565
T275 26427-26432 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T276 26446-26459 Body_part denotes B lymphocytes http://purl.org/sig/ont/fma/fma62869
T277 26486-26518 Body_part denotes major histocompatibility complex http://purl.org/sig/ont/fma/fma84079
T278 26566-26572 Body_part denotes stroma http://purl.org/sig/ont/fma/fma81494
T279 26581-26607 Body_part denotes follicular dendritic cells http://purl.org/sig/ont/fma/fma83037
T280 26602-26607 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T281 26619-26627 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T282 26658-26666 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T283 26684-26696 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T284 26684-26688 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T285 26737-26742 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T286 26873-26884 Body_part denotes lymphocytes http://purl.org/sig/ont/fma/fma62863
T287 26985-26989 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T288 27010-27015 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T289 27032-27037 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T290 27139-27142 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T291 27181-27193 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T292 27181-27185 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T293 27206-27210 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T294 27325-27329 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T295 27432-27436 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T296 27538-27542 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T297 27600-27604 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T298 27725-27729 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T299 27777-27782 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T300 27800-27809 Body_part denotes monocytes http://purl.org/sig/ont/fma/fma62864
T301 27827-27831 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T302 27846-27854 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T303 27915-27920 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T304 28220-28224 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T305 28337-28341 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T306 28453-28458 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T307 28498-28501 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T308 28643-28646 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T309 28679-28682 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T310 28829-28841 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T311 28829-28833 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T312 29140-29143 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T313 29253-29256 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T314 29383-29386 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T315 29484-29487 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T316 29498-29501 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T317 29624-29629 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T318 29743-29746 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T319 29812-29822 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T320 30533-30546 Body_part denotes phenylalanine http://purl.org/sig/ont/fma/fma82754
T321 30547-30553 Body_part denotes valine http://purl.org/sig/ont/fma/fma82766
T322 30587-30590 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T323 31063-31072 Body_part denotes histidine http://purl.org/sig/ont/fma/fma82755
T324 31096-31099 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T325 31293-31301 Body_part denotes arginine http://purl.org/sig/ont/fma/fma82763
T326 31326-31329 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T327 31391-31394 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T328 31613-31616 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T329 31656-31659 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T330 31867-31870 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T331 32436-32439 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T332 32636-32639 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T333 32717-32723 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T334 32741-32756 Body_part denotes oligosaccharide http://purl.org/sig/ont/fma/fma82742
T335 33856-33867 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T336 33916-33924 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T337 33930-33933 Body_part denotes arm http://purl.org/sig/ont/fma/fma24890
T338 35274-35281 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T339 35350-35358 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T340 35603-35606 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T341 35659-35664 Body_part denotes chest http://purl.org/sig/ont/fma/fma9576
T342 36105-36108 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T343 36269-36272 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T344 36331-36334 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T345 36746-36754 Body_part denotes cytokine http://purl.org/sig/ont/fma/fma84050
T346 36968-36976 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T347 37397-37400 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T348 37431-37434 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T349 37953-37957 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T350 37978-37982 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T351 38279-38287 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T352 38594-38599 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T353 38702-38712 Body_part denotes macrophage http://purl.org/sig/ont/fma/fma63261
T354 38747-38751 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T355 38929-38933 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T356 38965-38969 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T357 39128-39132 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T358 39766-39771 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T359 40352-40362 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T360 40530-40533 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T361 40534-40542 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T362 40992-41005 Body_part denotes Interleukin 5 http://purl.org/sig/ont/fma/fma264830
T363 40992-41003 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578
T364 41093-41096 Body_part denotes ear http://purl.org/sig/ont/fma/fma52780
T365 41097-41101 Body_part denotes nose http://purl.org/sig/ont/fma/fma46472
T366 41102-41108 Body_part denotes throat http://purl.org/sig/ont/fma/fma228738
T367 41335-41342 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T368 41493-41515 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T369 41549-41560 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578
T370 41803-41812 Body_part denotes chemokine http://purl.org/sig/ont/fma/fma241981
T371 41898-41920 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T372 43152-43174 Body_part denotes Central nervous system http://purl.org/sig/ont/fma/fma55675
T373 43196-43198 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T374 43200-43214 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871
T375 43666-43672 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T376 43676-43686 Body_part denotes Antibodies http://purl.org/sig/ont/fma/fma62871
T377 43702-43708 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T378 44380-44387 Body_part denotes NK cell http://purl.org/sig/ont/fma/fma63147
T379 44383-44387 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T380 44415-44425 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T381 44501-44511 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T382 44774-44785 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T383 44825-44831 Body_part denotes fucose http://purl.org/sig/ont/fma/fma82790
T384 45036-45047 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T385 45066-45077 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T386 45110-45113 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T387 45175-45183 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T388 45265-45276 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T389 45729-45740 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T390 46053-46058 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T391 46325-46336 Body_part denotes lymphocytic http://purl.org/sig/ont/fma/fma62863
T392 46741-46744 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T393 46865-46868 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T394 47241-47244 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T395 47543-47552 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T396 47699-47702 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T397 47841-47850 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T398 48122-48130 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T399 48424-48432 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T400 48454-48462 Body_part denotes backbone http://purl.org/sig/ont/fma/fma13478
T401 48505-48510 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T402 48712-48722 Body_part denotes neutrophil http://purl.org/sig/ont/fma/fma62860
T403 49618-49628 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T404 49765-49772 Body_part denotes leucine http://purl.org/sig/ont/fma/fma82757
T405 49840-49847 Body_part denotes alanine http://purl.org/sig/ont/fma/fma82749
T406 50077-50087 Body_part denotes amino acid http://purl.org/sig/ont/fma/fma82739
T407 50253-50264 Body_part denotes amino acids http://purl.org/sig/ont/fma/fma82739
T408 50749-50757 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T409 51179-51181 Body_part denotes Ig http://purl.org/sig/ont/fma/fma62871
T410 51458-51467 Body_part denotes backbones http://purl.org/sig/ont/fma/fma13478
T411 51841-51849 Body_part denotes tyrosine http://purl.org/sig/ont/fma/fma82768
T412 52080-52088 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T413 52168-52173 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T414 52236-52245 Body_part denotes basophils http://purl.org/sig/ont/fma/fma62862
T415 52250-52259 Body_part denotes mast cell http://purl.org/sig/ont/fma/fma66784
T416 52255-52259 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T417 52332-52342 Body_part denotes leukocytes http://purl.org/sig/ont/fma/fma62852
T418 52346-52354 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T419 52364-52370 Body_part denotes tissue http://purl.org/sig/ont/fma/fma9637
T420 52507-52519 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T421 52507-52511 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T422 53170-53175 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T423 53188-53191 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T424 53475-53478 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T425 53527-53535 Body_part denotes basophil http://purl.org/sig/ont/fma/fma62862
T426 53540-53549 Body_part denotes mast cell http://purl.org/sig/ont/fma/fma66784
T427 53545-53549 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T428 53664-53667 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T429 53689-53693 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T430 53694-53697 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T431 53739-53742 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T432 53756-53768 Body_part denotes cell surface http://purl.org/sig/ont/fma/fma67653
T433 53756-53760 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T434 53880-53883 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T435 53898-53901 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T436 53905-53910 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T437 53952-53955 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T438 54043-54046 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T439 54176-54184 Body_part denotes arginine http://purl.org/sig/ont/fma/fma82763
T440 54203-54206 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T441 55074-55084 Body_part denotes Antibodies http://purl.org/sig/ont/fma/fma62871
T442 55098-55106 Body_part denotes proteins http://purl.org/sig/ont/fma/fma67257
T443 55177-55180 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T444 55184-55193 Body_part denotes cytokines http://purl.org/sig/ont/fma/fma84050
T445 55410-55413 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T446 55469-55472 Body_part denotes IgE http://purl.org/sig/ont/fma/fma62875
T447 55645-55650 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T448 55798-55822 Body_part denotes antigen‐presenting cells http://purl.org/sig/ont/fma/fma273565
T449 55817-55822 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T450 55828-55833 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T451 55918-55923 Body_part denotes cells http://purl.org/sig/ont/fma/fma68646
T452 57118-57126 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T453 57444-57452 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T454 57584-57587 Body_part denotes IgG http://purl.org/sig/ont/fma/fma62872
T455 57939-57947 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T456 58223-58231 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T457 59398-59411 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T458 59497-59505 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871

LitCovid-sample-PD-MAT

Id Subject Object Predicate Lexical cue
T1 9634-9647 http://purl.obolibrary.org/obo/MAT_0000303 denotes smooth muscle
T2 9641-9647 http://purl.obolibrary.org/obo/MAT_0000025 denotes muscle
T3 9655-9663 http://purl.obolibrary.org/obo/MAT_0000279 denotes placenta
T4 11812-11817 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T5 12374-12379 http://purl.obolibrary.org/obo/MAT_0000098 denotes brain
T6 16760-16773 http://purl.obolibrary.org/obo/MAT_0000303 denotes smooth muscle
T7 16767-16773 http://purl.obolibrary.org/obo/MAT_0000025 denotes muscle
T8 16778-16783 http://purl.obolibrary.org/obo/MAT_0000097 denotes liver
T9 16824-16829 http://purl.obolibrary.org/obo/MAT_0000097 denotes liver
T10 21798-21806 http://purl.obolibrary.org/obo/MAT_0000491 denotes proximal
T11 23320-23325 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T12 24205-24210 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T13 41093-41096 http://purl.obolibrary.org/obo/MAT_0000317 denotes ear
T14 41093-41096 http://purl.obolibrary.org/obo/MAT_0000233 denotes ear
T15 41093-41096 http://purl.obolibrary.org/obo/MAT_0000138 denotes ear
T16 41097-41101 http://purl.obolibrary.org/obo/MAT_0000139 denotes nose
T17 41493-41515 http://purl.obolibrary.org/obo/MAT_0000457 denotes Central nervous system
T18 41501-41515 http://purl.obolibrary.org/obo/MAT_0000026 denotes nervous system
T19 41898-41920 http://purl.obolibrary.org/obo/MAT_0000457 denotes Central nervous system
T20 41906-41920 http://purl.obolibrary.org/obo/MAT_0000026 denotes nervous system
T21 43152-43174 http://purl.obolibrary.org/obo/MAT_0000457 denotes Central nervous system
T22 43160-43174 http://purl.obolibrary.org/obo/MAT_0000026 denotes nervous system
T23 53642-53647 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T24 54136-54141 http://purl.obolibrary.org/obo/MAT_0000488 denotes later
T25 56296-56304 http://purl.obolibrary.org/obo/MAT_0000491 denotes proximal

LitCovid-sample-PD-GO-BP-0

Id Subject Object Predicate Lexical cue
T3 967-982 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T4 1041-1063 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T5 1054-1063 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T6 1260-1281 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T7 2336-2340 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T8 2389-2401 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T9 2403-2415 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T10 2623-2632 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T11 2940-2960 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T12 3464-3476 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T13 3705-3725 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T14 3775-3804 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T15 3789-3804 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T16 3878-3887 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T17 3956-3969 http://purl.obolibrary.org/obo/GO_0045087 denotes innate immune
T18 4132-4147 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T19 4247-4259 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T20 4290-4299 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T21 4456-4472 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T22 4743-4765 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T23 4756-4765 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T24 4825-4834 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T25 4914-4918 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T26 5333-5345 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T27 5417-5437 http://purl.obolibrary.org/obo/GO_0019882 denotes Antigen presentation
T28 5523-5543 http://purl.obolibrary.org/obo/GO_0042100 denotes B‐cell proliferation
T29 5525-5543 http://purl.obolibrary.org/obo/GO_0008283 denotes cell proliferation
T30 5554-5569 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T31 5612-5627 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T32 5882-5891 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T33 5882-5891 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T34 10676-10684 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T35 10893-10901 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T36 12604-12620 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T37 14937-14946 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T38 15005-15015 http://purl.obolibrary.org/obo/GO_0065007 denotes regulation
T39 15067-15092 http://purl.obolibrary.org/obo/GO_0050869 denotes inhibit B‐cell activation
T40 15075-15092 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T41 15077-15092 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T42 15394-15403 http://purl.obolibrary.org/obo/GO_0051235 denotes retention
T43 16994-17003 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T44 17164-17186 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammatory responses
T45 17557-17566 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T46 17643-17652 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T47 18115-18130 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T48 18322-18331 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T49 18599-18608 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T50 18698-18713 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T51 18773-18785 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T52 18826-18841 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T53 19274-19286 http://purl.obolibrary.org/obo/GO_0008228 denotes opsonization
T54 19943-19947 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T55 20447-20462 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T56 20602-20617 http://purl.obolibrary.org/obo/GO_1990256 denotes ligand, cluster
T57 20857-20861 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T58 20874-20878 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T59 20990-21001 http://purl.obolibrary.org/obo/GO_0000746 denotes conjugation
T60 21135-21139 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T61 21156-21189 http://purl.obolibrary.org/obo/GO_0097278 denotes complement‐dependent cytotoxicity
T62 21564-21568 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T63 22493-22497 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T64 22502-22514 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T65 22515-22519 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T66 22774-22778 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T67 23217-23229 http://purl.obolibrary.org/obo/GO_0001906 denotes cell killing
T68 23328-23357 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T69 23342-23357 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T70 23471-23480 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T71 23573-23582 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T72 23599-23616 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T73 23601-23616 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T74 24219-24236 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T75 24221-24236 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T76 24675-24687 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T77 24688-24699 http://purl.obolibrary.org/obo/GO_0006897 denotes endocytosis
T78 25304-25310 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T79 25358-25373 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T80 25577-25583 http://purl.obolibrary.org/obo/GO_0007613 denotes memory
T81 25854-25860 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T82 26019-26039 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T83 26486-26518 http://purl.obolibrary.org/obo/GO_0046776 denotes major histocompatibility complex
T84 26529-26549 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen presentation
T85 26951-26967 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T86 27827-27841 http://purl.obolibrary.org/obo/GO_0016049 denotes cell expansion
T87 27846-27864 http://purl.obolibrary.org/obo/GO_0050663 denotes cytokine secretion
T88 27855-27864 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T89 28319-28324 http://purl.obolibrary.org/obo/GO_0016265 denotes death
T90 29710-29722 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T91 33935-33943 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T92 34265-34273 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T93 35163-35174 http://purl.obolibrary.org/obo/GO_0006508 denotes proteolysis
T94 36528-36546 http://purl.obolibrary.org/obo/GO_0006956 denotes complement cascade
T95 36731-36735 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T96 37754-37758 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T97 37762-37774 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T98 37943-37963 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptotic cell death
T99 37953-37963 http://purl.obolibrary.org/obo/GO_0008219 denotes cell death
T100 37958-37963 http://purl.obolibrary.org/obo/GO_0016265 denotes death
T101 38027-38036 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T102 38054-38058 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T103 38118-38122 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T104 38242-38246 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T105 38830-38839 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T106 39735-39739 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T107 44071-44075 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T108 44397-44401 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T109 44435-44447 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T110 45483-45487 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 45492-45504 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 45536-45542 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 45579-45583 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 46034-46038 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 46500-46504 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T116 48347-48355 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T117 48482-48486 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T118 48712-48733 http://purl.obolibrary.org/obo/GO_0042119 denotes neutrophil activation
T119 48738-48747 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T120 48738-48747 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T121 49570-49591 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T122 51182-51190 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 51303-51324 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T124 52038-52056 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathways
T125 52038-52047 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T126 52119-52128 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T127 52412-52421 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T128 52585-52594 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T129 53125-53134 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T130 53540-53560 http://purl.obolibrary.org/obo/GO_0045576 denotes mast cell activation
T131 53545-53560 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T132 55666-55675 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T133 55870-55879 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T134 55870-55879 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T135 55892-55897 http://purl.obolibrary.org/obo/GO_0016265 denotes death
T136 56725-56730 http://purl.obolibrary.org/obo/GO_0016265 denotes death
T137 56751-56757 http://purl.obolibrary.org/obo/GO_0040007 denotes growth

LitCovid-sample-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T6 325-346 Disease denotes inflammatory diseases http://purl.obolibrary.org/obo/MONDO_0021166
T7 831-849 Disease denotes autoimmune disease http://purl.obolibrary.org/obo/MONDO_0007179
T8 883-901 Disease denotes virus in infection http://purl.obolibrary.org/obo/MONDO_0005108
T9 929-936 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T10 1811-1817 Disease denotes injury http://purl.obolibrary.org/obo/MONDO_0021178
T11 6285-6293 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T12 9877-9885 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T13 11027-11035 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T14 12942-12966 Disease denotes immune thrombocytopenias http://purl.obolibrary.org/obo/MONDO_0002048
T15 13285-13313 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T16 13428-13439 Disease denotes anaphylaxis http://purl.obolibrary.org/obo/MONDO_0100053
T17 22865-22871 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T18 25712-25717 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T19 29710-29722 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166
T20 37825-37831 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T21 37971-37977 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T22 38130-38135 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T23 38683-38688 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T24 38740-38746 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T25 39760-39765 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T26 40178-40184 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T27 41093-41118 Disease denotes ear nose throat disorders http://purl.obolibrary.org/obo/MONDO_0024623
T28 41381-41400 Disease denotes Metabolic disorders http://purl.obolibrary.org/obo/MONDO_0005066
T29 41626-41651 Disease denotes musculoskeletal disorders http://purl.obolibrary.org/obo/MONDO_0002081
T30 42112-42130 Disease denotes Infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T31 42420-42429 Disease denotes Infection http://purl.obolibrary.org/obo/MONDO_0005550
T32 42532-42555 Disease denotes Hematological disorders http://purl.obolibrary.org/obo/MONDO_0005570
T33 42738-42757 Disease denotes Metabolic disorders http://purl.obolibrary.org/obo/MONDO_0005066
T34 43321-43329 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T35 44026-44031 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T36 44766-44794 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T37 45257-45285 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T38 45527-45535 Disease denotes lymphoma http://purl.obolibrary.org/obo/MONDO_0005062
T39 46134-46139 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T40 46292-46312 Disease denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/MONDO_0018908
T41 46317-46345 Disease denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/MONDO_0004948
T42 48073-48078 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T43 48220-48226 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T44 52193-52221 Disease denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/MONDO_0007915
T45 52851-52869 Disease denotes autoimmune disease http://purl.obolibrary.org/obo/MONDO_0007179
T46 53252-53260 Disease denotes allergic http://purl.obolibrary.org/obo/MONDO_0004980
T47 54013-54020 Disease denotes allergy http://purl.obolibrary.org/obo/MONDO_0005271
T48 55911-55917 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T49 56745-56750 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T50 58507-58525 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T51 58633-58651 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T52 58660-58707 Disease denotes severe acute respiratory syndrome coronavirus 2 http://purl.obolibrary.org/obo/MONDO_0100096
T53 58709-58719 Disease denotes SARS‐CoV‐2 http://purl.obolibrary.org/obo/MONDO_0100096
T54 58721-58730 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T55 58986-59004 Disease denotes infectious disease http://purl.obolibrary.org/obo/MONDO_0005550
T56 59038-59052 Disease denotes adenocarcinoma http://purl.obolibrary.org/obo/MONDO_0004970

LitCovid-sample-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T2 831-849 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T3 929-936 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T4 4898-4912 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T5 12942-12966 Phenotype denotes immune thrombocytopenias http://purl.obolibrary.org/obo/HP_0001973
T6 13285-13313 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T7 13428-13439 Phenotype denotes anaphylaxis http://purl.obolibrary.org/obo/HP_0100845
T8 22865-22871 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T9 25712-25717 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T10 37825-37831 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T11 37971-37977 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T12 38130-38135 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T13 38683-38688 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T14 38740-38746 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T15 39760-39765 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T16 40178-40184 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T17 40707-40715 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T18 40959-40967 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T19 41283-41291 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T20 41517-41525 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T21 41764-41772 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T22 41922-41930 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T23 42040-42048 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T24 42132-42140 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T25 42244-42252 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T26 42344-42352 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T27 42431-42439 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T28 42969-42977 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T29 43052-43060 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T30 43176-43184 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T31 44026-44031 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T32 44766-44794 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T33 45257-45285 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T34 45527-45535 Phenotype denotes lymphoma http://purl.obolibrary.org/obo/HP_0002665
T35 46134-46139 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T36 46292-46312 Phenotype denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/HP_0012539
T37 46317-46345 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T38 48073-48078 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T39 48220-48226 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T40 52193-52221 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T41 52851-52869 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T42 54013-54020 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T43 55911-55917 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T44 56745-56750 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sample-GO-BP

Id Subject Object Predicate Lexical cue
T3 967-982 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T4 1041-1063 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T5 1054-1063 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T6 1260-1281 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T7 2336-2340 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T8 2389-2401 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T9 2403-2415 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T10 2623-2632 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T11 2940-2960 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T12 3464-3476 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T13 3705-3725 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T14 3775-3804 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T15 3789-3804 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T16 3878-3887 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T17 3956-3969 http://purl.obolibrary.org/obo/GO_0045087 denotes innate immune
T18 4132-4147 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T19 4247-4259 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T20 4290-4299 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T21 4456-4472 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T22 4743-4765 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T23 4756-4765 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T24 4825-4834 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T25 4914-4918 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T26 5333-5345 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T27 5417-5437 http://purl.obolibrary.org/obo/GO_0019882 denotes Antigen presentation
T28 5523-5543 http://purl.obolibrary.org/obo/GO_0042100 denotes B‐cell proliferation
T29 5525-5543 http://purl.obolibrary.org/obo/GO_0008283 denotes cell proliferation
T30 5554-5569 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T31 5612-5627 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T32 5882-5891 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T33 5882-5891 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T34 10676-10684 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T35 10893-10901 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T36 12604-12620 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T37 14937-14946 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T38 15005-15015 http://purl.obolibrary.org/obo/GO_0065007 denotes regulation
T39 15067-15092 http://purl.obolibrary.org/obo/GO_0050869 denotes inhibit B‐cell activation
T40 15075-15092 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T41 15077-15092 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T42 15394-15403 http://purl.obolibrary.org/obo/GO_0051235 denotes retention
T43 16994-17003 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T44 17164-17186 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammatory responses
T45 17557-17566 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T46 17643-17652 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T47 18115-18130 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T48 18322-18331 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T49 18599-18608 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T50 18698-18713 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T51 18773-18785 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T52 18826-18841 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T53 19274-19286 http://purl.obolibrary.org/obo/GO_0008228 denotes opsonization
T54 19943-19947 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T55 20447-20462 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T56 20602-20617 http://purl.obolibrary.org/obo/GO_1990256 denotes ligand, cluster
T57 20857-20861 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T58 20874-20878 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T59 20990-21001 http://purl.obolibrary.org/obo/GO_0000746 denotes conjugation
T60 21135-21139 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T61 21156-21189 http://purl.obolibrary.org/obo/GO_0097278 denotes complement‐dependent cytotoxicity
T62 21564-21568 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T63 22493-22497 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T64 22502-22514 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T65 22515-22519 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T66 22774-22778 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T67 23217-23229 http://purl.obolibrary.org/obo/GO_0001906 denotes cell killing
T68 23328-23357 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T69 23342-23357 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T70 23471-23480 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T71 23573-23582 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T72 23599-23616 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T73 23601-23616 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T74 24219-24236 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T75 24221-24236 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T76 24675-24687 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T77 24688-24699 http://purl.obolibrary.org/obo/GO_0006897 denotes endocytosis
T78 25304-25310 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T79 25304-25310 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T80 25358-25373 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T81 25577-25583 http://purl.obolibrary.org/obo/GO_0007613 denotes memory
T82 25854-25860 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T83 25854-25860 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T84 26019-26039 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T85 26486-26518 http://purl.obolibrary.org/obo/GO_0046776 denotes major histocompatibility complex
T86 26529-26549 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen presentation
T87 26951-26967 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T88 27827-27841 http://purl.obolibrary.org/obo/GO_0016049 denotes cell expansion
T89 27846-27864 http://purl.obolibrary.org/obo/GO_0001816 denotes cytokine secretion
T90 27855-27864 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T91 29710-29722 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T92 33935-33943 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T93 34265-34273 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T94 35163-35174 http://purl.obolibrary.org/obo/GO_0006508 denotes proteolysis
T95 36528-36546 http://purl.obolibrary.org/obo/GO_0006956 denotes complement cascade
T96 36731-36735 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T97 37754-37758 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T98 37762-37774 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T99 37943-37963 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptotic cell death
T100 37953-37963 http://purl.obolibrary.org/obo/GO_0008219 denotes cell death
T101 38027-38036 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T102 38054-38058 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T103 38118-38122 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T104 38242-38246 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T105 38830-38839 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T106 39735-39739 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T107 44071-44075 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T108 44397-44401 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T109 44435-44447 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T110 45483-45487 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 45492-45504 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 45536-45542 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 45579-45583 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 46034-46038 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 46500-46504 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T116 48347-48355 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T117 48482-48486 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T118 48712-48733 http://purl.obolibrary.org/obo/GO_0042119 denotes neutrophil activation
T119 48738-48747 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T120 48738-48747 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T121 49570-49591 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T122 51182-51190 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 51303-51324 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T124 52038-52056 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathways
T125 52038-52047 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T126 52119-52128 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T127 52412-52421 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T128 52585-52594 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T129 53125-53134 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T130 53540-53560 http://purl.obolibrary.org/obo/GO_0045576 denotes mast cell activation
T131 53545-53560 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T132 55666-55675 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T133 55870-55879 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T134 55870-55879 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T135 56751-56757 http://purl.obolibrary.org/obo/GO_0040007 denotes growth

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T3 967-982 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T4 1041-1063 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T5 1054-1063 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T6 1260-1281 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T7 2336-2340 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T8 2389-2401 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T9 2403-2415 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T10 2623-2632 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T11 2940-2960 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T12 3464-3476 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T13 3705-3725 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T14 3775-3804 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T15 3789-3804 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T16 3878-3887 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T17 3956-3969 http://purl.obolibrary.org/obo/GO_0045087 denotes innate immune
T18 4132-4147 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T19 4247-4259 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T20 4290-4299 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T21 4456-4472 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T22 4743-4765 http://purl.obolibrary.org/obo/GO_0006915 denotes induction of apoptosis
T23 4756-4765 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T24 4825-4834 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T25 4914-4918 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T26 5333-5345 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T27 5417-5437 http://purl.obolibrary.org/obo/GO_0019882 denotes Antigen presentation
T28 5523-5543 http://purl.obolibrary.org/obo/GO_0042100 denotes B‐cell proliferation
T29 5525-5543 http://purl.obolibrary.org/obo/GO_0008283 denotes cell proliferation
T30 5554-5569 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T31 5612-5627 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T32 5882-5891 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T33 5882-5891 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T34 10676-10684 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T35 10893-10901 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T36 12604-12620 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T37 14937-14946 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T38 15005-15015 http://purl.obolibrary.org/obo/GO_0065007 denotes regulation
T39 15067-15092 http://purl.obolibrary.org/obo/GO_0050869 denotes inhibit B‐cell activation
T40 15075-15092 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T41 15077-15092 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T42 15394-15403 http://purl.obolibrary.org/obo/GO_0051235 denotes retention
T43 16994-17003 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T44 17164-17186 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammatory responses
T45 17557-17566 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T46 17643-17652 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T47 18115-18130 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T48 18322-18331 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T49 18599-18608 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T50 18698-18713 http://purl.obolibrary.org/obo/GO_0016310 denotes phosphorylation
T51 18773-18785 http://purl.obolibrary.org/obo/GO_0016791 denotes phosphatases
T52 18826-18841 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T53 19274-19286 http://purl.obolibrary.org/obo/GO_0008228 denotes opsonization
T54 19943-19947 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T55 20447-20462 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T56 20602-20617 http://purl.obolibrary.org/obo/GO_1990256 denotes ligand, cluster
T57 20857-20861 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T58 20874-20878 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T59 20990-21001 http://purl.obolibrary.org/obo/GO_0000746 denotes conjugation
T60 21135-21139 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T61 21156-21189 http://purl.obolibrary.org/obo/GO_0097278 denotes complement‐dependent cytotoxicity
T62 21564-21568 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T63 22493-22497 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T64 22502-22514 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T65 22515-22519 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T66 22774-22778 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T67 23217-23229 http://purl.obolibrary.org/obo/GO_0001906 denotes cell killing
T68 23328-23357 http://purl.obolibrary.org/obo/GO_0050866 denotes Inhibition of cell activation
T69 23342-23357 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T70 23471-23480 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T71 23573-23582 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T72 23599-23616 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T73 23601-23616 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T74 24219-24236 http://purl.obolibrary.org/obo/GO_0042113 denotes B‐cell activation
T75 24221-24236 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T76 24675-24687 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T77 24688-24699 http://purl.obolibrary.org/obo/GO_0006897 denotes endocytosis
T78 25304-25310 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T79 25304-25310 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T80 25358-25373 http://purl.obolibrary.org/obo/GO_0006955 denotes immune response
T81 25577-25583 http://purl.obolibrary.org/obo/GO_0007613 denotes memory
T82 25854-25860 http://purl.obolibrary.org/obo/GO_0098739 denotes uptake
T83 25854-25860 http://purl.obolibrary.org/obo/GO_0098657 denotes uptake
T84 26019-26039 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen‐presentation
T85 26486-26518 http://purl.obolibrary.org/obo/GO_0046776 denotes major histocompatibility complex
T86 26529-26549 http://purl.obolibrary.org/obo/GO_0019882 denotes antigen presentation
T87 26951-26967 http://purl.obolibrary.org/obo/GO_0006955 denotes immune responses
T88 27827-27841 http://purl.obolibrary.org/obo/GO_0016049 denotes cell expansion
T89 27846-27864 http://purl.obolibrary.org/obo/GO_0001816 denotes cytokine secretion
T90 27855-27864 http://purl.obolibrary.org/obo/GO_0046903 denotes secretion
T91 29710-29722 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T92 33935-33943 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T93 34265-34273 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T94 35163-35174 http://purl.obolibrary.org/obo/GO_0006508 denotes proteolysis
T95 36528-36546 http://purl.obolibrary.org/obo/GO_0006956 denotes complement cascade
T96 36731-36735 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T97 37754-37758 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T98 37762-37774 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T99 37943-37963 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptotic cell death
T100 37953-37963 http://purl.obolibrary.org/obo/GO_0008219 denotes cell death
T101 38027-38036 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T102 38054-38058 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T103 38118-38122 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T104 38242-38246 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T105 38830-38839 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T106 39735-39739 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T107 44071-44075 http://purl.obolibrary.org/obo/GO_0005006 denotes EGFR
T108 44397-44401 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T109 44435-44447 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T110 45483-45487 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T111 45492-45504 http://purl.obolibrary.org/obo/GO_0006909 denotes phagocytosis
T112 45536-45542 http://purl.obolibrary.org/obo/GO_0040007 denotes growth
T113 45579-45583 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T114 46034-46038 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T115 46500-46504 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T116 48347-48355 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T117 48482-48486 http://purl.obolibrary.org/obo/GO_0001788 denotes ADCC
T118 48712-48733 http://purl.obolibrary.org/obo/GO_0042119 denotes neutrophil activation
T119 48738-48747 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T120 48738-48747 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T121 49570-49591 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T122 51182-51190 http://purl.obolibrary.org/obo/GO_0015297 denotes exchange
T123 51303-51324 http://purl.obolibrary.org/obo/GO_0006956 denotes complement activation
T124 52038-52056 http://purl.obolibrary.org/obo/GO_0007165 denotes signaling pathways
T125 52038-52047 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T126 52119-52128 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T127 52412-52421 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T128 52585-52594 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T129 53125-53134 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T130 53540-53560 http://purl.obolibrary.org/obo/GO_0045576 denotes mast cell activation
T131 53545-53560 http://purl.obolibrary.org/obo/GO_0001775 denotes cell activation
T132 55666-55675 http://purl.obolibrary.org/obo/GO_0023052 denotes signaling
T133 55870-55879 http://purl.obolibrary.org/obo/GO_0097194 denotes apoptosis
T134 55870-55879 http://purl.obolibrary.org/obo/GO_0006915 denotes apoptosis
T135 56751-56757 http://purl.obolibrary.org/obo/GO_0040007 denotes growth

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T17 0-12 Sentence denotes Introduction
T18 13-148 Sentence denotes The regulatory approval of the first therapeutic monoclonal antibodies (mAbs) in the 1980s ushered in the modern era of immune therapy.
T19 149-274 Sentence denotes Since then, mAbs have become one of the most clinically successful therapeutic modalities across a diverse array of diseases.
T20 275-728 Sentence denotes They have revolutionized the treatment of chronic inflammatory diseases and of some cancers including otherwise incurable malignancies.1 They are commercially important and in 2017, five mAbs collectively grossed $45.6 billion in sales, placing them in the top ten drugs globally.2 MAb development is expanding rapidly with over 100 mAbs approved for clinical use or in late‐stage clinical trials and over 600 in various stages of clinical development.1
T21 729-1103 Sentence denotes The therapeutic actions of mAbs can take many forms—neutralization of the target such as cytokines in autoimmune disease, clearance of the target such as virus in infection or immunoglobulin (Ig)E in allergy, induction of innate effector cell activation that leads to target destruction by direct killing or the induction of apoptosis and the induction of adaptive immunity.
T22 1104-1496 Sentence denotes Most therapeutic mAbs are IgG in origin and the heavy‐chain subclass determines many of their biological properties including their long plasma half‐life3; complement activation, which is important in the action of some cytotoxic mAbs4, 5, 6 and importantly engagement by their fragment crystallizable (Fc) region with specific cell surface receptors, called FcγR, the subject of this review.
T23 1497-1830 Sentence denotes In normal homeostatic immunity, there is a balance between IgG immune complex activation of proinflammatory responses through the activating‐type FcγRs—which leads to the destruction of opsonized pathogens—and of the modulation of these destructive effector responses by the inhibitory‐type FcγR, thereby avoiding injury to the host.
T24 1831-2019 Sentence denotes Thus, therapeutic mAbs powerfully exploit these opposing activities, making them versatile drugs whose therapeutic potency can be improved by specific engineering of Fc–FcγR interactions.7
T25 2020-2183 Sentence denotes Many therapeutic mAbs depend, to varying degrees, on FcγR function (Figure 1, Table 1) for their mechanism of action (MOA) and/or their pharmacokinetic properties.
T26 2184-2436 Sentence denotes For some mAbs interaction with FcγR is central to their MOA, such as the destruction of a target cell by antibody‐dependent cell‐mediated cytotoxicity (ADCC; Figure 1a) or antibody‐dependent cell‐mediated phagocytosis (phagocytosis or ADCP; Figure 1b).
T27 2437-2655 Sentence denotes This also includes mAbs that may harness the inhibitory action of FcγRIIb to modulate the proinflammatory responses of immunoreceptor tyrosine activation motif (ITAM)‐dependent receptor signaling complexes (Figure 1c).
T28 2656-2982 Sentence denotes For other mAbs, FcγR may play a secondary role, such as the removal or “sweeping” of all immune complexes formed by cytokine or virus‐specific neutralizing antibodies or of opsonized fragments of lysed target cells which in antigen‐presenting cells may also feed the antigen into the antigen‐presentation pathways (Figure 1d).
T29 2983-3275 Sentence denotes In addition, FcγRs, particularly FcγRIIb (Figure 1e), are also key participants in the MOA of immune‐stimulating agonistic mAbs or apoptotic mAbs by acting as a scaffold for the additional cross‐linking of mAbs already bound to a cellular target, thereby inducing a signal in the target cell.
T30 3276-3601 Sentence denotes Figure 1 Graphical representation of the FcγR effector functions. (a) Natural killer cell antibody‐dependent cell‐mediated cytotoxicity via FcγRIIIa. (b) Antibody‐dependent cell‐mediated phagocytosis, and/or trogocytosis of large immune complexes, by professional phagocytes via activating FcγR such as FcγRIIIa and FcγRIIa.
T31 3602-3816 Sentence denotes Biological sequelae include the destruction of the ingested complexes which may also feed antigen into antigen‐presentation pathways of antigen‐presenting cells (APCs). (c) Inhibition of cell activation by FcγRIIb.
T32 3817-4117 Sentence denotes The immunoreceptor tyrosine activation motif (ITAM)‐mediated signaling of B‐cell antigen receptors (left) or of activating FcγR (right) on innate immune cells such as macrophages and basophils is inhibited by IgG Fc‐mediated co‐cross‐linking of these activating receptors with the inhibitory FcγRIIb.
T33 4118-4529 Sentence denotes This leads to phosphorylation of the FcγRIIb immunoreceptor tyrosine‐based inhibitory motif (ITIM) and consequently recruits the phosphatases that modulate the ITAM‐driven signaling responses leading to diminished cell responses. (d) Sweeping or internalization of small immune complexes leading to their removal and, in APC, to enhanced immune responses. (e) Scaffolding in which the FcγRs play a passive role.
T34 4530-4848 Sentence denotes Typically involving FcγRIIb, no signal is generated in the effector cell but “super‐cross‐linking” of the opsonizing antibody by the FcγR on one cell generates a signal in the conjugated target cell, for example, induction of apoptosis or activation in agonistic expansion of cells and/or their secretion of cytokines.
T35 4849-4913 Sentence denotes In extreme cases, this leads to life‐threatening cytokine storm.
T36 4914-5041 Sentence denotes ADCC, antibody‐dependent cell‐mediated cytotoxicity; Ag, antigen; BCR, B‐cell receptor; Ig, immunoglobulin; NK, natural killer.
T37 5042-5119 Sentence denotes Table 1 FcγR responses relevant to therapeutic monoclonal antibodies (mAbs).
T38 5120-5200 Sentence denotes FcγR‐mediated mechanism of action Effector responses Action Dominant receptor
T39 5201-5299 Sentence denotes Activation Antibody‐dependent cell‐mediated cytotoxicity Direct killing of target cell FcγRIIIa
T40 5300-5416 Sentence denotes Antibody‐dependent cell‐mediated phagocytosis, trogocytosis Direct killing of target cell FcγRIIIa, FcγRIIa, FcγRI
T41 5417-5503 Sentence denotes Antigen presentation Vaccine‐like immunity post‐mAb therapy FcγRIIa, FcγRI, FcγRIIIa
T42 5504-5688 Sentence denotes Inhibition Reduce B‐cell proliferation or innate cell activation by antibody complexes Inhibition of ITAM cell activation (i.e. BCR) or activating‐type FcR (i.e. FcγR, FcεRI, FcαRI).
T43 5689-5769 Sentence denotes Note that the FcγRIIb must be co‐cross‐linked with the ITAM activating receptor.
T44 5771-5778 Sentence denotes FcγRIIb
T45 5779-5850 Sentence denotes Sweeping Internalization Removal of small immune complexes FcγRIIb a
T46 5851-6045 Sentence denotes Scaffolding Target agonism or apoptosis Passive “super‐cross‐linking” of mAb on opsonized target cell, for example, CD40, CD28, CD20, by FcγR on an adjacent cell FcγRIIb; also FcγRIIa, FcγRI?
T47 6046-6115 Sentence denotes BCR, B‐cell receptor; ITAM, immunoreceptor tyrosine activation motif.
T48 6116-6179 Sentence denotes a Activating FcγR can also contribute to removal of complexes.
T49 6180-6327 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T50 6328-6510 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T51 6511-6998 Sentence denotes This review focuses on the cell‐based effector functions that arise from the interaction of IgG with the classical human leukocyte FcγR.7 Although beyond the scope of this review, it should be noted that the IgG‐Fc portion dictates other aspects of an antibody’s biology, including its serum half‐life mediated by the neonatal FcR (FcRn), 3 the activation of complement C1,8 antiviral protection via the intracellular receptor TRIM219 and interactions with the Fc receptor‐like family.10
T52 7000-7029 Sentence denotes Human FcγR General Properties
T53 7030-7397 Sentence denotes The human leukocyte receptors fall into two functional groups, namely, proinflammatory, activating‐type receptors (FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa and FcγRIIIb, which are also known as CD64, CD32a, CD32c, CD16a and CD16b, respectively) and the anti‐inflammatory, inhibitory‐receptor group (FcγRIIb also called CD32b) which was the first immune checkpoint described.
T54 7398-7505 Sentence denotes These FcγRs are high‐avidity sensors of immune complexes which initiate, and then modulate, cell responses.
T55 7506-7714 Sentence denotes In the context of normal immune physiology, opsonized target molecules can engage various FcγRs and induce a spectrum of effector responses which can be harnessed by many therapeutic mAbs (Figure 1, Table 1).
T56 7715-7862 Sentence denotes These responses are not mutually exclusive and one therapeutic mAb may initiate various responses via different FcγRs and via different cell types.
T57 7863-8118 Sentence denotes Understanding the importance of cell‐based effector functions in the MOA of therapeutic mAbs requires an appreciation of FcγR biology (Tables 1, 2, 3) which also underpins future efforts to tailor new mAbs for the exploitation‐specific effector responses.
T58 8119-8261 Sentence denotes In this review, we address only key aspects of the extensive knowledge of the human leukocyte FcγR family as it relates to effector functions.
T59 8262-8762 Sentence denotes A number of other reviews more comprehensively explore FcγR biology physiology, biochemistry, genetics and structure.7, 11, 12, 13, 14 Notwithstanding the recognized differences between the immunobiology of human FcγR and of rodents or nonhuman primates, animal models of FcR effector function in vivo have helped shape the strategies for the development of current therapeutic mAbs and are well reviewed.12, 15 Furthermore, humanized FcγR models will provide even greater insights into the future.16
T60 8763-8791 Sentence denotes Table 2 Properties of FcγR.
T61 8792-8846 Sentence denotes Receptor Affinity IgG specificity Cell distribution
T62 8847-8983 Sentence denotes FcγRI High IgG1, IgG3, IgG4 Induced by interferon‐γ on monocytes, neutrophils, macrophages, dendritic cell subpopulations; mast cells
T63 8984-9130 Sentence denotes FcγRIIa Low IgG1, IgG3, but IgG2 binding limited to the FcγRIIa‐H131 form, ~70% people) All leukocytes and platelets except T and B lymphocytes
T64 9131-9173 Sentence denotes FcγRIIc a Low IgG1, IgG3, IgG4 NK cells
T65 9174-9200 Sentence denotes FcγRIIIa Low IgG1, IgG3.
T66 9202-9320 Sentence denotes NK cells, macrophages, subpopulation of circulating monocytes, myeloid dendritic cells, neutrophils at very low levels
T67 9321-9367 Sentence denotes Binding avidity reduced by Phe at position 158
T68 9368-9406 Sentence denotes FcγRIIIb Low IgG1, IgG3 Neutrophils
T69 9407-9514 Sentence denotes FcγRIIb Low IgG1, IgG3, IgG4 B lymphocytes, some monocytes (can be upregulated); basophils; eosinophils?
T70 9515-9626 Sentence denotes Plasmacytoid and myeloid dendritic cells; NK cells only of individuals with FcγRIIIb gene copy number variation
T71 9627-9690 Sentence denotes Airway smooth muscle, LSEC, placenta, follicular dendritic cell
T72 9691-9740 Sentence denotes Ig, immunoglobulin; NK cell, natural killer cell.
T73 9741-9771 Sentence denotes a Expressed in 20% of people.
T74 9772-9919 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T75 9920-10102 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T76 10103-10157 Sentence denotes Table 3 Unique features of IgG subclass Fc and hinge.
T77 10158-10258 Sentence denotes IgG subclass FcγR specificity Light‐chain attachment Hinge characteristics Fc stability Comment
T78 10259-10369 Sentence denotes IgG1 All FcγR Upper hinge Light‐chain attachment Stable Fc is >100× times more stable than IgG4 and IgG2.
T79 10370-10387 Sentence denotes Stable core hinge
T80 10388-10524 Sentence denotes IgG2 FcγRIIa His131 CH1 of Fab and/or upper hinge Stable core hinge with additional inter H‐chain disulfide bonds in the upper hinge.
T81 10526-10607 Sentence denotes Unstable CH3:CH3 Alternative light‐chain attachment creates distinct conformers.
T82 10608-10739 Sentence denotes Unlike IgG4, the CH3:CH3 instability does not lead to half‐molecule exchange as a result of stable core and upper hinge disulfides.
T83 10740-10901 Sentence denotes IgG4 FcγRI, FcγRIIb, FcγRIIc CH1 of Fab Labile core hinge Unstable CH3:CH3 Combined instability of core hinge and CH3:CH3 permits half‐IgG molecule exchange
T84 10902-10921 Sentence denotes Ig, immunoglobulin.
T85 10922-11069 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T86 11070-11252 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T87 11254-11290 Sentence denotes FcγR expression on hemopoietic cells
T88 11291-11555 Sentence denotes The tissue distribution of the human leukocyte FcγR is well documented and reviewed comprehensively elsewhere.7, 11, 17 In the context of effector functions harnessed by therapeutic mAbs, several aspects of the cellular distribution (Table 2) should be emphasized.
T89 11556-11701 Sentence denotes FcγR expression profiles differ between cell lineages but almost all mature human leukocytes, and platelets, express at least one FcγR (Table 2).
T90 11702-12143 Sentence denotes It should also be appreciated that the cellular expression levels and receptor diversity as will be described later is also influenced by the activation state of the cells, anatomical location and the cytokine environment which modulates FcγR expression, particularly for FcγRI and FcγRIIb.18 For example, resting monocyte subpopulations may express only FcγRIIa but activated macrophages express FcγRI, FcγRIIa and FcγRIIIa and/or FcγRIIb.7
T91 12144-12230 Sentence denotes Thus, specific characteristics of leukocyte FcγR expression are summarized as follows:
T92 12231-12412 Sentence denotes FcγRI is not usually expressed until induced by cytokines such as interferon‐γ on monocytes, neutrophils, macrophages, microglial cells in the brain, dendritic cells and mast cells.
T93 12413-12698 Sentence denotes The sensitivity of FcγRI to interferon‐γ suggests that its in vivo activity is closely tied to immune activation events, and mouse studies have suggested that it has a critical role early in immune responses.19, 20 Its role in the MOA of antibodies may vary with anatomical location.21
T94 12699-12824 Sentence denotes FcγRIIa is expressed only in primates and shows the broadest expression of all FcγRs, being present on all innate leukocytes.
T95 12825-12967 Sentence denotes It is also present on platelets but its role in effector functions is not established but it is important in certain immune thrombocytopenias.
T96 12968-13046 Sentence denotes A polymorphic form of this receptor is the only human receptor for human IgG2.
T97 13047-13221 Sentence denotes This, together with its limited species expression and unique ITAM‐containing cytoplasmic tail (reviewed by Anania et al. 11), suggests a unique function in human leukocytes.
T98 13222-13468 Sentence denotes Interestingly, polymorphism of the receptor is associated with systemic lupus erythematosus and resistance to Gram‐negative organisms.11 A rare, hyper‐responsive form is a risk factor for neutrophil‐driven anaphylaxis in Ig replacement therapy.22
T99 13469-13908 Sentence denotes FcγRIIc is an activating FcγR whose expression is regulated single nucleotide polymorphism that permits expression in approximately 20% of humans and in whom it is present at low levels on natural killer (NK) and B cells.11 It has arisen by gene duplication/recombination resulting in an extracellular region  derived from  FcγRIIb, which binds IgG4, and with an ITAM‐containing cytoplasmic tail related to the activating receptor FcγRIIa.
T100 13909-14027 Sentence denotes Thus FcγRIIc provides IgG4 with an activation receptor pathway and confers a new biology of IgG4 in these individuals.
T101 14028-14160 Sentence denotes Its low frequency in the population may also confound in vivo mAb clinical testing or use, but as yet there is no evidence for this.
T102 14161-14235 Sentence denotes FcγRIII forms are two highly related gene products, FcγRIIIa and FcγRIIIb.
T103 14236-14328 Sentence denotes The FcγRIIIa is expressed on NK cells and professional phagocytes, particularly macrophages.
T104 14329-14576 Sentence denotes It is only recently apparent that FcγRIIIa is expressed on neutrophils, albeit at low levels, but plays a role in their function.23 FcγRIIIb is unique to humans and unlike other FcγRs it is attached to cell membrane via a glycophosphatidyl anchor.
T105 14577-14718 Sentence denotes It is expressed, predominantly and abundantly, on human neutrophils.7 Its effector function depends in part on its coexpression with FcγRIIa.
T106 14719-14832 Sentence denotes The lack of FcγRIIIb on macaque neutrophils appears to be compensated for by an increase in FcγRIIa expression.15
T107 14833-14900 Sentence denotes FcγRIIbs are the inhibitory‐type FcγR and arise from a single gene.
T108 14901-14982 Sentence denotes They lack intrinsic proinflammatory signaling and are instead immune checkpoints.
T109 14983-15113 Sentence denotes They provide feedback regulation by antibodies, in the form of immune complexes, to inhibit B‐cell activation by specific antigen.
T110 15114-15178 Sentence denotes They also control activating‐type FcγR function on innate cells.
T111 15179-15272 Sentence denotes Two major splice variant forms of FcγRIIb exist with differential tissue expression profiles.
T112 15273-15457 Sentence denotes FcγRIIb1 preferentially expressed on B lymphocytes contains a 20‐amino acid cytoplasmic insertion necessary for membrane retention and cocapping with the B‐cell antigen receptor (BCR).
T113 15458-15633 Sentence denotes FcγRIIb2 is the predominant inhibitory receptor found on basophils and neutrophils, as well as on subpopulations of mast cells, dendritic cells and some monocytes/macrophages.
T114 15634-15850 Sentence denotes FcγRIIb2 lacks the cytoplasmic insertion of FcγRIIb1 and consequently can internalize rapidly including with the activating FcR when they are co‐cross‐linked.11 It is not clear which form is present on human T cells.
T115 15851-15978 Sentence denotes One additional comment on tissue distribution is that FcγR expression on T cells has been difficult to establish unequivocally.
T116 15979-16060 Sentence denotes However, there is increasing evidence that T‐lymphocyte populations express FcγR.
T117 16061-16272 Sentence denotes Some γδ T cells express FcγRIIIa and αβ T cells reportedly express FcγRIIa, FcγRIIb or FcγRIIIa but the significance with respect to effector function mediated by antibody is presently unclear.24, 25, 26, 27, 28
T118 16274-16308 Sentence denotes Expression on nonhemopoietic cells
T119 16309-16532 Sentence denotes The immunobiology of FcγR is studied and understood almost exclusively in the context of hematopoietic cell function but relatively recent investigations have identified and explored FcγR expression on nonhemopoietic cells.
T120 16533-16637 Sentence denotes These studies suggest important roles in normal immune function and in the MOA of some therapeutic mAbs.
T121 16638-16796 Sentence denotes The most extensively characterized receptor expression is FcγRIIb which is expressed on follicular dendritic cell, airway smooth muscle and liver endothelium.
T122 16797-17187 Sentence denotes Its abundant expression on liver sinusoidal endothelial cells (LSECs) is estimated to represent the majority of in vivo FcγRIIb expression.17, 29, 30, 31 As FcγRIIb lacks intrinsic proinflammatory signaling function, its role on these nonhemopoietic cells involves immune complex handling without the danger of, or the need for, induction of local tissue destructive inflammatory responses.
T123 17188-17525 Sentence denotes On LSEC its major role appears to be immune complex sweeping, a process of removal of small immune complexes such as opsonized virus or macromolecules.17 This scavenging role by FcγRIIb on LSEC can be exploited in principle by mAbs forming small soluble complexes with their targets such as antiviral, anticytokine or similar antibodies.
T124 17527-17566 Sentence denotes FcγR activating or inhibitory signaling
T125 17567-17694 Sentence denotes Effector functions that are initiated via the activating‐type FcγR occur by signaling via the ITAM pathway of immune receptors.
T126 17695-17879 Sentence denotes This well‐characterized pathway is used by BCR and T‐cell antigen receptors, the IgE receptor FcεRI and IgA receptor FcαRI (reviewed extensively by Hogarth and Pietersz 7 Anania et al.
T127 17880-18047 Sentence denotes 11 and Getahun and Cambier 32) Induction of an activating signal requires the aggregation of activating FcγR by immune complexes, or by antigen in the case of the BCR.
T128 18048-18208 Sentence denotes This aggregation at the cell membrane results in specific tyrosine phosphorylation of the ITAM by Src kinases, thus initiating the activation cascade.32, 33, 34
T129 18209-18842 Sentence denotes The inhibitory‐type FcγRs, FcγRIIb1 and FcγRIIb2, whose expression is cell lineage restricted, modulate the ITAM signaling of the BCR or the activating‐type FcγRs, respectively.11 Their function is dependent on the immunoreceptor tyrosine inhibition motif in their cytoplasmic tail.32, 33 This checkpoint action requires that FcγRIIbs are coaggregated with the tyrosine‐phosphorylated ITAM‐signaling receptor complex which results also in immunoreceptor tyrosine inhibition motif tyrosine phosphorylation and consequential recruitment of lipid or protein tyrosine phosphatases that powerfully dampen the ITAM‐induced cell activation.
T130 18844-18877 Sentence denotes FcγR‐Dependent Effector Responses
T131 18879-18970 Sentence denotes Not all opsonized targets are equal: size, distance, valency and Fc geometry affect potency
T132 18971-19266 Sentence denotes To understand the immunobiology of FcγR effector responses particularly in the therapeutic mAb context, it is important to appreciate that the quality and potency of such effector responses is greatly affected by the nature of the IgG immune complex and/or the state of potential effector cells.
T133 19267-19410 Sentence denotes First, opsonization, per se, of a target is not necessarily sufficient to ensure FcγR interaction in a way that initiates an effector response.
T134 19411-20085 Sentence denotes Although it is the IgG Fc that interacts with and clusters the FcγR to induce a response, the nature of the Fab interaction with its epitope can strongly influence the likelihood or potency of FcγR effector responses by influencing the density of appropriately presented Fc portions.35 and also the size of the immune complex.36 Furthermore, the display/orientation and geometry of the Fc portions, as a consequence of the fragment antigen‐binding (Fab) interaction with the target epitope, can result in effector responses such as ADCC that differ substantially in potency, presumably because the orientation of the Fc makes FcγR engagement more, or less, accessible.37, 38
T135 20086-20441 Sentence denotes Second, in innate effector cells at rest, the largely linear actin cytoskeleton and the extracellular glycosaminoglycan glycocalyx regulate function by interacting with large glycoproteins, such as CD44, arranging these into ordered “picket” fences.39, 40 These corral receptors, including the FcγRs, and sterically inhibit their interaction with ligands.
T136 20442-21140 Sentence denotes Upon cell activation, cytoskeletal remodeling is associated with the loss of the receptor corrals, allowing FcγRs and other receptors to freely diffuse, engage ligand, cluster and signal.39 The influence of such surface constraints on receptors and effector cell function helps explain some of the observed epitope distance requirements for optimal mAb function,39, 41 which were apparent in a comparative study of ADCC and ADCP.42 ADCC was optimal when the epitope was displayed close, 0.3 nm “flush” or 1.5 nm, to the target membrane where close conjugation of effector and target by the mAb presumably facilitates the delivery of pore‐forming proteins to the target membrane as required by ADCC.
T137 21141-21286 Sentence denotes Interestingly, complement‐dependent cytotoxicity which also utilizes pore‐forming proteins for its cytotoxicity has similar distance constraints.
T138 21287-21580 Sentence denotes By contrast, ADCP was poor  when targeting epitopes displayed close or "flush" to the target cell membrane (within ~0.3 nm) but ADCP activity was restored when the epitope was displayed 1.5 nm off the membrane, demonstrating different optimal epitope distance requirements for ADCC and ADCP.42
T139 21581-21776 Sentence denotes Although the action of agonistic/antagonistic mAbs is mechanistically distinct to those eliciting cytotoxicity and ADCP, the distance segregation between target and FcγR+ cells is also important.
T140 21777-21908 Sentence denotes Indeed, the membrane proximal epitopes of CD28 and CD40 are important for the FcγR function in the complex MOA of these mAbs.43, 44
T141 21909-22153 Sentence denotes Clearly, the effects of immune complex valency, Fc density, presentation and geometry together with FcγR organization in the cell membrane suggest that the development of mAbs to certain targets will be heavily influenced by the context of use.
T142 22154-22270 Sentence denotes Thus, improved mAb potency may not necessarily be achieved by engineering of the Fc polypeptide or its glycan alone.
T143 22271-22491 Sentence denotes A more function‐oriented approach early in mAb selection and development by, for example, application of rapid screening technologies that select for effector potency,34 followed by Fc engineering may be more productive.
T144 22493-22514 Sentence denotes ADCC and phagocytosis
T145 22515-22726 Sentence denotes ADCC and ADCP are the most widely appreciated FcγR‐dependent effector functions (Figure 1a, b) and are, respectively, mediated primarily via  FcγRIIIa on NK cells and professional phagocytes such as macrophages.
T146 22727-22880 Sentence denotes These effector functions, particularly NK cell ADCC, are believed to be major components of the MOA of cytotoxic therapeutic mAbs used in cancer therapy.
T147 22881-23054 Sentence denotes In addition, ADCP can also occur via FcγRIIa and FcγRI,45 but the extent to which cytotoxic anticancer therapeutic mAbs depend on these for their MOA in patients is unclear.
T148 23055-23326 Sentence denotes The improvement in clinical utility of mAbs engineered for selectively increased FcγRIII binding suggests that FcγRIIa and FcγRI may be less important in vivo in cell killing effects but perhaps are more important in other aspects of therapeutic efficacy—discussed later.
T149 23328-23368 Sentence denotes Inhibition of cell activation by FcγRIIb
T150 23369-23493 Sentence denotes FcγRIIb is an immune checkpoint46, 47 and its splice variants are potent modulators of ITAM‐dependent signaling (Figure 1c).
T151 23494-23592 Sentence denotes This modulatory function occurs only when FcγRIIb is coaggregated with an ITAM signaling receptor.
T152 23593-24006 Sentence denotes Thus, B‐cell activation by the binding of the antigen in the immune complex to the BCR is regulated by the simultaneous binding of the Fcs of the immune complex to FcγRIIb1 on the same cell. In innate leukocytes, the activating‐type FcR (i.e. FcγRI, FcγRIIa, FcγRIIc, FcγRIII) and the high‐affinity IgE receptor, FcεRI, and the IgA receptor, FcαRI, are all modulated by immune complex co‐engagement with FcγRIIb2.
T153 24007-24212 Sentence denotes The inhibitory function contributes to the MOA of therapeutic antibodies that target cell‐activating molecules where the target cells also express the inhibitory FcγRIIbs such as the BCR (discussed later).
T154 24213-24411 Sentence denotes Thus, B‐cell activation is modulated by the simulatenous binding of the antigen in the immune complex to the BCR and the binding of the Fcs, also in the immune complex, to FcγRIIB1 on the same cell.
T155 24413-24458 Sentence denotes Sweeping: clearance of small immune complexes
T156 24459-24586 Sentence denotes The removal of immune complexes in humans depends primarily on the complement receptor pathway and to a lesser degree the FcγR.
T157 24587-24724 Sentence denotes Among the FcγRs, it has been widely believed that immune complex removal only occurs by phagocytosis/endocytosis of activating‐type FcγR.
T158 24725-25045 Sentence denotes Surprisingly, the inhibitory FcγRIIb, which lacks intrinsic activating function, plays a major role in clearance, and rapidly “sweeps” away small complexes from the circulation (Figure 1d).48, 49 A major tissue involved in the clearance is likely to be the LSEC, where FcγRIIb is expressed abundantly in mice and humans.
T159 25046-25297 Sentence denotes This role is potentially important in resistance to viruses and toxins but may also be key to optimal performance of therapeutic IgG mAbs whose primary MOA is believed to be only neutralization of soluble macromolecules, for example, cytokines or IgE.
T160 25299-25373 Sentence denotes FcγR uptake of antigen: antibody complexes and shaping the immune response
T161 25374-25436 Sentence denotes Monoclonal antibody therapy is a form of passive immunization.
T162 25437-25758 Sentence denotes Indeed, longer‐term vaccine‐like or vaccinal immunity has been demonstrated in anti‐CD20‐treated mice via FcγRIIa50, 51 and in vitro recall memory responses from CD20‐treated patients.52 Although this is dependent on FcγR and anti‐CD20, the mechanism by which long‐term anti‐tumor response is established remains unclear.
T163 25759-26460 Sentence denotes Nonetheless, the active involvement of FcγR in the enhancement of antigen‐specific immunity by uptake of immune complexes through FcγR is historically well documented in experimental systems where FcγRs bind immune complexes and thereby feed antigens into the antigen‐presentation pathways.53 This has been demonstrated in vivo for small immune complexes via human FcγRI on human antigen‐presenting cells54 and in mice.19 Similarly, the capacity of FcγRIIbs to bind and rapidly internalize antigen–antibody complexes suggests that it too may significantly influence feeding antigens into professional antigen‐presenting cells of hematopoietic origin such as dendritic cells and possibly B lymphocytes.
T164 26461-26745 Sentence denotes Although not a classical major histocompatibility complex‐dependent antigen presentation, FcγRIIb on the stroma‐derived follicular dendritic cells influences antibody immunity by recycling antigen–antibody complexes to the cell surface for presentation of intact antigen to B cells.55
T165 26746-26968 Sentence denotes Although somewhat speculative, FcγRIIb’s rapid internalization/sweeping of complexes by the abundant LSEC, which interact with lymphocytes and can present antigen,56 may have a significant role in shaping immune responses.
T166 26970-27015 Sentence denotes Scaffolding of cell‐bound mAbs by FcγR+ cells
T167 27016-27117 Sentence denotes FcγR‐expressing cells can be critical, but passive, participants in the MOA of some mAbs (Figure 1e).
T168 27118-27330 Sentence denotes In FcγR scaffolding, IgG mAb molecules that have opsonized the cell surface of a target cell are additionally cross‐linked by their Fc portions engaging the FcγRs that are arrayed on the surface of a second cell.
T169 27331-27543 Sentence denotes This “super‐cross‐linking” of the target‐bound mAb by the FcγR lattice or “scaffold” on the adjacent cell greatly exceeds the target cross‐linking by the mAb alone, thereby inducing a response in the target cell.
T170 27544-28137 Sentence denotes Scaffolding was originally identified as the basis of T‐cell mitogenesis induced by anti‐CD3 mAb.57, 58 The CD3 mAbs alone were poor mitogens but the “super‐cross‐linking” of the T‐cell‐bound CD3 mAb by the membrane FcγR on adjacent cells, particularly by monocytes, induced rapid T‐cell expansion and cytokine secretion but did not require activation of FcγR‐expressing cells.57 Regrettably, FcγR scaffolding came to prominence and clinical relevance because of its causal role in the catastrophic adverse events resulting from the administration of anti‐CD357 and anti‐CD28 (TGN1412)59 mAbs.
T171 28138-28273 Sentence denotes Nonetheless, FcγR scaffold‐based induction of intracellular responses in a target cell can also lead to beneficial therapeutic effects.
T172 28274-28496 Sentence denotes Such examples are the induction of apoptotic death in a target cell, which is likely part of the MOA of daratumumab in multiple myeloma60 or the controlled agonistic expansion of cells, for example, via CD40 mAb agonism.43
T173 28498-28547 Sentence denotes IgG subclasses: specificity and affinity for FcγR
T174 28548-28771 Sentence denotes Most FcγRs (Table 2) are weak, low‐affinity receptors (affinities in the micromolar range) for IgG‐Fc, irrespective of whether the IgG is uncomplexed, monomeric or when it is complexed with antigen (i.e. an immune complex).
T175 28772-29013 Sentence denotes The very avid binding of immune complexes to an effector cell surface that displays an array of FcγR molecules is the result of the collective contributions of the low‐affinity interactions of each Fc of the IgGs in the complex with an FcγR.
T176 29014-29166 Sentence denotes This avidity effect is necessary as the FcγRs operate in vivo in environments of high concentrations of uncomplexed monomeric IgG (normally 3–12 g L–1).
T177 29167-29257 Sentence denotes Thus, the avid multivalent binding of the complex out competes uncomplexed, monomeric IgG.
T178 29258-29311 Sentence denotes The notable exception to this is the enigmatic FcγRI.
T179 29312-29488 Sentence denotes This receptor shows high, nanomolar affinity for uncomplexed monomeric IgG and thus would be expected to be constantly occupied in vivo by the normal circulating monomeric IgG.
T180 29489-29556 Sentence denotes However, IgG dissociation permits engagement with immune complexes.
T181 29557-29723 Sentence denotes Furthermore, FcγRI is not expressed or expressed poorly on resting cells, requiring interferon‐γ for induction of its expression, presumably at sites of inflammation.
T182 29724-29905 Sentence denotes Although the human IgG heavy‐chain constant domains have greater than 90% identity, key amino acid differences confer each subclass with unique structural and functional properties.
T183 29906-29977 Sentence denotes IgG1 and IgG3 are “universal” ligands, that is, they bind to all FcγRs.
T184 29978-30300 Sentence denotes Formal measurement of the weak, micromolar KD interactions of the low‐affinity receptors with monomeric IgG1 also revealed differing affinities between the low‐affinity FcγRs, with inhibitory FcγRIIb generally having the lowest affinity and FcγRIII the higher, sometimes referred to as a “moderate” affinity receptor.7, 61
T185 30301-30464 Sentence denotes The strength of IgG1 interaction can also be affected by FcγR polymorphism and in the context of therapeutic mAbs, variation in FcγRIIIa is particularly important.
T186 30465-30676 Sentence denotes The most common and possibly clinically significant polymorphism is phenylalanine/valine variation at position 158 in the IgG‐binding site, wherein FcγRIIIa‐F158 binds IgG1 less well than the FcγRIIIa‐V158 form.
T187 30677-30729 Sentence denotes IgG4 and IgG2 have more restricted FcγR specificity.
T188 30730-30867 Sentence denotes IgG4 has low affinity (KA = ~2 × 105 m –1) for the inhibitory FcγRIIb, but is also a high‐affinity ligand for FcγRI (KA = ~4 × 108 m –1).
T189 30868-31113 Sentence denotes IgG2 exhibits a highly restricted specificity, showing functional activity with only one polymorphic form of FcγRIIa (binding affinity KA = ~4.5 × 105 m –1) which is permitted by the presence of histidine at position 131 of its IgG‐binding site.
T190 31114-31324 Sentence denotes This FcγRIIa–H131 form is expressed in approximately 70% of the population, whereas IgG2 has no functional activity on the other common allelic form, FcγRIIa‐R131, which contains arginine at position 131.11, 61
T191 31326-31341 Sentence denotes IgG Subclasses:
T192 31342-31366 Sentence denotes Structure and Properties
T193 31368-31416 Sentence denotes The molecular basis of IgG and FcγR interactions
T194 31417-31480 Sentence denotes The extracellular regions of the FcγR are structurally similar.
T195 31481-31627 Sentence denotes Each low‐affinity FcγR has two ectodomains, whereas the high‐affinity FcγRI has a third domain but this is not directly involved in IgG binding.62
T196 31628-31922 Sentence denotes The interaction between the IgG subclasses and the FcγR is most comprehensively defined for human IgG1 by both X‐ray crystallographic7, 62, 63 and mutagenesis structure/function analyses.64, 65, 66 These studies defined key regions of the IgG sequence required for interaction with their FcγRs.
T197 31923-32089 Sentence denotes Crystallographic analyses of the human IgG1‐Fc complexed with FcγRI, FcγRII or FcγRIII show that these interactions are similar in topology, and asymmetric in nature.
T198 32090-32171 Sentence denotes The second extracellular domain of the FcγR inserts between the two heavy chains.
T199 32172-32322 Sentence denotes Here it makes contacts with the lower hinge of both H chains and with residues of the adjacent BC loop of one CH2 domain and the FG loop of the other.
T200 32323-32504 Sentence denotes The N‐linked glycan at asparagine 297 (N297) of the heavy chain is essential for the structural integrity of the IgG‐Fc by affecting the spacing and conformation of the CH2 domains.
T201 32505-32759 Sentence denotes Indeed, its removal ablates FcγR binding.67 Of particular relevance to therapeutic mAb development is that the normal low‐affinity IgG interaction with FcγRIIIa is profoundly increased by the removal of the core fucose from the N297 Fc oligosaccharide.68
T202 32760-33011 Sentence denotes No crystallographic data are available for IgG2 or IgG4 Fc in complex with FcγR, but mutagenesis studies of the Fc and the FcγR revealed general similarity, but with critical differences, in the interaction of these subclasses with their cognate FcγR.
T203 33013-33060 Sentence denotes Unique features of the IgG2 and IgG4 subclasses
T204 33061-33268 Sentence denotes In IgG1, the stable interaction of the two heavy chains results from the combined effects of stable covalent inter H‐chain disulfide bonds and strong noncovalent interaction of the two CH3 domains (Table 3).
T205 33269-33364 Sentence denotes In stark contrast, in IgG2 and IgG4 the interaction of the CH3 domains of each H‐chain is weak.
T206 33365-33460 Sentence denotes Residues 392, 397 and 409 (Eu numbering) profoundly affect the stability of these interactions.
T207 33461-33657 Sentence denotes The difference at position 409 (R409 in IgG4 and K409 in IgG1) confers a 100‐fold decrease in stability of the interface between the two CH3 domains of IgG4 compared with that of IgG1 (Table 3).69
T208 33658-33817 Sentence denotes Furthermore, the core hinge of IgG4 differs from IgG1 at position 228 (P228 in IgG1 and S228 in IgG4), resulting in unstable inter‐heavy‐chain disulfide bonds.
T209 33818-34286 Sentence denotes This, together with the destabilizing amino acids in the CH3, confers the unique property of half‐antibody (Fab arm) exchange between different IgG4 antibodies,69 thereby creating monovalent, bispecific IgG4 antibodies in vivo.69, 70 The similarly unstable interactions between the CH3 domains in IgG2 are conferred by the interface residue M397; however, the stable inter‐H‐chain disulfide bonds of the core and upper hinge prevent half‐molecule exchange (Table 3).69
T210 34287-34360 Sentence denotes In addition, IgG2 uniquely has three disulfide bond conformers (Table 3).
T211 34361-34970 Sentence denotes The distinct conformers are formed when (1) each light chain is attached to the Cys131 residue of CH1 in the heavy chain (IgG2‐A conformer), (2) both light chains attach to the upper hinge (IgG2‐B) or (3) one light chain is attached to the CH1 Cys131 and one to the upper hinge of the other heavy chain (IgG2‐AB).71 This results in distinct positioning of the Fabs relative to the Fc portions in the different conformers, which has implications for the interaction with antigen and the capacity of IgG2 to cross‐link target molecules in the absence of FcγR binding, for example, in an agonistic mAb setting.72
T212 34971-35070 Sentence denotes It should also be noted that IgG3 has not been used in therapeutic mAbs despite its unique biology.
T213 35071-35336 Sentence denotes The main impediment to its use are its physicochemical properties such as susceptibility to proteolysis and propensity to aggregate that present challenges to industry‐scale production and stability but protein engineering is attempting to overcome these hurdles.73
T214 35338-35388 Sentence denotes Therapeutic antibody design: improving mAb potency
T215 35389-35479 Sentence denotes Many factors affecting FcγR‐dependent responses in vivo come into play during mAb therapy.
T216 35480-35786 Sentence denotes The experience of three decades of clinical use of mAbs taken together with our extensive, albeit incomplete, knowledge of IgG and FcγR structure and immunobiology provides a war chest for the innovative development of new and highly potent mAbs through the manipulation of their interaction with the FcγR.
T217 35787-36085 Sentence denotes Therapeutic mAb engineering strategies are directed by many factors including the biology of the target, the nature of the antigen, the desired MOA and possibly the anatomical location of the therapeutic effect,21 and thus to optimize potency for a desired response, the context of use is critical.
T218 36087-36116 Sentence denotes The nature of the IgG isotype
T219 36117-36284 Sentence denotes Different capabilities for the recruitment and activation of the different immune effector functions are naturally found in the Fc regions of the human IgG subclasses.
T220 36285-36432 Sentence denotes Thus, to achieve a desired MOA, the different IgG subclasses are important starting points for the selection and engineering of the optimal mAb Fc.
T221 36433-36763 Sentence denotes IgG1 is, in many ways, a proinflammatory or “effector‐active” subclass, as it can initiate the complement cascade and is a “universal” FcγR ligand.74 Notwithstanding it is also a ligand for the inhibitory FcγRIIb, IgG1 elicits proinflammatory responses through all activating‐type FcγRs, including ADCC, ADCP and cytokine release.
T222 36764-36940 Sentence denotes Because of their more restricted FcγR‐binding profile, IgG2 and IgG4 have offered some choice in potentially avoiding FcR effector function without the need for Fc engineering.
T223 36941-37410 Sentence denotes They have been used as the backbone for therapeutic mAbs either because recruitment of patients’ effector functions was unlikely to be necessary for the primary MOA of the mAb or is possibly detrimental to the desired therapeutic effect.75 However, the use of these unmodified “inert” subclasses is not without consequences and underscores the need for Fc engineering to modify FcγR interactions—See the “Attenuating and ablating FcγR related functions of IgG” section.
T224 37411-37577 Sentence denotes Thus, the choice of IgG subclass for therapeutic mAb engineering is an important first step for engineering of novel mAbs of improved specificity, potency and safety.
T225 37579-37630 Sentence denotes Fc engineering for enhanced anticancer therapeutics
T226 37631-37810 Sentence denotes IgG1 is the predominant subclass used in the development of cytotoxic mAbs where induction of an activation‐type response, ADCC or phagocytosis, is considered desirable.45, 76, 77
T227 37811-37903 Sentence denotes Cytotoxic mAb cancer therapeutics can control disease progression by one or more mechanisms.
T228 37904-38060 Sentence denotes Their MOAs include direct induction of apoptotic cell death of the cancer cell (anti‐CD20, anti‐CD52) or blocking receptor signaling (anti‐HER2, anti‐EGFR).
T229 38061-38473 Sentence denotes They may also harness FcγR effector functions, including ADCC in the tumor microenvironment.78 The approved mAbs, rituximab (anti‐CD20), trastuzumab (anti‐HER2) and cetuximab (anti‐EGFR), are formatted on a human IgG1 backbone and all require activating‐type FcγR engagement for optimal therapeutic activity.79, 80 This presents an example where context of therapeutic use is critical for therapeutic mAb design.
T230 38474-38563 Sentence denotes IgG1 antibodies bind both the activating FcγR (e.g. FcγRIIIa) and the inhibitory FcγRIIb.
T231 38564-38713 Sentence denotes In some environments effector cells will coexpress FcγRIIb together with FcγRI, FcγRIIa and FcγIIIa, as may occur on a tumor‐infiltrating macrophage.
T232 38714-38970 Sentence denotes Therapy with an IgG1 anti‐cancer cell mAb may then be compromised by the inhibitory action of FcγRIIb upon the ITAM signaling of the activating FcγR as both types of receptor would be coengaged on  such an effector cell by the mAb bound to the target cell.
T233 38971-39017 Sentence denotes This leads to reduced therapeutic mAb potency.
T234 39018-39467 Sentence denotes Thus, the relative contributions of the activating (A) and inhibitory (I) FcγR to the response by an effector cell, the A‐to‐I ratio, may be an important determinant in clinical outcome of therapeutic mAb activity,76, 81, 82 that is, the higher the A‐to‐I ratio, the greater the proinflammatory response induced by the therapeutic mAb or conversely the lower the A‐to‐I ratio, the greater the inhibition or dampening of the proinflammatory response.
T235 39468-39579 Sentence denotes Thus, the challenge for the development of more potent FcγR effector mAbs is to overcome three major obstacles.
T236 39580-39772 Sentence denotes First, improving activation potency by selectively enhancing interaction with activating‐type FcγR, particularly FcγRIIIa owing to its predominant role in ADCC‐mediated killing of tumor cells.
T237 39773-39839 Sentence denotes Second, reducing binding interactions with the inhibitory FcγRIIb.
T238 39840-39914 Sentence denotes These two approaches improve the FcγR A‐to‐I ratio of cytotoxic IgG1 mAbs.
T239 39915-40185 Sentence denotes Third, overcoming the significant affinity difference in the interaction with the main FcγRIII allelic forms of FcγRIIIa‐V158 and FcγRIIIa‐F158 76, 83, 84 which appears to be an important source of patient variability in responses to therapeutic mAb treatment of cancer.
T240 40186-40271 Sentence denotes At the time of writing, some mAbs with improved potency are coming into clinical use.
T241 40272-40404 Sentence denotes Their improved action has been achieved by modifying the N‐linked glycan or the amino acid sequence of the heavy‐chain Fc (Table 4).
T242 40405-40511 Sentence denotes Table 4 Fc or hinge‐engineered monoclonal antibodies (mAbs) approved or in advanced clinical development.
T243 40512-40621 Sentence denotes mAb name Target IgG backbone Fc modification Effect on mAb Therapy area Most advanced development stage
T244 40622-40726 Sentence denotes Andecaliximab Matrix Metalloproteinase 9 (MMP9) IgG4 S228P Stabilize core hinge Oncology Phase III
T245 40727-40887 Sentence denotes Anifrolumab Interferon alpha/beta receptor 1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2/F/G loop; plus ablate FcγR binding Immunology Phase III
T246 40888-40977 Sentence denotes Atezolizumab PD‐L1 IgG1 Aglycosylated (N297A) Ablate FcγR binding Oncology Marketed
T247 40978-41171 Sentence denotes Benralizumab Interleukin 5 IgG1 Afucosylated Selectively enhance FcγRIII interaction Respiratory dermatology; ear nose throat disorders; gastrointestinal; hematology; immunology; Marketed
T248 41172-41301 Sentence denotes Durvalumab PD‐L1 IgG1 L234F; L235E; P331S Mimic IgG4 hinge and its CH2 F/G loop; plus ablate FcγR binding Oncology Marketed
T249 41302-41411 Sentence denotes Evinacumab Angiopoietin‐related protein 3 IgG4 S228P Stabilize core hinge Metabolic disorders Phase III
T250 41412-41536 Sentence denotes Inebilizumab CD19 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III
T251 41537-41661 Sentence denotes Ixekizumab Interleukin 17A IgG4 S228P Stabilize core hinge Dermatology; immunology; musculoskeletal disorders Marketed
T252 41662-41783 Sentence denotes Margetuximab HER2 IgG1 F243L; L235V; R292P; Y300L; P396L Selectively enhance FcγRIII interaction Oncology Phase III
T253 41784-41940 Sentence denotes Mogamulizumab C–C chemokine receptor type 4 (CCR4) IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Marketed
T254 41941-42059 Sentence denotes Tafasitamab (MOR208 XmAb 5574) CD19 IgG1 S239D; I332E Selectively enhance FcγRIII interaction Oncology Phase III
T255 42060-42150 Sentence denotes Nivolumab PD‐1 IgG4 S228P Stabilize core hinge Infectious disease; oncology Marketed
T256 42151-42262 Sentence denotes Obinutuzumab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Immunology; oncology Marketed
T257 42263-42363 Sentence denotes Ocaratuzumab CD20 IgG1 P247I; A339Q Selectively enhance FcγRIII interaction Oncology Phase III
T258 42364-42449 Sentence denotes Pembrolizumab PD‐1 IgG4 S228P Stabilize core hinge Infection; oncology Marketed
T259 42450-42566 Sentence denotes Roledumab Rhesus D IgG1 Afucosylated Selectively enhance FcγRIII interaction Hematological disorders Phase III
T260 42567-42679 Sentence denotes Spesolimab (BI‐655130) IL‐36R IgG1 L234A; L235A Ablate FcγR binding Gastrointestinal; immunology Phase III
T261 42680-42767 Sentence denotes Teplizumab CD3 IgG1 L234A; L235A Ablate FcγR binding Metabolic disorders Phase II
T262 42768-42988 Sentence denotes Tislelizumab PD‐1 IgG4 S228P; E233P; F234V; L235A; D265A; L309V; R409K Stabilize core hinge; mimic IgG2 lower hinge for restricted FcγR specificity; ablate FcγR binding; stabilize CH3 interaction Oncology Phase III
T263 42989-43071 Sentence denotes Toripalimab (JS 001) PD‐1 IgG4 S228P Stabilize core hinge Oncology Phase III
T264 43072-43195 Sentence denotes Ublituximab CD20 IgG1 Afucosylated Selectively enhance FcγRIII interaction Central nervous system; oncology Phase III
T265 43196-43215 Sentence denotes Ig, immunoglobulin.
T266 43216-43363 Sentence denotes John Wiley & Sons, Ltd This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response.
T267 43364-43546 Sentence denotes It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
T268 43548-43577 Sentence denotes Modification of the Fc glycan
T269 43578-43858 Sentence denotes The typical complex N‐linked glycan attached to N297 of the heavy chain includes a core fucose.85 Antibodies that lack this fucose have approximately 50‐fold improved binding to FcγRIIIa and FcγRIIIb and importantly retain the weak, low‐affinity binding to the inhibitory FcγRIIb.
T270 43859-44233 Sentence denotes Furthermore, this glycoengineering increased binding affinity of the modified IgG1 mAb for both FcγRIIIa V158 and F158 allelotypes.86, 87, 88 Afucosyl versions of the tumor targeting mAbs such as anti‐HER2, anti‐EGFR and anti‐CD20 had greater antitumor effects and increased survival,68, 88, 89 which is a reflection of the greatly increased, and selective, FcγRIII binding.
T271 44234-44559 Sentence denotes Compared with their unmodified counterparts, the afucosyl mAbs showed dramatic improvement of FcγRIII‐related effector responses such as stronger NK cell‐mediated ADCC, or enhanced neutrophil‐mediated phagocytosis through FcγRIIIb and/or FcγRIIIa.23 However, certain neutrophil functions via FcγRIIa may be compromised.90, 91
T272 44560-44664 Sentence denotes There are six afucosylated antibodies in late‐stage clinical trials or approved for treatment (Table 4).
T273 44665-45015 Sentence denotes Notable is obinutuzumab, an afucosyl anti‐CD20 mAb which nearly doubles progression‐free survival in chronic lymphocytic leukemia patients as compared with the fucose‐containing rituximab.68 This dramatic improvement in clinical utility reinforces the value of glycan engineering specifically and of Fc engineering generally in anticancer treatments.
T274 45017-45047 Sentence denotes Mutation of the Fc amino acids
T275 45048-45160 Sentence denotes Alteration of the amino acids in the heavy‐chain Fc can alter IgG specificity and affinity for activating FcγRs.
T276 45161-45441 Sentence denotes The anti‐CD19 antibody MOR208 (XmAb 5574) is currently in phase III trials for the treatment of chronic lymphocytic leukemia.92 It contains two mutations in its IgG1 Fc, S329D and I332E, which increases affinity to FcγRIIIa, particularly the “lower‐affinity” FcγRIIIa F158 allele.
T277 45442-45559 Sentence denotes The mAb shows increased FcγRIII‐mediated ADCC and phagocytosis in vitro, and reduced lymphoma growth in mouse models.
T278 45560-45939 Sentence denotes Margetuximab is an ADCC‐enhanced IgG1 Fc‐engineered variant of the approved anti‐HER2 mAb trastuzumab in phase III for HER2‐expressing cancers.66, 93 Alteration of five amino acids (L235V, F243L, R292P, Y300L and P396L) enhanced binding to FcγRIIIa which also had the additional effect of decreasing binding to the inhibitory FcγRIIb, and thereby increased its A‐to‐I FcγR ratio.
T279 45940-46154 Sentence denotes This was apparent when compared with unmodified trastuzumab the  margetuximab showed enhanced ADCC against HER2+ cells in vitro and demonstrated superior antitumor effects in an HER2‐expressing tumor model in mice.
T280 46155-46526 Sentence denotes The anti‐CD20 ocaratuzumab is an Fc‐engineered IgG1 mAb in late‐stage clinical trials for the treatment of a range of cancers, including non‐Hodgkin lymphoma and chronic lymphocytic leukemia.94 Two Fc mutations, P247I and A339Q, conferred about 20‐fold increase in binding to both major allelic variants of FcγRIIIa and elicited sixfold greater ADCC than unmodified IgG1.
T281 46527-46688 Sentence denotes Thus, the engineering of the Fc domain or glycan for improved FcγRIIIa binding is a powerful tool to create more potent and clinically effective anticancer mAbs.
T282 46690-46744 Sentence denotes Attenuating and ablating FcγR‐related functions of IgG
T283 46745-46853 Sentence denotes There are circumstances where binding to FcγR is unnecessary or undesirable in the MOA of a therapeutic mAb.
T284 46854-47191 Sentence denotes Unmodified IgG irrespective of its subclass or intended therapeutic effect has the potential to engage an FcγR which may lead to suboptimal therapeutic performance or to unexpected and catastrophic consequences.57, 59 Clearly reducing or eliminating FcγR interactions, when they are not required for therapeutic effect, may be desirable.
T285 47192-47284 Sentence denotes Indeed, this had been addressed by the choice of IgG subclass or by modifying the Fc region.
T286 47285-47446 Sentence denotes Indeed, most efforts in Fc engineering mAbs that have translated to an approved drug have focused on the reduction or elimination of FcγR interactions (Table 4).
T287 47447-47714 Sentence denotes One approach to minimize interactions with the activating FcγR has been the use of IgG4 or IgG2 backbones, which show a more restricted specificity for the activating FcγR and consequently have been traditionally, and simplistically, viewed as “inert” IgG subclasses.
T288 47715-47896 Sentence denotes Notwithstanding the unexpected, and FcγR‐dependent, severe adverse reaction induced by the IgG4 TGN1412 mAb, the IgG4 or IgG2 backbones have been successfully used in many settings.
T289 47897-48131 Sentence denotes Indeed, checkpoint inhibitors, such as mAbs targeting CTLA‐4 or the PD‐L1/PD‐1 interaction for the suppression of inhibitory signals that contribute to immune tolerance in the tumor microenvironment, are formatted on an IgG4 backbone.
T290 48132-48356 Sentence denotes Pembrolizumab, nivolumab and cemiplimab are all anti‐PD‐1 antibodies currently used for cancer therapy and have been formatted on an IgG4 backbone95, 96, 97 with a stabilized core hinge (S228P) to prevent half‐IgG4 exchange.
T291 48357-48513 Sentence denotes Similarly, the checkpoint inhibitor tremelimumab is an anti‐CTLA‐4 antibody formatted on an IgG2 backbone to avoid potential ADCC killing of target cells.98
T292 48514-48585 Sentence denotes However, the use of IgG2 and IgG4 as “inert” subclasses is problematic.
T293 48586-48981 Sentence denotes Both bind to the activating receptors FcγRIIa‐H131 and FcγRI, respectively (Table 2), and initiate effector functions such as neutrophil activation and apoptosis induction.75, 99 Interestingly, in experimental systems, cross‐linking of anti‐PD‐1 IgG4‐based mAb by FcγRI switched its activity from blocking to activatory.10 Moreover, IgG4 binds to FcγRIIb, which may scaffold the therapeutic mAb.
T294 48982-49299 Sentence denotes Although scaffolding may be beneficial in some contexts, for example, in immune agonism,43 it can be disastrous and unexpected in others as it was for the anti‐CD28 TGN1412 mAb.59 Thus, the IgG2 and IgG4 subclasses are not the optimum choice for “FcR‐inactive” mAbs, and so modifying the Fc is a more direct approach.
T295 49300-49594 Sentence denotes The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13
T296 49595-49706 Sentence denotes Modification to the Fc amino acid sequence of the FcγR‐contact regions can also be used to reduce FcγR binding.
T297 49707-49862 Sentence denotes A widely used modification of IgG1 is the substitution of leucine 234 and 235 in the lower hinge sequence (L234 L235 G236 G237) with alanine (L234A L235A).
T298 49863-50031 Sentence denotes It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4).
T299 50032-50236 Sentence denotes A separate strategy has used combinations of amino acid residues from the FcγR‐binding regions of IgG2 and IgG4, which have restricted FcγR specificity, together with other binding‐inactivating mutations.
T300 50237-50415 Sentence denotes The lower hinge amino acids of the IgG1 mAbs durvalumab (anti‐PD‐L1) and anifrolumab (anti‐interferon‐α receptor; Table 4) were modified to mimic the lower hinge of IgG4 (L234F).
T301 50416-50633 Sentence denotes They additionally incorporated L235E in the lower hinge and P331S in the F/G loop of the CH2 domain to ablate FcγR binding by disrupting two major FcγR contact sites7 and also coincidently decreasing C1q activation.16
T302 50634-50729 Sentence denotes IgG4 mAbs have been similarly engineered to eliminate their interaction with FcγRI and FcγRIIb.
T303 50730-51004 Sentence denotes The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2.
T304 51005-51222 Sentence denotes It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4.
T305 51223-51327 Sentence denotes Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17
T306 51328-51590 Sentence denotes Thus, Fc engineering is an effective way to remove FcγR effector functions and may be preferable to using unmodified IgG2 or IgG4 backbones that have a more restricted repertoire of FcγR interactions but which are still able to induce certain effector functions.
T307 51592-51622 Sentence denotes Improving FcγRIIb interactions
T308 51623-51792 Sentence denotes Preferential or specific Fc engagement of FcγRIIb over the activating FcγR offers several potential therapeutic advantages for new mAbs in distinct therapeutic settings.
T309 51794-51896 Sentence denotes Improved recruitment of FcγRIIb immunoreceptor tyrosine inhibition motif‐dependent inhibitory function
T310 51897-52383 Sentence denotes Harnessing the physiological inhibitory function of FcγRIIb by mAbs that target ITAM receptors has the potential to shut down ITAM‐dependent signaling pathways of major importance in antibody pathologies.32, 108 Such ITAM signaling receptors include the BCR complex on B cells which is active in systemic lupus erythematosus, the FcεRI on basophils and mast cell subsets in allergies or the activating‐type FcγR on a variety of innate leukocytes in antibody‐mediated tissue destruction.
T311 52384-52548 Sentence denotes In such scenarios, the ITAM signaling receptor complex that is targeted by the therapeutic mAb must be co‐expressed on the cell surface with the inhibitory FcγRIIb.
T312 52549-52752 Sentence denotes This permits coengagement with ITAM signaling receptor by the Fab of the mAb and inhibitory FcγRIIb by its Fc which is the critical requirement in the inhibitory MOA for such therapeutic mAbs (Figure 1).
T313 52753-53178 Sentence denotes Obexelimab (also known as XmAb5871; Table 4), currently in early clinical testing in inflammatory autoimmune disease, is an IgG1 mAb that targets CD19 of the BCR complex.19 It contains two Fc modifications, S267E and L328F (also known as “SELF” mutations), that selectively increased FcγRIIb binding by 400‐fold to about 1 nm, which results in powerful suppression of BCR signaling and the proliferation of primary B cells.19
T314 53179-54143 Sentence denotes The anti‐IgE mAb omalizumab is an IgG1 mAb approved for the treatment of allergic disorders.110, 111 A similar but Fc‐engineered IgG1 mAb XmAb7195, currently in early clinical testing, contains the affinity‐enhancing SELF modifications.112 Both mAbs sterically neutralize the interaction between IgE and its high‐affinity receptor FcεRI to prevent basophil and mast cell activation.113, 114 However, XmAb7195 exhibited more efficient removal (sweeping; discussed later) of circulating IgE and also inhibited B‐cell IgE production, presumably by binding to the IgE BCR on the B‐cell surface and coclustering with FcγRIIb via its affinity‐enhanced Fc domain.112 Thus, XmAb7195’s selective modulation of IgE production by IgE+ B cells in addition to its enhanced clearance of IgE may offer significantly improved therapeutic benefits in allergy therapy beyond simple IgE neutralization.112 The “SELF” mutations have also been used in agonistic mAbs (discussed later).
T315 54144-54375 Sentence denotes One cautionary note is that the arginine 131 (R131) of the IgG‐binding site in FcγRIIb is critical for the enhanced affinity binding of “SELF”‐mutated Fcs but it is also present in the activating‐type “high responder” FcγRIIa‐R131.
T316 54376-54638 Sentence denotes Thus, antibodies modified with “SELF” have very‐high‐affinity binding to FcγRIIa‐R131 115 with a potentially increased risk of FcγRIIa‐dependent complications in patients expressing this allelic form, although, so far, none have been reported in clinical trials.
T317 54639-54829 Sentence denotes However, an alternative set of six Fc mutations, termed “V12” (P238D, E233D, G237D, H268D, P271G and A330R), potently enhanced FcγRIIb binding without increasing FcγRIIa–R131 interaction.115
T318 54831-54879 Sentence denotes Enhancing the sweeping of small immune complexes
T319 54880-55252 Sentence denotes The expression of FcγRIIb on LSEC and its action in the “sweeping” or removal of small immune complexes has opened up new possibilities for the application of FcγRIIb‐enhancing modifications.17 Antibodies or Fc fusion proteins, whose primary MOA is the neutralization of soluble molecules such as IgE or cytokines, are particularly attractive candidates for this approach.
T320 55253-55561 Sentence denotes Proof‐of‐concept for this strategy has been demonstrated in experimental models.48 Indeed, this may be a significant component of the rapid disappearance of IgE from the circulation of patients treated with the anti‐IgE XmAb7195 containing the FcγRIIb enhancing “SELF” modifications, as described previously.
T321 55563-55602 Sentence denotes Immune agonism through FcγR scaffolding
T322 55603-55702 Sentence denotes Agonistic mAbs induce responses in target cells by stimulating signaling of their molecular target.
T323 55703-55948 Sentence denotes Typically, this is to either enhance antitumor immunity by engaging costimulatory molecules on antigen‐presenting cells or T cells (i.e. CD40, 4‐1BB, OX40) or promote apoptosis by engaging death receptors on cancer cells (i.e. DR4, DR5, Fas).116
T324 55949-56041 Sentence denotes The role of FcγR in the action of these types of mAbs appears to be primarily as a scaffold.
T325 56042-56138 Sentence denotes FcγRIIb is often the predominate receptor involved and the extent of its involvement is complex.
T326 56139-56459 Sentence denotes In the case of CD40, the degree of FcγRIIb scaffolding potency is linked to the epitope location of the targeting mAb with greater potency seen for membrane proximal epitopes.43, 117 It is also noteworthy that depending on the epitope location, the scaffolding of anti‐CD40 mAbs may convert antagonist mAbs to agonistic.
T327 56460-56952 Sentence denotes Engineering of the IgG1 Fc region for enhanced and/or specific binding to FcγRIIb can greatly improve agonistic function.72, 118, 119, 120 Such mutations induced significantly greater agonistic activity in an anti‐DR5 model through increased induction of apoptotic death and decreased tumor growth compared with unmodified IgG1.121 The “SELF” modifications that dramatically and selectively increase affinity for FcγRIIb have also been used to enhance immune agonism in an anti‐OX40 model.122
T328 56953-57156 Sentence denotes The incorporation of the "V12" Fc mutations into IgG1 specifically enhance FcγRIIb interaction 200‐fold, conferring the enhanced agonistic activity of an anti‐CD137 antibody and an anti‐OX40 mAb.115, 122
T329 57158-57187 Sentence denotes Future Engineering Strategies
T330 57188-57284 Sentence denotes Monoclonal antibodies are potent therapeutics in a number of chronic or once incurable diseases.
T331 57285-57414 Sentence denotes However, there is still extensive unmet clinical need as well as considerable room for improvement in many existing therapeutics.
T332 57415-57555 Sentence denotes Further understanding of how antibody structure affects FcγR function is essential for future development of more potent and effective mAbs.
T333 57556-57823 Sentence denotes Already, engineering of the IgG Fc and its glycan has proved a potent and effective approach for increasing the clinical effectiveness, functional specificity and safety of therapeutic mAbs and is an emerging pathway to the development of the “next‐gen” therapeutics.
T334 57824-58167 Sentence denotes Future directions in the development and use of therapeutic antibodies should increasingly mimic normal protective antibody responses, which are polyclonal and elicited in the context of innate receptor engagement which includes the FcR as well as other powerfully responsive systems including the Toll‐like receptors and complement receptors.
T335 58168-58421 Sentence denotes Furthermore, the mixed subclass nature of these normal antibody responses suggests that circumstances may arise in therapeutic strategies where there is value in having distinctly modified Fcs for the nuanced engagement of different FcγR family members.
T336 58422-58573 Sentence denotes Treatments comprising multiple mAbs and immune stimulants are under investigation in infectious disease for neutralization coverage of variant strains.
T337 58574-58731 Sentence denotes Indeed, such an approach may be most effective in emerging infectious disease such as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection.
T338 58732-58930 Sentence denotes The use of multiple mAbs tailored for distinct effector functions and targeting different epitopes will maximize the opportunity for cocktailing of effector functions in different types of diseases.
T339 58931-59134 Sentence denotes Indeed, in a small but contemporary example outside of infectious disease, the FDA‐approved combination in adenocarcinoma therapy uses a cocktail of two mAbs, pertuzumab and trastuzumab, against Her2.123
T340 59135-59412 Sentence denotes Rather than one type of Fc to conquer all, the combined use of appropriately selected mAbs whose individual components are enhanced for the engagement of different FcγR members may utilize multiple components of the spectrum of effector responses on offer by the immune system.
T341 59413-59616 Sentence denotes Such “next‐gen” biologics will begin to realize the full potential of FcγR‐mediated antibody immune therapeutics and offer transformational change for the treatment of intractable and incurable diseases.
T342 59618-59638 Sentence denotes Conflict of Interest
T343 59639-59644 Sentence denotes None.

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T2 831-849 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T3 929-936 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T4 4898-4912 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T5 12942-12966 Phenotype denotes immune thrombocytopenias http://purl.obolibrary.org/obo/HP_0001973
T6 13285-13313 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T7 13428-13439 Phenotype denotes anaphylaxis http://purl.obolibrary.org/obo/HP_0100845
T8 22865-22871 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T9 25712-25717 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T10 37825-37831 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T11 37971-37977 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T12 38130-38135 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T13 38683-38688 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T14 38740-38746 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T15 39760-39765 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T16 40178-40184 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T17 40707-40715 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T18 40959-40967 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T19 41283-41291 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T20 41517-41525 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T21 41764-41772 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T22 41922-41930 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T23 42040-42048 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T24 42132-42140 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T25 42244-42252 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T26 42344-42352 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T27 42431-42439 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T28 42969-42977 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T29 43052-43060 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T30 43176-43184 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T31 44026-44031 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T32 44766-44794 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T33 45257-45285 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T34 45527-45535 Phenotype denotes lymphoma http://purl.obolibrary.org/obo/HP_0002665
T35 46134-46139 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T36 46292-46312 Phenotype denotes non‐Hodgkin lymphoma http://purl.obolibrary.org/obo/HP_0012539
T37 46317-46345 Phenotype denotes chronic lymphocytic leukemia http://purl.obolibrary.org/obo/HP_0005550
T38 48073-48078 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T39 48220-48226 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T40 52193-52221 Phenotype denotes systemic lupus erythematosus http://purl.obolibrary.org/obo/HP_0002725
T41 52851-52869 Phenotype denotes autoimmune disease http://purl.obolibrary.org/obo/HP_0002960
T42 54013-54020 Phenotype denotes allergy http://purl.obolibrary.org/obo/HP_0012393
T43 55911-55917 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T44 56745-56750 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sample-Glycan

Id Subject Object Predicate Lexical cue
T1 9075-9078 https://glytoucan.org/Structures/Glycans/G05518TD denotes All
T2 10265-10268 https://glytoucan.org/Structures/Glycans/G05518TD denotes All